<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Int J Clin Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>International Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">1341-9625</issn><issn pub-type="epub">1437-7772</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12770061</article-id><article-id pub-id-type="pmcid-ver">PMC12770061.1</article-id><article-id pub-id-type="pmcaid">12770061</article-id><article-id pub-id-type="pmcaiid">12770061</article-id><article-id pub-id-type="pmid">41214301</article-id><article-id pub-id-type="doi">10.1007/s10147-025-02892-1</article-id><article-id pub-id-type="publisher-id">2892</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Special Article</subject></subj-group></article-categories><title-group><article-title>Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2024 for the clinical practice of hereditary colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8901-6911</contrib-id><name name-style="western"><surname>Tanakaya</surname><given-names initials="K">Kohji</given-names></name><address><email>tanakaya.kouji.tb@mail.hosp.go.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yamaguchi</surname><given-names initials="T">Tatsuro</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hirata</surname><given-names initials="K">Keiji</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yamada</surname><given-names initials="M">Masayoshi</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kumamoto</surname><given-names initials="K">Kensuke</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Akiyama</surname><given-names initials="Y">Yasuki</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ishimaru</surname><given-names initials="K">Kei</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Okamoto</surname><given-names initials="K">Koichi</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kawasaki</surname><given-names initials="Y">Yuko</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Komine</surname><given-names initials="K">Keigo</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sakamoto</surname><given-names initials="A">Akira</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shigeyasu</surname><given-names initials="K">Kunitoshi</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shibata</surname><given-names initials="Y">Yoshiko</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shimamoto</surname><given-names initials="Y">Yusaku</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shimodaira</surname><given-names initials="H">Hideki</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sekine</surname><given-names initials="S">Shigeki</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Takao</surname><given-names initials="A">Akinari</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Takao</surname><given-names initials="M">Misato</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Takamizawa</surname><given-names initials="Y">Yasuyuki</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names initials="Y">Yoji</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tanabe</surname><given-names initials="N">Noriko</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Taniguchi</surname><given-names initials="F">Fumitaka</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chino</surname><given-names initials="A">Akiko</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cho</surname><given-names initials="H">Hourin</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Doi</surname><given-names initials="S">Satoru</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nakajima</surname><given-names initials="T">Takeshi</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nakamori</surname><given-names initials="S">Sakiko</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nakayama</surname><given-names initials="Y">Yoshiko</given-names></name><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nagasaki</surname><given-names initials="T">Toshiya</given-names></name><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hasumi</surname><given-names initials="H">Hisashi</given-names></name><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Banno</surname><given-names initials="K">Kouji</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hinoi</surname><given-names initials="T">Takao</given-names></name><xref ref-type="aff" rid="Aff29">29</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fujiyoshi</surname><given-names initials="K">Kenji</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Horimatsu</surname><given-names initials="T">Takahiro</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Masuda</surname><given-names initials="K">Kenta</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Miguchi</surname><given-names initials="M">Masashi</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mizuuchi</surname><given-names initials="Y">Yusuke</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Miyakura</surname><given-names initials="Y">Yasuyuki</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mutoh</surname><given-names initials="M">Michihiro</given-names></name><xref ref-type="aff" rid="Aff36">36</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yoshioka</surname><given-names initials="T">Takahiro</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tanaka</surname><given-names initials="S">Shinji</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sakamoto</surname><given-names initials="K">Kazuhiro</given-names></name><xref ref-type="aff" rid="Aff39">39</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sakamaki</surname><given-names initials="K">Kentaro</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Itabashi</surname><given-names initials="M">Michio</given-names></name><xref ref-type="aff" rid="Aff41">41</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ishida</surname><given-names initials="H">Hideyuki</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tomita</surname><given-names initials="N">Naohiro</given-names></name><xref ref-type="aff" rid="Aff43">43</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sugihara</surname><given-names initials="K">Kenichi</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ajioka</surname><given-names initials="Y">Yoichi</given-names></name><on-behalf-of>Japanese Society for Cancer of the Colon, Rectum</on-behalf-of><xref ref-type="aff" rid="Aff45">45</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03kcxpp45</institution-id><institution-id institution-id-type="GRID">grid.414860.f</institution-id><institution>Department of Surgery, </institution><institution>National Hospital Organization Iwakuni Clinical Center, </institution></institution-wrap>1-1-1 Atago-Machi, Iwakuni, 740-8510 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04eqd2f30</institution-id><institution-id institution-id-type="GRID">grid.415479.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0561 8609</institution-id><institution>Department of Clinical Genetics, </institution><institution>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/020p3h829</institution-id><institution-id institution-id-type="GRID">grid.271052.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0374 5913</institution-id><institution>Department of Surgery 1, </institution><institution>University of Occupational and Environmental Health, </institution></institution-wrap>Kitakyushu, Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03rm3gk43</institution-id><institution-id institution-id-type="GRID">grid.497282.2</institution-id><institution>Endoscopy Division, </institution><institution>National Cancer Center Hospital, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04j7mzp05</institution-id><institution-id institution-id-type="GRID">grid.258331.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 8662 309X</institution-id><institution>Department of Genome Medical Science and Medical Genetics, Faculty of Medicine, </institution><institution>Kagawa University, </institution></institution-wrap>Kita-Gun, Japan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017hkng22</institution-id><institution-id institution-id-type="GRID">grid.255464.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 1011 3808</institution-id><institution>Division of Gastrointestinal Surgery and Surgical Oncology, Graduate School of Medicine, </institution><institution>Ehime University, </institution></institution-wrap>Toon, Japan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/044vy1d05</institution-id><institution-id institution-id-type="GRID">grid.267335.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 1092 3579</institution-id><institution>Department of Gastroenterology and Oncology, </institution><institution>Tokushima University Graduate School of Medical Science, </institution></institution-wrap>Tokushima, Japan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0151bmh98</institution-id><institution-id institution-id-type="GRID">grid.266453.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0724 9317</institution-id><institution>College of Nursing, </institution><institution>University of Hyogo, </institution></institution-wrap>Akashi, Japan </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00kcd6x60</institution-id><institution-id institution-id-type="GRID">grid.412757.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0641 778X</institution-id><institution>Department of Medical Oncology, </institution><institution>Tohoku University Hospital, </institution></institution-wrap>Sendai, Japan </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04eqd2f30</institution-id><institution-id institution-id-type="GRID">grid.415479.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0561 8609</institution-id><institution>Department of Surgery, </institution><institution>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02pc6pc55</institution-id><institution-id institution-id-type="GRID">grid.261356.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1302 4472</institution-id><institution>Department of Gastroenterological Surgery, </institution><institution>Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, </institution></institution-wrap>Okayama, Japan </aff><aff id="Aff12"><label>12</label>Himawari-No-Kai (Sunflower Association), a Patient Advocacy Group for Individuals and Families Affected By Lynch Syndrome, Iwakuni, Japan </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03tgsfw79</institution-id><institution-id institution-id-type="GRID">grid.31432.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 1092 3077</institution-id><institution>Division of Gastroenterology, Department of Internal Medicine, </institution><institution>Kobe University Graduate School of Medicine, </institution></institution-wrap>Kobe, Japan </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0264zxa45</institution-id><institution-id institution-id-type="GRID">grid.412755.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2166 7427</institution-id><institution>Division of Medical Oncology, Faculty of Medicine, </institution><institution>Tohoku Medical and Pharmaceutical University, </institution></institution-wrap>Sendai, Japan </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02kn6nx58</institution-id><institution-id institution-id-type="GRID">grid.26091.3c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9959</institution-id><institution>Department of Pathology, </institution><institution>Keio University School of Medicine, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04eqd2f30</institution-id><institution-id institution-id-type="GRID">grid.415479.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0561 8609</institution-id><institution>Department of Gastroenterology, </institution><institution>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03rm3gk43</institution-id><institution-id institution-id-type="GRID">grid.497282.2</institution-id><institution>Department of Colorectal Surgery, </institution><institution>National Cancer Center Hospital, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/046fm7598</institution-id><institution-id institution-id-type="GRID">grid.256642.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 9269 4097</institution-id><institution>Department of Gastroenterology and Hepatology, </institution><institution>Gunma University Graduate School of Medicine, </institution></institution-wrap>Gunma, Japan </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04zb31v77</institution-id><institution-id institution-id-type="GRID">grid.410802.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2216 2631</institution-id><institution>Department of Clinical Genetics, Saitama Medical Center, </institution><institution>Saitama Medical University, </institution></institution-wrap>Saitama, Japan </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="GRID">grid.517838.0</institution-id><institution>Department of Surgery, </institution><institution>Hiroshima City Hospital Organization Hiroshima City Hiroshima Citizens Hospital, </institution></institution-wrap>Hiroshima, Japan </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00bv64a69</institution-id><institution-id institution-id-type="GRID">grid.410807.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0037 4131</institution-id><institution>Department of Gastroenterology, </institution><institution>Cancer Institute Hospital, Japanese Foundation for Cancer Research, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/012e6rh19</institution-id><institution-id institution-id-type="GRID">grid.412781.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1775 2495</institution-id><institution>Endoscopy Center, </institution><institution>Tokyo Medical University Hospital, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff23"><label>23</label>Harmony Line (Association for Patients and Families With Familial Adenomatous Polyposis), Osaka, Japan </aff><aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05xvwhv53</institution-id><institution-id institution-id-type="GRID">grid.416963.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1793 0765</institution-id><institution>Division of Hereditary Tumors, Department of Genetic Oncology, </institution><institution>Osaka International Cancer Institute, </institution></institution-wrap>Osaka, Japan </aff><aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05b7rex33</institution-id><institution-id institution-id-type="GRID">grid.444226.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0373 4173</institution-id><institution>Department of Pediatrics, </institution><institution>Shinshu University School of Medicine, </institution></institution-wrap>Matsumoto, Japan </aff><aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03a4d7t12</institution-id><institution-id institution-id-type="GRID">grid.416695.9</institution-id><institution-id institution-id-type="ISNI">0000 0000 8855 274X</institution-id><institution>Department of Gastroenterological Surgery, </institution><institution>Saitama Cancer Center, </institution></institution-wrap>Saitama, Japan </aff><aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0135d1r83</institution-id><institution-id institution-id-type="GRID">grid.268441.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 1033 6139</institution-id><institution>Department of Urology, </institution><institution>Yokohama City University, </institution></institution-wrap>Yokohama, Japan </aff><aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/038dg9e86</institution-id><institution-id institution-id-type="GRID">grid.470097.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0618 7953</institution-id><institution>Center of Maternal -Fetal/Neonatal Medicine, </institution><institution>Hiroshima University Hospital, </institution></institution-wrap>Hiroshima, Japan </aff><aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/038dg9e86</institution-id><institution-id institution-id-type="GRID">grid.470097.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0618 7953</institution-id><institution>Department of Clinical and Molecular Genetics, </institution><institution>Hiroshima University Hospital, </institution></institution-wrap>Hiroshima, Japan </aff><aff id="Aff30"><label>30</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/057xtrt18</institution-id><institution-id institution-id-type="GRID">grid.410781.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0706 0776</institution-id><institution>Department of Surgery, </institution><institution>Kurume University School of Medicine, </institution></institution-wrap>Kurume, Japan </aff><aff id="Aff31"><label>31</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04k6gr834</institution-id><institution-id institution-id-type="GRID">grid.411217.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0531 2775</institution-id><institution>Institute for Advancement of Clinical and Translational Science, </institution><institution>Kyoto University Hospital, </institution></institution-wrap>Kyoto, Japan </aff><aff id="Aff32"><label>32</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02kn6nx58</institution-id><institution-id institution-id-type="GRID">grid.26091.3c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9959</institution-id><institution>Department of Obstetrics and Gynecology, </institution><institution>Keio University School of Medicine, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff33"><label>33</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01rrd4612</institution-id><institution-id institution-id-type="GRID">grid.414173.4</institution-id><institution-id institution-id-type="ISNI">0000 0000 9368 0105</institution-id><institution>Department of Gastroenterological Surgery, </institution><institution>Hiroshima Prefectural Hospital, </institution></institution-wrap>Hiroshima, Japan </aff><aff id="Aff34"><label>34</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00p4k0j84</institution-id><institution-id institution-id-type="GRID">grid.177174.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2242 4849</institution-id><institution>Department of Surgery and Oncology, Graduate School of Medical Sciences, </institution><institution>Kyushu University, </institution></institution-wrap>Fukuoka, Japan </aff><aff id="Aff35"><label>35</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03eg72e39</institution-id><institution-id institution-id-type="GRID">grid.420115.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8729</institution-id><institution>Department of Colon and Pelvic Surgery, </institution><institution>Cancer Prevention and Genetic Counseling, Tochigi Cancer Center, </institution></institution-wrap>Utsunomiya, Japan </aff><aff id="Aff36"><label>36</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/028vxwa22</institution-id><institution-id institution-id-type="GRID">grid.272458.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0667 4960</institution-id><institution>Department of Molecular-Targeting Prevention, Graduate School of Medical Science, </institution><institution>Kyoto Prefectural University of Medicine, </institution></institution-wrap>Kyoto, Japan </aff><aff id="Aff37"><label>37</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04b3jbx04</institution-id><institution>Department of Gastroenterological Surgery, </institution><institution>Kochi Health Sciences Center, </institution></institution-wrap>Kochi, Japan </aff><aff id="Aff38"><label>38</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05nr3de46</institution-id><institution-id institution-id-type="GRID">grid.416874.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0604 7643</institution-id><institution>JA Onomichi General Hospital, </institution></institution-wrap>Onomichi, Japan </aff><aff id="Aff39"><label>39</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02n22cc74</institution-id><institution-id institution-id-type="GRID">grid.415496.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1772 243X</institution-id><institution>Koshigaya Municipal Hospital, </institution></institution-wrap>Koshigaya, Japan </aff><aff id="Aff40"><label>40</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01692sz90</institution-id><institution-id institution-id-type="GRID">grid.258269.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1762 2738</institution-id><institution>Faculty of Health Data Science, </institution><institution>Juntendo University, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff41"><label>41</label>Saiseikai Kazo Hospital, Kazo, Japan </aff><aff id="Aff42"><label>42</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04zb31v77</institution-id><institution-id institution-id-type="GRID">grid.410802.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2216 2631</institution-id><institution>Department of Digestive Tract and General Surgery, Saitama Medical Center, </institution><institution>Saitama Medical University, </institution></institution-wrap>Kawagoe, Japan </aff><aff id="Aff43"><label>43</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0056qeq43</institution-id><institution-id institution-id-type="GRID">grid.417245.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1774 8664</institution-id><institution>Division of Cancer Treatment , </institution><institution>Toyonaka Municipal Hospital, </institution></institution-wrap>Toyonaka, Japan </aff><aff id="Aff44"><label>44</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05dqf9946</institution-id><institution>Institute of Science Tokyo , </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff45"><label>45</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04ww21r56</institution-id><institution-id institution-id-type="GRID">grid.260975.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0671 5144</institution-id><institution>Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences, </institution><institution>Niigata University, </institution></institution-wrap>Niigata, Japan </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>11</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2026</year></pub-date><volume>31</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">504149</issue-id><fpage>1</fpage><lpage>66</lpage><history><date date-type="received"><day>21</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>11</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-07 00:25:15.160"><day>07</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10147_2025_Article_2892.pdf"/><abstract id="Abs1"><p id="Par1">Approximately 5% of all colorectal cancers have a strong genetic component and are classified as hereditary colorectal cancer (HCRC). Some of the unique features commonly seen in HCRC cases include early age of onset, synchronous/metachronous cancer occurrence, and multiple cancers in other organs. These characteristics require different management approaches, including diagnosis, treatment or surveillance, from those used in the management of sporadic colorectal cancer. Accurate diagnosis of HCRC is essential because it enables targeted surveillance and risk reduction strategies that improve patient outcomes. Recent genetic advances revealed several causative genes for polyposis and non-polyposis syndromes. The Japanese Society for Cancer of the Colon and Rectum (JSCCR) first published guidelines for the management of HCRC in 2012, with subsequent revisions every 4&#160;years. The 2024 update to the JSCCR guidelines for HCRC was developed by meticulously reviewing evidence from systematic reviews and the consensus of the JSCCR HCRC Guidelines Committee, which includes representatives from patient advocacy groups for FAP and Lynch syndrome. These guidelines provide an up-to-date summary of HCRC, along with clinical recommendations for managing FAP and Lynch syndrome.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hereditary colorectal cancer</kwd><kwd>Guidelines</kwd><kwd>Familial adenomatous polyposis</kwd><kwd>Lynch syndrome</kwd></kwd-group><funding-group><award-group><funding-source><institution>Japanese Society for Cancer of the Colon and Rectum</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Japan Society of Clinical Oncology 2026</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><sec id="Sec2"><title>Guideline objective</title><p id="Par2">The number of patients with colorectal cancer (CRC) has been increasing in Japan, and societal interest is high given that it is one of the most common types of cancer. Most CRCs are thought to arise from the accumulation of gene variants in the colonic mucosa caused by the effects of lifestyle, environmental factors, and aging. Between 20 and 30% of all CRCs develop in relatives (i.e., familial clustering) and are sometimes called familial CRCs. A causative gene is identified in up to 5% of CRCs, regardless of familial clustering, and these cases are collectively referred to as hereditary colorectal cancer (HCRC). HCRC tends to be complicated by a young onset, synchronous/metachronous CRC, and multiple cancers in other organs. Therefore, it is necessary to take measures different from those for sporadic CRC. However, awareness of HCRC is not always high among clinicians.</p><p id="Par3">The most common HCRCs are familial adenomatous polyposis (FAP) and Lynch syndrome. FAP is diagnosed by the characteristic clinical finding of colorectal adenomatous polyposis. However, recent investigations have found that colonic adenomatous polyposis can be caused by several genes other than <italic toggle="yes">APC</italic>, which is the causative gene for FAP. Therefore, genetic testing, rather than relying on clinical findings alone, is recommended for accurate diagnosis of colorectal adenomatous polyposis. Furthermore, although the frequency of Lynch syndrome is higher than that of FAP, many cases of Lynch syndrome are overlooked and undiagnosed because of the lack of characteristic clinical features. In recent years, however, with the spread of companion diagnoses and comprehensive genome profiling tests, Lynch syndrome is increasingly being suspected and diagnosed.</p><p id="Par4">Against this backdrop, the Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the Clinical Practice of Hereditary Colorectal Cancer (&#8220;2024 JSCCR Guidelines for HCRC&#8221; or &#8220;these guidelines&#8221; below) were developed with four aims in mind: (1) to deepen the understanding of the concept of HCRC, (2) to provide guidance on management strategies for HCRC, including diagnosis and surveillance, (3) to emphasize the importance of considering the psychosocial burden caused by hereditary diseases and the need to provide support for patients and their families, and (4) to promote mutual understanding by healthcare professionals and patients by making these guidelines available to the public.</p><p id="Par5">Inclusion of Lynch syndrome in these guidelines may be considered inappropriate given the diversity of these tumors. However, in view of the history of the creation of these guidelines, this question will be left for future examination and revision.</p></sec><sec id="Sec3"><title>Principles underlying development of these guidelines</title><p id="Par6">These guidelines provide evidence in support of clinical strategies for the diagnosis, treatment, and surveillance of HCRC but do not discuss treatment methods. We have attempted to develop these guidelines in accordance with the concept of evidence-based medicine. However, the incidence of HCRC is relatively low, and it is difficult to design studies that can provide a high level of evidence. Therefore, the guidelines have been developed by consensus among members of the JSCCR based on information obtained from a literature search and considering the health insurance system and actual clinical practice in Japan. Moreover, considering the specific characteristics of HCRC, members of the Japanese Society for Hereditary Tumors and patient/family associations also participated in the Guideline Development Committee. This committee comprised specialists in internal medicine, surgery, gynecology, pediatrics, pathology, genetic diagnosis, genetic counseling, and nursing, as well as representatives of patient/family associations.</p></sec><sec id="Sec4"><title>Topics</title><p id="Par7">The main topics addressed in these guidelines are the diagnosis, treatment, and surveillance of HCRCs (FAP and Lynch syndrome) and genetic counseling for patients with these diseases in Japan.</p></sec><sec id="Sec5"><title>Perspectives</title><p id="Par8">These guidelines adopted an individual perspective.</p></sec><sec id="Sec6"><title>Users and facilities</title><p id="Par9">The guidelines are intended for use by physicians, nurses, genetic counselors, and experts in genetic medicine engaged in the diagnosis and management of HCRCs and related conditions in hospitals, clinics, and screening facilities.</p></sec><sec id="Sec7"><title>Scope of coverage</title><p id="Par10">The guidelines cover patients and families with FAP, Lynch syndrome, and related HCRCs. Sporadic (non-hereditary) CRC, hamartomatous polyposis syndromes (Peutz-Jeghers syndrome, juvenile polyposis syndrome, Cowden syndrome/<italic toggle="yes">PTEN</italic> hamartoma tumor syndrome) and serrated polyposis syndrome are excluded.</p></sec><sec id="Sec8"><title>Collection of evidence</title><p id="Par11">Evidence was collected by a literature search conducted in September 2022 using PubMed, Ichushi-Web (Japan Medical Abstracts Society), and the Cochrane Library to develop the Clinical Questions (CQ).</p></sec><sec id="Sec9"><title>Evaluation of evidence</title><p id="Par12">We comprehensively collected studies related to the CQs and grouped the evidence presented in individual papers with respect to critical outcomes by study design. Individual studies were then assessed for risk of bias, indirectness, inconsistency, imprecision, and publication bias according to the study design (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Next, as in the 2022 JSCCR guidelines for the treatment of CRC [<xref ref-type="bibr" rid="CR1">1</xref>], we assessed the body of evidence at the literature level according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system [<xref ref-type="bibr" rid="CR2">2</xref>] and finally determined the evidence level for the CQs. The evidence level is described at four levels: &#8220;A: There is strong confidence in the estimated values of the effect&#8221;; &#8220;B: There is moderate confidence in the estimated values of the effect&#8221;; &#8220;C: There is limited confidence in the estimated values of the effect&#8221;; and &#8220;D: There is little confidence in the estimated values of the effect&#8221; (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Judgment about the quality of the underlying evidence</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="1" rowspan="1">1. Initial study design</td></tr><tr><td align="left" colspan="1" rowspan="1">Level A: systematic review, metanalysis, or randomized control study</td></tr><tr><td align="left" colspan="1" rowspan="1">Level B: other</td></tr><tr><td align="left" colspan="1" rowspan="1">Level C: observational study, cohort study, or case&#8211;control study</td></tr><tr><td align="left" colspan="1" rowspan="1">Level D; case series, or case report</td></tr><tr><td align="left" colspan="1" rowspan="1">2. Factors that can reduce the quality of the evidence</td></tr><tr><td align="left" colspan="1" rowspan="1">Limitations in study design or execution (risk of bias)</td></tr><tr><td align="left" colspan="1" rowspan="1">Inconsistency of results</td></tr><tr><td align="left" colspan="1" rowspan="1">Indirectness of evidence</td></tr><tr><td align="left" colspan="1" rowspan="1">Imprecision</td></tr><tr><td align="left" colspan="1" rowspan="1">Publication bias</td></tr><tr><td align="left" colspan="1" rowspan="1">3. Factors that can increase the quality of the evidence</td></tr><tr><td align="left" colspan="1" rowspan="1">Large magnitude of effect</td></tr><tr><td align="left" colspan="1" rowspan="1">All plausible confounding would reduce the demonstrated effect or increase the effect if no effect was observed</td></tr><tr><td align="left" colspan="1" rowspan="1">Dose&#8211;response gradient</td></tr><tr><td align="left" colspan="1" rowspan="1">4. The final total evidence was determined by evaluating the above in the order of 1, 2, and 3</td></tr></tbody></table></table-wrap><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Definition of the evidence level for CQs</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="1" rowspan="1">Evidence level A (high)</td><td align="left" colspan="1" rowspan="1">We are very confident that the true effect lies close to that of the</td></tr><tr><td align="left" colspan="1" rowspan="1">Evidence level B (moderate)</td><td align="left" colspan="1" rowspan="1"><p>estimate of the effect</p><p>We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Evidence level C (low)</td><td align="left" colspan="1" rowspan="1">Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect</td></tr><tr><td align="left" colspan="1" rowspan="1">Evidence level D (very low)</td><td align="left" colspan="1" rowspan="1">We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec10"><title>Strength of recommendations</title><p id="Par13">Draft recommendations were developed based on the outcomes and evidence levels generated as described above and were assessed at a consensus meeting convened by members of the Guideline Development Committee. In the CQ text, the determined recommendations were expressed directly, and inconsistencies were removed. HCRC is an area with limited high-level evidence, except for chemoprevention. Therefore, local and international guidelines were referenced to determine the strength of the recommendations. Insurance coverage was not considered in determining the strength of the recommendations. The strength of the draft recommendations was determined by voting according to the GRADE Grid method, which assesses the following four items: certainty of evidence, patients&#8217; preferences, benefits and harms, and costs (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Strength of CQ recommendations</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Recommendations</th><th align="left" colspan="1" rowspan="1"/></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1 (Strong recommendation)</td><td align="left" colspan="1" rowspan="1">Strong &#8220;For&#8221; an intervention</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Strong &#8220;Against&#8221; an intervention</td></tr><tr><td align="left" colspan="1" rowspan="1">2 (Weak recommendation)</td><td align="left" colspan="1" rowspan="1">Weak &#8220;For&#8221; an intervention</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Weak &#8220;Against&#8221; an intervention</td></tr></tbody></table></table-wrap></p><sec id="Sec11"><title>Voting method</title><p id="Par14">
<list list-type="order"><list-item><p id="Par15">Select one of the following five options:<list list-type="order"><list-item><p id="Par16">Strong &#8220;For&#8221; intervention</p></list-item><list-item><p id="Par17">Weak &#8220;For&#8221; intervention</p></list-item><list-item><p id="Par18">Weak &#8220;Against&#8221; intervention</p></list-item><list-item><p id="Par19">Strong &#8220;Against&#8221; intervention</p></list-item><list-item><p id="Par20">Not graded</p></list-item></list></p></list-item><list-item><p id="Par21">If&#8201;&#8805;&#8201;70% of all votes agreed on one of the options (1)&#8211;(5) in the first vote, that option was chosen by consensus. This condition did not apply in the case of the following:<list list-type="order"><list-item><p id="Par22">If (1)&#8201;+&#8201;(2) exceeds 50% and (3)&#8201;+&#8201;(4) is 20% or lower, &#8220;weakly recommend to perform&#8221; is selected</p></list-item><list-item><p id="Par23">If (3)&#8201;+&#8201;(4) exceeds 50% and (1)&#8201;+&#8201;(2) is 20% or lower, &#8220;weakly recommend not to perform&#8221; is selected</p></list-item></list></p></list-item><list-item><p id="Par24">If neither of the two conditions were met at the time of the first vote, a second discussion was held under the category of &#8220;no consensus was reached,&#8221; while taking into account the medical circumstances in Japan and disclosing the voting results; a second round of voting was then held.</p></list-item><list-item><p id="Par25">If no consensus was reached in the second vote, &#8220;Not graded&#8221; was selected.</p></list-item></list></p><p id="Par26">Representatives of the patient/family association also voted on the CQs after receiving an interpretation of the guidelines and freely expressing their opinions at the meeting. In brief, a total of 18 committee members participated in the voting for each CQ. Among them, one representative of the patient/family association voted for the CQ relevant to his or her condition (i.e., either familial adenomatous polyposis or Lynch syndrome).</p></sec></sec><sec id="Sec12"><title>Explanatory text</title><p id="Par27">Attempts were made to use clear and unambiguous language in the CQs. Ease of understanding and avoidance of convoluted text were emphasized in the CQ explanations. Descriptions of specific figures and values in the research results when referring to a large number of clinical trials were abbreviated as appropriate. The study design based on which the recommendations were to be determined was specified whenever possible, including meta-analyses, randomized controlled trials, and observational studies.</p></sec><sec id="Sec13"><title>Chapters</title><p id="Par28">In terms of the extraction of key clinical issues, well-established evidence has been described in each chapter, which include &#8220;I. Overview of hereditary colorectal cancers,&#8221; &#8220;II. Familial adenomatous polyposis,&#8221; and &#8220;III. Lynch syndrome.&#8221; Clinical topics for which insufficient data were available from the literature search are also included in each chapter. The outline, diagnosis, treatment, and surveillance of these diseases are described with the abundant use of flowcharts, figures, and tables. Easy-to-understand explanations are added as side notes when possible, given the specific characteristics of HCRC, to ensure correct understanding of the disease characteristics and terminology.</p></sec></sec><sec id="Sec14"><title>Chapter I. Overview of hereditary colorectal cancers</title><sec id="Sec15"><title>Basic concepts</title><sec id="Sec16"><title>Definition</title><p id="Par29">Hereditary colorectal cancers (HCRCs) are disorders for which causative genes have been identified that increase the risk of colorectal cancer (CRC). In HCRCs, the mode of inheritance, density of colorectal polyps, histological type, risk of CRC, and extra-colorectal manifestations vary depending on the causative gene. Table <xref rid="Tab4" ref-type="table">4</xref> summarizes the molecular genetic characteristics and clinicopathological features of the representative HCRCs.
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>Genetic and clinical characteristics of representative hereditary colorectal cancers.&#160;<italic toggle="yes">FAP</italic>, familial adenomatous polyposis; <italic toggle="yes">AFAP</italic>, attenuated familial adenomatous polyposis; <italic toggle="yes">GAPPS</italic>, gastric adenocarcinoma and proximal polyposis of the stomach; <italic toggle="yes">MAP</italic>, <italic toggle="yes">MUTYH</italic>-associated polyposis; <italic toggle="yes">PPAP</italic>, polymerase proofreading-associated polyposis; <italic toggle="yes">CMMRD</italic>, constitutional mismatch repair deficiency; <italic toggle="yes">PJS</italic>, Peutz-Jeghers syndrome; <italic toggle="yes">JPS</italic>, juvenile polyposis syndrome; <italic toggle="yes">HMPS</italic>, hereditary mixed polyposis syndrome; <italic toggle="yes">CS/PHTS</italic>, Cowden syndrome/<italic toggle="yes">PTEN</italic> hamartoma tumor syndrome; <italic toggle="yes">SPS</italic>, serrated polyposis syndrome; <italic toggle="yes">AD</italic>, autosomal dominant; <italic toggle="yes">AR</italic>, autosomal recessive; <italic toggle="yes">NA</italic>, not applicable</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Polyposis</th><th align="left" colspan="1" rowspan="1">Disorder</th><th align="left" colspan="1" rowspan="1">mode of inheritance</th><th align="left" colspan="1" rowspan="1">Causative gene</th><th align="left" colspan="1" rowspan="1">Prevalence</th><th align="left" colspan="1" rowspan="1">Number of colonic polyps</th><th align="left" colspan="1" rowspan="1">Histology</th><th align="left" colspan="1" rowspan="1">Risk of colorectal cancer</th><th align="left" colspan="1" rowspan="1">Extra-colonic polyposis</th><th align="left" colspan="1" rowspan="1">Extra-colonic neoplasms</th></tr></thead><tbody><tr><td align="left" rowspan="11" colspan="1">Adenomatous polyposis</td><td align="left" colspan="1" rowspan="1">FAP</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">APC</italic></td><td align="left" rowspan="2" colspan="1">1/20,000&#8201;~&#8201;1/10,000</td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>100</td><td align="left" colspan="1" rowspan="1">adenoma</td><td align="left" colspan="1" rowspan="1">100%</td><td align="left" rowspan="2" colspan="1">stomach, duodenum</td><td align="left" rowspan="2" colspan="1">gastric cancer, duodenal (papillary) cancer, desmoid tumor, papillary thyroid cancer, brain tumor, hepatoblastoma, etc</td></tr><tr><td align="left" colspan="1" rowspan="1">AFAP</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">APC</italic></td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>10,&#8201;&lt;&#8201;100</td><td align="left" colspan="1" rowspan="1">adenoma</td><td align="left" colspan="1" rowspan="1">70%</td></tr><tr><td align="left" colspan="1" rowspan="1">GAPPS</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">APC</italic> (1B)</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">adenoma</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">stomach</td><td align="left" colspan="1" rowspan="1">gastric cancer</td></tr><tr><td align="left" colspan="1" rowspan="1">MAP</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">MUTYH</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;100</td><td align="left" colspan="1" rowspan="1">adenoma, HP</td><td align="left" colspan="1" rowspan="1">70&#8201;~&#8201;90%</td><td align="left" colspan="1" rowspan="1">duodenum</td><td align="left" colspan="1" rowspan="1">duodenal (papillary) cancer, papillary thyroid cancer, sebaceous tumor, etc</td></tr><tr><td align="left" colspan="1" rowspan="1">PPAP</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">POLD1</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>30,&#8201;&lt;&#8201;100</td><td align="left" colspan="1" rowspan="1">adenoma</td><td align="left" colspan="1" rowspan="1">&#8201;&gt;&#8201;20%</td><td align="left" colspan="1" rowspan="1">duodenum</td><td align="left" colspan="1" rowspan="1">endometrial cancer, breast cancer, brain tumor</td></tr><tr><td align="left" colspan="1" rowspan="1">PPAP</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">POLE</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>30,&#8201;&lt;&#8201;100</td><td align="left" colspan="1" rowspan="1">adenoma</td><td align="left" colspan="1" rowspan="1">&#8201;&gt;&#8201;20%</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">duodenal cancer, brain tumor</td></tr><tr><td align="left" colspan="1" rowspan="1">CMMRD syndrome</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">MLH1, MSH2, MSH6, PMS2</italic></td><td align="left" colspan="1" rowspan="1">1/1,000,000&#8201;~&#8201;3/1,000,000</td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>10,&#8201;&lt;&#8201;100</td><td align="left" colspan="1" rowspan="1">adenoma</td><td align="left" colspan="1" rowspan="1">80&#8201;~&#8201;95%</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">hematological tumor, brain tumor</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">MSH3</italic>-associated polyposis</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">MSH3</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>30,&#8201;&lt;&#8201;100</td><td align="left" colspan="1" rowspan="1">adenoma</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">duodenum</td><td align="left" colspan="1" rowspan="1">goiter, intraductal papilloma, gastric cancer, brain tumor, etc</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">MLH3</italic>-associated polyposis</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">MLH3</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>30,&#8201;&lt;&#8201;100</td><td align="left" colspan="1" rowspan="1">adenoma</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">NTHL1</italic>-associated polyposis</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">NTHL1</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>1,&#8201;&lt;&#8201;100</td><td align="left" colspan="1" rowspan="1">adenoma</td><td align="left" colspan="1" rowspan="1">&#8201;&gt;&#8201;20%</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">breast cancer, endometrial cancer, bladder cancer, HNSCC, skin cancer, etc</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">AXIN2</italic>-associated polyposis</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">AXIN2</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;100</td><td align="left" colspan="1" rowspan="1">adenoma</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" rowspan="4" colspan="1">Hamartomatous polyposis</td><td align="left" colspan="1" rowspan="1">PJS</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">STK11</italic></td><td align="left" colspan="1" rowspan="1">1/280,000&#8201;~&#8201;1/8,300</td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>5</td><td align="left" colspan="1" rowspan="1">hamartoma</td><td align="left" colspan="1" rowspan="1">39%</td><td align="left" colspan="1" rowspan="1">stomach, small bowel</td><td align="left" colspan="1" rowspan="1">gastric cancer, small bowel cancer, pancreatic cancer, breast cancer, adenocarcinoma of the cervix, etc</td></tr><tr><td align="left" colspan="1" rowspan="1">JPS, HMPS</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">BMPR1A</italic></td><td align="left" rowspan="2" colspan="1">1/100,000&#8201;~&#8201;1/16,000</td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>5</td><td align="left" colspan="1" rowspan="1">hamartoma</td><td align="left" colspan="1" rowspan="1">40&#8201;~&#8201;50%</td><td align="left" colspan="1" rowspan="1">stomach, small bowel</td><td align="left" rowspan="2" colspan="1">gastric cancer, small bowel cancer, pancreatic cancer, etc</td></tr><tr><td align="left" colspan="1" rowspan="1">JPS</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">SMAD4</italic></td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>5</td><td align="left" colspan="1" rowspan="1">hamartoma</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;50%</td><td align="left" colspan="1" rowspan="1">stomach, small bowel</td></tr><tr><td align="left" colspan="1" rowspan="1">CS/PHTS</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">PTEN</italic></td><td align="left" colspan="1" rowspan="1">1/200,000</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;100</td><td align="left" colspan="1" rowspan="1">hamartoma</td><td align="left" colspan="1" rowspan="1">11&#8201;~&#8201;20%</td><td align="left" colspan="1" rowspan="1">stomach, small bowel</td><td align="left" colspan="1" rowspan="1">breast cancer, endometrial cancer, thyroid follicular carcinoma, renal cell carcinoma, etc</td></tr><tr><td align="left" colspan="1" rowspan="1">Serrated polyposis</td><td align="left" colspan="1" rowspan="1">SPS</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">RNF43</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>5,&#8201;&lt;&#8201;100</td><td align="left" colspan="1" rowspan="1">SL</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Mixed polyposis</td><td align="left" colspan="1" rowspan="1">HMPS</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">GREM1</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">adenoma, HP, inflammatory</td><td align="left" colspan="1" rowspan="1">11&#8201;~&#8201;20%</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" rowspan="13" colspan="1">Non-polyposis</td><td align="left" rowspan="5" colspan="1">LS</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">MLH1</italic></td><td align="left" rowspan="5" colspan="1">1&#8201;~&#8201;4% of colorectal cancer</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">adenoma, SSL</td><td align="left" colspan="1" rowspan="1">46&#8201;~&#8201;61%</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" rowspan="5" colspan="1">endometrial cancer, gastric cancer, ovarian cancer, small bowel cancer, biliary tract cancer, pancreatic cancer, upper urinary tract cancer, brain tumor, sebaceous tumor, etc</td></tr><tr><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">MSH2</italic></td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">adenoma, SSL</td><td align="left" colspan="1" rowspan="1">33&#8201;~&#8201;52%</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">MSH6</italic></td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">adenoma, SSL</td><td align="left" colspan="1" rowspan="1">10&#8201;~&#8201;44%</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">PMS2</italic></td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">adenoma, SSL</td><td align="left" colspan="1" rowspan="1">8.7&#8201;~&#8201;20%</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">EPCAM</italic></td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">adenoma</td><td align="left" colspan="1" rowspan="1">33&#8201;~&#8201;52%</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">LFS</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">TP53</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8201;&gt;&#8201;20%</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">bone and soft tissue sarcoma, adrenocortical tumor, brain tumor, leukemia, breast cancer, etc</td></tr><tr><td align="left" colspan="1" rowspan="1">BHDS</td><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">FLCN</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">renal cell carcinoma</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><italic toggle="yes">MUTYH</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">10&#8201;~&#8201;13%</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><italic toggle="yes">ATM</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">5&#8201;~&#8201;10%</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><italic toggle="yes">BLM</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">5&#8201;~&#8201;10%</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><italic toggle="yes">CHEK2</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">5&#8201;~&#8201;10%</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><italic toggle="yes">GALNT12</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">5&#8201;~&#8201;10%</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><italic toggle="yes">RPS20</italic></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec17"><title>Classification</title><p id="Par30">HCRCs are classified into two groups, namely, polyposis and non-polyposis. HCRCs with polyposis are further classified into adenomatous, hamartomatous, and serrated polyposis according to histological type.<list list-type="bullet"><list-item><p id="Par31">Adenomatous polyposis is defined as&#8201;&#8805;&#8201;10 adenomatous polyps in the colon and rectum. It is sometimes classified as severe/profuse/dense type (&#8805;&#8201;1,000&#8211;2,000), sparse type (100&#8211;1,000), or attenuated type (10&#8211;100) based on the number of polyps. However, the number of polyps observed depends on the patient's age, the use of high-resolution endoscopy, chromoendoscopy, and image enhanced endoscopy, including spraying dye and narrow-band imaging, and the physician. Patients with thousands of adenomatous polyps are often diagnosed with familial adenomatous polyposis (FAP), which frequently involves gastric and duodenal polyps. In patients with an attenuated type, it is difficult to estimate the causative gene because there are numerous conditions characterized by the development of 10&#8211;100 polyps, including FAP, <italic toggle="yes">MUTYH</italic>-associated polyposis, polymerase proofreading-associated polyposis, constitutional mismatch repair deficiency syndrome, <italic toggle="yes">MSH3</italic>-associated polyposis, <italic toggle="yes">MLH3</italic>-associated polyposis, and <italic toggle="yes">NTHL1</italic>-associated polyposis. Furthermore, these HCRCs sometimes involve more than 100 polyps. Therefore, it is difficult to diagnose HCRC as adenomatous polyposis based on the number of polyps alone. In terms of the mode of inheritance, adenomatous polyposis caused by a germline pathogenic variant (GPV) in any of the <italic toggle="yes">APC</italic>, <italic toggle="yes">POLE</italic>, <italic toggle="yes">POLD1</italic>, or <italic toggle="yes">AXIN2</italic> genes is inherited in an autosomal dominant manner, whereas other adenomatous polyposis conditions are inherited in an autosomal recessive manner.</p></list-item><list-item><p id="Par32">Hamartomatous polyposis syndrome occasionally involves fewer than 10 colorectal polyps. Representative hamartomatous polyposis syndromes include Peutz-Jeghers syndrome, juvenile polyposis syndrome, and Cowden syndrome/<italic toggle="yes">PTEN</italic> hamartoma tumor syndrome, which are distinguished by histological type. Patients with hamartomatous polyposis syndrome develop multiple polyps in the stomach and small intestine (including the duodenum) and other features, such as lip pigmentation or macrocephaly, depending on the syndrome [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>].</p></list-item><list-item><p id="Par33">Serrated polyposis syndrome includes the development of various types of polyps, including hyperplastic polyps and serrated lesions. Some patients with this syndrome have GPVs of <italic toggle="yes">RNF43</italic>, <italic toggle="yes">GREM1</italic>, and <italic toggle="yes">MUTYH</italic> [<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref>]; however, the causative genes are not well defined. Environmental factors may also be involved in the development of serrated polyps.</p></list-item></list></p><p id="Par34">HCRCs without polyposis include Lynch syndrome and Li&#8211;Fraumeni syndrome, neither of which has a characteristic appearance. Therefore, patients with these syndromes cannot be diagnosed with HCRC based on clinicopathological factors.</p></sec><sec id="Sec18"><title>Epidemiology</title><p id="Par35">Approximately 30% of patients with CRC have familial clustering of CRC or GPVs of cancer predisposition genes (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Patients with autosomal recessive inheritance, somatic mosaicism, or autosomal dominant inheritance de novo do not have familial clustering of CRC.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Percentage of genetically predisposed colorectal cancers among all colorectal cancers. FAP, familial adenomatous polyposis; CS/PHTS, Cowden syndrome/<italic toggle="yes">PTEN</italic> hamartoma tumor syndrome; LFS, Li-Fraumeni syndrome; JPS, juvenile polyposis syndrome; MAP, <italic toggle="yes">MUTYH</italic>-associated polyposis; PJS, Peutz-Jeghers syndrome</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig1_HTML.jpg"/></fig></p><p id="Par36">According to studies of germline multi-gene panel testing (<sup>*</sup>MGPT) for CRC patients, FAP accounts for 0.5% and Lynch syndrome for 3% of cases, with GPVs in <italic toggle="yes">ATM</italic>, <italic toggle="yes">CHEK2</italic>, <italic toggle="yes">MUTYH</italic>, and <italic toggle="yes">TP53</italic> also observed, resulting in approximately 5% of CRCs being HCRC [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Furthermore, <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic>, which are causative genes for hereditary breast and ovarian cancers, have each been detected in 1% of patients, and <italic toggle="yes">PALB2</italic>, <italic toggle="yes">BRIP1</italic>, <italic toggle="yes">NBN</italic>, and <italic toggle="yes">RAD51D</italic> were detected in 3% overall. Therefore, approximately 10% of patients with CRC are estimated to have a hereditary cancer predisposition syndrome.</p><p id="Par37"><sup>*</sup>Unless otherwise specified, &#8220;MGPT&#8221; refers to &#8220;germline MGPT.&#8221;</p></sec><sec id="Sec19"><title>Risk of tumorigenesis</title><p id="Par38">The risk of developing CRC depends on the type of HCRC. Not all patients with genetic predispositions will develop CRC, with the exception of typical FAP, which has almost 100% penetrance. Furthermore, the risk of developing CRC depends on the causative gene, even within the same syndrome, as in Lynch syndrome [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par39">Patients with HCRC are also at high risk of developing extra-colorectal tumors or lesions, known as associated lesions. FAP-associated tumors (lesions) include fundic gland polyposis and duodenal adenoma, while Lynch syndrome is associated with gynecological and urological tumors. These associated lesions develop in an organ-specific manner. Moreover, some patients with HCRC develop associated lesions before development of CRC. For example, approximately 35% of women with Lynch syndrome reportedly develop endometrial cancer as a sentinel cancer [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Therefore, a multidisciplinary approach involving gastroenterology, colorectal surgery, and other departments is critical in the surveillance of HCRC.</p></sec><sec id="Sec20"><title>Mechanisms of carcinogenesis</title><p id="Par40">All of the causative genes for HCRC identified to date are tumor suppressor genes, and their functions include inhibiting cell proliferation (e.g., <italic toggle="yes">APC</italic>, <italic toggle="yes">TP53</italic>, <italic toggle="yes">PTEN</italic>, and <italic toggle="yes">SMAD4</italic>) or DNA repair (e.g., <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, and <italic toggle="yes">MUTYH</italic>). Thus, variants considered pathogenic in HCRC are those that result in loss of function of the causative genes, including truncating variants, loss of heterozygosity, large duplications/deletions, and pathogenic missense variants.</p><p id="Par41">In autosomal dominant HCRCs, in addition to the GPV of the causative gene, an acquired pathogenic variant in the wild-type allele results in loss of function of the corresponding protein, causing the associated tumor [<xref ref-type="bibr" rid="CR12">12</xref>]. Multiple tumors develop at a younger age in patients with HCRC than in those with sporadic CRC because all the cells carry a pathogenic variant in one allele of the causative gene (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Tumorigenesis mechanism in the two-hit theory of tumor suppressor genes based on Knudson's two-hit theory</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig2_HTML.jpg"/></fig></p><p id="Par42">Development of CRC in FAP is explained by the multistep model of carcinogenesis. Initially, loss of function of the APC protein in colonic epithelial cells results in accumulation of &#946;-catenin in the cytoplasm, which increases its translocation into the nucleus, where it forms a complex with TCF4, promoting transcription of oncogenes leading to cell proliferation. Morphologically, this process is thought to give rise to aberrant crypt foci as the initial lesion. Additional genetic alterations, such as those in <italic toggle="yes">KRAS</italic> and <italic toggle="yes">TP53</italic>, are required for progression from aberrant crypt foci to adenoma and eventually to CRC. This process is associated with a condition known as chromosomal instability, which predisposes cells to genetic abnormalities (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Representative tumorigenesis mechanisms in familial adenomatous polyposis and Lynch syndrome. FAP, familial adenomatous polyposis</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig3_HTML.jpg"/></fig></p><p id="Par43">Development of CRC in Lynch syndrome involves disruption of the mismatch repair system. DNA replication during cell division is highly accurate, with an error rate of 10<sup>&#8211;10</sup> to 10<sup>&#8211;8</sup>. However, in the event of replication errors, mismatch repair proteins encoded by the causative genes for Lynch syndrome identify these errors, including mismatches and small insertions/deletions. When an additional acquired pathogenic variant occurs alongside the GPV in a mismatch repair gene, the mismatch repair system becomes defective, losing its ability to detect replication errors. These replication errors frequently occur in microsatellite regions, which are repetitive sequences of up to a few bases within the genome. Some genes containing these repetitive sequences code for proteins involved in tumor suppression (e.g., <italic toggle="yes">TGFBR2</italic>), cellular proliferation, DNA repair (e.g., <italic toggle="yes">MSH3</italic>, <italic toggle="yes">MSH6</italic>), and apoptosis (e.g., <italic toggle="yes">BAX</italic>). Disruption of the mismatch repair system leads to microsatellite instability (MSI), resulting in accumulation of variants in these genes and development of tumors.</p><p id="Par44">Autosomal recessive HCRCs increase the risk of developing cancer when each of the alleles with a GPV is inherited from parents who are carriers of a GPV of the causative gene. The causative genes for autosomal recessive HCRC are involved in DNA repair, so tumors develop because of the inability to repair certain types of DNA damage.</p></sec></sec><sec id="Sec21"><title>Diagnosis</title><sec id="Sec22"><title>Significance of diagnosis</title><p id="Par45">HCRCs are diagnosed by genetic testing because some HCRCs have a similar phenotype. However, some of the HCRCs can be diagnosed by their characteristic phenotype. The mode of inheritance, penetrance of malignant tumors, associated tumors (lesions), and surveillance depend on the causative gene. The diagnosis is useful for risk assessment and estimation of the risk of recurrence in relatives.</p><p id="Par46">Genetic counseling should be provided at appropriate times during genetic testing and diagnosis and involves the provision of information as well as psychological and social support that allows patients and clinicians to make informed choices. This process is best performed as a team effort by experienced physicians and professionals skilled in genetic counseling [<xref ref-type="bibr" rid="CR13">13</xref>]. Providing detailed information on the suspected disease and the benefits and limitations of testing is essential before proceeding with genetic tests.</p></sec><sec id="Sec23"><title>Diagnostic process</title><p id="Par47">HCRC is diagnosed in a three-step process: risk assessment based on clinical information (step 1), pathological and molecular pathological assessments (step 2), and genetic testing (step 3) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Risk assessment of hereditary colorectal cancer. MMR-IHC, mismatch repair-immunohistochemistry; MSI, microsatellite instability</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig4_HTML.jpg"/></fig></p><p id="Par48">Step 1: Risk assessment based on clinical information</p><p id="Par49">The first step in the diagnosis of HCRC is risk assessment based on clinical information, including (1) early onset, (2) synchronous/metachronous CRC, (3) history of malignancy other than CRC, (4) physical features, and (5) a maternal and paternal family history of up to a third-degree relative (at least second-degree relative) with CRC (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>).</p><p id="Par50">Patients with HCRC often develop extra-colorectal lesions, which may include dental abnormalities, lip pigmentation, and macrocephaly, findings of which help with diagnosis and estimation of the causative gene. The current trend toward nuclear families may make it difficult to obtain information concerning even second-degree relatives. Therefore, we recommend collecting the information needed to distinguish the paternal and maternal sides to create a pedigree and assess the mode of inheritance. The presence of associated tumors is a key point in screening, particularly in patients with HCRC without polyposis.</p><p id="Par51">Endoscopic findings in the gastrointestinal tract are crucial in the diagnosis of HCRC. Therefore, the number, type, and location of polyps detected by both lower and upper gastrointestinal endoscopy should be accurately recorded.</p><p id="Par52">If HCRC is suspected based on clinical information, clinicians should proceed to step 2 and then to step 3 if a patient with CRC has a family member already diagnosed with HCRC and their phenotype matches that of the disease [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par53">Step 2: Pathological and molecular pathological assessments</p><p id="Par54">Patients with polyposis should undergo biopsy for pathologic assessment. The process for diagnosing hereditary colorectal polyposis based on histological findings is summarized in Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref> and Table&#160;<xref rid="Tab5" ref-type="table">5</xref>. Each type of polyposis, including adenomatous, hamartomatous, and serrated, has several differential conditions and candidate causative genes.<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Flowchart of the diagnosis of hereditary colorectal polyposis.&#160;<italic toggle="yes">GPVs</italic>, germline pathogenic variants; <italic toggle="yes">FAP</italic>, familial adenomatous polyposis; <italic toggle="yes">MAP</italic>, <italic toggle="yes">MUTYH</italic>-associated polyposis; <italic toggle="yes">PPAP</italic>, polymerase proofreading-associated polyposis; <italic toggle="yes">MSH3</italic>-<italic toggle="yes">AP</italic>, <italic toggle="yes">MSH3</italic>-associated polyposis; <italic toggle="yes">NTHL1</italic>-<italic toggle="yes">AP</italic>, <italic toggle="yes">NTHL1</italic>-associated polyposis; <italic toggle="yes">CPUE</italic>, colonic adenomatous polyposis of unknown etiology; <italic toggle="yes">PJS</italic>, Peutz-Jeghers syndrome; <italic toggle="yes">JPS</italic>, juvenile polyposis syndrome; <italic toggle="yes">HMPS</italic>, hereditary mixed polyposis syndrome; <italic toggle="yes">CS/PHTS</italic>, Cowden syndrome/<italic toggle="yes">PTEN</italic> hamartoma tumor syndrome; <italic toggle="yes">SPS</italic>, serrated polyposis syndrome</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig5_HTML.jpg"/></fig><table-wrap id="Tab5" position="float" orientation="portrait"><label>Table&#160;5</label><caption><p>Classification of polyposis and diseases to be differentiated</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Colonoscopy findings</th><th align="left" colspan="1" rowspan="1">Histology</th><th align="left" colspan="1" rowspan="1">Number of polyps</th><th align="left" colspan="1" rowspan="1">Diseases to be differentiated</th><th align="left" colspan="1" rowspan="1">Candidate causative genes</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Adenomatous polyposis</td><td align="left" colspan="1" rowspan="1">Adenoma</td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>10</td><td align="left" colspan="1" rowspan="1">FAP, MAP, PPAP, CMMRD syndrome</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">APC, MUTYH, POLD1, POLE, MLH1, MSH2, MSH6, PMS2, MSH3, MLH3, NTHL1, AXIN2</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Hamartomatous polyposis</td><td align="left" colspan="1" rowspan="1">Hamartoma</td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>2</td><td align="left" colspan="1" rowspan="1">PJS, JPS, CS/PHTS, HMPS</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">STK11, BMPR1A, SMAD4, PTEN</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Serrated polyposis</td><td align="left" colspan="1" rowspan="1">HP, SSL</td><td align="left" colspan="1" rowspan="1"><underline>&#8201;&gt;&#8201;</underline>5 in the oral side of the sigmoid colon</td><td align="left" colspan="1" rowspan="1">SPS, MAP</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">RNF43, MUTYH, GREM1</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Mixed polyposis</td><td align="left" colspan="1" rowspan="1">JP, HP, SSL</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">HMPS, JP</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">GREM1, BMPR1A</italic></td></tr></tbody></table><table-wrap-foot><p>PJP, Peutz&#8211;Jeghers polyp; JP, juvenile polyp; HP, hyperplastic polyp; SSL, sessile serrated lesion; FAP, familial adenomatous polyposis; MAP, <italic toggle="yes">MUTYH</italic>-associated polyposis; PPAP, polymerase proofreading-associated polyposis; CMMRD, constitutional mismatch repair deficient; PJS, Peutz&#8211;Jeghers syndrome; JPS, juvenile polyposis syndrome; HMPS, hereditary mixed polyposis syndrome; CS, Cowden syndrome; PHTS, <italic toggle="yes">PTEN</italic> hamartoma tumor syndrome; SPS, serrated polyposis syndrome</p></table-wrap-foot></table-wrap></p><p id="Par55">Patients with a non-polyposis syndrome should undergo MSI or mismatch repair immunohistochemistry testing using CRC tissue, given that most CRCs associated with Lynch syndrome show MSI-High or loss of expression of mismatch repair proteins corresponding to the causative gene. However, regardless of the results, clinicians should proceed to step 3 if the patient&#8217;s family history indicates a high incidence of Lynch syndrome-associated tumors.</p><p id="Par57">Step 3: Genetic testing</p><p id="Par58">Genetic testing for diagnosis of HCRC involves analysis of DNA extracted from whole blood to detect the GPV of the causative gene, which allows estimation of the cancer risk. The results are useful for informed consent and surveillance [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>] and can also be used to diagnose relatives.</p><p id="Par59">Genetic testing for HCRC includes (1) direct sequencing, (2) multiplex ligation-dependent probe amplification (MLPA), (3) targeted sequencing by MGPT, (4) whole-exome sequencing, and (5) whole-genome sequencing (Table&#160;<xref rid="Tab6" ref-type="table">6</xref>).
<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table&#160;6</label><caption><p>Types of germline genetic tests for diagnosis of hereditary colorectal cancer</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="1" rowspan="1">Direct sequencing (Sanger sequencing)</td></tr><tr><td align="left" colspan="1" rowspan="1">e.g., Diagnosis of relatives, including asymptomatic individuals (Relative Diagnosis)</td></tr><tr><td align="left" colspan="1" rowspan="1">Multiplex Ligation-dependent Probe Amplification(MLPA)</td></tr><tr><td align="left" colspan="1" rowspan="1">e.g., Diagnosis of relatives, including asymptomatic individuals (Relative Diagnosis)</td></tr><tr><td align="left" colspan="1" rowspan="1">Multi-gene panel testing (Target sequencing)</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>e.g., <italic toggle="yes">MLH1, MSH2, MSH6, PMS2, EPCAM</italic> for Lynch syndrome</p><p>e.g., <italic toggle="yes">APC, MUTYH, POLD1, POLE, MLH1, MSH2, MSH6, PMS2, MSH3, MLH3, NTHL1, AXIN2</italic> for adenomatous polyposis</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Whole exome sequencing</td></tr><tr><td align="left" colspan="1" rowspan="1">e.g., Genetic testing for colorectal cancer patients with atypical phenotypes</td></tr><tr><td align="left" colspan="1" rowspan="1">Whole genome sequencing</td></tr><tr><td align="left" colspan="1" rowspan="1">e.g., Genetic testing for colorectal cancer patients suspected of having inversions or translocations in causative genes that result in pseudo-exon generation</td></tr></tbody></table></table-wrap></p><p id="Par60">Direct sequencing reads the base sequence of the exons and exon&#8211;intron boundary regions encoding the protein of the suspected causative gene one base at a time. MLPA detects large deletions or duplications by adding specific probes to each exon. Direct sequencing or MLPA is used when the causative gene is strongly suspected. However, pathogenic variants in <italic toggle="yes">APC</italic> may not be detected, even in cases with thousands of adenomatous polyps. For diagnosis of relatives, it is sufficient to analyze only the pathogenic variant identified in the proband (single-site analysis); therefore, direct sequencing or MLPA is used depending on the variant to be detected. Targeted sequencing by MGPT generates a panel of candidate causative genes for HCRC, which are then analyzed by next-generation sequencing. Targeted sequencing by MGPT is now widely used because multiple causative genes are often suspected based on clinical findings in HCRCs. Genes should be analyzed such as <italic toggle="yes">APC</italic>, <italic toggle="yes">MUTYH</italic>, <italic toggle="yes">POLD1</italic>, and <italic toggle="yes">POLE</italic> for adenomatous polyposis and <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, <italic toggle="yes">MSH6</italic>, <italic toggle="yes">PMS2</italic>, and <italic toggle="yes">EPCAM</italic> for Lynch syndrome. Targeted sequencing allows the simultaneous analysis of multiple genes, with the addition of <italic toggle="yes">BRCA1/2</italic> to MGPT for diagnosis of hereditary breast and ovarian cancers [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Whole-exome sequencing analyzes all exons and exon&#8211;intron boundary regions of all genes, whereas whole-genome sequencing analyzes all regions, including introns, using next-generation sequencing. Therefore, these sequences sometimes detect hereditary diseases unrelated to tumor development. Whole-genome sequencing can also detect genetic alterations, such as translocations or inversions, that are difficult to detect using other sequencing methods.</p><p id="Par61">In HCRC with somatic mosaicism, only some cells in the body have pathogenic variants, potentially resulting in variant frequencies that fall below the detection sensitivity of direct sequencing. However, next-generation sequencing can detect variants at low frequencies, making it useful for diagnosing somatic mosaicism.</p><p id="Par62">MGPT has been reported to identify GPVs in approximately 20% of patients with CRC under 50 years of age [<xref ref-type="bibr" rid="CR19">19</xref>]. The National Comprehensive Cancer Network Guidelines (version 2. 2023) [<xref ref-type="bibr" rid="CR9">9</xref>] recommend MGPT-based targeted sequencing for all patients with CRC under 50 years of age, whereas MSI-High/deficient mismatch repair (dMMR) is recommended for patients older than 50 years. Therefore, genetic testing using targeted sequencing by MGPT is highly recommended for suspected cases of HCRC.</p></sec><sec id="Sec24"><title>Germline (secondary) findings in cancer genome profiling tests</title><p id="Par63">In some patients, HCRCs are diagnosed or suspected based on germline findings in comprehensive cancer genomic profiling tests. Pathogenic variants identified in normal samples are considered to be GPVs. Genetic testing is required when presumed GPVs are detected in tumor-only testing.</p></sec><sec id="Sec25"><title>Interpretation of genetic test results</title><p id="Par64">The clinical relevance of detected variants is generally assessed using classifications from ClinVar (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/">https://www.ncbi.nlm.nih.gov/clinvar/</ext-link>) or InSiGHT (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.insightgroup.org/variants/databases/">https://www.insightgroup.org/variants/databases/</ext-link>) (Table&#160;<xref rid="Tab7" ref-type="table">7</xref>).
<table-wrap id="Tab7" position="float" orientation="portrait"><label>Table&#160;7</label><caption><p>Classification of Gene Variants in Public Databases</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">ClinVar/Clinical significance value</th><th align="left" colspan="1" rowspan="1">InSiGHT/MMR gene variant classification criteria</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Pathogenic</td><td align="left" colspan="1" rowspan="1">Class 5 Pathogenic</td></tr><tr><td align="left" colspan="1" rowspan="1">Likely pathogenic</td><td align="left" colspan="1" rowspan="1">Class 4 Likely pathogenic</td></tr><tr><td align="left" colspan="1" rowspan="1">Uncertain significance</td><td align="left" colspan="1" rowspan="1">Class 3 Uncertain significance</td></tr><tr><td align="left" colspan="1" rowspan="1">Likely benign</td><td align="left" colspan="1" rowspan="1">Class 2 Likely not pathogenic/little clinical significance</td></tr><tr><td align="left" colspan="1" rowspan="1">Benign</td><td align="left" colspan="1" rowspan="1">Class 1 Not pathogenic/no clinical significance</td></tr></tbody></table><table-wrap-foot><p>InSiGHT, International Society for Gastrointestinal Hereditary Tumours; MMR, mismatch repair</p></table-wrap-foot></table-wrap></p><p id="Par65">A) &#8220;Pathogenic variant or likely pathogenic variant&#8221;.</p><p id="Par66">The genetic disorder is managed medically. However, it should be understood that individuals who have a pathogenic variant will not always develop cancer during their lifetime, except for diseases that have nearly 100% penetrance, such as FAP.</p><p id="Par67">B) &#8220;Variants of uncertain significance were detected&#8221;.</p><p id="Par68">Genetic changes with unknown implications for the development of disease are reported as variants of uncertain significance. Examples include silent variants (where a single change in the base sequence does not affect amino acid synthesis) or missense variants (where amino acid substitution occurs), which do not affect the likelihood of disease development. In such cases, the recommendation is to proceed in accordance with the following section on &#8220;Genetic abnormalities are not detected&#8221; until the significance of this variant is known.</p><p id="Par69">C) &#8220;Genetic abnormalities are not detected&#8221;.</p><p id="Par70">When no genetic abnormalities are confirmed in the family.</p><p id="Par71">If the same genetic changes are not found in other members of a pedigree when a definitive diagnosis is obtained by genetic testing, it is determined that it is not a genetic disease. However, the risk of tumorigenesis in the general population should still be understood in such cases.</p><p id="Par72">When no diagnosis is made in the family</p><p id="Par73">Given that some variants cannot be detected by genetic testing or may result from abnormalities in unknown causative genes, these cases should be treated with caution. For example, the clinical detection rate of pathogenic variants of APC even in FAP with 100&#8211;1000 polyps does not reach 100%, with values of approximately 60% [20]. Therefore, the possibility that unknown variants have not been detected because of technical problems or the presence of other gene abnormalities must be considered. In clinical practice, such cases should ideally be managed in the same way as patients with diseases that are considered to be hereditary, even when no pathogenic variant is detected by genetic testing.</p></sec></sec><sec id="Sec26"><title>Genetic counseling</title><sec id="Sec27"><title>Definition</title><p id="Par74">Genetic counseling is the process of helping individuals to understand and adjust to the medical, psychological, and family implications of a genetic disease. This process includes (1) interpretation of family and medical histories to assess the likelihood of disease occurrence and recurrence; (2) education about genetic phenomena, testing, management, prevention, resources, and research; and (3) counseling to promote informed choices and adaptation to risks and circumstances [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec28"><title>Risk communication and decision-making support</title><p id="Par75">In genetic counseling for cancer, it is important to assess the risk of hereditary tumor syndromes and provide accurate and easy-to-understand information for patients and their families. Risk communication in genetic counseling helps patients and their families to understand complex genetic information, make informed choices about their health, and improve their quality of life.</p><p id="Par76">When patients with hereditary tumor syndromes and their families face psychosocial issues, decision-making is an important aspect of helping them to cope with and move forward from these challenges. Shared decision-making is a collaborative process in which healthcare professionals and patients work together to make health decisions. It involves discussing the available options, benefits, and risks while considering the patient's values, preferences, and circumstances.</p><p id="Par77">In view of the diverse and complex psychosocial issues faced by patients and their families, multiple specialists with appropriate expertise should be involved in providing decision-making support.</p></sec><sec id="Sec29"><title>Psychosocial issues</title><p id="Par78">The specific psychosocial issues faced by individuals undergoing genetic counseling for cancer include coping with the risk of cancer, practical, family, and children-related considerations, living with cancer, and emotions [<xref ref-type="bibr" rid="CR20">20</xref>]. These issues should be identified as early as possible in genetic counseling, and patients and their families should be supported to cope with and adapt to them within the framework of a multidisciplinary team.</p></sec><sec id="Sec30"><title>Approaches</title><p id="Par79">Genetic counseling about hereditary tumor syndromes and genetic testing provides accurate medical information as well as opportunities for clients to discuss their concerns and anxieties and the support required for autonomous decision-making. A receptive attitude, non-directiveness, and empathy are essential in genetic counseling. Healthcare professionals should keep in mind that each client has their own individual preferences, sensitivities, prior knowledge, comprehension, level of anxiety, and trust in medical care.</p><p id="Par80">All physicians should possess fundamental knowledge and skills in genetic counseling. Healthcare providers and institutions offering genetic testing should ensure the provision of appropriate genetic specialists for their clients as necessary. When genetic counseling services are unavailable at the primary hospital, clients should be referred to genetic specialists at an appropriate external facility [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec31"><title>Obtaining medical information from the client</title><p id="Par81">In genetic counseling, medical information should be obtained from the client and their family for accurate risk assessment. The information gathered during genetic counseling includes medical history, family history, needs regarding genetic counseling, awareness of the disease, values, and psychosocial aspects.</p></sec><sec id="Sec32"><title>Contents of information provided</title><p id="Par82">Clients require a considerable amount of information about cancer and heredity in order for them to have an accurate understanding of hereditary colorectal cancer. The information provided includes an overview of hereditary tumors and genetic testing, and the social resources available. The psychosocial impact of a genetic test result should also be considered. The clinical significance of genetic testing should be explained in advance, so that the client can understand its advantages and disadvantages. The advantages are that it provides a definitive diagnosis, requires taking only a small amount of blood, and can be used for diagnosis regardless of whether or not there is a family history of cancer, for surveillance of other diseases that may develop, and for identification of biological relatives who may carry the same pathogenic variant. The disadvantages of genetic testing include certain diagnostic limitations, the possibility that it may not be able to etect or predict the onset of a specific disease, lack of insurance coverage, psychological effects, and potential social discrimination or stigma.</p><p id="Par83">Genetic testing should be performed while considering the client&#8217;s burden from the medical, ethical, economic, and technical perspectives. The client must receive a written explanation of genetic testing, and informed consent should be obtained. Genetic counseling should be provided as needed, not only before and after genetic testing but also on an ongoing basis. It is also important to ascertain the client&#8217;s preferences in advance as to whether relatives should be informed about their genetic test results.</p></sec><sec id="Sec33"><title>Timing of initial genetic counseling for HCRC</title><p id="Par84">Genetic counseling should be started as early as possible in the following scenarios:<list list-type="order"><list-item><p id="Par85">HCRC is suspected based on clinical information (e.g., age of onset, multiple or synchronous cancers, family history, histopathological findings)</p></list-item><list-item><p id="Par86">MSI-High or dMMR is identified by companion diagnostics</p></list-item><list-item><p id="Par87">A hereditary tumor syndrome is diagnosed or suspected by comprehensive genomic profiling (CGP). CGP refers to tests used in cancer genomic medicine, primarily targeting somatic genetic alterations in tumor tissues.</p></list-item></list></p><p id="Par88">In addition to ongoing genetic counseling for the client with HCRC, genetic counseling for at-risk relatives is essential.</p></sec><sec id="Sec34"><title>Genetic testing in minors</title><p id="Par89">Genetic testing should generally be delayed until the individual reaches adulthood and can make autonomous decisions, especially in cases where the condition typically manifests in adulthood. If early diagnosis can lead to prevention or early treatment, genetic testing may be performed with parental consent and informed assent from the minor following an explanation appropriate to the child&#8217;s level of understanding [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec35"><title>Genetic counseling for patients with hereditary tumors</title><p id="Par90">The role of genetic counseling extends beyond providing information related to genetic testing. It is also important to ensure that clients with a hereditary tumor syndrome receive comprehensive care, including surveillance, through multidisciplinary and cross-departmental collaboration, supporting the client&#8217;s autonomous decision-making, lifestyle adaptations, and psychosocial needs. To achieve this, it is necessary to establish a multidisciplinary team consisting of genetic specialists, physicians from various disciplines, nurses, clinical psychologists, medical social workers, and clinical laboratory technicians.</p></sec></sec></sec><sec id="Sec36"><title>Chapter II. Familial adenomatous polyposis</title><sec id="Sec37"><title>Overview</title><p id="Par91">
<list list-type="bullet"><list-item><p id="Par92">Familial adenomatous polyposis (FAP) is an autosomal dominant disorder characterized by the presence of colorectal adenomatous polyposis, which is caused primarily by a germline pathogenic variant (GPV) in the <italic toggle="yes">APC</italic> gene located on chromosome 5q22.2 (Side note II-1: <italic toggle="yes">APC</italic>-associated polyposis).</p></list-item><list-item><p id="Par93">Patients with FAP have an increased risk of developing colorectal cancer (CRC); therefore, timely and appropriate treatment interventions are crucial. FAP is also associated with extracolonic manifestations, necessitating surveillance and treatment considering these related conditions.</p></list-item></list></p><p id="Par94">Side note II-1: <italic toggle="yes">APC</italic>-associated polyposis</p><p id="Par95">Multiple causative genes and modes of inheritance are responsible for colorectal adenomatous polyposis, along with associated extracolonic manifestations. Therefore, surveillance, treatment, and familial management protocols have been developed based on specific causative genes. Consequently, there has been an increase in the number of disease names linked to these causative genes. For example, FAP and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) are sometimes collectively referred to as <italic toggle="yes">APC</italic>-associated polyposis [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], while diseases that result in adenomatous polyposis, including FAP, are occasionally grouped under the term &#8220;adenomatous polyposis syndrome&#8221; [<xref ref-type="bibr" rid="CR9">9</xref>].</p><sec id="Sec38"><title>Clinical features</title><p id="Par96">
<list list-type="bullet"><list-item><p id="Par97">FAP is a syndrome predisposing individuals to CRC, which includes both classical and attenuated forms.</p></list-item><list-item><p id="Par98">Classical FAP is characterized by the development of hundreds to thousands of colorectal adenomatous polyps, with onset typically at an average age of 16&#160;years (range, 7&#8211;36). Ninety-five percent of individuals with classical FAP develop polyps by the age of 35&#160;years, and CRC is inevitable without interventions such as proctocolectomy. The average age at diagnosis of CRC in untreated individuals is 39&#160;years (range, 34&#8211;43). Classical FAP can be subcategorized based on adenoma density. Severe/profuse/dense FAP is characterized by&#8201;&gt;&#8201;1,000 adenomas covering the mucosa with no normal mucosa visible (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>). In contrast, sparse FAP involves approximately 100 to 1,000 adenomas against a background of normal mucosa (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>). However, adenoma density can vary according to the colorectal region, so the clinical significance of distinguishing strictly between severe/profuse/dense and sparse FAP is limited.</p></list-item><list-item><p id="Par99">Attenuated FAP (AFAP) is characterized by the presence of approximately 10&#8211;100 adenomas and is associated with GPVs in the <italic toggle="yes">APC</italic> gene. AFAP typically features fewer polyps, which are predominantly proximal, have a later age of onset (average 50&#8211;55&#160;years), and have a lower lifetime risk of CRC (70%).</p></list-item><list-item><p id="Par100">Extracolonic manifestations of FAP include polyps in the stomach and duodenum, osteomas, dental abnormalities, congenital hypertrophy of the retinal pigment epithelium (CHRPE), benign skin lesions, desmoid tumors, adrenal masses, and other related cancers.</p></list-item><list-item><p id="Par101">GAPPS is characterized by proximal gastric polyposis and a high risk of gastric adenocarcinoma, with most reported cases showing no duodenal or colorectal lesions.</p></list-item></list><fig id="Fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>Severe/profuse/dense familial adenomatous polyposis</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig6_HTML.jpg"/></fig><fig id="Fig7" position="float" orientation="portrait"><label>Fig.&#160;7</label><caption><p>Sparse familial adenomatous polyposis</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO7" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig7_HTML.jpg"/></fig></p></sec><sec id="Sec39"><title>Causative gene and mode of inheritance</title><p id="Par102">The causative gene for FAP is the <italic toggle="yes">APC</italic>, and it follows an autosomal dominant mode of inheritance.</p><p id="Par103">The <italic toggle="yes">APC</italic> gene is located on the long arm of chromosome 5 (5q22.2) and is a tumor suppressor gene encoding a 311.8-kDa protein comprising 2,843 amino acid residues, with domains for binding &#946;-catenin and Axin. APC plays a crucial role in suppressing formation of tumors by regulating degradation of &#946;-catenin in the Wnt signaling pathway. &#946;-catenin is phosphorylated by a complex that includes APC, Axin, and GSK3&#946; when Wnt signaling is inhibited, leading to its ubiquitination and proteasomal degradation. However, when Wnt signaling is active, &#946;-catenin is not degraded, accumulates in the cytoplasm, and translocates to the nucleus, where it activates the transcription of target genes via TCF. When a pathogenic variant occurs in the <italic toggle="yes">APC</italic> gene, the resulting APC protein is unable to bind &#946;-catenin, even when Wnt signaling is active. This failure prevents degradation of &#946;-catenin, leading to its accumulation within the cytosol, where it promotes the transcription of Wnt target genes, driving cell proliferation and ultimately leading to the development of adenoma [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Patients with FAP carry a GPV in one allele of the <italic toggle="yes">APC</italic> gene in all their cells. Development of adenoma is triggered by acquisition of additional loss-of-function variants or deletions in the opposing <italic toggle="yes">APC</italic> allele, leading to the formation of numerous adenomas [<xref ref-type="bibr" rid="CR24">24</xref>]. If left untreated, further genetic alterations occur in oncogenes like <italic toggle="yes">KRAS</italic> and tumor suppressor genes like <italic toggle="yes">TP53</italic>, with nearly all patients developing CRC by approximately 60&#160;years of age.</p><p id="Par104">Adenoma density is associated with the location of the germline variant in the <italic toggle="yes">APC</italic> gene and with the risk of development of CRC. In severe/profuse/dense FAP, germline variants often occur in <italic toggle="yes">APC</italic> codons 1250&#8211;1464 (particularly codon 1309) [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. In contrast, in AFAP, germline variants are frequently found in the 5&#8242;or 3&#8242; ends of the <italic toggle="yes">APC</italic> gene or in regions subject to selective splicing (i.e., regions where specific exons are skipped during transcription because of the variant) [<xref ref-type="bibr" rid="CR27">27</xref>]. Patients with severe/profuse/dense FAP generally develop adenoma and cancer at a younger age than those with other forms of FAP. In a multicenter study, the median age at which CRC developed was 41&#160;years for severe/profuse/dense FAP, 48&#160;years for sparse FAP, and 59&#160;years for AFAP [<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec40"><title>Associated tumors and extracolonic manifestations</title><p id="Par105">FAP has both neoplastic and non-neoplastic extracolonic manifestations. Notably, extracolonic manifestations can be useful as auxiliary diagnostic criteria for FAP, regardless of the number of colorectal adenomas. Major manifestations associated with FAP include fundic gland polyposis, gastric and duodenal adenomas, periampullary adenomas, small bowel adenomas, desmoid tumors, skull osteomas, mandibular osteomas, epitheliomas, thyroid cancer, hepatoblastoma, adrenal tumors, and brain tumors.</p></sec><sec id="Sec41"><title>Epidemiological features</title><p id="Par106">
<list list-type="bullet"><list-item><p id="Par107">The prevalence of FAP in the general population is approximately 1:20,000 to 1:10,000 in Western countries and approximately 1:17,400 in Japan [<xref ref-type="bibr" rid="CR29">29</xref>]. Patients with FAP account for&#8201;&lt;&#8201;1% of all CRC cases [<xref ref-type="bibr" rid="CR30">30</xref>].</p></list-item><list-item><p id="Par108">CRC can occur in patients with FAP during their teenage years; however, approximately 50% of patients develop CRC in their 40&#160;s, and nearly all will develop CRC by around 60&#160;years of age if untreated [<xref ref-type="bibr" rid="CR31">31</xref>].</p></list-item><list-item><p id="Par109">CRC remains the leading cause of death in patients with FAP. In the 1980s, approximately 80% of FAP-related deaths were attributable to CRC; however, this figure has decreased to approximately 60% since the 1990s [<xref ref-type="bibr" rid="CR32">32</xref>].</p></list-item><list-item><p id="Par110">Among the major extracolonic manifestations, desmoid tumors and duodenal cancer are significant causes of death in patients with FAP, with respective frequencies of approximately 10% and 6% [<xref ref-type="bibr" rid="CR32">32</xref>].</p></list-item></list></p></sec></sec><sec id="Sec42"><title>Diagnosis</title><sec id="Sec43"><title>Diagnostic process</title><p id="Par111">
<list list-type="bullet"><list-item><p id="Par112">FAP is diagnosed using the following three steps:<list list-type="simple"><list-item><label>o</label><p id="Par113"><bold>Step 1: Risk assessment based on clinical information</bold></p></list-item><list-item><label>o</label><p id="Par114">If&#8201;&gt;&#8201;10 polyps are identified during a colonoscopy, proceed to Step 2.</p></list-item><list-item><label>o</label><p id="Par115"><bold>Step 2: Pathological and molecular pathological evaluation</bold></p></list-item><list-item><label>o</label><p id="Par116">If pathological evaluation confirms that the polyps are adenomatous, proceed to Step 3.</p></list-item><list-item><label>o</label><p id="Par117"><bold>STEP 3: Genetic testing</bold></p></list-item><list-item><label>o</label><p id="Par118">A FAP diagnosis is confirmed if a GPV in the <italic toggle="yes">APC</italic> gene is detected. The classification of colorectal adenomatous polyposis diagnosed by genetic testing is shown in Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>.</p></list-item></list></p></list-item><list-item><p id="Par119">No GPV in the <italic toggle="yes">APC</italic> gene is identified in 20%&#8211;40% of patients with colorectal adenomatous polyposis [<xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR35">35</xref>]. Possible reasons include somatic <italic toggle="yes">APC</italic> mosaicism, colorectal adenomatous polyposis due to non-<italic toggle="yes">APC</italic> causative genes, colorectal adenomatous polyposis of unknown etiology, and limitations in analytical techniques.</p></list-item><list-item><p id="Par120">Extracolonic manifestations are useful as auxiliary diagnostic criteria for FAP, regardless of the number of colorectal adenomas.</p></list-item></list><fig id="Fig8" position="float" orientation="portrait"><label>Fig.&#160;8</label><caption><p>Classification of adenomatous polyposis according to causative gene</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO8" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig8_HTML.jpg"/></fig></p></sec><sec id="Sec44"><title>Diseases/conditions requiring differential diagnosis</title><sec id="Sec45"><title>Somatic <italic toggle="yes">APC</italic> mosaicism</title><p id="Par121">Somatic <italic toggle="yes">APC</italic> variants occurring during embryonic development can result in a mosaic state in which some cells have the <italic toggle="yes">APC</italic> variant and others do not. Colorectal adenomatous polyposis resembling FAP can develop if the pathogenic variant in the <italic toggle="yes">APC</italic> gene occurs in cells that differentiate into colonic mucosal cells. The degree of mosaicism depends on the timing of the somatic <italic toggle="yes">APC</italic> variant. For example, adenomatous polyposis will be present in the left colon and rectum but not in the right colon if the variant arises only in cells that contribute to the hindgut. Adenomatous polyposis can be inherited if the pathogenic variant occurs before differentiation of the mesoderm into the gonads but not if the variant occurs after the three germ layers have differentiated, when only the endoderm (which differentiates into structures like the gastrointestinal tract) would be affected. Somatic <italic toggle="yes">APC</italic> mosaicism has been reported in 1.6%&#8211;4% of patients with FAP and identified <italic toggle="yes">APC</italic> variants and is thought to account for 11%&#8211;20% of cases of FAP without a family history [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Recent advances in next-generation sequencing have made it possible to detect low-frequency GPVs that are undetectable by conventional Sanger sequencing. Low-frequency pathogenic variants have been identified in 25&#8211;50% of patients clinically suspected of having FAP or thought to have colorectal polyposis of unknown etiology, leading to a diagnosis of somatic <italic toggle="yes">APC</italic> mosaicism [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. In a multicenter study in Japan, somatic <italic toggle="yes">APC</italic> mosaicism was identified in 9 (7.3%) of 123 cases of colorectal adenomatous polyposis [<xref ref-type="bibr" rid="CR35">35</xref>]. Low-frequency pathogenic variants were identified in 3 of these patients, and the remaining 6 were diagnosed based on the presence of the same pathogenic variant in multiple tumor tissues or in tumor tissue and adjacent normal mucosa.</p></sec><sec id="Sec46"><title>Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)</title><p id="Par122">
<list list-type="bullet"><list-item><p id="Par123">GAPPS is an autosomal dominant disorder that is primarily characterized by fundic gland polyposis, caused by GPVs in the promoter 1B region of the <italic toggle="yes">APC</italic> gene, and characterized as <italic toggle="yes">APC</italic>-associated polyposis [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR40">40</xref>].</p></list-item><list-item><p id="Par124">In the stomach, the <italic toggle="yes">APC</italic> promoter 1A region is inactivated by hypermethylation, whereas the promoter 1B region regulates gene expression. A pathogenic variant in the promoter 1B region results in the loss of normal expression of APC protein in the stomach. In contrast, expression of APC protein in the colon/rectum is primarily regulated by the promoter 1A region; therefore, a pathogenic variant in the promoter 1B region does not affect expression of APC protein in the colon/rectum. Thus, GAPPS is characterized by fundic gland polyposis with minimal colorectal adenomas [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR40">40</xref>].</p></list-item><list-item><p id="Par125">Patients with GAPPS have a 12%&#8211;25% lifetime risk of developing gastric cancer [<xref ref-type="bibr" rid="CR41">41</xref>]; however, their risk of CRC is unknown, and risk management should be based on family history. Surveillance for gastric cancer should begin at the age of 15&#160;years, and prophylactic total gastrectomy may be considered after the age of 20&#8211;30&#160;years [<xref ref-type="bibr" rid="CR42">42</xref>]. Total colonoscopy must be considered to exclude colorectal polyposis.</p></list-item></list></p></sec><sec id="Sec47"><title><italic toggle="yes">MUTYH</italic>-associated polyposis (MAP)</title><p id="Par126">
<list list-type="bullet"><list-item><p id="Par127">MAP is an autosomal recessive disorder caused by biallelic pathogenic variants in the <italic toggle="yes">MUTYH</italic> gene, which is involved in base excision repair [<xref ref-type="bibr" rid="CR43">43</xref>]. Patients with MAP typically develop 10&#8211;100 colorectal adenomas; however, over 100 lesions can be found [<xref ref-type="bibr" rid="CR44">44</xref>]. Multiple serrated polyps may also be observed, and 18% of patients with MAP meet the diagnostic criteria for serrated polyposis syndrome [<xref ref-type="bibr" rid="CR9">9</xref>]. The penetrance of CRC in MAP by the age of 60&#160;years ranges from 43 to 100% [<xref ref-type="bibr" rid="CR45">45</xref>], and surveillance with total colonoscopy should begin at 25&#8211;30&#160;years of age. Patients with MAP also have extracolonic manifestations similar to those observed in FAP, with lifetime risks of duodenal polyposis of 17%&#8211;34%, duodenal cancer of 4%&#8211;5%, and fundic gland polyps of 11%, necessitating esophagogastroduodenoscopy (EGD) as early as 30&#8211;35&#160;years of age. Treatment follows the same principles as those for AFAP [<xref ref-type="bibr" rid="CR44">44</xref>]. This disease is rarely reported in Japan, and the frequency of <italic toggle="yes">MUTYH</italic> variants and proportion of CRC cases attributed to MAP in the Japanese population are unknown. However, a MGPT study that included 123 patients with colorectal adenomatous polyposis identified 2 patients with MAP (1.6%), both of whom had&#8201;&gt;&#8201;100 adenomas [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p></list-item><list-item><p id="Par128">Recently, germline monoallelic pathogenic variants in <italic toggle="yes">MUTYH</italic> have been detected by comprehensive genome profiling tests. Individuals with a family history of CRC and a monoallelic <italic toggle="yes">MUTYH</italic> pathogenic variant have an increased risk of CRC [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]; however, meta-analyses and recent large-scale studies have reported that the risk of CRC is not increased in monoallelic <italic toggle="yes">MUTYH</italic> carriers [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. In view of these conflicting findings, the National Comprehensive Cancer Network guidelines in Western countries recommend that asymptomatic monoallelic <italic toggle="yes">MUTYH</italic> carriers with a family history of CRC in a first-degree relative should consider surveillance with colonoscopy every 5&#160;years, starting at the age of 40&#160;years or 10&#160;years younger than the age at which CRC was diagnosed in the first-degree relative. This recommendation aligns with the standard surveillance protocol for individuals without genetic information but with a family history of CRC in a first-degree relative. Specific recommendations cannot be made for individuals with a family history of CRC in a second-degree relative because of insufficient data [<xref ref-type="bibr" rid="CR9">9</xref>].</p></list-item></list></p></sec><sec id="Sec48"><title>Polymerase proofreading-associated polyposis (PPAP)</title><p id="Par129">PPAP is an autosomal dominant disorder caused by GPVs in the exonuclease domain of the <italic toggle="yes">POLE</italic> or <italic toggle="yes">POLD1</italic> gene, which are involved in proofreading during DNA replication [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. PPAP accounts for 0.1%&#8211;0.4% of familial tumors and 0.3%&#8211;0.7% of CRCs and cases of colorectal polyposis [<xref ref-type="bibr" rid="CR53">53</xref>]. Patients often present with dozens of colorectal adenomas; however, cases without adenomas have also been reported, and the condition is associated with an increased risk of CRC [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR54">54</xref>&#8211;<xref ref-type="bibr" rid="CR57">57</xref>]. While CRC is the most common tumor associated with PPAP, extracolonic manifestations vary depending on the causative gene. <italic toggle="yes">POLD1</italic>- related cases are linked to endometrial cancer, breast cancer, and brain tumors, whereas <italic toggle="yes">POLE</italic>- related cases are associated with duodenal adenomas and cancer, ovarian cancer, brain tumors, pancreatic cancer, breast cancer, and melanoma [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR56">56</xref>&#8211;<xref ref-type="bibr" rid="CR63">63</xref>]. Somatic <italic toggle="yes">POLE</italic> variants have been observed in 2%&#8211;8% of CRCs and 7%&#8211;15% of endometrial cancers; however, somatic <italic toggle="yes">POLD1</italic> variants are extremely rare. Cancers caused by these somatic variants are characterized by a microsatellite-stable, ultra-mutated tumor phenotype with distinct mutational signatures [<xref ref-type="bibr" rid="CR53">53</xref>]. Recently, a Japanese family with a <italic toggle="yes">POLD1</italic> variant was identified in which the proband had attenuated colorectal polyposis and endometrial cancer [<xref ref-type="bibr" rid="CR64">64</xref>].</p></sec><sec id="Sec49"><title>MSH3-associated polyposis</title><p id="Par130"><italic toggle="yes">MSH3</italic> is a DNA mismatch repair gene that contributes to colorectal carcinogenesis via microsatellite instability. Autosomal recessive colorectal polyposis is associated with biallelic GPVs in the <italic toggle="yes">MSH3</italic> gene; however, whether monoallelic <italic toggle="yes">MSH3</italic> variants increase the risk of CRC cannot be determined owing to insufficient evidence [<xref ref-type="bibr" rid="CR65">65</xref>&#8211;<xref ref-type="bibr" rid="CR67">67</xref>]. Surveillance for asymptomatic biallelic <italic toggle="yes">MSH3</italic> carriers should begin with colonoscopy at the age of 25&#8211;30&#160;years, with repeated examinations every 2&#8211;3&#160;years if no polyps are found. The interval should be shortened to 1&#8211;2&#160;years if polyps are detected, and surgery should be considered if endoscopic management becomes challenging [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec><sec id="Sec50"><title><italic toggle="yes">MLH3</italic>-associated polyposis</title><p id="Par131"><italic toggle="yes">MLH3</italic> is another DNA mismatch repair gene, and autosomal recessive colorectal polyposis is linked to biallelic GPVs (e.g., p.S1188X) in <italic toggle="yes">MLH3</italic>. In an initial report involving 4 families and 5 cases, patients were diagnosed at a relatively older age (48&#8211;52&#160;years), with 1&#8211;200 colorectal adenomatous polyps, and some had developed malignancies such as CRC and breast cancer [<xref ref-type="bibr" rid="CR68">68</xref>]. Another variant (p.N121Mfs*49) causes male infertility without associated adenomatous polyposis [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>].</p></sec><sec id="Sec51"><title>NTHL1-associated polyposis</title><p id="Par132"><italic toggle="yes">NTHL1</italic> is involved in base excision repair and acts on oxidized pyrimidine bases [<xref ref-type="bibr" rid="CR71">71</xref>]. Biallelic pathogenic variants of <italic toggle="yes">NTHL1</italic> are associated with colorectal polyposis [<xref ref-type="bibr" rid="CR72">72</xref>&#8211;<xref ref-type="bibr" rid="CR74">74</xref>] and with breast and endometrial cancers [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. Lifetime risks for CRC and extracolonic cancers are 64% and 86%, respectively, for men and 47% and 100% for women [<xref ref-type="bibr" rid="CR75">75</xref>]. Monoallelic pathogenic variants of <italic toggle="yes">NTHL1</italic> are not associated with colorectal polyposis or CRC [<xref ref-type="bibr" rid="CR76">76</xref>]. Colonoscopy surveillance for asymptomatic biallelic <italic toggle="yes">NTHL1</italic> carriers should begin at the age of 25&#8211;30&#160;years, with repeated examinations every 2&#8211;3&#160;years if no polyps are found. The interval should be shortened to 1&#8211;2&#160;years if polyps are detected, and surgery should be considered if endoscopic management becomes difficult. Surveillance for breast cancer should begin with annual mammography with tomosynthesis or contrast-enhanced magnetic resonance imaging (MRI) at the age of 40&#160;years. However, there is insufficient evidence to recommend risk-reducing mastectomy. For endometrial cancer, early diagnosis based on awareness of abnormal uterine bleeding and endometrial cytology is crucial [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec><sec id="Sec52"><title><italic toggle="yes">MBD4</italic>-associated polyposis (<italic toggle="yes">MBD4</italic>-associated neoplasia syndrome)</title><p id="Par133">Biallelic GPVs in <italic toggle="yes">MBD4</italic>, a base excision repair gene, cause colorectal adenomatous polyposis [<xref ref-type="bibr" rid="CR77">77</xref>]. Affected patients and their relatives develop various tumors, including up to hundreds of colorectal adenomatous polyps, CRC, acute myeloid leukemia, uveal melanoma, granulosa cell tumors of the ovary, and meningioma. A Japanese case report described a patient with 30 adenomatous polyps who harbored a monoallelic GPV in <italic toggle="yes">MBD4</italic> [<xref ref-type="bibr" rid="CR78">78</xref>].</p></sec><sec id="Sec53"><title><italic toggle="yes">AXIN2</italic>-associated polyposis</title><p id="Par134"><italic toggle="yes">AXIN2</italic> plays an important role in the Wnt signaling pathway, where it regulates the stability of &#946;-catenin, and is essential for development of the teeth. Families with GPVs in <italic toggle="yes">AXIN2</italic> have oligodontia (congenital absence of multiple teeth) and multiple colorectal adenomatous polyps, and develop CRC [<xref ref-type="bibr" rid="CR79">79</xref>]. Serrated lesions have also been reported in some cases [<xref ref-type="bibr" rid="CR80">80</xref>]. Extracolonic manifestations include upper gastrointestinal polyps, breast cancer, lung cancer, hepatocellular carcinoma, and prostate cancer [<xref ref-type="bibr" rid="CR81">81</xref>].</p></sec><sec id="Sec54"><title>Constitutional mismatch repair deficiency (CMMRD) syndrome</title><p id="Par135">CMMRD syndrome is an autosomal recessive disorder caused by biallelic GPVs in mismatch repair genes and is associated with colorectal adenomatous polyposis. Affected individuals develop hematologic malignancies, brain tumors, and CRC during childhood.</p></sec><sec id="Sec55"><title>Colonic adenomatous polyposis of unknown etiology (CPUE)</title><p id="Par136">If genetic testing using MGPT does not identify a causative gene, the condition is termed CPUE [<xref ref-type="bibr" rid="CR9">9</xref>]. However, conventional genetic testing may not detect somatic mosaicism [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR37">37</xref>], gene inversions [<xref ref-type="bibr" rid="CR82">82</xref>], translocations [<xref ref-type="bibr" rid="CR83">83</xref>], intronic variants distant from exon&#8211;intron junctions [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>], or promoter region variants [<xref ref-type="bibr" rid="CR86">86</xref>]. As a result, some cases of CPUE may be attributed to technical limitations in identifying the causative genes. If&#8201;&#8805;&#8201;100 adenomas are identified in the colon/rectum, surveillance, treatment, and familial management should be implemented as for FAP, even if genetic testing has not been performed or no pathogenic variants are detected.</p></sec></sec></sec><sec id="Sec56"><title>Surveillance and treatment</title><sec id="Sec57"><title>Colorectal adenomas and carcinomas</title><sec id="Sec58"><title>Characteristics and classification</title><p id="Par137">
<list list-type="bullet"><list-item><p id="Par138">FAP can be classified as dense FAP, sparse FAP, or AFAP based on adenoma density. Dense and sparse FAP together are sometimes referred to as classical FAP.</p></list-item><list-item><p id="Par139">The density of adenomas is associated with the location of the GPV in the <italic toggle="yes">APC</italic> gene and the risk of development of CRC.</p></list-item><list-item><p id="Par140">InSiGHT has proposed a staging system based on endoscopic evaluation using the number and size of adenomas (i.e., the polyp burden). The polyp burden correlates strongly with the interval between surveillance colonoscopies and the indication for surgery [<xref ref-type="bibr" rid="CR87">87</xref>]. A marked increase in polyp burden over time is used as a clinical criterion for determining the need for surgery [<xref ref-type="bibr" rid="CR88">88</xref>].</p></list-item></list></p></sec><sec id="Sec59"><title>Surveillance and cancer prevention</title><p id="Par141">
<italic toggle="yes">Surveillance</italic>
<list list-type="bullet"><list-item><p id="Par142">Surveillance by total colonoscopy for FAP should start at around 10&#160;years of age, with intervals of 1&#8211;2&#160;years for classical FAP and 2&#8211;3&#160;years for AFAP starting at 18&#8211;20&#160;years. The age at which to start surveillance by total colonoscopy should be considered for both genetically diagnosed cases of FAP and those without genetic testing.</p></list-item><list-item><p id="Par143">A European study that investigated the frequency of CRC in patients with FAP who were younger than 20&#160;years found no cases of CRC before the age of 10&#160;years and an incidence rate of 0.2% in the 11&#8211;15-year age group [<xref ref-type="bibr" rid="CR30">30</xref>]. Therefore, the recommended age for initiating surveillance by total colonoscopy in patients with FAP is approximately 10&#160;years [<xref ref-type="bibr" rid="CR22">22</xref>]. However, patients with dense FAP can develop CRC before the age of 10&#160;years [<xref ref-type="bibr" rid="CR89">89</xref>], so require careful attention.</p></list-item><list-item><p id="Par144">The onset of CRC occurs 10&#8211;15&#160;years later in AFAP than in classical FAP [<xref ref-type="bibr" rid="CR90">90</xref>], with cases of CRC before the age of 30&#160;years being rare [<xref ref-type="bibr" rid="CR91">91</xref>]. Therefore, surveillance by total colonoscopy should begin in the late teens (18&#8211;20&#160;years) [<xref ref-type="bibr" rid="CR21">21</xref>].</p></list-item><list-item><p id="Par145">If no colorectal adenomas are detected by total colonoscopy, the interval between examinations can be extended in cases where genetic testing has not been performed. Further extension of the interval can be considered based on clinical judgment if multiple consecutive surveillance colonoscopies do not show any adenomas [<xref ref-type="bibr" rid="CR9">9</xref>].</p></list-item></list>
</p><p id="Par146">
<italic toggle="yes">Chemoprevention</italic>
</p><p id="Par147">During surveillance, Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used during surveillance to suppress development and growth of adenomatous polyps. However, their effectiveness in preventing cancer and the effects in long-term use are unclear.</p></sec><sec id="Sec60"><title>Treatment</title><p id="Par148">
<italic toggle="yes">Endoscopic treatment</italic>
</p><p id="Par149">The most reliable treatment for prevention of death from CRC is prophylactic colectomy before the development of cancer. However, technical advances have made it possible to resect many colorectal polyps safely during colonoscopy. A single-center trial investigated the outcomes in patients with sparse FAP who declined surgery and were managed by regular endoscopic polypectomy and follow-up [<xref ref-type="bibr" rid="CR92">92</xref>]. No cases of perforation or severe bleeding were observed during colonoscopy, and no cases of advanced cancer were detected during follow-up. A subsequent multicenter, prospective, exploratory Phase I/II study (J-FAPP III) evaluated the safety and efficacy of intensive downstaging polypectomy [<xref ref-type="bibr" rid="CR93">93</xref>]. Colonoscopies were performed until all adenomas&#8201;&#8805;&#8201;10&#160;mm were resected, followed by removal of adenomas&#8201;&#8805;&#8201;5&#160;mm and, if possible, those that were smaller. Of 166 patients who had not undergone colectomy, 150 (90.4%) completed the 5-year intervention period without surgery.</p><p id="Par150">
<italic toggle="yes">Surgical treatment</italic>
<list list-type="bullet"><list-item><p id="Par151">The most reliable treatment for prevention of death from CRC is prophylactic colectomy before cancer onset.</p></list-item><list-item><p id="Par152">The primary surgical procedures are total proctocolectomy with permanent ileostomy, total proctocolectomy with ileal pouch&#8211;anal anastomosis (IPAA), and total colectomy with ileorectal anastomosis (IRA) (Fig.&#160;<xref rid="Fig9" ref-type="fig">9</xref> and Table&#160;<xref rid="Tab8" ref-type="table">8</xref>).</p></list-item><list-item><p id="Par153">The timing of prophylactic colectomy should be decided based on following considerations, (1) the cumulative prevalence of CRC [<xref ref-type="bibr" rid="CR32">32</xref>], (2) adenoma density [<xref ref-type="bibr" rid="CR94">94</xref>], (3) adenoma size and morphology, (4) age at death and cancer onset in at-risk relatives and the presence of desmoid tumors [<xref ref-type="bibr" rid="CR95">95</xref>], (5) location of <italic toggle="yes">APC</italic> gene variants [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>], (6) the patient&#8217;s educational and occupational environment [<xref ref-type="bibr" rid="CR98">98</xref>], (7) fertility post-IPAA [<xref ref-type="bibr" rid="CR99">99</xref>] and male sexual dysfunction [<xref ref-type="bibr" rid="CR100">100</xref>], (8) gastrointestinal symptoms such as diarrhea, abdominal pain, and rectal bleeding, and (9) pathological findings in the tumors. Considering the prevalence of CRC, patients with classical FAP should undergo surgery as early as their late teens, with the most common age for surgery being in the 20&#160;s [<xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR102">102</xref>]. A Japanese study in patients who had FAP with known locations of pathogenic <italic toggle="yes">APC</italic> variants reported a rapid increase in the risk of developing stage II or higher CRC after the age of 34&#160;years in patients with the classical FAP genotype and after the age of 49&#160;years in those with the AFAP genotype [<xref ref-type="bibr" rid="CR97">97</xref>]. Identifying the location of pathogenic variants by genetic testing can help to determine the timing of prophylactic colectomy.</p></list-item><list-item><p id="Par154">Total proctocolectomy with IPAA is currently the standard procedure and accounts for an increasing proportion of the procedures performed [<xref ref-type="bibr" rid="CR103">103</xref>&#8211;<xref ref-type="bibr" rid="CR106">106</xref>]. Use of laparoscopic surgery has also been increasing [<xref ref-type="bibr" rid="CR105">105</xref>&#8211;<xref ref-type="bibr" rid="CR110">110</xref>]. Considering the balance between benefits and risks, the decision to perform a temporary ileostomy should be made on an individual basis in cases of IPAA.</p></list-item><list-item><p id="Par155">If a desmoid tumor is identified in the mesentery, the indication for IPAA should be assessed carefully because of the risk of recurrence or growth of the tumor and the technical challenges involved. Notably, laparoscopic surgery, particularly for IRA, is associated with a lower postoperative incidence of desmoid tumors [<xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR112">112</xref>].</p></list-item><list-item><p id="Par156">Total colectomy in women with FAP may reduce fertility (Side Note II-2: Surgery, fertility, pregnancy, and childbirth).</p></list-item><list-item><p id="Par157">The surgical approach for a patient with FAP who has developed CRC should be determined based on the stage and location of the CRC as well as other clinical considerations. If curative resection is possible, total proctocolectomy or total colectomy with regional lymph node dissection should be considered. Managing unresectable advanced CRC, metastatic lesions, and chemotherapy should follow the same protocols as those for sporadic CRC.</p></list-item></list>
<fig id="Fig9" position="float" orientation="portrait"><label>Fig.&#160;9</label><caption><p>Surgical procedures for patients with familial adenomatous polyposis</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO9" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig9_HTML.jpg"/></fig>
<table-wrap id="Tab8" position="float" orientation="portrait"><label>Table&#160;8</label><caption><p>Characteristics of the surgical procedure for FAP</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Surgical procedures</th><th align="left" colspan="1" rowspan="1">Total proctocolectomy with permanent ileostomy</th><th align="left" colspan="1" rowspan="1">Total proctocolectomy with ileal-pouch anal anastomosis (IPAA)</th><th align="left" colspan="1" rowspan="1">Total colectomy with ileorectal anastomosis (IRA)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Advantages</td><td align="left" colspan="1" rowspan="1">Colorectal cancer completely prevented</td><td align="left" colspan="1" rowspan="1"><p>Colorectal cancer almost prevented</p><p>Preservation of natural anal function</p></td><td align="left" colspan="1" rowspan="1"><p>Good bowel function</p><p>Relatively easy surgical technique</p><p>Lower complication rate than that of IPAA</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Disadvantages</td><td align="left" colspan="1" rowspan="1">Deteriorated body image with permanent colostomy</td><td align="left" colspan="1" rowspan="1"><p>A complex surgical technique</p><p>Unstable bowel function</p><p>Possibility of cancer development at the remaining rectal mucosa near the anus</p><p>Possibility of pouchitis</p></td><td align="left" colspan="1" rowspan="1">Possibility of rectal cancer development (depending on the number of adenomas, location of the germline variant in the <italic toggle="yes">APC</italic> gene, or length of the residual rectum)</td></tr></tbody></table></table-wrap>
</p><p id="Par158">Side Note II-2: Surgery, fertility, pregnancy, and childbirth.<list list-type="bullet"><list-item><p id="Par159">A study of 58 women with FAP in Denmark [<xref ref-type="bibr" rid="CR113">113</xref>] reported a fertility rate of 90%, which was comparable to that in the general population. Another study involving 162 European women with FAP found that the fertility rate in patients with FAP who had not undergone surgery was comparable to that in the general population, as was that in patients who underwent IRA; however, those who underwent IPAA had a 0.46 times lower fertility rate [<xref ref-type="bibr" rid="CR30">30</xref>]. In contrast, a study of 138 patients with FAP in the Netherlands reported that fertility was unrelated to the type of surgery but was associated with age at the time of initial surgery [<xref ref-type="bibr" rid="CR114">114</xref>].</p></list-item><list-item><p id="Par160">Reduced fertility after IPAA may be a result of postoperative adhesions. In one study, hysterosalpingography performed after total colectomy showed adhesions of the fallopian tubes to the pelvic wall in 48% of cases, unilateral occlusion in 43%, and bilateral occlusion in 10% [<xref ref-type="bibr" rid="CR115">115</xref>].</p></list-item><list-item><p id="Par161">The fertility rate has been reported to be significantly higher after laparoscopic surgery than after open surgery in patients with FAP and ulcerative colitis [<xref ref-type="bibr" rid="CR116">116</xref>]. Research specifically involving patients with FAP also found that laparoscopic surgery was associated with a lower rate of postoperative bowel obstruction and a smaller reduction in female fertility [<xref ref-type="bibr" rid="CR107">107</xref>]. However, no prospective studies have been conducted specifically in patients with FAP. Furthermore, vaginal delivery after IPAA is reportedly safe [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]; however, the risk of damage to the anal sphincter and pudendal nerve injury after episiotomy should be considered in vaginal delivery post-IPAA.</p></list-item></list></p></sec><sec id="Sec61"><title>Surveillance of the lower gastrointestinal tract after colorectal surgery</title><p id="Par163">After IRA, long-term surveillance, including endoscopy, is required to monitor for development of cancer in the remaining rectum (Side Note II-3: Risk of rectal cancer post-total colectomy with IRA). After stapled IPAA, 2&#8211;3&#160;cm of rectal mucosa typically remains, and a small amount of rectal mucosa may remain even after hand-sewn IPAA. Therefore, long-term postoperative surveillance of the remaining rectal mucosa is necessary, whether stapled or hand-sewn. The reported incidence of adenoma in the ileal pouch after IPAA ranges from 6.7% to 74% [<xref ref-type="bibr" rid="CR119">119</xref>&#8211;<xref ref-type="bibr" rid="CR122">122</xref>]. Development of cancer has also been reported, necessitating long-term endoscopic surveillance [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>]. Pouchitis after IPAA for FAP occurs in approximately 5% of patients, which is lower than the rate observed after IPAA for ulcerative colitis [<xref ref-type="bibr" rid="CR125">125</xref>]. Clinical symptoms include fever, diarrhea, and anemia, and endoscopic surveillance should be performed promptly if such symptoms appear. Surveillance for recurrence should be performed as for sporadic CRC where curative resection is performed for concomitant CRC.</p><p id="Par164">Side Note II-3: Risk of rectal cancer post-total colectomy with IRA</p><p id="Par165">Long-term follow-up after IRA shows that rectal cancer occurs in 24%&#8211;43% of cases [<xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR127">127</xref>]. In one study, rectal resection was necessary during up to 20&#160;years of follow-up post-IRA in 10% of patients with AFAP, 39% of those with sparse FAP, and 61% of those with dense FAP [<xref ref-type="bibr" rid="CR128">128</xref>]. With advances in surgical techniques and the increased frequency of IPAA [<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR104">104</xref>], the rate of rectal resection after IRA has decreased from 40 to 13%, with a decline in the cumulative incidence of residual rectal cancer post-IRA [<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR130">130</xref>].</p></sec></sec><sec id="Sec62"><title>Fundic gland polyposis and gastric adenomas</title><sec id="Sec63"><title>Characteristics and classification</title><p id="Par166">
<list list-type="bullet"><list-item><p id="Par167">Fundic gland polyposis (Fig.&#160;<xref rid="Fig10" ref-type="fig">10</xref>) is distinct from fundic gland polyps observed in the stomachs of individuals without FAP in terms of number and size. Fundic gland polyposis has been observed in 88% of patients with FAP [<xref ref-type="bibr" rid="CR131">131</xref>], making it useful for auxiliary diagnosis.</p></list-item><list-item><p id="Par168">Fundic gland polyposis occurs more frequently in patients with FAP who are not infected with <italic toggle="yes">Helicobacter pylori</italic> [<xref ref-type="bibr" rid="CR131">131</xref>].</p></list-item><list-item><p id="Par169">Adenomas (Fig.&#160;<xref rid="Fig11" ref-type="fig">11</xref>) and cancers can develop within fundic gland polyposis.</p></list-item><list-item><p id="Par170">The relationship between fundic gland polyposis, gastric adenomas, and the <italic toggle="yes">APC</italic> genotype is unclear [<xref ref-type="bibr" rid="CR132">132</xref>].</p></list-item><list-item><p id="Par171">In patients with FAP, neoplastic lesions in the stomach are classified based on morphology, and location [<xref ref-type="bibr" rid="CR133">133</xref>].</p></list-item></list><fig id="Fig10" position="float" orientation="portrait"><label>Fig.&#160;10</label><caption><p>Fundic gland polyposis</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO10" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig10_HTML.jpg"/></fig><fig id="Fig11" position="float" orientation="portrait"><label>Fig.&#160;11</label><caption><p>Gastric adenoma (left, depressive type; right, elevated type)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO11" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig11_HTML.jpg"/></fig></p></sec><sec id="Sec64"><title>Surveillance</title><p id="Par172">
<list list-type="bullet"><list-item><p id="Par173">EGD surveillance is necessary because neoplastic lesions such as adenomas and cancers can develop within fundic gland polyposis.</p></list-item><list-item><p id="Par174">Low-grade dysplastic lesions occur frequently, but high-grade dysplastic lesions are less common [<xref ref-type="bibr" rid="CR131">131</xref>, <xref ref-type="bibr" rid="CR134">134</xref>]. There have also been reports of gastric cancer, albeit less frequently [<xref ref-type="bibr" rid="CR135">135</xref>].</p></list-item><list-item><p id="Par175">The timing and frequency of EGD surveillance should generally follow the degree of duodenal lesions (staged using the Spigelman classification), which occur frequently.</p></list-item><list-item><p id="Par176">Neoplastic lesions are more common in Asian patients with fundic gland polyposis than in their Western counterparts [<xref ref-type="bibr" rid="CR131">131</xref>, <xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR136">136</xref>&#8211;<xref ref-type="bibr" rid="CR138">138</xref>]. Given that some of these lesions can be difficult to diagnose, EGD surveillance at intervals of 1&#8211;2&#160;years may be considered [<xref ref-type="bibr" rid="CR136">136</xref>]. Particularly careful EGD surveillance is required in patients with diffuse (carpet-like) polyposis and lesions with significant elevation.</p></list-item></list></p></sec><sec id="Sec65"><title>Treatment</title><p id="Par177">
<list list-type="bullet"><list-item><p id="Par178">Active treatment for fundic gland polyposis itself is generally not necessary.</p></list-item><list-item><p id="Par179">Although no established consensus exists regarding the endoscopic treatment of gastric adenomas, treating all low-grade adenomas is generally unnecessary. Typically, treatment is considered for tumorous lesions&#8201;&#8805;&#8201;10&#160;mm or high-grade adenomas [<xref ref-type="bibr" rid="CR9">9</xref>].</p></list-item></list></p></sec></sec><sec id="Sec66"><title>Duodenal adenomas and carcinomas</title><sec id="Sec67"><title>Characteristics and classification</title><p id="Par180">
<list list-type="bullet"><list-item><p id="Par181">Duodenal and ampullary adenomas (Fig.&#160;<xref rid="Fig12" ref-type="fig">12</xref>) are rarely observed in healthy individuals without FAP, and the presence of multiple duodenal adenomas is a hallmark of FAP, making it useful for auxiliary diagnosis.</p></list-item><list-item><p id="Par182">Duodenal adenomas are observed in 30%&#8211;90% of patients with FAP [<xref ref-type="bibr" rid="CR139">139</xref>&#8211;<xref ref-type="bibr" rid="CR141">141</xref>], with an increase in prevalence after the age of 40&#160;years [<xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR141">141</xref>].</p></list-item><list-item><p id="Par183">According to a multicenter study in Japan, the cumulative incidence of duodenal adenoma was 39.2% by the age of 50&#160;years, with classical FAP having a substantially higher cumulative incidence than AFAP (42.5% vs. 23.5%) [<xref ref-type="bibr" rid="CR142">142</xref>].</p></list-item><list-item><p id="Par184">Ampullary tumors have been observed in up to 72% of cases [<xref ref-type="bibr" rid="CR143">143</xref>].</p></list-item><list-item><p id="Par185">Forward-viewing and side-viewing endoscopy is used to observe duodenal lesions and the ampullary region.</p></list-item><list-item><p id="Par186">The relationship between duodenal adenomas, ampullary tumors, and the <italic toggle="yes">APC</italic> genotype is not clearly established [<xref ref-type="bibr" rid="CR132">132</xref>].</p></list-item><list-item><p id="Par187">The Spigelman classification has reproducibility between and within examiners [<xref ref-type="bibr" rid="CR144">144</xref>].</p></list-item><list-item><p id="Par188">Duodenal cancer accounts for approximately 3% of deaths in patients with FAP and is one of the leading causes of death after prophylactic colectomy [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR145">145</xref>].</p></list-item><list-item><p id="Par189">The relative risk of duodenal cancer is approximately 250&#8211;330.8 times higher in patients with FAP than in the general population [<xref ref-type="bibr" rid="CR146">146</xref>, <xref ref-type="bibr" rid="CR147">147</xref>], with an estimated cumulative incidence rate of 4&#8211;10% [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR149">149</xref>].</p></list-item><list-item><p id="Par190">The Spigelman scoring system is used for clinicopathological classification of duodenal adenomas in patients with FAP [<xref ref-type="bibr" rid="CR137">137</xref>].</p></list-item><list-item><p id="Par191">The Spigelman classification is determined based on the number and maximum diameter of duodenal adenomas seen on endoscopic examination and assesses the structure of the adenoma (Fig.&#160;<xref rid="Fig13" ref-type="fig">13</xref>) for histological type and dysplasia. Minor modifications have been made to the original classification system [<xref ref-type="bibr" rid="CR150">150</xref>].</p></list-item><list-item><p id="Par192">Use of narrow-band imaging increases the detection rate of duodenal adenomas but does not affect the Spigelman classification [<xref ref-type="bibr" rid="CR151">151</xref>].</p></list-item></list><fig id="Fig12" position="float" orientation="portrait"><label>Fig.&#160;12</label><caption><p>Ampullary adenoma (left) and multiple duodenal adenomas (right)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO12" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig12_HTML.jpg"/></fig><fig id="Fig13" position="float" orientation="portrait"><label>Fig.&#160;13</label><caption><p>Histology of familial adenomatous polyposis-associated duodenal adenomas. <bold>A</bold> Low- grade adenoma: the tumor glands are rather uniform and the adenomatous epithelial cells show basally oriented, elongated nuclei. <bold>B</bold> Intramucosal carcinoma: tumor glands show significant irregularity, nuclear stratification, and occasional prominent nucleoli. Note that high-grade dysplasia in the Spigelman classification includes non-invasive intramucosal carcinoma in the Japanese classification. <bold>C</bold> Tubular adenoma: this lesion shows a relatively regular tubular architecture. <bold>D</bold> Tubulo-villous adenoma: this lesion partially exhibits villous architecture, composed of fibrovascular cores lined by dysplastic epithelium </p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO13" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig13_HTML.jpg"/></fig></p></sec><sec id="Sec68"><title>Surveillance</title><p id="Par193">
<list list-type="bullet"><list-item><p id="Par194">Although duodenal adenomas grow slowly [<xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR153">153</xref>], regular endoscopic surveillance is necessary because of the risk of progression and malignant transformation.</p></list-item><list-item><p id="Par195">Generally, surveillance should begin at around the age of 20&#8211;25&#160;years, with surveillance intervals of 4&#8211;5&#160;years for Spigelman stage 0, 2&#8211;5&#160;years for stage I, 2&#8211;3&#160;years for stage II, and every 6&#160;months to 2&#160;years for stage III [<xref ref-type="bibr" rid="CR141">141</xref>]. However, endoscopic examinations at intervals of once every 1&#8211;3&#160;years may also be considered, given the possibility of missed lesions and occurrence of fundic gland polyposis or gastric adenomas.</p></list-item><list-item><p id="Par196">Biopsies from the ampulla are safe with a low risk of pancreatitis and can elevate the Spigelman stage in the absence of visible abnormalities [<xref ref-type="bibr" rid="CR154">154</xref>]. However, routine biopsies from ampullae without visible abnormalities are usually not necessary because ampullary tumors generally progress slowly [<xref ref-type="bibr" rid="CR148">148</xref>].</p></list-item></list></p></sec><sec id="Sec69"><title>Treatment</title><p id="Par197">
<list list-type="bullet"><list-item><p id="Par198">Guidelines for management of duodenal adenomas according to the modified Spigelman classification are shown in Fig.&#160;<xref rid="Fig14" ref-type="fig">14</xref></p></list-item><list-item><p id="Par199">Endoscopic treatments for duodenal adenoma include snare resection, argon plasma coagulation, and other techniques [<xref ref-type="bibr" rid="CR143">143</xref>]. Recent reports on the safety and efficacy of new treatment techniques (such as bipolar snare resection, cold snare polypectomy, and underwater endoscopic mucosal resection) have expanded the treatment options [<xref ref-type="bibr" rid="CR155">155</xref>&#8211;<xref ref-type="bibr" rid="CR158">158</xref>].</p></list-item><list-item><p id="Par200">Complete endoscopic resection of Spigelman stage II/III duodenal adenoma is associated with high recurrence and complication rates (50%&#8211;100%) [<xref ref-type="bibr" rid="CR141">141</xref>]. However, recent improvements in endoscopic resection techniques and the introduction of new treatments have increased the safety and efficacy of endoscopic resection [<xref ref-type="bibr" rid="CR155">155</xref>&#8211;<xref ref-type="bibr" rid="CR159">159</xref>].</p></list-item><list-item><p id="Par201">A systematic review identified modified Spigelman stage IV as a risk factor for the development of non-ampullary duodenal carcinoma [<xref ref-type="bibr" rid="CR160">160</xref>]. The incidence of duodenal cancer was approximately 2.3% for stage II, 2.4% for stage III [<xref ref-type="bibr" rid="CR161">161</xref>], and 7%&#8211;36% for stage IV [<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR161">161</xref>]. Therefore, evaluation by a specialist for surgical intervention or surveillance every 6&#8211;12&#160;months is recommended. Although downgrading by endoscopic treatment has recently been described [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR162">162</xref>, <xref ref-type="bibr" rid="CR163">163</xref>], whether this significantly alters the natural history of the disease is still not known.</p></list-item><list-item><p id="Par202">The standard surgical procedure for patients with concomitant carcinoma (Spigelman stage V) is pancreaticoduodenectomy. However, less invasive surgeries, such as pancreas-preserving duodenectomy, which does not hinder postoperative endoscopic surveillance and has a stronger prophylactic intent, are selected for stage IV cases [<xref ref-type="bibr" rid="CR164">164</xref>&#8211;<xref ref-type="bibr" rid="CR166">166</xref>].</p></list-item><list-item><p id="Par203">Treatment for ampullary tumors should be considered when maximum diameters are&#8201;&#8805;&#8201;1&#160;cm or showing advanced histology (such as tubulovillous adenoma or high-grade dysplasia), or if symptoms of obstruction (such as liver dysfunction or pancreatitis) are present. Endoscopic ampullectomy by experts should be considered first [<xref ref-type="bibr" rid="CR167">167</xref>].</p></list-item><list-item><p id="Par204">Endoscopic ampullectomy has been reported to have an adverse event rate of approximately 10%, a residual lesion rate of 28%, and a recurrence rate of 17%, necessitating careful case selection and meticulous surveillance [<xref ref-type="bibr" rid="CR167">167</xref>].</p></list-item></list><fig id="Fig14" position="float" orientation="portrait"><label>Fig.&#160;14</label><caption><p>Surveillance of duodenal adenoma based on revised Spigelman&#8217;s classification. PD, pancreaticoduodenectomy; PSD, pancreas sparing duodenectomy</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO14" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig14_HTML.jpg"/></fig></p></sec></sec><sec id="Sec70"><title>Desmoid tumors</title><sec id="Sec71"><title>Characteristics and classification</title><p id="Par205">
<list list-type="bullet"><list-item><p id="Par206">Desmoid tumors (Fig.&#160;<xref rid="Fig15" ref-type="fig">15</xref>) are observed in 8%&#8211;20% of patients with FAP [<xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR168">168</xref>&#8211;<xref ref-type="bibr" rid="CR170">170</xref>]. These tumors are a type of non-metastasizing fibroma but grow invasively.</p></list-item><list-item><p id="Par207">Desmoid tumors are classified as intra-abdominal, extra-abdominal, or mixed, with the intra-abdominal type accounting for 70% of all desmoid tumors [<xref ref-type="bibr" rid="CR101">101</xref>]. These tumors often develop in the abdominal wall, mesentery, or retroperitoneum within 2&#8211;3&#160;years after total proctocolectomy [<xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR172">172</xref>].</p></list-item><list-item><p id="Par208">In Japan, the incidence of desmoid tumors is 10%&#8211;15%, with intra-abdominal desmoids accounting for 71.8%&#8211;80% of all these tumors. They are considerably more common in individuals under 30&#160;years of age and in females, with approximately two-thirds of cases occurring within 1&#160;year within 1&#160;year after total proctocolectomy [<xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR173">173</xref>].</p></list-item><list-item><p id="Par209">Desmoid tumors associated with FAP differ from sporadic desmoid tumors in terms of mechanisms of development and clinical characteristics, including their location, making them useful for auxiliary diagnosis of FAP. "Usually, FAP-related desmoid tumors develop due to somatic variants in the opposite allele of <italic toggle="yes">APC</italic>, resulting in functional impairment of both <italic toggle="yes">APC</italic> alleles (two-hit theory). In clinical practice, compared to sporadic desmoid tumors, FAP-related desmoid tumors tend to be larger, more commonly multiple, more often intra-abdominal, and have an earlier age of onset.&#8221;</p></list-item><list-item><p id="Par210">Desmoid tumors may spontaneously regress or stabilize over time [<xref ref-type="bibr" rid="CR174">174</xref>&#8211;<xref ref-type="bibr" rid="CR176">176</xref>].</p></list-item><list-item><p id="Par211">When desmoid tumors develop intra-abdominally (including in the retroperitoneum), they can cause complications such as bowel obstruction, perforation, abscess formation, and ureteral obstruction, making treatment challenging.</p></list-item><list-item><p id="Par212">Data from a multicenter study in Japan found no difference in the risk of development of desmoid tumors between laparoscopic surgery and open surgery [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR106">106</xref>].</p></list-item><list-item><p id="Par213">Recent reports, including data from Japan, suggest that the risk of development of desmoid tumors is higher after IPAA than after IRA [<xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR177">177</xref>].</p></list-item><list-item><p id="Par214">The mortality rate for desmoid tumors is in the range of 0% to 14% [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR168">168</xref>, <xref ref-type="bibr" rid="CR170">170</xref>, <xref ref-type="bibr" rid="CR174">174</xref>].</p></list-item><list-item><p id="Par215">There is a correlation between the development of desmoid tumors and pathogenic <italic toggle="yes">APC</italic> variants, particularly on the 3&#8242;side of codon 1444 or within codons 1445&#8211;1580 [<xref ref-type="bibr" rid="CR178">178</xref>, <xref ref-type="bibr" rid="CR179">179</xref>]. Another report showed a high incidence of desmoid tumors in cases with pathogenic variants on the 3&#8242; side of codon 1399, noting severe and potentially lethal symptoms [<xref ref-type="bibr" rid="CR180">180</xref>]. There is also a correlation between desmoid tumors and 3&#8242; side pathogenic variants of <italic toggle="yes">APC</italic> in patients with AFAP [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p></list-item><list-item><p id="Par216">The staging system for intra-abdominal desmoid tumors developed by Church et al. [<xref ref-type="bibr" rid="CR181">181</xref>] requires evaluation of the trend in growth, necessitating prospective assessment over 6&#160;months. Retrospective evaluations may lack accurate data on growth trends.</p></list-item><list-item><p id="Par217">For desmoid tumors associated with FAP that occur outside the abdominal cavity (mostly in the abdominal wall), a &#8220;wait and see&#8221; approach or surgical resection is generally selected, with a good prognosis. Intra-abdominal desmoid tumors are typically managed noninvasively, but tumor growth or progression leading to organ dysfunction (urinary tract, bowel) may result in a decline in quality of life or a poor prognosis. Therefore, a new classification has been proposed in Japan that accounts for the location and size of the tumor, organ dysfunction affecting quality of life (mobility restrictions, urinary tract obstruction, bowel obstruction), and complications (abscess and fistula formation and dehiscence of the abdominal wall) (Table&#160;<xref rid="Tab9" ref-type="table">9</xref>) [<xref ref-type="bibr" rid="CR182">182</xref>, <xref ref-type="bibr" rid="CR183">183</xref>]. Unlike the Church classification, this new classification can be used at any time point during the clinical course.</p></list-item></list><fig id="Fig15" position="float" orientation="portrait"><label>Fig.&#160;15</label><caption><p>Intra-abdominal desmoid tumor</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO15" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig15_HTML.jpg"/></fig><table-wrap id="Tab9" position="float" orientation="portrait"><label>Table&#160;9</label><caption><p>Classification of desmoid tumors.</p><p>Reproduced with permission from Ishida H, Chikatani K, Mori Y, et al. (2020) Diagnosis, treatment, and proposal of the new classification system for the severity of desmoid tumors associated with familial adenomatous polyposis. J Hered Tumors 20:45&#8211;58</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Grade</th><th align="left" colspan="1" rowspan="1">Location</th><th align="left" colspan="1" rowspan="1">Maximum diameter</th><th align="left" colspan="1" rowspan="1">Number of tumor</th><th align="left" colspan="1" rowspan="1">Symptom</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Extra-abdominal<sup>*</sup></td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;10&#160;cm</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">None&#8211;any</td></tr><tr><td align="left" colspan="1" rowspan="1">2A</td><td align="left" colspan="1" rowspan="1">Extra-abdominal<sup>a</sup></td><td align="left" colspan="1" rowspan="1">&#8201;&#8805;&#8201;10&#160;cm</td><td align="left" colspan="1" rowspan="1">Any</td><td align="left" colspan="1" rowspan="1">None&#8211;any</td></tr><tr><td align="left" colspan="1" rowspan="1">2B</td><td align="left" colspan="1" rowspan="1">Extra-abdominal<sup>a</sup></td><td align="left" colspan="1" rowspan="1">Any</td><td align="left" colspan="1" rowspan="1">Any</td><td align="left" colspan="1" rowspan="1">Motion restriction (&#8201;+)</td></tr><tr><td align="left" colspan="1" rowspan="1">3A</td><td align="left" colspan="1" rowspan="1">Intra-abdominal</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;10&#160;cm</td><td align="left" colspan="1" rowspan="1">Any</td><td align="left" colspan="1" rowspan="1"><p>Urinary tract obstruction (-) and</p><p>Bowel obstruction (-)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">3B</td><td align="left" colspan="1" rowspan="1">Intra-abdominal</td><td align="left" colspan="1" rowspan="1">&#8201;&#8805;&#8201;10&#160;cm</td><td align="left" colspan="1" rowspan="1">Any</td><td align="left" colspan="1" rowspan="1"><p>Urinary tract obstruction (-) and</p><p>Bowel obstruction (-)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">4A</td><td align="left" colspan="1" rowspan="1">Intra-abdominal</td><td align="left" colspan="1" rowspan="1">Any</td><td align="left" colspan="1" rowspan="1">Any</td><td align="left" colspan="1" rowspan="1"><p>Urinary tract obstruction (&#8201;+) and</p><p>Bowel obstruction (-)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">4B</td><td align="left" colspan="1" rowspan="1">Intra-abdominal</td><td align="left" colspan="1" rowspan="1">Any</td><td align="left" colspan="1" rowspan="1">Any</td><td align="left" colspan="1" rowspan="1">Incomplete bowel obstruction (&#8201;+)</td></tr><tr><td align="left" colspan="1" rowspan="1">4C</td><td align="left" colspan="1" rowspan="1">Intra-abdominal</td><td align="left" colspan="1" rowspan="1">Any</td><td align="left" colspan="1" rowspan="1">Any</td><td align="left" colspan="1" rowspan="1">Complete bowel obstruction (&#8201;+)</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Intra-abdominal</td><td align="left" colspan="1" rowspan="1">Any</td><td align="left" colspan="1" rowspan="1">Any</td><td align="left" colspan="1" rowspan="1">Abscess/ Fistula formation/ Abdominal wall dehiscence</td></tr></tbody></table><table-wrap-foot><p><sup><italic toggle="yes">a</italic></sup><italic toggle="yes">Extra-abdominal</italic> abdominal wall, limbs or trunk</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec72"><title>Surveillance</title><p id="Par218">
<list list-type="bullet"><list-item><p id="Par219">Surveillance is important for early diagnosis of desmoid tumors because of the negative treatment outcomes and poor long-term prognosis when these tumors are advanced [<xref ref-type="bibr" rid="CR181">181</xref>].</p></list-item><list-item><p id="Par220">Desmoid tumors frequently develop within 2&#8211;3&#160;years after total proctocolectomy, typically in the abdominal wall, mesentery, or retroperitoneum [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR172">172</xref>]. Therefore, during this period, attention should be paid to clinical symptoms (e.g., abdominal pain, bloating, masses, gastrointestinal passage obstruction), with abdominal palpation every 6&#160;months and imaging studies (contrast-enhanced computed tomography [CT] or MRI of the abdomen and pelvis) annually.</p></list-item><list-item><p id="Par221">Regular contrast-enhanced CT or MRI of the abdomen and pelvis is recommended in cases with a personal or family history of desmoid tumors [<xref ref-type="bibr" rid="CR9">9</xref>].</p></list-item></list></p></sec><sec id="Sec73"><title>Treatment</title><p id="Par222">Intra-abdominal desmoid tumors detected during surveillance should be managed according to the Church classification [<xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR181">181</xref>] or the new Japanese classification [<xref ref-type="bibr" rid="CR182">182</xref>]. The treatment plan should be considered based on the symptoms of extra-abdominal desmoid tumors (primarily in the abdominal wall) and their impact on day-to-day life.</p><p id="Par223">
<italic toggle="yes">Pharmacotherapy</italic>
<list list-type="bullet"><list-item><p id="Par224">There is minimal evidence on pharmacotherapy for desmoid tumors in patients with FAP. Some of the research on desmoid tumors has included patients with FAP, and treatment can generally follow the approach for sporadic desmoid tumors [<xref ref-type="bibr" rid="CR184">184</xref>].</p></list-item><list-item><p id="Par225">Anti-estrogen drugs and NSAIDs<list list-type="alpha-lower"><list-item><p id="Par226">Given the high expression of estrogen receptors and cyclooxygenase (COX)-2 in desmoid tumors, anti-estrogen drugs (e.g., tamoxifen, raloxifene, and toremifene) and NSAIDs (e.g., sulindac and indomethacin) have been investigated, mostly in retrospective analyses. A systematic review of anti-estrogen drugs reported a response rate of 51%, with no remarkable difference in efficacy or safety when used as monotherapy and in combination with NSAIDs. A comparison of desmoid tumors between patients with FAP (<italic toggle="yes">n</italic>&#8201;=&#8201;91) and sporadic cases (<italic toggle="yes">n</italic>&#8201;=&#8201;50) found no significant difference in the response rate (51% vs. 48%) or disease control rate (78% vs. 86%) [<xref ref-type="bibr" rid="CR185">185</xref>]. The only relevant prospective Phase II trial investigated a combination of sulindac and tamoxifen in pediatric patients (20% of whom had FAP) and reported a response rate of 8% and a 2-year progression-free survival rate of 36%, showing less favorable outcomes than in the retrospective reports [<xref ref-type="bibr" rid="CR186">186</xref>].</p></list-item></list></p></list-item><list-item><p id="Par227">Molecular targeted therapy<list list-type="alpha-lower"><list-item><p id="Par228">Several prospective Phase II trials of the tyrosine kinase inhibitor imatinib have reported high disease control rates (84%&#8211;91%) despite low response rates (6%&#8211;19%) [<xref ref-type="bibr" rid="CR187">187</xref>&#8211;<xref ref-type="bibr" rid="CR190">190</xref>]. A randomized controlled trial that compared the multikinase inhibitor sorafenib with a placebo found a significant increase in median progression-free survival in the sorafenib group (not reached vs. 11.3&#160;months, hazard ratio 0.13, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) with a good response rate (33% vs. 20%) [<xref ref-type="bibr" rid="CR191">191</xref>]. In the randomized Phase II DESMOPAZ trial, which compared the multikinase inhibitor pazopanib with oral methotrexate plus vinblastine, the response rate and 1-year progression-free survival rate were better in the pazopanib group (37% vs. 25% and 86% vs. 67%, respectively) [<xref ref-type="bibr" rid="CR192">192</xref>].</p></list-item></list></p></list-item><list-item><p id="Par229">Cytotoxic chemotherapy<list list-type="alpha-lower"><list-item><p id="Par230">Most reports on cytotoxic chemotherapy are retrospective; however, a systematic review reported response rates of 11%&#8211;82% and disease control rates of 71%&#8211;100% for low-dose methotrexate plus a vinca alkaloid (vinblastine or vinorelbine) and response rates of 33%&#8211;100% and disease control rates of 89%&#8211;100% for standard-dose anthracycline-based treatment [<xref ref-type="bibr" rid="CR193">193</xref>]. A prospective phase II trial of methotrexate plus vinblastine reported response rates of 35%&#8211;40% [<xref ref-type="bibr" rid="CR194">194</xref>, <xref ref-type="bibr" rid="CR195">195</xref>]. Retrospective studies have demonstrated the efficacy of doxorubicin plus dacarbazine and low-dose methotrexate plus vinca alkaloids for desmoid tumors in patients with FAP, with respective response rates of 63.6% and 40.3% [<xref ref-type="bibr" rid="CR196">196</xref>, <xref ref-type="bibr" rid="CR197">197</xref>].</p></list-item></list></p></list-item><list-item><p id="Par231">Gamma-secretase inhibitors<list list-type="alpha-lower"><list-item><p id="Par232">In November 2023, the US Food and Drug Administration approved nirogacestat, a gamma-secretase inhibitor targeting NOTCH receptors, for adult patients with progressive desmoid tumors requiring systemic therapy. The randomized Phase III DeFi trial evaluated the efficacy of nirogacestat for desmoid tumors and found that progression-free survival was significantly longer in the nirogacestat group than in the placebo group (hazard ratio 0.29). In a subgroup analysis limited to individuals with a family history of FAP, 8 of the 13 patients in the placebo group experienced progression compared with only 2 of the 11 patients in the nirogacestat group; however, there was no significant difference in progression-free survival between the two groups.</p></list-item></list></p></list-item></list>
</p><p id="Par233">
<italic toggle="yes">Surgery</italic>
<list list-type="bullet"><list-item><p id="Par234">Intra-abdominal desmoid tumors have a recurrence rate of 10%&#8211;68% even after complete resection [<xref ref-type="bibr" rid="CR169">169</xref>], while 5%&#8211;33% may spontaneously regress [<xref ref-type="bibr" rid="CR174">174</xref>&#8211;<xref ref-type="bibr" rid="CR176">176</xref>]. Given the substantial surgical trauma involved [<xref ref-type="bibr" rid="CR198">198</xref>], surgery should be limited to patients with symptoms such as bowel obstruction [<xref ref-type="bibr" rid="CR199">199</xref>]. Asymptomatic cases should be managed with observation or pharmacotherapy based on the Church classification [<xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR181">181</xref>] or the new Japanese classification [<xref ref-type="bibr" rid="CR182">182</xref>, <xref ref-type="bibr" rid="CR200">200</xref>]. Extra-abdominal desmoid tumors (mostly in the abdominal wall) are also generally managed with observation; however, surgery may be considered if the tumors are having a considerable impact on quality of life, such as by limiting movement.</p></list-item><list-item><p id="Par235">Recurrence may occur because of not only incomplete resection but also new tumor formation at the resection site; therefore, excessive resection of tumor margins should be avoided [<xref ref-type="bibr" rid="CR201">201</xref>].</p></list-item><list-item><p id="Par236">Surgery may be considered for gastrointestinal obstruction in patients with intra-abdominal desmoid tumors; however, resection can be challenging and may require extensive bowel resection [<xref ref-type="bibr" rid="CR199">199</xref>, <xref ref-type="bibr" rid="CR202">202</xref>].</p></list-item><list-item><p id="Par237">One report suggests no difference in the survival rate between complete resection and non-resection, including bypass procedures [<xref ref-type="bibr" rid="CR203">203</xref>].</p></list-item><list-item><p id="Par238">Data from Japan indicate that surgical resection was performed in 86% of extra-abdominal, 48% of intra-abdominal, and 71% of mixed-type desmoid tumors, with complete resection rates of 91% for extra-abdominal tumors and 46% for intra-abdominal tumors [<xref ref-type="bibr" rid="CR204">204</xref>].</p></list-item><list-item><p id="Par239">An analysis of 26 cases in Japan showed a tendency to treat stage I desmoid tumors with NSAIDs (primarily sulindac) or chemotherapy without surgery. In contrast, surgery was performed in 62.5% of stage III cases, with frequent use of NSAIDs (primarily sulindac), hormone therapy, and chemotherapy [<xref ref-type="bibr" rid="CR204">204</xref>].</p></list-item><list-item><p id="Par240">Although no prospective studies have been conducted, the Church classification [<xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR181">181</xref>] suggests observation or NSAIDs for stage I (maximum diameter&#8201;&lt;&#8201;10&#160;cm without size increasing trend for 6&#160;months, no tumor palpation, no symptomatic pain, nor restriction on daily life), NSAIDs&#8201;+&#8201;tamoxifen for stage II (maximum diameter&#8201;&lt;&#8201;10&#160;cm without size increasing trend for 6&#160;months, tumor palpation and/or symptomatic pain, without restriction on daily life), chemotherapy&#8201;&#177;&#8201;NSAIDs&#8201;&#177;&#8201;tamoxifen for stage III (maximum diameter between 10 to 20&#160;cm with size increasing trend, with urinary tract and/or intestinal obstruction, with restriction on daily life), and chemotherapy or bypass surgery for stage IV (maximum diameter&#8201;&gt;&#8201;20&#160;cm with more than 50% size increasing within 6&#160;months, with urinary tract and/or intestinal obstruction, necessitating hospitalization). No deaths have been reported for stages I/II, whereas the mortality rates for stages III and IV have been 15% and 44%, respectively [<xref ref-type="bibr" rid="CR181">181</xref>] (Fig.&#160;<xref rid="Fig16" ref-type="fig">16</xref>). Stent placement is recommended for ureteral obstruction [<xref ref-type="bibr" rid="CR181">181</xref>, <xref ref-type="bibr" rid="CR205">205</xref>].</p></list-item></list>
<fig id="Fig16" position="float" orientation="portrait"><label>Fig.&#160;16</label><caption><p>Disease classification by Church, et al. [<xref ref-type="bibr" rid="CR181">181</xref>] and treatment plans for intra-abdominal desmoid tumors. NSAIDs, nonsteroidal anti-inflammatory drugs, TAM, tamoxifen</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO16" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig16_HTML.jpg"/></fig>
</p></sec><sec id="Sec74"><title>Postoperative surveillance</title><p id="Par241">Surgical treatment of desmoid tumors (especially the intra-abdominal type) should be avoided whenever possible. However, if surgery is unavoidable, strict postoperative surveillance is necessary to monitor for early recurrence, and regular imaging examinations such as abdominal ultrasound, MRI, and CT scans should be included.</p></sec></sec><sec id="Sec75"><title>Other associated manifestations</title><p id="Par242">In addition to colorectal tumors, patients with FAP may also develop small bowel tumors, hepatoblastomas, adrenal tumors, and thyroid cancer.</p><sec id="Sec76"><title>Small bowel (jejunal and ileal) tumors</title><p id="Par243">
<list list-type="bullet"><list-item><p id="Par244">The cumulative risk of small bowel cancer in patients with FAP is&#8201;&lt;&#8201;1% (compared with 0.3% in the general population), with an average age of onset of 43&#160;years [<xref ref-type="bibr" rid="CR9">9</xref>]. A meta-analysis showed a positive correlation between the occurrence of small bowel tumors and duodenal tumors [<xref ref-type="bibr" rid="CR206">206</xref>]. The small intestine should be included during CT/MRI monitoring of desmoid tumors; however, no established evidence exists for regular imaging or endoscopic surveillance of the small intestine in patients with FAP [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR207">207</xref>]. Capsule endoscopy may also be considered, especially in cases with severe duodenal polyposis [<xref ref-type="bibr" rid="CR9">9</xref>].</p></list-item><list-item><p id="Par245">Reports suggest that capsule endoscopy can be completed safely in patients with FAP, even after total proctocolectomy, and in younger patients [<xref ref-type="bibr" rid="CR207">207</xref>&#8211;<xref ref-type="bibr" rid="CR210">210</xref>]. However, care should be taken to confirm the absence of obstructive lesions before capsule endoscopy and to retrieve the capsule after the examination, particularly in patients who have undergone total proctocolectomy [<xref ref-type="bibr" rid="CR211">211</xref>]. In patients with FAP, the detection rate of jejunal and ileal polyps using capsule endoscopy ranges from 30.4% to 60% [<xref ref-type="bibr" rid="CR207">207</xref>&#8211;<xref ref-type="bibr" rid="CR210">210</xref>]. A study of the distribution of jejunal and ileal polyps using capsule endoscopy in 29 patients with FAP found small bowel polyps in 21 cases, with 76% in the proximal jejunum and only 3% in the distal jejunum and ileum [<xref ref-type="bibr" rid="CR212">212</xref>]. However, the frequency of malignancy arising from small bowel polyps is unknown, and use of capsule endoscopy in the small bowel remains limited [<xref ref-type="bibr" rid="CR213">213</xref>, <xref ref-type="bibr" rid="CR214">214</xref>]. Capsule endoscopy should be considered in patients with FAP when malignancy is suspected in areas not observable by EGD.</p></list-item></list></p></sec><sec id="Sec77"><title>Adrenal tumors</title><p id="Par246">Adrenal tumors occur in 7.4%&#8211;16% of patients with FAP (compared with 1%&#8211;3% in the general population) [<xref ref-type="bibr" rid="CR215">215</xref>&#8211;<xref ref-type="bibr" rid="CR217">217</xref>]. In one study that included 311 patients with FAP, 48 (16%) were identified to have adrenal tumors, with an average age at diagnosis of 45&#160;years and bilateral tumors found in 23% of cases [<xref ref-type="bibr" rid="CR215">215</xref>]. Most were incidentally discovered on CT scans, with 80% being adenomas and over 97% being benign (including myelolipomas and hyperplasia). Only 1 case (approximately 2%) was cancer.</p></sec><sec id="Sec78"><title>Hepatoblastoma</title><p id="Par247">The incidence of hepatoblastoma is higher in young patients with FAP than in the general population [<xref ref-type="bibr" rid="CR218">218</xref>]. The cumulative risk ranges from 0.4% to 2.5%, with an average age of onset between 18 and 33&#160;months [<xref ref-type="bibr" rid="CR9">9</xref>]. A recent review of 109 patients with FAP-associated hepatoblastoma reported a male-to-female ratio of 2.6:1 and a median age of 20&#160;months (ranging from newborn to 11.6&#160;years) [<xref ref-type="bibr" rid="CR219">219</xref>]. Hepatoblastoma was identified before diagnosis of FAP in 35 cases (out of 49 with available data). De novo occurrence was observed in 12% of cases, with no correlation found between location of the <italic toggle="yes">APC</italic> variant and development of hepatoblastoma. Screening for hepatoblastoma by liver palpation, abdominal ultrasound, and serum alpha-fetoprotein every 3&#8211;6&#160;months until the age of 5&#160;years [<xref ref-type="bibr" rid="CR9">9</xref>] or every 2&#160;years until the age of 7&#160;years [<xref ref-type="bibr" rid="CR220">220</xref>] has been proposed. However, no high-evidence routine screening method exists for hepatoblastoma [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR220">220</xref>].</p></sec><sec id="Sec79"><title>Thyroid cancer</title><p id="Par248">The cumulative risk of thyroid cancer is higher in patients with FAP than in the general population (1.2&#8211;12% vs. 1.2%) [<xref ref-type="bibr" rid="CR9">9</xref>]. A recent meta-analysis reported thyroid cancer in approximately 2.6% of patients with FAP, with an average age at diagnosis of 31&#160;years and 95% of cases occurring in females. Papillary carcinoma accounted for 83% of cases, of which 26% were the cribriform-morular variant. In approximately one-third of the cases, thyroid cancer was diagnosed before FAP was identified. The tumor was bilateral in 46% of cases and multicentric in 59%. Furthermore, 79% of pathogenic variants were located at the 5&#8242; end of the <italic toggle="yes">APC</italic> gene [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. A Japanese study reported a frequency of 6.4% for thyroid cancer in patients with FAP, with a higher prevalence in women (a female to male ratio of 8:1) and an age range of 17&#8211;41&#160;years for women and 39&#8211;57&#160;years for men, which is consistent with another report [<xref ref-type="bibr" rid="CR221">221</xref>]. The prevalence of thyroid cancer was significantly higher in groups screened with ultrasound than in those without ultrasound screening (6.9% vs. 1.4%). Therefore, annual thyroid ultrasound examinations starting in adolescence are recommended [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Ultrasound should begin in late adolescence, followed by regular surveillance every 2&#8211;5&#160;years if the results are normal. Consultation with a thyroid specialist is recommended if abnormalities are detected. Shorter intervals between surveillance examinations should be considered if there is a family history of thyroid cancer [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec></sec></sec><sec id="Sec80"><title>Management of at-risk relatives and children</title><sec id="Sec81"><title>At-risk relatives</title><p id="Par249">
<list list-type="bullet"><list-item><p id="Par250">At-risk relatives (especially first-degree relatives, which include parents, children, and siblings) should receive a thorough explanation of the disease, and gastrointestinal surveillance, particularly of the colon/rectum, should be conducted with their consent.</p></list-item><list-item><p id="Par251">If at-risk relatives have colorectal adenomas (especially multiple adenomas), the diagnostic chart for hereditary colorectal polyposis (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>) should be followed.</p></list-item><list-item><p id="Par252">At-risk relatives with clinical symptoms related to FAP should be managed regardless of age.</p></list-item><list-item><p id="Par253">In patients with hereditary tumors, including FAP, collection and accurate recording of a family history using standard pedigree documentation is essential [<xref ref-type="bibr" rid="CR222">222</xref>&#8211;<xref ref-type="bibr" rid="CR224">224</xref>]. Updating family information periodically is recommended because a personal medical history may change.</p></list-item><list-item><p id="Par254">Genetic counseling should also be offered to at-risk relatives.</p></list-item><list-item><p id="Par255">If a GPV of the <italic toggle="yes">APC</italic> gene has been identified within a family, a diagnosis can be confirmed by genetic testing of normal tissue, such as a blood sample, and the appropriate timing for predictive diagnosis should be considered during genetic counseling. A genetic specialist must provide genetic counseling before and after genetic testing.</p></list-item></list></p></sec><sec id="Sec82"><title>Management of children</title><p id="Par256">
<list list-type="bullet"><list-item><p id="Par257">For classical FAP, consider genetic counseling and predictive diagnosis with parental involvement at the recommended age for starting colorectal surveillance (early to mid-teens). For AFAP, consider this in late adolescence.</p></list-item><list-item><p id="Par258">If active hepatoblastoma screening is considered, predictive diagnosis during infancy should also be considered.</p></list-item></list></p><sec id="Sec83"><title>Pediatric FAP</title><p id="Par259">
<italic toggle="yes">Gastrointestinal lesions</italic>
<list list-type="bullet"><list-item><p id="Par260">Multiple adenomas appear in the colon/rectum during adolescence. A registry study in the UK found that the number of colorectal polyps at the time of first total colonoscopy (at an average age of 13&#160;years) was&#8201;&lt;&#8201;100 in 79% of cases, 101&#8211;500 in 17%, and&#8201;&gt;&#8201;500 in 4%, with a median maximum polyp size of 2&#160;mm (range, 1&#8211;15) [<xref ref-type="bibr" rid="CR225">225</xref>]. Surveillance after the initial examination found that the number of polyps increased by a mean of 12.5 (range, 0&#8211;145) per year. The annual rate of increase in the number of colorectal polyps in pediatric patients with the codon 1309 pathogenic variant has been reported to be more rapid at 89 per year [<xref ref-type="bibr" rid="CR226">226</xref>].</p></list-item><list-item><p id="Par261">CRC is extremely rare in patients under 20&#160;years of age, and occurs in&#8201;&lt;&#8201;0.2% of patients with FAP [<xref ref-type="bibr" rid="CR30">30</xref>]. However, a total colonoscopy should be performed regardless of age if gastrointestinal symptoms, such as diarrhea or bloody stools, or anemia are present.</p></list-item><list-item><p id="Par262">Pediatric endoscopy: Care should be taken to avoid traumatic experiences from endoscopy that would make the child unwilling to undergo future examinations. In view of the varying stages of development and understanding among children in the target age group for FAP surveillance, it is important to explain the procedure and obtain informed assent in a way that is appropriate to the child&#8217;s developmental stage. Although bowel preparation is challenging, ascorbic acid-containing polyethylene glycol electrolyte solution is effective and safe [<xref ref-type="bibr" rid="CR227">227</xref>]. Active use of sedation and appropriately managed anesthesia is also recommended.</p></list-item></list>
</p><p id="Par263">
<italic toggle="yes">Extra-gastrointestinal lesions</italic>
<list list-type="bullet"><list-item><p id="Par264">Hepatoblastoma: Fewer than 2% of pediatric patients with FAP develop hepatoblastoma and primarily before the age of 3&#160;years [<xref ref-type="bibr" rid="CR228">228</xref>]. There are differing opinions on whether to recommend screening for hepatoblastoma (abdominal palpation, abdominal ultrasound, and serum alpha-fetoprotein every 3&#8211;6&#160;months until 5&#160;years of age [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR229">229</xref>] or every 2&#160;years until the age of 7&#160;years [<xref ref-type="bibr" rid="CR220">220</xref>]), depending on whether the effectiveness of screening is supported by evidence. For infants at risk of FAP, parents should be informed about the risk of hepatoblastoma, and the decision should be made considering the parents&#8217; wishes.</p></list-item><list-item><p id="Par265">Thyroid cancer, desmoid tumors, brain tumors (e.g., medulloblastoma) may also occur in pediatric patients.</p></list-item></list>
</p><p id="Par266">
<italic toggle="yes">Congenital hypertrophy of the retinal pigment epithelium (CHRPE)</italic>
</p><p id="Par267">CHRPE is a discontinuous flat pigmented lesion of the retina that is present from birth in approximately 80% of patients with FAP. It is asymptomatic and does not require treatment because it does not affect vision or become malignant. Bilateral or multiple CHRPE is a characteristic finding in FAP.</p></sec></sec></sec><sec id="Sec84"><title>Clinical questions</title><sec id="Sec85"><title>CQ1: Should genetic testing be performed in patients with colorectal adenomatous polyposis?</title><p id="Par268">(Evidence level: C, Recommendation grade: 1, Agreement rate: 88.9%).</p><p id="Par269"><bold>Recommendation:</bold> Genetic testing must be performed in patients with colorectal adenomatous polyposis for several reasons, including diagnostic guidance, therapeutic decision-making, and aiding in surveillance strategies for the proband as well as diagnosis for at-risk relatives.</p><sec id="Sec86"><title>Comments</title><p id="Par270">Eight clinical guidelines, seven case series studies, and one cross-sectional study on genetic testing for patients with colorectal adenomatous polyposis were reviewed. Patients with FAP often develop adenomatous polyposis in the colon/rectum as a characteristic clinical feature, which means that genetic testing is often omitted. However, certain pathogenic <italic toggle="yes">APC</italic> variants are associated with the density of colorectal adenomas and the occurrence of extracolonic manifestations (e.g., fundic gland polyposis, duodenal adenomas, osteomas, desmoid tumors, and the CHRPE phenotype) in patients with FAP [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR128">128</xref>]. Therefore, the genotype can be a reference for surveillance, timing of prophylactic colectomy, choice of surgical procedure, and prediction of the risk of postoperative desmoid tumors.</p><p id="Par271">Notably, 20%&#8211;25% of FAP cases arise de novo, and there may be individuals with a pathogenic <italic toggle="yes">APC</italic> variant even in the absence of a family history of adenomatous polyposis [<xref ref-type="bibr" rid="CR230">230</xref>]. In contrast, while relatives who share the same pathogenic variant as the proband also develop colorectal adenomatous polyposis, their colorectal adenomas may not be prominent even in adulthood in families with low adenoma density. Moreover, some individuals hesitate to undergo colonoscopy because of fear or embarrassment, even those who are members of families in which adenomatous polyposis occurs from a relatively young age. For these individuals, genetic testing can be substituted for colonoscopy to diagnose FAP. Surveillance interventions should be initiated if the same pathogenic variant is found in a relative [<xref ref-type="bibr" rid="CR220">220</xref>].</p><p id="Par272">In some cases, pathogenic <italic toggle="yes">APC</italic> variants are not detected, even when FAP is clinically suspected. Reports from Western countries indicate that pathogenic <italic toggle="yes">APC</italic> variants are found in 60%&#8211;70% of patients who have&#8201;&#8805;&#8201;100 adenomas; however, pathogenic variants of <italic toggle="yes">APC</italic>, biallelic <italic toggle="yes">MUTYH</italic> are observed in only 10%, 7% of those who have 20&#8211;99 adenomas, respectively. The detection rates decrease further to 5% and 4%, respectively, in those who have 10&#8211;19 adenomas [<xref ref-type="bibr" rid="CR33">33</xref>]. A Japanese study in which 123 patients with&#8201;&#8805;&#8201;10 adenomatous polyps in the colon/rectum were investigated by next-generation sequencing identified pathogenic <italic toggle="yes">APC</italic> variants in 93% of patients with dense adenomatous polyposis, 72% of those with sparse adenomatous polyposis, and 17% of those with&#8201;&lt;&#8201;100 adenomas, suggesting a correlation between the density of colorectal adenomas and the detection rate of pathogenic <italic toggle="yes">APC</italic> variants [<xref ref-type="bibr" rid="CR35">35</xref>]. Furthermore, 7.3%&#8211;20% of cases with colorectal adenomatous polyposis involve somatic <italic toggle="yes">APC</italic> mosaicism [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Somatic <italic toggle="yes">APC</italic> mosaicism may be associated with atypical phenotypes, such as adenomatous polyposis confined to certain areas of the colon/rectum or an absence of FAP-associated manifestations. Diagnosis of somatic mosaicism requires the ability to detect low-frequency variants, for which next-generation sequencing is preferable to traditional Sanger sequencing.</p><p id="Par273">Reasons for not detecting GPVs in the <italic toggle="yes">APC</italic> gene, even when FAP is suspected, may include (1) <italic toggle="yes">APC</italic> variants that are undetectable by the method used, (2) somatic <italic toggle="yes">APC</italic> mosaicism, and (3) MAP, PPAP, or other known or unknown genes that cause colorectal adenomatous polyposis. This tendency is more apparent in patients with oligopolyposis (10&#8211;99 adenomas), which is genetically heterogeneous. Therefore, MGPT, which simultaneously analyzes multiple genes associated with hereditary tumors, is recommended for genetic testing in patients with colorectal adenomatous polyposis [<xref ref-type="bibr" rid="CR231">231</xref>]. Genetic testing for <italic toggle="yes">APC</italic> may be selected in cases where FAP is strongly suspected based on adenoma density, the presence of extracolonic manifestations, or family history. However, MGPT for hereditary tumors should be considered if no pathogenic variants are found.</p><p id="Par274">Western guidelines recommend genetic testing for adolescent patients with colorectal adenomatous polyposis, including those who are school-aged [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR232">232</xref>, <xref ref-type="bibr" rid="CR233">233</xref>]. They also strongly recommend predictive genetic testing for at-risk relatives, including children, if an at-risk relative carries a pathogenic <italic toggle="yes">APC</italic> variant [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR220">220</xref>, <xref ref-type="bibr" rid="CR229">229</xref>]. Genetic testing in patients with colorectal adenomatous polyposis should be considered useful for diagnosis, therapeutic decision-making, and surveillance of the proband, as well as for diagnosis of at-risk relatives.</p></sec></sec><sec id="Sec87"><title>CQ2: Is chemoprevention effective for patients with FAP who have not undergone colectomy and not developed CRC?</title><p id="Par275">(<bold>Evidence level: B</bold>, <bold>Recommendation grade: None</bold>, <bold>Agreement rate: 94.4%).</bold></p><p id="Par276"><bold>Recommendation:</bold> Chemoprevention has shown some ability to suppress adenoma in patients with FAP who do not have a past history of CRC or colectomy during limited periods of administration and observation, despite the risk of treatment-related adverse events. However, there is insufficient evidence for recommending chemoprevention because of the lack of robust data on its efficacy and long-term safety.</p><sec id="Sec88"><title>Comments</title><p id="Par277">Fifteen randomized controlled trials and one cohort study of chemoprevention in patients with FAP who had not undergone colectomy or developed CRC were reviewed. A manual search of the reference lists for these studies identified four additional studies concerning cardiovascular events related to COX-2 inhibitors.</p><p id="Par278">The chemopreventive effects of sulindac (an NSAID) have been evaluated in patients with FAP. Sulindac was found to suppress the growth and proliferation of colorectal adenomas [<xref ref-type="bibr" rid="CR234">234</xref>, <xref ref-type="bibr" rid="CR235">235</xref>]; however, adenomas tended to increase and enlarge after sulindac was discontinued [<xref ref-type="bibr" rid="CR235">235</xref>]. A recent retrospective observational study also found that sulindac administered for an average of 7.4&#160;years in 39 patients with FAP and confirmed pathogenic <italic toggle="yes">APC</italic> variants who refused prophylactic colectomy stabilized polyp numbers in all but 1 case [<xref ref-type="bibr" rid="CR236">236</xref>]. Clinical trials of combined therapies involving sulindac and other NSAIDs (e.g., eflornithine or erlotinib) also found a reduction in the numbers of adenomatous polyps and a delay in the need for colectomy; however, these combination therapies were also associated with adverse events [<xref ref-type="bibr" rid="CR237">237</xref>&#8211;<xref ref-type="bibr" rid="CR239">239</xref>].</p><p id="Par279">In another study that included 77 patients with FAP, administration of celecoxib (a selective COX-2 inhibitor) at a dosage of 800&#160;mg/day for 6&#160;months resulted in a reduction in the number and size of colorectal adenomas [<xref ref-type="bibr" rid="CR240">240</xref>]. In pediatric patients with FAP, celecoxib suppressed development of adenomatous polyps without an increase in the adverse event rate above that with placebo [<xref ref-type="bibr" rid="CR241">241</xref>]. However, a clinical trial that investigated the polyp-suppressing effects of celecoxib in patients without FAP but with a history of colorectal tumors found an increase in cardiovascular adverse events [<xref ref-type="bibr" rid="CR242">242</xref>]. Other selective COX-2 inhibitors, such as rofecoxib and tiracoxib, have a limited ability to suppress adenomatous polyps [<xref ref-type="bibr" rid="CR243">243</xref>, <xref ref-type="bibr" rid="CR244">244</xref>]; however, like celecoxib, they are associated with an increase in thrombotic cardiovascular events [<xref ref-type="bibr" rid="CR245">245</xref>].</p><p id="Par280">Eicosapentaenoic acid, derived from fish oil, has been found to decrease the number and size of colorectal adenomas in patients with FAP after IRA [<xref ref-type="bibr" rid="CR246">246</xref>]. However, it does not reduce the risk of adenoma in the general population [<xref ref-type="bibr" rid="CR247">247</xref>].</p><p id="Par281">The CAPP1 trial evaluated the chemopreventive effects of high-dose aspirin (600&#160;mg/day) and resistant starch in young patients with FAP (age 10&#8211;21&#160;years). However, neither intervention significantly reduced the number of adenomas in the sigmoid colon and rectum [<xref ref-type="bibr" rid="CR248">248</xref>]. In Japan, a small, double-blind, randomized controlled trial (J-FAPP II) of low-dose aspirin (100&#160;mg/day for 6&#8211;10&#160;months) found no significant reduction in the size of adenomas [<xref ref-type="bibr" rid="CR249">249</xref>]. Subsequently, J-FAPP IV, conducted with a 2&#8201;&#215;&#8201;2 factorial design comparing low-dose aspirin (100&#160;mg/day) and mesalazine (2&#160;g/day) against placebo, demonstrated a significant reduction in polyp growth after 8&#160;months of low-dose aspirin [<xref ref-type="bibr" rid="CR250">250</xref>]. Moreover, an economic analysis suggested that combining low-dose aspirin with intensive downstaging polypectomy may be more cost-effective than intensive downstaging polypectomy alone or surgical colectomy in patients who have FAP without dense adenomas but have not previously undergone colectomy [<xref ref-type="bibr" rid="CR251">251</xref>]. However, administration of low-dose aspirin in healthy older individuals increases the risk of intracranial hemorrhage [<xref ref-type="bibr" rid="CR252">252</xref>], highlighting the need for clinical trials to assess the long-term impact of low-dose aspirin on progression of the FAP phenotype.</p><p id="Par282">In conclusion, chemoprevention in patients with FAP who have not undergone colectomy or developed CRC has demonstrated adenoma-suppressing effects during limited periods of administration and observation. However, the evidence remains insufficient regarding its effectiveness in avoiding colectomy and preventing cancer and its safety in long-term use.</p></sec></sec><sec id="Sec89"><title>CQ3: Is endoscopic treatment useful for duodenal adenomas, including periampullary adenomas, in patients with FAP?</title><p id="Par283">(Evidence level: C, Recommendation grade: 2, Agreement rate: 100%).</p><sec id="Sec90"><title>Recommendation:</title><p id="Par284">
<list list-type="bullet"><list-item><p id="Par285">Endoscopic treatment for non-periampullary duodenal adenomas in patients with FAP is weakly recommended when performed with careful case selection and is a safe treatment method that could potentially avoid surgical intervention.</p></list-item><list-item><p id="Par286">Endoscopic treatment for periampullary adenomas in patients with FAP is also weakly recommended for lesions that are clinically significant and warrant treatment.</p></list-item></list></p></sec><sec id="Sec91"><title>Comments</title><p id="Par287">One prospective cohort study, seven retrospective studies, and one study identified by manual searching were reviewed to evaluate the effectiveness and safety of endoscopic treatment for non-periampullary duodenal adenomas. One systematic review and two retrospective studies were reviewed for periampullary adenomas (ampullary adenomas).</p><p id="Par288">Duodenal adenomas occur in 90% of patients with FAP by the age of 70&#160;years [<xref ref-type="bibr" rid="CR253">253</xref>], with the incidence of duodenal cancer increasing to 5%&#8211;8% by the age of 50&#8211;60&#160;years and reaching 18% by the age of 75&#160;years [<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR161">161</xref>, <xref ref-type="bibr" rid="CR253">253</xref>, <xref ref-type="bibr" rid="CR254">254</xref>]. Duodenal cancer is the second leading cause of death in patients with FAP [<xref ref-type="bibr" rid="CR138">138</xref>], accounting for 3%&#8211;12% of deaths [<xref ref-type="bibr" rid="CR253">253</xref>, <xref ref-type="bibr" rid="CR255">255</xref>], and it is increasing as the proportion of deaths caused by CRC decreases. Periampullary adenoma progresses slowly [<xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR256">256</xref>], necessitating use of treatment strategies that are different from those used for non-periampullary adenoma.</p><p id="Par289">
<italic toggle="yes">1. Endoscopic treatment for non-periampullary duodenal adenomas in patients with FAP</italic>
</p><p id="Par290">The necessity for and use of endoscopic treatment for duodenal adenomas in patients with FAP have been investigated. Until the early 2010s, endoscopic mucosal resection and argon plasma coagulation were commonly performed. However, these procedures are associated with high adverse event rates (5&#8211;25%), and 73&#8211;100% of patients develop multiple new adenomas in the long term [<xref ref-type="bibr" rid="CR257">257</xref>, <xref ref-type="bibr" rid="CR258">258</xref>]. Consequently, both local and international guidelines have made limited recommendations for endoscopic treatment of duodenal adenomas in patients with FAP [<xref ref-type="bibr" rid="CR233">233</xref>, <xref ref-type="bibr" rid="CR259">259</xref>].</p><p id="Par291">However, since the late 2010s, the introduction of cold polypectomy for small lesions and selective endoscopic treatment targeting only lesions measuring&#8201;&gt;&#8201;10&#160;mm and those with morphological changes have resulted in lower adverse event rates (2%&#8211;13%) [<xref ref-type="bibr" rid="CR157">157</xref>, <xref ref-type="bibr" rid="CR260">260</xref>, <xref ref-type="bibr" rid="CR261">261</xref>]. The occurrence of invasive or advanced cancer has been minimal after endoscopic treatment of duodenal adenomas, and surgical intervention has been avoided in 74%&#8211;100% of cases during follow-up periods of 49&#8211;101&#160;months [<xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR261">261</xref>]. A prospective interventional study also suggests the possibility of downgrading from Spigelman stage IV [<xref ref-type="bibr" rid="CR261">261</xref>]. However, many studies are retrospective, with insufficient follow-up durations and a lack of direct comparison with untreated or surgical cases; therefore, the cost-effectiveness of endoscopic intervention remains unclear. Endoscopic treatment for non-periampullary duodenal adenomas should be performed cautiously, considering the risks and benefits, and only by experts. The use of a thin colonoscope, capsule endoscopy, or balloon endoscopy should be considered if polyps are also present distal to the duodenum, including in the horizontal portion [<xref ref-type="bibr" rid="CR213">213</xref>, <xref ref-type="bibr" rid="CR261">261</xref>, <xref ref-type="bibr" rid="CR262">262</xref>].</p><p id="Par292">
<italic toggle="yes">2. Endoscopic treatment for periampullary adenomas in patients with FAP</italic>
</p><p id="Par293">Periampullary adenomas in patients with FAP often progress slowly [<xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR256">256</xref>], and biopsies from visually normal ampullas offer little benefit [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR153">153</xref>]. Treatment for periampullary adenomas should target lesions&#8201;&gt;&#8201;10&#160;mm, those suspected of high-grade dysplasia on endoscopic observation, and those with villous components (tubulovillous or villous adenoma) confirmed by biopsy [<xref ref-type="bibr" rid="CR256">256</xref>]. Endoscopic ampullectomy is performed for periampullary adenomas with technical success rates of 78%&#8211;90%; however, recurrence rates are also high at 25%&#8211;33% [<xref ref-type="bibr" rid="CR263">263</xref>&#8211;<xref ref-type="bibr" rid="CR265">265</xref>]. In one report, 75% of recurrences could be treated with additional endoscopic interventions [<xref ref-type="bibr" rid="CR264">264</xref>], indicating that endoscopic ampullectomy could potentially avoid surgical intervention. However, the adverse event rates for endoscopic ampullectomy have included bleeding (in 9%&#8211;11% of cases), acute pancreatitis (2%&#8211;15%), and perforation (2%&#8211;4%) [<xref ref-type="bibr" rid="CR263">263</xref>&#8211;<xref ref-type="bibr" rid="CR265">265</xref>], which means that the procedure should be performed cautiously and only by experts.</p></sec></sec><sec id="Sec92"><title>CQ4: Is surveillance for desmoid tumors useful in patients with FAP?</title><p id="Par294">(Evidence level: C, Recommendation grade: 2, Agreement rate: 94.4%).</p><p id="Par295"><bold>Recommendation:</bold> Surveillance for desmoid tumors in patients with FAP is weakly recommended, especially considering that treatment interventions may become more invasive if the tumors are diagnosed when symptomatic.</p><sec id="Sec93"><title>Comments</title><p id="Par296">One meta-analysis, two systematic reviews, one cohort study, three case&#8211;control studies, five case series, three case reports, and eight review articles were reviewed to evaluate the use of surveillance for desmoid tumors in patients with FAP.</p><p id="Par297">Intra-abdominal desmoid tumors are the second leading cause of death in patients with FAP and can affect life expectancy. In a meta-analysis that included 4,625 patients with FAP [<xref ref-type="bibr" rid="CR15">15</xref>], risk factors for development of a desmoid tumor included a family history (odds ratio [OR] 7.02, 95% confidence interval [CI] 4.15&#8211;11.9), GPVs in the <italic toggle="yes">APC</italic> gene located distal to codon 1399 (OR 4.37, 95% CI 2.14&#8211;8.91), a history of abdominal surgery (OR 3.35, 95% CI 1.33&#8211;8.41), and female sex (OR 1.57, 95% CI 1.13&#8211;2.18), with 41% of desmoid tumors occurring intra-abdominally. Furthermore, a registry study from four European countries reported that 53% of desmoid tumors developed after colectomy [<xref ref-type="bibr" rid="CR179">179</xref>]. A recent meta-analysis of 6,452 patients with FAP also identified a history of abdominal surgery as a risk factor for desmoid tumors (OR 3.40, 95% CI 1.64&#8211;7.03). No significant difference in the incidence of desmoid tumors was observed between patients who underwent total colectomy with IRA and those who underwent total proctocolectomy with IPAA or between open surgery and laparoscopic surgery [<xref ref-type="bibr" rid="CR266">266</xref>]. However, when analyzing among laparoscopic surgery, they reported higher desmoid tumor incidence after laparoscopic IPAA compared to laparoscopic IRA [<xref ref-type="bibr" rid="CR266">266</xref>]. A multicenter study in Japan reported that 71.8% of desmoid tumors that developed in patients with FAP after colectomy were intra-abdominal [<xref ref-type="bibr" rid="CR172">172</xref>]. Therefore, surveillance for intra-abdominal desmoid tumors is particularly important after abdominal surgery in patients with FAP.</p><p id="Par298">In terms of timing of onset, several international reports indicate that desmoid tumors occur at a median of 3&#8211;4&#160;years after surgery, with some cases reported as late as 9&#160;years postoperatively [<xref ref-type="bibr" rid="CR15">15</xref>]. A multicenter study in Japan found the median time of onset to be 2.2&#160;years after surgery [<xref ref-type="bibr" rid="CR172">172</xref>].</p><p id="Par299">Although no prospective studies have directly demonstrated the usefulness of postoperative surveillance for desmoid tumors in patients with FAP, the available evidence suggests that not all desmoid tumors in patients with FAP require intervention. However, more invasive interventions may be necessary if a desmoid tumor is very advanced at the time of diagnosis. Specifically, when symptomatic intra-abdominal desmoid tumors are detected, they are often at an advanced stage, such as stage III using Church&#8217;s system [<xref ref-type="bibr" rid="CR205">205</xref>] or grade 4&#8211;5 using Ishida&#8217;s severity classification [<xref ref-type="bibr" rid="CR182">182</xref>], and typically require invasive treatment [<xref ref-type="bibr" rid="CR183">183</xref>]. Therefore, diagnosing asymptomatic desmoid tumors during postoperative surveillance could potentially allow for less invasive treatment interventions.</p><p id="Par300">In conclusion, given that early diagnosis of asymptomatic desmoid tumors may afford patients the chance to try less invasive treatment, it is weakly recommended to conduct surveillance for desmoid tumors in patients with FAP, particularly after abdominal surgery.</p></sec></sec><sec id="Sec94"><title>CQ5: Is surveillance for thyroid cancer useful in patients with FAP?</title><p id="Par301">(Evidence level: C, Recommendation grade: 2, Agreement rate: 100%).</p><p id="Par302"><bold>Recommendation:</bold> Surveillance for thyroid cancer is weakly recommended for young female patients with FAP because of their increased risk of developing the disease.</p><sec id="Sec95"><title>Comments</title><p id="Par303">One meta-analysis, one systematic review, two case&#8211;control studies, one case series, and eight review articles were reviewed for surveillance of thyroid cancer in patients with FAP. Most thyroid cancers in these patients are papillary carcinomas, with&#8201;&gt;&#8201;50% exhibiting the distinctive cribriform-morular variant histology. The incidence of multifocality is high (28.6%&#8211;69%), as is that of bilaterality (42%&#8211;67%); however, the prognosis is relatively favorable. A meta-analysis that investigated thyroid cancer in FAP analyzed 9,821 patients and found that 79.2% of those who developed thyroid cancer had a GPV in the <italic toggle="yes">APC</italic> mutation cluster region (codons 1286&#8211;1513), and 95% of these cases were female [<xref ref-type="bibr" rid="CR16">16</xref>]. Furthermore, a Japanese study that included 129 patients with FAP who underwent neck ultrasound reported that women under 35 years of age were at higher risk of thyroid cancer [<xref ref-type="bibr" rid="CR267">267</xref>].</p><p id="Par304">While there are recommendations for thyroid cancer surveillance in patients with FAP using neck palpation and ultrasound, there is no high-level evidence from prospective studies that directly demonstrates its effectiveness. A multicenter study performed by the Colorectal Cancer Study Group that included 282 patients with FAP found that the median age at the time of diagnosis of FAP was 30 years [<xref ref-type="bibr" rid="CR221">221</xref>]. In contrast, the median age at diagnosis of thyroid cancer was 27.5 years, with some patients being diagnosed with thyroid cancer before the diagnosis of FAP. The cumulative incidence of thyroid cancer was significantly higher in women (11.4%, 16 cases) than in men (1.4%, only 2 cases), and most cases occurred before the age of 50 years. Female sex and age younger than 33 years were independent high-risk factors for thyroid cancer. In the same study, a meta-analysis was conducted that found a 1.6% incidence of thyroid cancer among patients with FAP, with an increasing trend in incidence since 2000. The study recommended considering ultrasound surveillance of the neck from the age of 20 years onward.</p><p id="Par305">International reports also recommend biennial neck ultrasound for patients with FAP and thyroid nodules or other findings because of the increased risk of thyroid cancer [<xref ref-type="bibr" rid="CR268">268</xref>]. However, there are no data to support use of thyroid surveillance in older patients with FAP, even for women.</p><p id="Par306">In conclusion, surveillance for thyroid cancer using neck palpation and ultrasound is weakly recommended for high-risk patients with FAP, particularly those who are young and female.</p></sec></sec></sec></sec><sec id="Sec96"><title>Chapter III. Lynch syndrome</title><sec id="Sec97"><title>Overview</title><p id="Par307">Lynch syndrome is a hereditary autosomal dominant disease that is primarily caused by a germline pathogenic variant (GPV) in one of the DNA mismatch repair (MMR) genes (Side Note III-1: Germline epimutation). Lynch syndrome is characterized mainly by colorectal cancer (CRC) and endometrial cancer, which have distinctive pathological features, owing to the breakdown of the MMR mechanism. Various associated tumors can develop in patients and their relatives, necessitating surveillance and treatment.</p><p id="Par308">Side Note III-1: Germline epimutation</p><p id="Par309">Epimutations have been found to contribute to tumorigenesis in some cases of Lynch syndrome. Epimutations are modifications of molecules involved in gene expression, such as aberrant DNA methylation, that can cause changes in gene expression without alterations in the DNA sequence. Although rare, aberrant germline methylation (i.e., hypermethylation) of the promoter region of the <italic toggle="yes">MLH1</italic> has been reported to be a cause of Lynch syndrome [<xref ref-type="bibr" rid="CR269">269</xref>].</p><sec id="Sec98"><title>Clinical characteristics</title><p id="Par310">
<list list-type="bullet"><list-item><p id="Par311">CRC associated with Lynch syndrome differs from sporadic CRC in the following ways:<list list-type="simple"><list-item><label>o</label><p id="Par312">Age of onset is younger.</p></list-item><list-item><label>o</label><p id="Par313">Multiple tumors (synchronous or metachronous) are present.</p></list-item><list-item><label>o</label><p id="Par314">Tumors develop predominantly in the proximal (right-sided) colon.</p></list-item><list-item><label>o</label><p id="Par315">Poorly differentiated adenocarcinoma is more common.</p></list-item></list></p></list-item><list-item><p id="Par316">The histological features of CRC associated with Lynch syndrome include the presence of tumor-infiltrating lymphocytes, a medullary growth pattern, mucinous/signet ring cell differentiation, and a Crohn&#8217;s-like lymphocytic reaction [<xref ref-type="bibr" rid="CR270">270</xref>&#8211;<xref ref-type="bibr" rid="CR273">273</xref>] (Section III-2&#8211;1-2: Characteristic histopathological features of CRC with MMR deficiency).</p></list-item><list-item><p id="Par317">A variety of other Lynch syndrome-associated extra-colonic cancers, such as endometrial cancer, can also develop (Section III-1&#8211;3: Lynch syndrome-associated tumors).</p></list-item></list></p></sec><sec id="Sec99"><title>Causative genes and mechanism of carcinogenesis</title><sec id="Sec100"><title>Causative genes and mode of inheritance</title><p id="Par318">
<list list-type="bullet"><list-item><p id="Par319"><italic toggle="yes">MSH2</italic> on chromosome 2 (2p21-p16)</p></list-item><list-item><p id="Par320"><italic toggle="yes">MSH6</italic> on chromosome 2 (2p16.3)</p></list-item><list-item><p id="Par321"><italic toggle="yes">EPCAM</italic> on chromosome 2 (2p21)</p></list-item><list-item><p id="Par322"><italic toggle="yes">MLH1</italic> on chromosome 3 (3p22.2)</p></list-item><list-item><p id="Par323"><italic toggle="yes">PMS2</italic> on chromosome 7 (7p22.1)</p></list-item><list-item><p id="Par324">Autosomal dominant inheritance</p></list-item></list></p><p id="Par325">Lynch syndrome is diagnosed when a GPV is identified in any of these causative genes.</p></sec><sec id="Sec101"><title>Mechanism of carcinogenesis</title><p id="Par326">
<list list-type="bullet"><list-item><p id="Par327">In patients with Lynch syndrome, a GPV is present in one allele of an MMR gene. The MMR mechanism becomes compromised when the wild-type allele subsequently mutates (or is methylated in the promoter region), resulting in abnormalities in repeat numbers, which frequently occur in microsatellite regions, which are simple repetitive sequences within the genome. Genes involved in tumor suppression (e.g., <italic toggle="yes">TGFBR2</italic>), cell proliferation, DNA repair (e.g., <italic toggle="yes">MSH3</italic>, <italic toggle="yes">MSH6</italic>), and apoptosis (e.g., <italic toggle="yes">BAX</italic>) contain these repetitive sequences in the coding regions, where alterations tend to develop. The proteins encoded by these MMR genes form heterodimers with specific MMR proteins, which recognize single base substitutions or small insertions/deletions that escape the proofreading function of DNA polymerase during replication.</p></list-item><list-item><p id="Par328"><italic toggle="yes">EPCAM</italic>, which is essential for transcription termination, is adjacent to the upstream region of <italic toggle="yes">MSH2</italic>; deletions in the 3&#8242; region of <italic toggle="yes">EPCAM</italic> can lead to Lynch syndrome by causing abnormal methylation in the <italic toggle="yes">MSH2</italic> promoter, resulting in loss of MSH2 protein expression.</p></list-item><list-item><p id="Par329">It has been suggested that Lynch syndrome-associated CRC involves a carcinogenesis pathway similar to that in sporadic CRC involving the adenoma-carcinoma sequence. However, many details remain unclear (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>: Representative mechanism of carcinogenesis in FAP and Lynch syndrome).</p></list-item></list></p></sec></sec><sec id="Sec102"><title>Lynch syndrome-associated tumors</title><p id="Par330">
<list list-type="bullet"><list-item><p id="Par331">Lynch syndrome is associated with various malignancies, including not only CRC but also endometrial, ovarian, gastric, small intestine, bile duct, pancreatic, renal pelvis, ureter, brain, and skin tumors (Side Note III-2: Muir&#8211;Torre syndrome [<xref ref-type="bibr" rid="CR274">274</xref>]). Breast, bladder [<xref ref-type="bibr" rid="CR275">275</xref>], and prostate cancers [<xref ref-type="bibr" rid="CR276">276</xref>] have also been reported to develop in association with Lynch syndrome [<xref ref-type="bibr" rid="CR11">11</xref>]. The risk of associated tumors in Lynch syndrome varies depending on the type of causative gene, type of pathogenic variant, and environmental factors, and is high for CRC and endometrial cancer. However, not all carriers of pathogenic variants will develop Lynch syndrome-associated tumors (Table&#160;<xref rid="Tab10" ref-type="table">10</xref>) [<xref ref-type="bibr" rid="CR271">271</xref>, <xref ref-type="bibr" rid="CR277">277</xref>&#8211;<xref ref-type="bibr" rid="CR283">283</xref>].</p></list-item><list-item><p id="Par332">In cases with deletions limited to <italic toggle="yes">EPCAM</italic>, the risk of CRC is comparable with that in Lynch syndrome caused by pathogenic variants in <italic toggle="yes">MSH2</italic>, but the risk of endometrial cancer is lower. The risk of malignancy is comparable with that in Lynch syndrome with <italic toggle="yes">MSH2</italic> pathogenic variants when the deletion extends to the 5&#8242; region of <italic toggle="yes">MSH2</italic> [<xref ref-type="bibr" rid="CR284">284</xref>&#8211;<xref ref-type="bibr" rid="CR286">286</xref>]. <italic toggle="yes">EPCAM</italic> deletions account for 1%&#8211;3% of cases of Lynch syndrome [<xref ref-type="bibr" rid="CR286">286</xref>].</p></list-item></list><table-wrap id="Tab10" position="float" orientation="portrait"><label>Table&#160;10</label><caption><p>Cumulative risks for diagnosis by the age of 80</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Cancer</th><th align="left" colspan="6" rowspan="1">Cumulative risks (%)</th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"><italic toggle="yes">MLH1</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">MSH2</italic> and<italic toggle="yes"> EPCAM</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">MSH6</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">PMS2</italic></th><th align="left" colspan="1" rowspan="1">General population in USA<sup>39)</sup></th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Colorectal</td><td align="left" colspan="1" rowspan="1">46&#8211;61</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">33&#8211;52</td><td align="left" colspan="1" rowspan="1">10&#8211;44</td><td align="left" colspan="1" rowspan="1">8.7&#8211;20</td><td align="left" colspan="1" rowspan="1">4.1</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR334">334</xref>, <xref ref-type="bibr" rid="CR410">410</xref>, <xref ref-type="bibr" rid="CR429">429</xref>, <xref ref-type="bibr" rid="CR433">433</xref>, <xref ref-type="bibr" rid="CR434">434</xref><xref ref-type="bibr" rid="CR466">466</xref>&#8211;<xref ref-type="bibr" rid="CR469">469</xref>, <xref ref-type="bibr" rid="CR471">471</xref>, <xref ref-type="bibr" rid="CR474">474</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Endometrial</td><td align="left" colspan="1" rowspan="1">34&#8211;54</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">21&#8211;57</td><td align="left" colspan="1" rowspan="1">16&#8211;49</td><td align="left" colspan="1" rowspan="1">13&#8211;26</td><td align="left" colspan="1" rowspan="1">3.1</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR410">410</xref>, <xref ref-type="bibr" rid="CR428">428</xref>, <xref ref-type="bibr" rid="CR434">434</xref>, <xref ref-type="bibr" rid="CR467">467</xref>, <xref ref-type="bibr" rid="CR469">469</xref>, <xref ref-type="bibr" rid="CR471">471</xref>, <xref ref-type="bibr" rid="CR473">473</xref>, <xref ref-type="bibr" rid="CR474">474</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Ovarian</td><td align="left" colspan="1" rowspan="1">4&#8211;20</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">8&#8211;38</td><td align="left" colspan="1" rowspan="1">&#8201;&#8804;&#8201;1&#8211;13</td><td align="left" colspan="1" rowspan="1">1.3&#8211;3</td><td align="left" colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR295">295</xref>, <xref ref-type="bibr" rid="CR410">410</xref>, <xref ref-type="bibr" rid="CR429">429</xref>, <xref ref-type="bibr" rid="CR434">434</xref>, <xref ref-type="bibr" rid="CR471">471</xref>, <xref ref-type="bibr" rid="CR473">473</xref>, <xref ref-type="bibr" rid="CR474">474</xref>&#8211;<xref ref-type="bibr" rid="CR472">472</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Upper urinary tract</td><td align="left" colspan="1" rowspan="1">0.2&#8211;5</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">2.2&#8211;28</td><td align="left" colspan="1" rowspan="1">0.7&#8211;5.5</td><td align="left" colspan="1" rowspan="1">&#8201;&#8804;&#8201;1&#8211;3.7</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR280">280</xref>, <xref ref-type="bibr" rid="CR410">410</xref>, <xref ref-type="bibr" rid="CR429">429</xref>, <xref ref-type="bibr" rid="CR434">434</xref>, <xref ref-type="bibr" rid="CR471">471</xref>, <xref ref-type="bibr" rid="CR473">473</xref>, <xref ref-type="bibr" rid="CR474">474</xref>&#8211;<xref ref-type="bibr" rid="CR472">472</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Bladder</td><td align="left" colspan="1" rowspan="1">2&#8211;7</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">4.4&#8211;12.8</td><td align="left" colspan="1" rowspan="1">1&#8211;8.2</td><td align="left" colspan="1" rowspan="1">&#8201;&#8804;&#8201;1&#8211;2.4</td><td align="left" colspan="1" rowspan="1">2.3</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR394">394</xref>, <xref ref-type="bibr" rid="CR410">410</xref>, <xref ref-type="bibr" rid="CR434">434</xref>, <xref ref-type="bibr" rid="CR471">471</xref>&#8211;<xref ref-type="bibr" rid="CR471">471</xref>, <xref ref-type="bibr" rid="CR474">474</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Gastric</td><td align="left" colspan="1" rowspan="1">5&#8211;27</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.2&#8211;27</td><td align="left" colspan="1" rowspan="1">&#8201;&#8804;&#8201;1&#8211;7.9</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.8</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR280">280</xref>, <xref ref-type="bibr" rid="CR295">295</xref>, <xref ref-type="bibr" rid="CR403">403</xref>, <xref ref-type="bibr" rid="CR404">404</xref>, <xref ref-type="bibr" rid="CR410">410</xref>, <xref ref-type="bibr" rid="CR429">429</xref>, <xref ref-type="bibr" rid="CR434">434</xref>, <xref ref-type="bibr" rid="CR471">471</xref>, <xref ref-type="bibr" rid="CR474">474</xref>, ]</td></tr><tr><td align="left" colspan="1" rowspan="1">Small bowel</td><td align="left" colspan="1" rowspan="1">0.4&#8211;11</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">1.1&#8211;10</td><td align="left" colspan="1" rowspan="1">&#8201;&#8804;&#8201;1&#8211;4</td><td align="left" colspan="1" rowspan="1">0.10&#8211;0.3</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR280">280</xref>, <xref ref-type="bibr" rid="CR295">295</xref>, <xref ref-type="bibr" rid="CR410">410</xref>, <xref ref-type="bibr" rid="CR429">429</xref>, <xref ref-type="bibr" rid="CR433">433</xref>, <xref ref-type="bibr" rid="CR434">434</xref>, <xref ref-type="bibr" rid="CR471">471</xref>, <xref ref-type="bibr" rid="CR474">474</xref>&#8211;<xref ref-type="bibr" rid="CR471">471</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Pancreatic</td><td align="left" colspan="1" rowspan="1">6.2</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.5&#8211;1.6</td><td align="left" colspan="1" rowspan="1">1.4&#8211;1.6</td><td align="left" colspan="1" rowspan="1">&#8201;&#8804;&#8201;10&#8211;1.6</td><td align="left" colspan="1" rowspan="1">1.7</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR410">410</xref>, <xref ref-type="bibr" rid="CR434">434</xref>, <xref ref-type="bibr" rid="CR471">471</xref>, <xref ref-type="bibr" rid="CR474">474</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Biliary tract</td><td align="left" colspan="1" rowspan="1">1.9&#8211;13</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.02&#8211;1.7</td><td align="left" colspan="1" rowspan="1">0.2&#8201;&#8804;&#8201;1</td><td align="left" colspan="1" rowspan="1">0.2&#8201;&#8804;&#8201;1</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR410">410</xref>, <xref ref-type="bibr" rid="CR429">429</xref>, <xref ref-type="bibr" rid="CR434">434</xref>, <xref ref-type="bibr" rid="CR471">471</xref>, <xref ref-type="bibr" rid="CR474">474</xref>, <xref ref-type="bibr" rid="CR476">484</xref><xref ref-type="bibr" rid="CR485">485</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Brain tumor</td><td align="left" colspan="1" rowspan="1">0.7&#8211;1.7</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">2.5&#8211;7.7</td><td align="left" colspan="1" rowspan="1">0.8&#8211;1.8</td><td align="left" colspan="1" rowspan="1">0.6&#8201;&#8804;&#8201;1</td><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR280">280</xref>, <xref ref-type="bibr" rid="CR410">410</xref>, <xref ref-type="bibr" rid="CR433">433</xref>, <xref ref-type="bibr" rid="CR434">434</xref>, <xref ref-type="bibr" rid="CR467">467</xref>, <xref ref-type="bibr" rid="CR470">470</xref>, <xref ref-type="bibr" rid="CR471">471</xref>, <xref ref-type="bibr" rid="CR474">474</xref>]</td></tr></tbody></table></table-wrap></p><p id="Par333">Side Note III-2: Muir&#8211;Torre syndrome</p><p id="Par334">Muir&#8211;Torre syndrome is characterized by sebaceous gland tumors (sebaceous adenomas, sebaceous epitheliomas, sebaceous carcinomas) and/or keratoacanthomas in association with various Lynch syndrome-associated tumors, including CRC. GPVs are identified mostly in <italic toggle="yes">MSH2</italic> [<xref ref-type="bibr" rid="CR274">274</xref>].</p></sec><sec id="Sec103"><title>Epidemiological characteristics</title><p id="Par335">Lynch syndrome has a prevalence of approximately 1 in 279&#8211;654 individuals in Western countries [<xref ref-type="bibr" rid="CR287">287</xref>&#8211;<xref ref-type="bibr" rid="CR289">289</xref>] and accounts for around 2.4%&#8211;3.7% of all CRCs [<xref ref-type="bibr" rid="CR290">290</xref>, <xref ref-type="bibr" rid="CR291">291</xref>]. In Japan, Lynch syndrome is reported to accounts for 0.7%&#8211;1.01% of all CRCs [<xref ref-type="bibr" rid="CR292">292</xref>, <xref ref-type="bibr" rid="CR293">293</xref>].</p></sec></sec><sec id="Sec104"><title>Diagnosis</title><sec id="Sec105"><title>Diagnostic process</title><p id="Par336">The diagnosis should be made according to the following steps in patients with clinicopathological findings (including family history) suggestive of Lynch syndrome (Fig.&#160;<xref rid="Fig17" ref-type="fig">17</xref>).<fig id="Fig17" position="float" orientation="portrait"><label>Fig.&#160;17</label><caption><p>Diagnostic process for Lynch syndrome. CRC, colorectal cancer; GPV, germline pathogenic variant; IHC, immunochemistry; LS, Lynch syndrome; MMR, mismatch repair; mMLH1, aberrant promoter hypermethylation of <italic toggle="yes">MLH1</italic>; MSI, microsatellite instability; MSI-H, high frequency of microsatellite instability; PGPV, presumed germline pathogenic variant; VUS, variant of uncertain significance</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO17" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig17_HTML.jpg"/></fig></p><p id="Par337"><bold>STEP 1:</bold> Confirm the applicable category among (1) to (4):<list list-type="bullet"><list-item><p id="Par338"><bold>Screening by criteria:</bold> Patient fulfills the Amsterdam criteria II [<xref ref-type="bibr" rid="CR294">294</xref>] or the criteria in the revised Bethesda guidelines [<xref ref-type="bibr" rid="CR295">295</xref>]: Lynch syndrome is suspected based on clinical and pathological information (including family history) or the results of microsatellite instability (MSI) testing or immunohistochemistry for MMR proteins (MMR-IHC).</p></list-item><list-item><p id="Par339">The Amsterdam criteria II (1999) [<xref ref-type="bibr" rid="CR294">294</xref>] are strict guidelines requiring that at least three relatives be diagnosed with Lynch syndrome-associated tumors (CRC, endometrial cancer, renal pelvis/ureter cancer, or small bowel cancer) and that all of the following five criteria are met:<list list-type="order"><list-item><p id="Par340">At least one of the affected individuals is a first-degree relative of the other two</p></list-item><list-item><p id="Par341">There are affected individuals in at least two successive generations</p></list-item><list-item><p id="Par342">At least one of the affected individuals was diagnosed before the age of 50&#160;years</p></list-item><list-item><p id="Par343">The tumors have been confirmed as malignant on histopathological examination</p></list-item><list-item><p id="Par344">Familial adenomatous polyposis (FAP) has been excluded.</p></list-item></list></p></list-item><list-item><p id="Par345">The revised Bethesda guidelines [<xref ref-type="bibr" rid="CR295">295</xref>] are more lenient, recommending MSI testing of tumors collected from individuals who meet any one of the following five conditions:<list list-type="order"><list-item><p id="Par346">CRC diagnosed under the age of 50&#160;years.</p></list-item><list-item><p id="Par347">Synchronous or metachronous CRC or other Lynch syndrome-associated tumors*, regardless of age.</p></list-item><list-item><p id="Par348">CRC with a high frequency of MSI (MSI-H) histological features** diagnosed under the age of 60&#160;years</p></list-item><list-item><p id="Par349">CRC in a patient with at least one first-degree relative diagnosed with a Lynch syndrome-associated tumor, with one of them diagnosed under the age of 50&#160;years</p></list-item><list-item><p id="Par350">CRC in a patient with two or more up to second-degree relatives diagnosed with Lynch syndrome-associated tumors, regardless of age.</p></list-item></list></p></list-item><list-item><p id="Par351"><bold>Universal screening:</bold> Screening tests should be performed for Lynch syndrome using MSI testing or MMR-IHC in all cases with CRC (or those aged&#8201;&lt;&#8201;70&#160;years). If MSI-H or loss of MMR protein expression is observed in the tumor tissue, the patient should be referred for genetic counseling. In cases of CRC where MMR-IHC shows loss of MLH1 and PMS2 protein expression, testing for the <italic toggle="yes">BRAF</italic> V600E variant or <italic toggle="yes">MLH1</italic> promoter methylation can help to exclude sporadic CRC.</p></list-item><list-item><p id="Par352"><bold>Companion diagnostics:</bold> Regardless of age, MSI testing or MMR-IHC can be performed as a companion diagnostic for treatment selection in CRC. If MSI-H or loss of expression of the MMR protein is observed in the tumor tissue, the patient should be referred for genetic counseling.</p></list-item><list-item><p id="Par353"><bold>Comprehensive genomic profiling</bold>: If a GPV is suspected from a comprehensive genomic profiling test performed on DNA derived from tumor cells, a referral for genetic counseling should be made.</p></list-item></list></p><p id="Par354"><bold>STEP 2:</bold> Perform MSI testing or MMR-IHC on tumor tissue and confirm MSI-H or loss of MMR protein expression.</p><p id="Par355"><bold>Note:</bold> If IHC reveals that the tumor has the <italic toggle="yes">BRAF</italic> V600E variant in cases with MSI-H or loss of expression of both MLH1 and PMS2 proteins, a sporadic tumor is likely and there is no need to proceed to genetic testing (STEP 3). Notably, a study in patients with CRC associated with Lynch syndrome found that 1.6% (15/969) of cases tested positive for the <italic toggle="yes">BRAF</italic> V600E variant, and 1.7% (8/482) were positive for <italic toggle="yes">MLH1</italic>, 0.7% (2/269) for <italic toggle="yes">MSH2</italic>, 9.3% (5/54) for <italic toggle="yes">PMS2</italic>, and 0% (0/27) for <italic toggle="yes">MSH6</italic> [<xref ref-type="bibr" rid="CR296">296</xref>].</p><p id="Par356"><bold>STEP 3:</bold> For diagnosis, genetic testing should be performed to identify the GPV in the MMR gene. If a GPV is directly identified by comprehensive genomic profiling of both tumor and non-tumor tissues and the patient wishes to know of the findings, the results should be provided, along with a referral for genetic counseling.</p><sec id="Sec106"><title>Universal screening</title><p id="Par357">
<list list-type="bullet"><list-item><p id="Par358">In Western countries, universal screening by MSI testing or MMR-IHC on all CRC cases (or those aged&#8201;&#8804;&#8201;70&#160;years) is recommended as a highly sensitive and cost-effective method for diagnosing Lynch syndrome.</p></list-item><list-item><p id="Par359">Pooled analyses have indicated that MSI testing, MMR-IHC, or a combination of both 0.93 (95% CI 0.87&#8211;0.96), 0.91 (95% CI 0.85&#8211;0.95), and 0.97 (95% CI 0.90&#8211;0.99), respectively [<xref ref-type="bibr" rid="CR297">297</xref>].</p></list-item><list-item><p id="Par360">The incidence of Lynch syndrome among patients with CRC identified by universal screening is 2.4%&#8211;3.7% internationally [<xref ref-type="bibr" rid="CR290">290</xref>, <xref ref-type="bibr" rid="CR291">291</xref>] and 0.7%&#8211;1.01% in Japan, suggesting that the efficiency of universal screening may be lower in Japan than in other countries.</p></list-item><list-item><p id="Par361">Among older patients with CRC, the prevalence of Lynch syndrome is relatively low but the frequency of sporadic MMR-deficient CRC is higher [<xref ref-type="bibr" rid="CR293">293</xref>, <xref ref-type="bibr" rid="CR298">298</xref>, <xref ref-type="bibr" rid="CR299">299</xref>]. Therefore, screening may be targeted to patients below a certain age, such as those aged&#8201;&#8804;&#8201;70&#160;years, rather than universally applied in all patients with CRC.</p></list-item><list-item><p id="Par362">In families with Lynch syndrome, 15%&#8211;27% of members meet the Amsterdam criteria II [<xref ref-type="bibr" rid="CR298">298</xref>, <xref ref-type="bibr" rid="CR300">300</xref>] and 68%&#8211;89% meet the revised Bethesda guidelines [<xref ref-type="bibr" rid="CR298">298</xref>].</p></list-item><list-item><p id="Par363">In a study by the Japanese Society for Cancer of the Colon and Rectum, 1.2% of all patients with CRC in Japan fulfilled the Amsterdam criteria II [<xref ref-type="bibr" rid="CR301">301</xref>]. In a study from Spain, approximately one quarter of patients with CRC fulfilled the revised Bethesda guidelines [<xref ref-type="bibr" rid="CR302">302</xref>]. Thus, the revised Bethesda guidelines provide high sensitivity but relatively low specificity when screening for Lynch syndrome, whereas the Amsterdam criteria II have lower sensitivity but higher specificity.</p></list-item><list-item><p id="Par364">All patients with endometrial cancer should undergo MSI testing or MMR-IHC as part of universal screening.</p></list-item></list></p></sec><sec id="Sec107"><title>Characteristic histopathological features of CRC with MMR deficiency</title><p id="Par365">
<list list-type="bullet"><list-item><p id="Par366">CRCs with MMR deficiency have several histological features. The revised Bethesda guidelines [<xref ref-type="bibr" rid="CR295">295</xref>] list the following four characteristics:<list list-type="order"><list-item><p id="Par367">Tumor-infiltrating lymphocytes</p></list-item><list-item><p id="Par368">Medullary growth</p></list-item><list-item><p id="Par369">Mucinous and signet-ring cell differentiation</p></list-item><list-item><p id="Par370">A Crohn&#8217;s-like lymphocytic reaction (Fig.&#160;<xref rid="Fig18" ref-type="fig">18</xref>).</p></list-item></list></p></list-item><list-item><p id="Par371">However, these histopathological features are not specific to CRC in patients with Lynch syndrome and are also commonly observed in sporadic MMR-deficient CRC [<xref ref-type="bibr" rid="CR304">304</xref>].</p></list-item><list-item><p id="Par372">In a Japanese study, IHC testing of colorectal tumors from patients with Lynch syndrome identified MMR deficiency in 68 (79%) of 89 cases, regardless of degree of atypia, suggesting that MMR deficiency precedes adenoma formation [<xref ref-type="bibr" rid="CR305">305</xref>].</p></list-item></list><fig id="Fig18" position="float" orientation="portrait"><label>Fig.&#160;18</label><caption><p>Histologic characteristics of MSI-H colorectal cancer. A Tumor-infiltrating lymphocytes. Numerous intra-epithelial lymphocytes showing clear halos. B Medullary carcinoma. Tumor showing a solid growth pattern without a glandular structure. C Mucinous carcinoma. Prominent extracellular mucin. D Crohn&#8217;s-like lymphocytic reaction. Characterized by peritumoral lymphocytic aggregates. MSI-H, high frequency of microsatellite instability</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO18" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig18_HTML.jpg"/></fig></p></sec><sec id="Sec108"><title>Screening tests for Lynch syndrome</title><p id="Par373">
<italic toggle="yes">MSI testing</italic>
<list list-type="bullet"><list-item><p id="Par374">In tumor cells with MMR deficiency, changes in the repeat number of microsatellites (short tandem repeat sequences in the genome), namely MSI, are more likely to occur.</p></list-item><list-item><p id="Par375">Over 90% of CRCs associated with Lynch syndrome are MSI-H [<xref ref-type="bibr" rid="CR306">306</xref>]. In contrast, the proportion of all CRCs with MSI-H is 12%&#8211;16% in Western countries [<xref ref-type="bibr" rid="CR306">306</xref>&#8211;<xref ref-type="bibr" rid="CR308">308</xref>] and 6%&#8211;7% in Japan [<xref ref-type="bibr" rid="CR309">309</xref>, <xref ref-type="bibr" rid="CR310">310</xref>]. Therefore, MSI testing is a useful screening tool for identifying suspected cases of Lynch syndrome.</p></list-item></list>
</p><p id="Par376">
<italic toggle="yes">MMR-IHC testing</italic>
<list list-type="bullet"><list-item><p id="Par377">In most tumors associated with Lynch syndrome, biallelic inactivation occurs in one of the MMR genes, namely <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, <italic toggle="yes">MSH6</italic>, or <italic toggle="yes">PMS2</italic>, leading to loss of the corresponding protein expression in most cases (Side Note III-4: Expression patterns and evaluation; Side Note III-5: Exceptional MMR-IHC expression results).</p></list-item><list-item><p id="Par378">Because MSI-H is caused by MMR dysfunction, MSI testing and MMR-IHC show a high concordance rate, which has been reported to be 98.8% in CRC tissues [<xref ref-type="bibr" rid="CR311">311</xref>].</p></list-item><list-item><p id="Par379">The advantage of MMR-IHC over MSI testing is the ability to estimate the causative gene. However, the specificity of these tests is comparable, and the decision as to which to perform should be made based on the testing capabilities of the facility, with either test being sufficient. Although rare, false negatives can occur with either test. Performing the other test can improve the sensitivity of detecting MMR deficiency if a false negative is clinically suspected.</p></list-item></list>
</p><p id="Par380">Side Note III-5: Exceptional MMR-IHC results</p><p id="Par381">Abnormal protein expression because of missense variants</p><p id="Par382">Nonfunctional proteins are expressed in some cases with missense variants. This is known to be relatively common in cases of Lynch syndrome with an <italic toggle="yes">MLH1</italic> variant, and only PMS2 expression is lost in most of these cases [<xref ref-type="bibr" rid="CR312">312</xref>]. However, there are rare cases in which no abnormalities are detected by IHC. In this situation, if the patient is strongly suspected to have Lynch syndrome on clinical grounds, MSI may be detectable by MSI testing.</p><p id="Par383">Secondary variants in MMR genes because of MSI</p><p id="Par384">Some MMR genes contain repeat sequences, which increase the likelihood of secondary variants. In cases with an <italic toggle="yes">MLH1</italic> variant (loss of MLH1/PMS2 protein expression), loss of MSH6 protein expression may be diffuse or follow a regional pattern [<xref ref-type="bibr" rid="CR313">313</xref>].</p><p id="Par385">Loss of MSH6 protein expression because of preoperative chemoradiotherapy</p><p id="Par386">Preoperative chemoradiotherapy can lead to loss of MSH6 protein expression, even in the absence of germline abnormalities in <italic toggle="yes">MSH6</italic> [<xref ref-type="bibr" rid="CR313">313</xref>].</p><p id="Par387">
<italic toggle="yes">Testing for the BRAF V600E variant</italic>
<list list-type="bullet"><list-item><p id="Par388">The majority of sporadic CRCs with MMR deficiency are caused by loss of MLH1 expression as a result of aberrant hypermethylation of the promoter region of the <italic toggle="yes">MLH1</italic> gene. In contrast, CRCs associated with Lynch syndrome attributable to a GPV in <italic toggle="yes">MLH1</italic> rarely have the <italic toggle="yes">BRAF</italic> V600E variant [<xref ref-type="bibr" rid="CR296">296</xref>]. Therefore, the presence of the <italic toggle="yes">BRAF</italic> V600E variant in tumor tissue almost excludes the possibility of Lynch syndrome in cases where MMR-IHC reveals loss of expression of both the MLH1 and PMS2 proteins [<xref ref-type="bibr" rid="CR314">314</xref>].</p></list-item><list-item><p id="Par389">Although <italic toggle="yes">BRAF</italic> V600E variants are rare in CRCs associated with <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, and <italic toggle="yes">MSH6</italic> pathogenic variants in Lynch syndrome, some CRCs with a GPV in <italic toggle="yes">PMS2</italic> have been reported to harbor the <italic toggle="yes">BRAF</italic> V600E variant, with a prevalence of 9.3%, which underscores the need for caution [<xref ref-type="bibr" rid="CR296">296</xref>].</p></list-item><list-item><p id="Par390">Identifying sporadic tumors using the <italic toggle="yes">BRAF</italic> V600E variant is only effective for CRC and cannot be applied to other types of cancer, such as endometrial cancer.</p></list-item></list>
</p><p id="Par391">
<italic toggle="yes">Testing for methylation of the MLH1 promoter</italic>
</p><p id="Par392">Most sporadic CRCs with MMR deficiency are caused by aberrant hypermethylation of the <italic toggle="yes">MLH1</italic> promoter, which suppresses MLH1 protein expression. Therefore, testing for methylation of the <italic toggle="yes">MLH1</italic> promoter can efficiently identify sporadic CRC and exclude it through genetic testing [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR231">231</xref>, <xref ref-type="bibr" rid="CR232">232</xref>, <xref ref-type="bibr" rid="CR315">315</xref>, <xref ref-type="bibr" rid="CR316">316</xref>].</p></sec></sec><sec id="Sec109"><title>Diseases and conditions in the differential diagnosis</title><sec id="Sec110"><title>Sporadic MSI-H CRC with aberrant hypermethylation of the <italic toggle="yes">MLH1</italic> promoter.</title><p id="Par393">Sporadic MSI-H CRC has certain typical clinicopathological characteristics, including occurrence in older women, poorly differentiated adenocarcinoma, and a right-sided predominance. The primary cause of MSI-H in sporadic CRC is acquired aberrant hypermethylation of the <italic toggle="yes">MLH1</italic> promoter region [<xref ref-type="bibr" rid="CR317">317</xref>]. Such tumors show loss of MLH1 and PMS2 protein expression on MMR-IHC. As noted earlier, 50%&#8211;67% of CRCs with aberrant hypermethylation of the <italic toggle="yes">MLH1</italic> promoter also harbor the <italic toggle="yes">BRAF</italic> V600E variant [<xref ref-type="bibr" rid="CR293">293</xref>, <xref ref-type="bibr" rid="CR318">318</xref>].</p></sec><sec id="Sec111"><title>Polymerase proofreading associated polyposis</title><p id="Par394">Polymerase proofreading associated polyposis (PPAP) [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR319">319</xref>] can present with clinical features similar to those of attenuated FAP and Lynch syndrome, necessitating differential diagnosis (II-2-2: Diseases/conditions requiring differential diagnosis). PPAP often involves endometrial cancer, making it a differential diagnosis for Lynch syndrome. CRC caused by <italic toggle="yes">POLE</italic>, the gene responsible for PPAP, can also be MSI-H.</p></sec><sec id="Sec112"><title>Lynch-like syndrome</title><p id="Par395">Lynch-like syndrome refers to CRC in which an MMR defect (MSI-H or loss of MMR protein expression) is found without aberrant hypermethylation of the <italic toggle="yes">MLH1</italic> promoter and is not diagnosed as Lynch syndrome based on genetic testing. The primary cause of this syndrome is somatic variants in both alleles of the MMR gene; however, cases involving undetectable germline MMR gene variants or variants in genes other than MMR may also be included [<xref ref-type="bibr" rid="CR320">320</xref>, <xref ref-type="bibr" rid="CR321">321</xref>].</p></sec><sec id="Sec113"><title>Constitutional mismatch repair deficiency syndrome</title><p id="Par396">Constitutional mismatch repair deficiency (CMMRD) syndrome is caused by biallelic GPVs in an MMR gene, leading to early onset of multiple synchronous or metachronous cancers, including CRC, during childhood [<xref ref-type="bibr" rid="CR322">322</xref>]. CMMRD follows an autosomal recessive mode of inheritance, with <italic toggle="yes">PMS2</italic> and <italic toggle="yes">MSH6</italic> being the genes most commonly affected. Non-tumor manifestations frequently include caf&#233;-au-lait spots resembling those observed in neurofibromatosis type 1 [<xref ref-type="bibr" rid="CR322">322</xref>, <xref ref-type="bibr" rid="CR323">323</xref>]. Patients with <italic toggle="yes">PMS2</italic> pathogenic variants may also present with immunodeficiency owing to class switch recombination defects, which are characterized by decreased IgG and IgA levels and an increased IgM level [<xref ref-type="bibr" rid="CR324">324</xref>]. In a prospective registry study, the median age at first diagnosis of cancer was 9.2&#160;years (range 1.7&#8211;39.5), with brain tumors being the most common, followed by CRC and hematological malignancies [<xref ref-type="bibr" rid="CR325">325</xref>]. The colon typically shows multiple adenomas, with clinical features resembling those of FAP. A surveillance protocol that includes brain and whole body magnetic resonance imaging, abdominal ultrasound, gastrointestinal endoscopy, and blood tests has been proposed [<xref ref-type="bibr" rid="CR326">326</xref>], and the potential for improved survival outcomes were demonstrated in a full-surveillance cohort [<xref ref-type="bibr" rid="CR325">325</xref>]. The condition formerly known as Turcot syndrome type 1 is now understood to be CMMRD syndrome.</p></sec><sec id="Sec114"><title>Familial CRC type X</title><p id="Par397">Familial CRC type X (FCCTX) is a term proposed for cases fulfilling the Amsterdam criteria I [<xref ref-type="bibr" rid="CR327">327</xref>] but lacking germline MMR gene variants and showing intact MMR function in colorectal tumors. FCCTX likely represents a heterogeneous group of conditions, including (1) coincidental clustering of sporadic CRCs, (2) clustering caused by shared lifestyle factors, and (3) hereditary cancers other than Lynch syndrome, including those caused by unidentified genes [<xref ref-type="bibr" rid="CR328">328</xref>]. Families with FCCTX have a significantly lower risk of Lynch syndrome-associated extra-colonic tumors [<xref ref-type="bibr" rid="CR329">329</xref>].</p></sec></sec></sec><sec id="Sec115"><title>Surveillance and treatment</title><sec id="Sec116"><title>Colorectal adenomas and cancer</title><sec id="Sec117"><title>Characteristics and classification</title><p id="Par398">
<list list-type="bullet"><list-item><p id="Par399">Colorectal adenomas in Lynch syndrome show higher degrees of dysplasia than conventional adenomas [<xref ref-type="bibr" rid="CR330">330</xref>] and progress to cancer more rapidly [<xref ref-type="bibr" rid="CR294">294</xref>, <xref ref-type="bibr" rid="CR331">331</xref>, <xref ref-type="bibr" rid="CR332">332</xref>]. The carcinogenesis pathway in Lynch syndrome may involve MMR deficiency from the adenoma stage and an alternative pathway originating from MMR-deficient crypts in addition to the conventional adenoma&#8211;carcinoma sequence [<xref ref-type="bibr" rid="CR305">305</xref>, <xref ref-type="bibr" rid="CR333">333</xref>]. However, distinguishing between these pathways during colonoscopy is challenging. Therefore, any neoplastic lesion should be considered for endoscopic treatment regardless of size [<xref ref-type="bibr" rid="CR330">330</xref>]. A thorough personal medical history should also be taken to identify any associated extra-colonic tumors characteristic of this condition [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR294">294</xref>] (Table&#160;<xref rid="Tab11" ref-type="table">11</xref>).</p></list-item><list-item><p id="Par400">Surveillance and screening for Lynch syndrome-associated extra-colonic tumors requires a different approach to that used in the general population. Regular screening of the relevant organs is essential, as is colonoscopy surveillance.</p></list-item></list><table-wrap id="Tab11" position="float" orientation="portrait"><label>Table&#160;11</label><caption><p>Recommended surveillance protocols for common Lynch syndrome-associated tumors</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Site</th><th align="left" colspan="1" rowspan="1">Test</th><th align="left" colspan="1" rowspan="1">Age at the start of tests</th><th align="left" colspan="1" rowspan="1">Intervals</th><th align="left" colspan="1" rowspan="1">Comments</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Colorectum</td><td align="left" colspan="1" rowspan="1">Colonoscopy</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">MLH1, MSH2</italic>:</p><p>20&#8211;25 years</p></td><td align="left" colspan="1" rowspan="1">1&#8211;2 years</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR229">229</xref>, <xref ref-type="bibr" rid="CR231">231</xref>, <xref ref-type="bibr" rid="CR232">232</xref>, <xref ref-type="bibr" rid="CR315">315</xref>, <xref ref-type="bibr" rid="CR316">316</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><italic toggle="yes">MSH6</italic>: 30&#8211;35 years</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><italic toggle="yes">PMS2</italic>: 30&#8211;35 years</td><td align="left" colspan="1" rowspan="1">1&#8211;3 years</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Uterus</td><td align="left" colspan="1" rowspan="1">Endometrial biopsy</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">MLH1, MSH2, MSH6</italic>: 30&#8211;35 years</td><td align="left" colspan="1" rowspan="1">1&#8211;2 years</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR229">229</xref>, <xref ref-type="bibr" rid="CR231">231</xref>, <xref ref-type="bibr" rid="CR232">232</xref>, <xref ref-type="bibr" rid="CR315">315</xref>, <xref ref-type="bibr" rid="CR316">316</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Ovary</td><td align="left" colspan="1" rowspan="1">Transvaginal US</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Consider at physician&#8217;s discretion</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR315">315</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Stomach/</p><p>duodenum</p></td><td align="left" colspan="1" rowspan="1">HP infection</td><td align="left" colspan="1" rowspan="1">30&#8211;35 years</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Sterilization if HP infection is present</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR229">229</xref>, <xref ref-type="bibr" rid="CR232">232</xref>, <xref ref-type="bibr" rid="CR315">315</xref>, <xref ref-type="bibr" rid="CR316">316</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Upper gastrointestinal endoscopy</td><td align="left" colspan="1" rowspan="1">30&#8211;35 years</td><td align="left" colspan="1" rowspan="1">1&#8211;3 years</td><td align="left" colspan="1" rowspan="1">Consider in cases with high risk factors or family history of gastric cancer</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR229">229</xref>, <xref ref-type="bibr" rid="CR232">232</xref>, <xref ref-type="bibr" rid="CR315">315</xref>, <xref ref-type="bibr" rid="CR316">316</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Urinary tract</td><td align="left" colspan="1" rowspan="1">Urinalysis or urine cytology</td><td align="left" colspan="1" rowspan="1">30&#8211;35 years</td><td align="left" colspan="1" rowspan="1">1 years</td><td align="left" colspan="1" rowspan="1">Consider in cases with pathogenic variants in the <italic toggle="yes">MSH2</italic> or family history of urothelial cancer</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR229">229</xref>, <xref ref-type="bibr" rid="CR231">231</xref>, <xref ref-type="bibr" rid="CR232">232</xref>, <xref ref-type="bibr" rid="CR316">316</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Pancreas</td><td align="left" colspan="1" rowspan="1">EUS or MRI/MRCP</td><td align="left" colspan="1" rowspan="1">50 years</td><td align="left" colspan="1" rowspan="1">1 years</td><td align="left" colspan="1" rowspan="1">Consider in cases with family history of pancreatic cancer</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR229">229</xref>, <xref ref-type="bibr" rid="CR411">411</xref>&#8211;<xref ref-type="bibr" rid="CR414">414</xref>]</td></tr></tbody></table><table-wrap-foot><p>US, ultrasonography; HP, Helicobacter pylori; EUS, endoscopic ultrasonography; MRI, magnetic resonance imaging; MRCP magnetic resonance cholangiopancreatography</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec118"><title>Cancer surveillance and prevention</title><p id="Par401">
<italic toggle="yes">Colonoscopy surveillance</italic>
</p><p id="Par402">The recommended starting age for colonoscopy surveillance in individuals with Lynch syndrome who have not yet developed CRC is generally between 20 and 25&#160;years for those with <italic toggle="yes">MLH1</italic> or <italic toggle="yes">MSH2</italic> variants and between 30 and 35&#160;years for those with <italic toggle="yes">MSH6</italic> or <italic toggle="yes">PMS2</italic> variants [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR207">207</xref>, <xref ref-type="bibr" rid="CR334">334</xref>, <xref ref-type="bibr" rid="CR335">335</xref>]. Lifelong regular colonoscopy surveillance is necessary for those who have undergone surgery for CRC because of the risk of metachronous cancer. Although a prospective study in Lynch syndrome families demonstrated that 3-yearly colonoscopy surveillance reduced mortality from CRC by 65% [<xref ref-type="bibr" rid="CR336">336</xref>], some observational studies have reported cases of advanced cancer developing within the 3-year interval, leading to proposals for shortening the surveillance interval to 1&#160;year [<xref ref-type="bibr" rid="CR229">229</xref>, <xref ref-type="bibr" rid="CR328">328</xref>, <xref ref-type="bibr" rid="CR337">337</xref>]. However, a study that compared surveillance intervals of 1&#8211;3&#160;years in three European countries (Germany, the Netherlands, and Finland) found no significant difference in cancer incidence or stage at diagnosis according to surveillance interval, and there is still no consensus on the optimal interval [<xref ref-type="bibr" rid="CR338">338</xref>, <xref ref-type="bibr" rid="CR339">339</xref>]. Risk stratification based on the causative gene and history of CRC is being explored. In Japan, the recommended interval is generally 1&#8211;2&#160;years [<xref ref-type="bibr" rid="CR229">229</xref>, <xref ref-type="bibr" rid="CR231">231</xref>, <xref ref-type="bibr" rid="CR232">232</xref>, <xref ref-type="bibr" rid="CR315">315</xref>], whereas a number of European and US guidelines suggest a 2-year interval [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR207">207</xref>]. High-quality colonoscopy using a high-resolution endoscope is important for surveillance, and adherence to quality indicators for colonoscopy (e.g., quality of bowel preparation, cecal intubation rate, adenoma detection rate, examination time) is also essential [<xref ref-type="bibr" rid="CR335">335</xref>, <xref ref-type="bibr" rid="CR340">340</xref>].</p><p id="Par403">
<italic toggle="yes">Lifestyle modifications</italic>
</p><p id="Par404">Several lifestyle factors related to diet, alcohol consumption, and physical activity are modifiable and can decrease the risk of CRC in patients with Lynch syndrome. Maintaining an appropriate body weight and smoking cessation are particularly important. High body mass index has been shown to increase the risks of developing adenomas and CRC [<xref ref-type="bibr" rid="CR315">315</xref>], so it is recommended to maintain body weight within the normal range. A prospective cohort study identified that men with a body mass index of&#8201;&gt;&#8201;25 were at increased risk of CRC [<xref ref-type="bibr" rid="CR341">341</xref>]. Moreover, randomized controlled trials found a 3.72-fold increase in risk of CRC in obese individuals with the <italic toggle="yes">MLH1</italic> variant but no increase in risk in their counterparts taking aspirin 600&#160;mg/day or those with <italic toggle="yes">MSH2</italic> or <italic toggle="yes">MSH6</italic> variants [<xref ref-type="bibr" rid="CR342">342</xref>, <xref ref-type="bibr" rid="CR343">343</xref>]. Case-control and retrospective observational studies have indicated that smoking also increases the risk of CRC [<xref ref-type="bibr" rid="CR315">315</xref>, <xref ref-type="bibr" rid="CR329">329</xref>, <xref ref-type="bibr" rid="CR344">344</xref>]; therefore, smoking cessation is recommended. Notably, current smokers have a higher risk of developing colorectal adenomas than former smokers [<xref ref-type="bibr" rid="CR345">345</xref>]. Multivitamins and calcium supplements reduce the risk of CRC [<xref ref-type="bibr" rid="CR346">346</xref>], as does increased fruit consumption [<xref ref-type="bibr" rid="CR347">347</xref>, <xref ref-type="bibr" rid="CR348">348</xref>]. Alcohol consumption is associated with an increased risk of an earlier onset of CRC [<xref ref-type="bibr" rid="CR348">348</xref>&#8211;<xref ref-type="bibr" rid="CR350">350</xref>], and increased physical activity may reduce the risk of CRC [<xref ref-type="bibr" rid="CR351">351</xref>].</p><p id="Par405">
<italic toggle="yes">Chemoprevention</italic>
</p><p id="Par406">Chemoprevention trials using aspirin in patients with Lynch syndrome have been conducted, but its effectiveness of low-dose aspirin remains unclear.</p></sec><sec id="Sec119"><title>Treatment</title><p id="Par407">
<italic toggle="yes">Surgery</italic>
<list list-type="bullet"><list-item><p id="Par408">Surgical options for CRC in patients with Lynch syndrome include the following:<list list-type="simple"><list-item><label>o</label><p id="Par409">Resection equivalent to that for sporadic CRC</p></list-item><list-item><label>o</label><p id="Par410">Extended surgery (total colectomy, proctocolectomy)</p></list-item></list></p></list-item><list-item><p id="Par411">The extent of resection is typically equivalent to that for sporadic CRC in Lynch syndrome. When selecting the surgical approach for Lynch syndrome, it is important to consider the location of the primary cancer, the gene responsible, the frequency and timing of colorectal tumors, and other risk factors. Currently, risk stratification for multiple CRCs is inadequate, and no systematic recommendation exists for a specific surgical approach. In Japan, the surgical approach for initial and metachronous CRC is individualized, taking into account the patient&#8217;s age, comorbidities, and other factors. The need for postoperative surveillance and its limitations should be explained in detail and the patient&#8217;s preferences ascertained before proceeding with surgery [<xref ref-type="bibr" rid="CR207">207</xref>, <xref ref-type="bibr" rid="CR352">352</xref>].</p></list-item><list-item><p id="Par412">In Western countries, extended surgery, such as total colectomy for colon cancer and proctocolectomy for rectal cancer, is recommended for patients with Lynch syndrome and <italic toggle="yes">MLH1</italic> or <italic toggle="yes">MSH2</italic> variants. However, there is not sufficient evidence of oncological benefit to recommend extended surgery in cases of CRC with <italic toggle="yes">MSH6</italic> or <italic toggle="yes">PMS2</italic> variants [<xref ref-type="bibr" rid="CR207">207</xref>, <xref ref-type="bibr" rid="CR335">335</xref>].</p></list-item><list-item><p id="Par413">In terms of prophylactic colorectal resection, while the lifetime risk of CRC in Lynch syndrome is 54%&#8211;74% for men and 30%&#8211;52% for women, some variant carriers never develop CRC. Therefore, no consensus exists on the usefulness of prophylactic colorectal resection, and it cannot be recommended for asymptomatic individuals.</p></list-item></list>
</p><p id="Par414">Side Note III-6: Extended surgery for CRC in Lynch syndrome</p><p id="Par415">In Lynch syndrome, initial CRCs associated with the <italic toggle="yes">MLH1</italic> and <italic toggle="yes">MSH2</italic> variants have been reported to occur in the proximal colon in 84% of cases with a 36% risk of developing metachronous CRC between the ages of 40 and 70&#160;years [<xref ref-type="bibr" rid="CR353">353</xref>]. Retrospective observational studies and meta-analyses worldwide have shown that metachronous CRC occurs in 22.4%&#8211;22.8% of cases after segmental colectomy, compared with 4.7%&#8211;6.8% following extended surgery, indicating a significantly increased risk of metachronous CRC with segmental colectomy [<xref ref-type="bibr" rid="CR354">354</xref>, <xref ref-type="bibr" rid="CR355">355</xref>]. However, no difference in mortality was observed between the two surgical approaches, with a relative risk of death after segmental colectomy of 1.65 (95% CI 0.90&#8211;3.02) [<xref ref-type="bibr" rid="CR355">355</xref>]. Approximately 15% of initial CRCs in Lynch syndrome occur in the rectum, and many metachronous CRCs occur in the right colon in cases where rectal resection is performed. A retrospective observational study reported a cumulative incidence of multiple metachronous CRCs of 19% at 10&#160;years, 47% at 20&#160;years, and 69% at 30&#160;years when endoscopic surveillance was conducted at an average interval of 14&#160;months [<xref ref-type="bibr" rid="CR356">356</xref>]. Reports on surgical procedures for initial CRC in Japan are limited. However, a favorable prognosis comparable with that for sporadic CRC can be achieved even with resection if quality indicators for colonoscopic examination are adhered to and endoscopic resection of precancerous lesions, including adenomas, is performed [<xref ref-type="bibr" rid="CR173">173</xref>, <xref ref-type="bibr" rid="CR357">357</xref>].</p><p id="Par416">
<italic toggle="yes">Adjuvant therapy post-surgery</italic>
<list list-type="bullet"><list-item><p id="Par417">The efficacy of adjuvant chemotherapy specifically for CRC in Lynch syndrome is still unclear; therefore, treatment is often based on the approaches used for sporadic MSI-H CRC. It is important to note the differences between Lynch syndrome-associated CRC and sporadic MSI-H CRC, such as the frequency of <italic toggle="yes">BRAF</italic> V600E variants and methylation status. For example, it has been found that while 5-fluorouracil-based adjuvant chemotherapy is not effective for sporadic MSI-H CRC, it could be beneficial for MSI-H CRC in individuals under 50&#160;years of age who are suspected of having Lynch syndrome [<xref ref-type="bibr" rid="CR358">358</xref>]. This finding suggests the need to consider Lynch syndrome-associated CRC separately from sporadic MSI-H CRC. However, little useful data are available on adjuvant chemotherapy for Lynch syndrome-associated and sporadic MSI-H rectal cancer.</p></list-item><list-item><p id="Par418">A meta-analysis that focused on the relationship between MSI status and the efficacy of 5-fluorouracil-based adjuvant chemotherapy in patients with stage II/III sporadic CRC found that while MSI-H CRC had a better prognosis than microsatellite-stable (MSS) CRC, adjuvant chemotherapy did not improve overall survival or relapse-free survival [<xref ref-type="bibr" rid="CR359">359</xref>, <xref ref-type="bibr" rid="CR360">360</xref>]. However, in the phase III NSABP-C07 and MOSAIC trials, adding oxaliplatin to adjuvant chemotherapy was beneficial in MSI-H and MSS CRCs [<xref ref-type="bibr" rid="CR361">361</xref>]. Furthermore, an analysis of the ACCENT database, which includes data from 12 clinical trials, showed that progression-free survival and overall survival were better in patients with stage III CRC who received combination therapy with oxaliplatin than in those who received fluoropyrimidine alone, regardless of MSI status [<xref ref-type="bibr" rid="CR362">362</xref>]. N2 MSI-H/ deficient mismatch repair (dMMR) CRC had a similar prognosis to that of MSS/pMMR CRC, whereas N1 MSI-H/dMMR CRC had a better prognosis than that of MSS/pMMR CRC. Therefore, the indication for adjuvant chemotherapy should not be determined based on MSI status in stage III CRC. Moreover, the benefit of adjuvant therapy is low and its use has not been established in stage II CRC, particularly in MSI-H cases, which generally have a good prognosis.</p></list-item></list>
</p><p id="Par419">
<italic toggle="yes">Chemotherapy for unresectable advanced/recurrent CRC</italic>
<list list-type="bullet"><list-item><p id="Par420">The frequency of MSI-H is lower in sporadic stage IV CRC than in stage II/III CRC [<xref ref-type="bibr" rid="CR363">363</xref>, <xref ref-type="bibr" rid="CR364">364</xref>]. While chemotherapy specific to advanced or recurrent MSI-H CRC has been well studied, few studies have focused specifically on Lynch syndrome. The phase II KEYNOTE-016 trial, which evaluated the efficacy of pembrolizumab as third-line or later treatment in MSI-H/dMMR CRC, MSI-H/dMMR non-colorectal solid tumors, and MSS CRC, reported response rates of 40%, 71%, and 0%, respectively [<xref ref-type="bibr" rid="CR365">365</xref>], demonstrating the efficacy of anti-programmed cell death protein 1 antibodies in MSI-H/dMMR solid tumors. Follow-up data for 86 cases of MSI-H/dMMR solid tumors across 12 types of cancer showed a response rate of 53% (52% in CRC and 54% in non-CRC), with response rates of 46% for Lynch syndrome-associated cancers and 59% for cancers not associated with Lynch syndrome [<xref ref-type="bibr" rid="CR366">366</xref>, <xref ref-type="bibr" rid="CR367">367</xref>].</p></list-item><list-item><p id="Par421">The efficacy of pembrolizumab as second-line or later chemotherapy in patients with MSI-H/dMMR CRC and those with previously treated non-CRC was also confirmed in the phase II KEYNOTE-164 and KEYNOTE-158 trials [<xref ref-type="bibr" rid="CR367">367</xref>, <xref ref-type="bibr" rid="CR368">368</xref>]. These trials have established pembrolizumab as a treatment option that can be administered for MSI-H/dMMR solid tumors across multiple organ systems.</p></list-item><list-item><p id="Par422">The phase II CheckMate-142 trial evaluated the efficacy of nivolumab monotherapy or nivolumab plus ipilimumab combination therapy as second-line or later treatment for MSI-H/dMMR CRC. The response rate was 31% with nivolumab monotherapy and 55% with the combination therapy. Grade 3 and 4 treatment-related adverse events were reported in 20% and 32% of patients, respectively [<xref ref-type="bibr" rid="CR369">369</xref>, <xref ref-type="bibr" rid="CR370">370</xref>]; among these cases, 36% and 29% of the cancers were associated with Lynch syndrome, with response rates of 33% and 71%, respectively, which were comparable with the overall results.</p></list-item><list-item><p id="Par423">Progression-free survival was significantly prolonged in the pembrolizumab group in the phase III KEYNOTE-177 trial, which compared the efficacy and safety of pembrolizumab with those of chemotherapy as first-line treatment for MSI-H/dMMR CRC [<xref ref-type="bibr" rid="CR371">371</xref>]. Approximately 90% of Lynch syndrome-associated CRCs are MSI-H/dMMR. Therefore, use of immune checkpoint inhibitors is strongly recommended for advanced or recurrent CRC in patients with Lynch syndrome.</p></list-item></list>
</p></sec></sec><sec id="Sec120"><title>Gynecological tumors</title><sec id="Sec121"><title>Characteristics and classification</title><p id="Par424">
<list list-type="bullet"><list-item><p id="Par425">Lynch syndrome-associated gynecological malignancies include endometrial cancer and ovarian cancer. Endometrial cancer is the second most common cancer after CRC in women with Lynch syndrome, with a penetrance of up to approximately 60% [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR372">372</xref>&#8211;<xref ref-type="bibr" rid="CR374">374</xref>]. Furthermore, endometrial cancer often precedes CRC in women with Lynch syndrome, making it a sentinel malignancy in these patients. Like CRCs, universal screening for Lynch syndrome using MSI testing or MMR-IHC on all endometrial cancers is recommended as a sensitive and cost-effective diagnostic method.</p></list-item><list-item><p id="Par426">Notably, the age of onset and cumulative risk of developing endometrial or ovarian cancer in women with Lynch syndrome vary depending on the type of MMR gene involved [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR315">315</xref>, <xref ref-type="bibr" rid="CR375">375</xref>].</p></list-item><list-item><p id="Par427">Women with pathogenic variants in <italic toggle="yes">MSH6</italic> develop endometrial cancer at an older age than those with <italic toggle="yes">MLH1</italic> or <italic toggle="yes">MSH2</italic> variants; however, the risk of developing this cancer is similar to or higher than that in women with <italic toggle="yes">MLH1</italic> or <italic toggle="yes">MSH2</italic> variants [<xref ref-type="bibr" rid="CR315">315</xref>, <xref ref-type="bibr" rid="CR334">334</xref>, <xref ref-type="bibr" rid="CR353">353</xref>]. There is little evidence to suggest an increased risk of ovarian cancer in women with pathogenic variants in <italic toggle="yes">PMS2</italic>.</p></list-item><list-item><p id="Par428">In Japan, endometrial cancer in women with Lynch syndrome is often of the well-differentiated endometrioid type, with many cases presenting at clinical stage I. These patients develop cancer at a younger age, are not obese, and have lower rates of hypertension and dyslipidemia [<xref ref-type="bibr" rid="CR376">376</xref>]. However, international studies have reported cases involving serous carcinoma, clear cell carcinoma, and carcinosarcoma, collectively known as type II endometrial cancer. Furthermore, endometrial cancer limited to the lower uterine segment occurs more frequently in patients with Lynch syndrome [<xref ref-type="bibr" rid="CR377">377</xref>, <xref ref-type="bibr" rid="CR378">378</xref>]. The prognosis of endometrial cancer in Lynch syndrome is better than that of sporadic cases, likely because of its MSI-H status and the efficacy of immune checkpoint inhibitors [<xref ref-type="bibr" rid="CR339">339</xref>, <xref ref-type="bibr" rid="CR379">379</xref>]. Ovarian malignancies in Lynch syndrome present as non-serous cancers such as endometrioid or clear cell carcinoma at stage I, which contrasts with the high-grade serous carcinomas typically observed in hereditary breast and ovarian cancers. Ovarian cancer in Lynch syndrome also has a better prognosis than sporadic ovarian cancer, with a higher incidence of concurrent endometrial cancer [<xref ref-type="bibr" rid="CR380">380</xref>, <xref ref-type="bibr" rid="CR381">381</xref>].</p></list-item></list></p></sec><sec id="Sec122"><title>Surveillance</title><p id="Par429">
<list list-type="bullet"><list-item><p id="Par430">Endometrial biopsy, which has high sensitivity and specificity, is the primary surveillance method for endometrial cancer [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR375">375</xref>]. While endometrial cytology is generally not a substitute for biopsy because of its lower diagnostic accuracy, it may be performed at the discretion of the physician, particularly when the biopsy procedure is invasive. The sensitivity of transvaginal ultrasound is approximately 34%, compared with 57% for endometrial biopsy [<xref ref-type="bibr" rid="CR375">375</xref>]. Transvaginal ultrasound is not recommended for routine surveillance because of the variation in endometrial thickness according to the menstrual cycle in premenopausal women [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR315">315</xref>]. Moreover, there is limited evidence to suggest that surveillance significantly reduces cancer-related mortality compared with diagnosis after symptom onset, considering that endometrial cancer generally has a good prognosis. While there is no strong evidence regarding the optimal age to start screening or screening intervals, surveillance starting between the ages of 30 and 35&#160;years or 5&#160;years earlier than the youngest age of cancer diagnosis in the family, with intervals of 1&#8211;2&#160;years, is often considered. Furthermore, because the age of onset and cumulative risk vary according to the causative gene, surveillance should start at the age of 35&#160;years for <italic toggle="yes">MLH1</italic> and <italic toggle="yes">MSH2</italic> and at the age of 40&#160;years for <italic toggle="yes">MSH6</italic> [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR382">382</xref>]. Also crucial is education on the importance of seeking a gynecological consultation in the event of abnormal vaginal bleeding, which is the main symptom of endometrial cancer.</p></list-item><list-item><p id="Par431">No established effective surveillance method or interval exists for ovarian cancer. However, transvaginal ultrasound and measurement of serum cancer antigen 125 may be considered at the discretion of the physician [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR315">315</xref>]. Consideration should be given to the risk of interval cancers, namely, cancers that develop and are detected after the last negative surveillance visit but before the next scheduled visit [<xref ref-type="bibr" rid="CR315">315</xref>]. Although ovarian cancer is often asymptomatic in the early stages, patients should be encouraged to seek a gynecological consultation if they experience symptoms such as lower abdominal pain, bloating, an increase in waist circumference, eating problems, or frequent or urgent urination, given that these are symptoms associated with ovarian cancer. A recent prospective study in patients with Lynch syndrome reported 10-year survival rates of 98% for endometrial cancer and 89% for ovarian cancer [<xref ref-type="bibr" rid="CR353">353</xref>]. However, whether these outcomes were attributable to the effectiveness of surveillance or the relatively low malignancy of gynecological cancers associated with Lynch syndrome remains unclear.</p></list-item></list></p></sec><sec id="Sec123"><title>Treatment</title><p id="Par432">
<italic toggle="yes">Surgery</italic>
<list list-type="bullet"><list-item><p id="Par433">In general, surgical management of endometrial and ovarian cancers in women with Lynch syndrome should follow the same principles as those for sporadic cases.</p></list-item><list-item><p id="Par434">While prophylactic hysterectomy does not reduce mortality in women with Lynch syndrome, it does prevent occurrence of endometrial cancer and should be considered as a risk-reducing option [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR229">229</xref>, <xref ref-type="bibr" rid="CR321">321</xref>].</p></list-item><list-item><p id="Par435">In the absence of an effective surveillance method for ovarian cancer, risk-reducing salpingo-oophorectomy (RRSO) may be considered as a primary preventive measure [<xref ref-type="bibr" rid="CR315">315</xref>]. However, no reduction in ovarian cancer-related mortality has been demonstrated for RRSO [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR229">229</xref>, <xref ref-type="bibr" rid="CR382">382</xref>, <xref ref-type="bibr" rid="CR383">383</xref>]. The timing of RSSO should be determined individually, considering factors such as the desire for childbearing, comorbidities, family history, and the causative MMR gene. However, performing hysterectomy and RRSO before the age of 40&#160;years has limited benefits [<xref ref-type="bibr" rid="CR384">384</xref>]. Concurrent hysterectomy and RRSO may be considered in women with Lynch syndrome undergoing surgery for CRC [<xref ref-type="bibr" rid="CR315">315</xref>].</p></list-item><list-item><p id="Par436">Depending on the timing of RRSO, concerns may arise regarding menopausal symptoms, changes in libido, lipid profile, and bone metabolism as consequences of ovarian depletion. Therefore, it is essential to involve experts in women&#8217;s health when considering RRSO. Hormone replacement therapy may be beneficial after RRSO in women without a history of breast cancer [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR384">384</xref>&#8211;<xref ref-type="bibr" rid="CR386">386</xref>].</p></list-item><list-item><p id="Par437">Occult cancer can be detected in resected specimens obtained by RRSO, with reported rates of approximately 5%&#8211;17% for endometrial cancers and 0.5% for ovarian cancers. Therefore, a thorough evaluation before surgery is recommended [<xref ref-type="bibr" rid="CR375">375</xref>, <xref ref-type="bibr" rid="CR383">383</xref>, <xref ref-type="bibr" rid="CR387">387</xref>, <xref ref-type="bibr" rid="CR388">388</xref>].</p></list-item></list>
</p><p id="Par438">
<italic toggle="yes">Chemoprevention</italic>
</p><p id="Par439">Chemoprevention may be considered in addition to risk-reducing surgery. Chemoprevention with high-dose aspirin is effective for CRCs. Oral contraceptives are also beneficial for preventing endometrial and ovarian cancers [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR389">389</xref>]. However, evidence from Japan is still lacking.</p></sec><sec id="Sec124"><title>Postoperative surveillance</title><p id="Par440">No specific guidelines or recommendations exist regarding the method or duration of postoperative gynecological surveillance after risk-reducing surgery for endometrial and ovarian cancers. Although cases of primary peritoneal cancer after RRSO have been reported in patients with Lynch syndrome [<xref ref-type="bibr" rid="CR390">390</xref>], the frequency of primary peritoneal cancer after RRSO in these patients remains unclear, and long-term follow-up is recommended.</p></sec></sec><sec id="Sec125"><title>Urological tumors</title><sec id="Sec126"><title>Characteristics and classification</title><p id="Par441">
<list list-type="bullet"><list-item><p id="Par442">Upper tract urothelial carcinoma (UTUC) occurs in the renal pelvis and ureter and is a relatively rare type of urological cancer. However, UTUC is involved in approximately 5% of urological cancers and is the third most common Lynch syndrome-associated tumor after CRC (63%) and endometrial cancer (9%) [<xref ref-type="bibr" rid="CR391">391</xref>&#8211;<xref ref-type="bibr" rid="CR393">393</xref>]. Bladder cancer has recently been recognized as an associated tumor, and associations with prostate cancer, testicular tumors, and adrenocortical carcinoma have been reported [<xref ref-type="bibr" rid="CR313">313</xref>, <xref ref-type="bibr" rid="CR394">394</xref>&#8211;<xref ref-type="bibr" rid="CR399">399</xref>].</p></list-item><list-item><p id="Par443">A screening study for UTUC, including sporadic cases, found that 5% of cases had GPVs in MMR genes [<xref ref-type="bibr" rid="CR393">393</xref>, <xref ref-type="bibr" rid="CR400">400</xref>, <xref ref-type="bibr" rid="CR401">401</xref>]. Therefore, screening for Lynch syndrome using MMR-IHC is increasingly being conducted for CRCs, endometrial cancers, and UTUC. Furthermore, 64% of Lynch syndrome-associated UTUC cases had a history of other Lynch syndrome-associated tumors, including CRC, underscoring the importance of considering Lynch syndrome in the clinical evaluation of UTUC and taking a thorough medical history [<xref ref-type="bibr" rid="CR400">400</xref>]. The average age of onset is 70&#160;years for sporadic UTUC and 64&#160;years for Lynch syndrome-associated UTUC, with a higher cumulative incidence in <italic toggle="yes">MSH2</italic> GPV carriers[<xref ref-type="bibr" rid="CR400">400</xref>].</p></list-item></list></p></sec><sec id="Sec127"><title>Surveillance</title><p id="Par444">Surveillance of the urinary tract, including urinalysis and urine cytology, is proposed annually for patients with Lynch syndrome, starting from the age of 30&#8211;35&#160;years. Ultrasound examinations should be considered in patients with GPVs in <italic toggle="yes">MSH2</italic> [<xref ref-type="bibr" rid="CR402">402</xref>]. Further evaluation with CT, retrograde pyeloureterography, and tumor biopsy via ureteroscopy is warranted if abnormalities are detected. Retrograde pyeloureterography and ureteroscopic tumor biopsy have high diagnostic accuracy but are invasive procedures that involve insertion of a catheter or ureteroscope into the ureter, making them unsuitable for regular surveillance.</p></sec><sec id="Sec128"><title>Treatment</title><p id="Par445">Treatment for UTUC in Lynch syndrome follows the same principles as those for sporadic UTUC. Depending on imaging findings and disease stage, surgical options with curative intent, such as nephroureterectomy, segmental ureterectomy, or ureteroscopic laser ablation, are considered, and chemotherapy or immune checkpoint inhibitors are options for metastatic cases [<xref ref-type="bibr" rid="CR485">485</xref>].</p></sec></sec><sec id="Sec129"><title>Upper gastrointestinal tumors</title><sec id="Sec130"><title>Characteristics and classification</title><p id="Par446">The cumulative risk of gastric cancer in Lynch syndrome is particularly high in East Asia, including Japan [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR295">295</xref>, <xref ref-type="bibr" rid="CR403">403</xref>&#8211;<xref ref-type="bibr" rid="CR405">405</xref>]. This high risk may be attributable to regional differences in the prevalence of <italic toggle="yes">Helicobacter pylori</italic> (HP) infection-associated gastritis, with a history of HP infection being a common risk factor for development of gastric cancer, as in the general population [<xref ref-type="bibr" rid="CR404">404</xref>, <xref ref-type="bibr" rid="CR405">405</xref>]. Other related factors include a higher risk of gastric cancer in patients who harbor pathogenic variants in <italic toggle="yes">MLH1</italic> and <italic toggle="yes">MSH2</italic> [<xref ref-type="bibr" rid="CR406">406</xref>].</p></sec><sec id="Sec131"><title>Surveillance</title><p id="Par447">
<list list-type="bullet"><list-item><p id="Par448">Surveillance with upper gastrointestinal endoscopy every 1&#8211;3&#160;years is recommended for patients with Lynch syndrome, similar to individuals with HP infection in regions with a high incidence of gastric cancer, like East Asia, and for patients with Lynch syndrome who have a family history of gastric cancer [<xref ref-type="bibr" rid="CR407">407</xref>]. The typical age of onset of gastric cancer in Lynch syndrome is in the 40&#160;s, with the youngest cases reported being aged 31&#8211;35&#160;years. Therefore, surveillance should start at 30&#8211;35&#160;years [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR404">404</xref>, <xref ref-type="bibr" rid="CR405">405</xref>].</p></list-item><list-item><p id="Par449">Surveillance for small bowel cancer in Lynch syndrome is not recommended owing to its rarity, and current guidelines do not support routine small bowel endoscopy, video capsule endoscopy, or contrast-enhanced CT. Careful observation of the deep duodenum during upper gastrointestinal endoscopy is suggested instead [<xref ref-type="bibr" rid="CR408">408</xref>].</p></list-item></list></p></sec><sec id="Sec132"><title>Treatment</title><p id="Par450">
<italic toggle="yes">Endoscopic and surgical treatment</italic>
</p><p id="Par451">The approach to endoscopic treatment for early gastric cancer and surgical procedures for advanced gastric cancer in Lynch syndrome should follow the same principles as those for sporadic cases.</p><p id="Par452">
<italic toggle="yes">Chemotherapy</italic>
</p><p id="Par453">The phase III comparative CheckMate-649 trial evaluated the efficacy and safety of nivolumab plus chemotherapy and nivolumab plus ipilimumab versus chemotherapy alone as first-line treatment in patients with advanced gastric cancer [<xref ref-type="bibr" rid="CR409">409</xref>]. Compared with the group that received chemotherapy alone (<italic toggle="yes">n</italic>&#160;=&#160;792), there was a significant overall survival benefit in the group that received nivolumab plus chemotherapy (<italic toggle="yes">n</italic>&#160;=&#160;789) (hazard ratio [HR], 0.79) but not in the group that received nivolumab plus ipilimumab. In a subgroup analysis of patients with MSI-H, the overall survival benefit was more pronounced in the group that received nivolumab plus chemotherapy (<italic toggle="yes">n</italic>&#160;=&#160;22) than in the group that received chemotherapy alone (<italic toggle="yes">n</italic>&#160;=&#160;21) (HR, 0.38). The group that received nivolumab plus ipilimumab (<italic toggle="yes">n</italic>&#160;=&#160;11) also showed an overall survival benefit when compared with the chemotherapy group (<italic toggle="yes">n</italic>&#160;=&#160;21) (HR, 0.28). Therefore, nivolumab plus chemotherapy is currently used as the standard first-line treatment for advanced gastric cancer, with Lynch syndrome-associated advanced gastric cancer being a particularly promising target for the added benefit of nivolumab.</p></sec></sec><sec id="Sec133"><title>Other associated tumors</title><p id="Par454">
<list list-type="bullet"><list-item><p id="Par455">Limited evidence exists regarding the optimal age to start screening for pancreatic cancer in Lynch syndrome or on the screening interval. However, the guidelines developed in Western countries suggest starting surveillance with endoscopic ultrasound or magnetic resonance imaging/cholangiopancreatography at the age of 50&#160;years or 10&#160;years younger than the earliest age of cancer onset in the family for carriers of pathogenic variants with a family history of pancreatic cancer [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR229">229</xref>, <xref ref-type="bibr" rid="CR410">410</xref>&#8211;<xref ref-type="bibr" rid="CR414">414</xref>].</p></list-item><list-item><p id="Par456">Limited and inconclusive evidence exists for the surveillance of biliary tract cancer and brain tumors in Lynch syndrome [<xref ref-type="bibr" rid="CR408">408</xref>].</p></list-item></list></p></sec></sec><sec id="Sec134"><title>Patients with CRC and unconfirmed lynch syndrome status</title><sec id="Sec135"><title>Cases without genetic testing or with variants of uncertain significance</title><p id="Par457">
<list list-type="bullet"><list-item><p id="Par458">Surveillance of associated tumors should be tailored to the individual based on clinical information and on MSI and MMR-IHC results if Lynch syndrome is suspected but not confirmed (Fig.&#160;<xref rid="Fig17" ref-type="fig">17</xref>). &#8220;Unconfirmed&#8221; refers to cases where genetic testing has not been performed or where no pathogenic variant has been identified (including cases where only variants of uncertain significance are detected).</p></list-item><list-item><p id="Par459">Surveillance is indicated if Lynch syndrome is confirmed in cases that meet the Amsterdam criteria II and those who have a strong personal or family history suggestive of Lynch syndrome if MSI testing shows MSI-H or MMR-IHC tests shows loss of MMR protein expression.</p></list-item><list-item><p id="Par460">Lynch syndrome cannot be excluded in cases that meet the Amsterdam criteria II or have a strong personal or family history suggestive of Lynch syndrome but MSS/MSI-Low or no loss of MMR protein expression is observed (i.e., no strong evidence of MMR gene abnormalities). In such cases, continued surveillance with attention to personal and family history is recommended, with colonoscopy every 3&#8211;5&#160;years at a minimum for CRC.</p></list-item><list-item><p id="Par461">If MSI-H or loss of MMR protein expression is detected in cases that meet the revised Bethesda guidelines but not the Amsterdam criteria II or in those with no strong personal or family history suggestive of Lynch syndrome, there is still a possibility of Lynch syndrome, although sporadic CRC is more likely. Continued surveillance with attention to personal and family history is recommended.</p></list-item><list-item><p id="Par462">No specific surveillance is required in cases of MSS/MSI-Low or those with no loss of MMR protein expression and a low likelihood of Lynch syndrome based on personal and family history. However, patients should seek medical attention if they develop symptoms suggestive of CRC or other Lynch syndrome-associated tumors or if new associated tumors develop in a relative.</p></list-item></list></p></sec></sec><sec id="Sec136"><title>Genetic counseling and management of relatives</title><p id="Par463">
<list list-type="bullet"><list-item><p id="Par464">The patient&#8217;s relatives should receive genetic counseling.</p></list-item><list-item><p id="Par465">At-risk family members (particularly first-degree relatives, such as parents, children, and siblings) should be provided with adequate information about the condition and, with their consent, undergo genetic testing or surveillance for associated tumors based on their risk assessment.</p></list-item><list-item><p id="Par466">In principle, considering that Lynch syndrome-associated tumors generally develop in adulthood, genetic testing should be performed in adult patients.</p></list-item></list></p><sec id="Sec137"><title>Patients with a confirmed genetic diagnosis</title><p id="Par467">Surveillance for Lynch syndrome-associated tumors is indicated for relatives confirmed to carry GPVs and those who have not undergone genetic testing (Fig. <xref rid="Fig19" ref-type="fig">19</xref>).<list list-type="bullet"><list-item><p id="Par468">Relatives who do not carry GPVs should undergo general screening for cancer.</p></list-item><list-item><p id="Par469">Information should be provided on the need for surveillance and the significance of genetic testing for relatives who have reached the age at which surveillance for Lynch syndrome-associated tumors should start. The decision to receive genetic counseling followed by genetic testing should be made on an individual basis.</p></list-item></list><fig id="Fig19" position="float" orientation="portrait"><label>Fig.&#160;19</label><caption><p>Management of biological relatives of patients with Lynch syndrome. GPV, germline pathogenic variant</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO19" position="float" orientation="portrait" xlink:href="10147_2025_2892_Fig19_HTML.jpg"/></fig></p></sec><sec id="Sec138"><title>Patients with unconfirmed genetic status</title><p id="Par470">In relatives of patients who have not undergone genetic testing or in whom genetic testing have failed to yield a diagnosis of Lynch syndrome, individual risk should be assessed based on considerations such as age of onset and the incidence of Lynch syndrome-associated tumors in family members. Surveillance for associated tumors should be conducted.</p></sec></sec></sec><sec id="Sec139"><title>Clinical questions</title><sec id="Sec140"><title>CQ6: Should universal screening for mismatch repair deficiency be performed in patients with CRC to screen for Lynch syndrome?</title><p id="Par471">(<bold>Evidence level: C</bold>, <bold>Recommendation level: 1</bold>, <bold>Agreement rate: 94.4%).</bold></p><p id="Par472"><bold>Recommendation:</bold> Universal screening for Lynch syndrome in patients with CRC is strongly recommended.</p><p id="Par473">Comments</p><p id="Par474">A meta-analysis, four prospective cohort studies, nine retrospective studies, four guidelines, and one article identified by hand searching were reviewed to determine the efficacy and cost-effectiveness of universal screening for diagnosis of Lynch syndrome in all patients with CRC. Screening methods based on clinicopathological information, such as the Amsterdam criteria II and the revised Bethesda guidelines, have been used to screen for Lynch syndrome. However, 12%&#8211;28% of patients with Lynch syndrome could not be identified even by the revised Bethesda guidelines, which provide sensitive clinicopathological criteria [<xref ref-type="bibr" rid="CR298">298</xref>, <xref ref-type="bibr" rid="CR299">299</xref>, <xref ref-type="bibr" rid="CR311">311</xref>]. Furthermore, accurately obtaining clinicopathological information, including a family history of cancer, is often challenging [<xref ref-type="bibr" rid="CR415">415</xref>]. An integrated analysis of four large cohort studies that together included 10,206 patients with CRC found that 3.1% of the patients had Lynch syndrome but only 2.5% fulfilled the Amsterdam criteria II [<xref ref-type="bibr" rid="CR298">298</xref>]. Specificity was high at 97.9% and sensitivity was low at 27.2%. However, 39.8% of patients met the revised Bethesda guidelines criteria, with high sensitivity of 88.1%, although specificity was low at 54.4% These findings suggest that screening for Lynch syndrome based on clinicopathological factors has limitations in terms of sensitivity, and balancing sensitivity and specificity is challenging.</p><p id="Par475">MSI testing and MMR-IHC are now widely used for universal screening in patients with CRC in Europe and the USA. Universal screening is more expensive per diagnosis of Lynch syndrome than screening with the Amsterdam criteria II or the revised Bethesda guidelines [<xref ref-type="bibr" rid="CR416">416</xref>]; however, universal screening does not rely on clinicopathological information and has extremely high sensitivity for a diagnosis of Lynch syndrome. The results of cost-effectiveness analyses that consider quality-adjusted life years gained also support use of universal screening [<xref ref-type="bibr" rid="CR417">417</xref>&#8211;<xref ref-type="bibr" rid="CR419">419</xref>]. Accordingly, guidelines from other countries recommend universal screening for all patients with CRC [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR207">207</xref>, <xref ref-type="bibr" rid="CR229">229</xref>].</p><p id="Par476">Notably, no cost-effectiveness analysis with Lynch syndrome has been conducted in Japan. The proportion of patients with Lynch syndrome among patients with CRC in Japan is approximately 1% [<xref ref-type="bibr" rid="CR292">292</xref>, <xref ref-type="bibr" rid="CR293">293</xref>, <xref ref-type="bibr" rid="CR420">420</xref>, <xref ref-type="bibr" rid="CR421">421</xref>], which is lower than the 2.2% reported in a recent global meta-analysis [<xref ref-type="bibr" rid="CR422">422</xref>]. Therefore, the cost-effectiveness of universal screening in Japan may be lower than that in Western countries. From a cost-effectiveness perspective, limiting universal screening to patients with CRC below a certain age, such as 70&#160;years, has also been proposed, considering that Lynch syndrome is less common in older patients with CRC [<xref ref-type="bibr" rid="CR423">423</xref>].</p><p id="Par477">In theory, universal screening can detect cases of Lynch syndrome with high sensitivity; however, in reality, the sensitivity of screening is affected by various factors, including the rate of uptake of genetic testing by patients. Providing genetic counseling for patients with MMR deficiency detected by screening increases the rate of uptake of genetic testing [<xref ref-type="bibr" rid="CR424">424</xref>]. Therefore, it is essential to establish a system that provides appropriate genetic counseling if universal screening is implemented to ensure diagnosis of Lynch syndrome with high sensitivity.</p><p id="Par478">MSI testing and MMR-IHC can identify Lynch syndrome with similarly high sensitivity [<xref ref-type="bibr" rid="CR425">425</xref>]. Screening by MMR-IHC with additional testing for the <italic toggle="yes">BRAF</italic> V600E variant can help to exclude sporadic MSI-H CRC in some cases (Fig.&#160;<xref rid="Fig17" ref-type="fig">17</xref>) and narrow down the target genes for genetic testing, making it more cost-effective than MSI testing [<xref ref-type="bibr" rid="CR418">418</xref>].</p></sec><sec id="Sec141"><title>CQ7: Should colonoscopy surveillance in patients with Lynch syndrome be personalized based on the causative gene?</title><p id="Par479">(<bold>Evidence level: C, Recommendation level: 1, Agreement rate: 100%).</bold></p><p id="Par480"><bold>Recommendation:</bold> It is strongly recommended that the causative gene should be considered when performing colonoscopy surveillance in patients with Lynch syndrome.</p><p id="Par481">Comments</p><p id="Par482">Two prospective cohort studies that examined the incidence of colorectal adenoma in patients with Lynch syndrome were identified [<xref ref-type="bibr" rid="CR426">426</xref>, <xref ref-type="bibr" rid="CR427">427</xref>]. The prevalence of colorectal adenoma was between 10.6% and 23% and increased with age. Colonoscopy surveillance in Lynch syndrome has been reported to reduce mortality from CRC by 60%&#8211;72% and is the only effective surveillance method [<xref ref-type="bibr" rid="CR336">336</xref>, <xref ref-type="bibr" rid="CR428">428</xref>]. Two prospective and eight retrospective cohort studies that analyzed the cumulative incidence of CRC based on the causative gene in patients with Lynch syndrome found that the cumulative incidence of CRC by the age of 80&#160;years was 46%&#8211;61% for <italic toggle="yes">MLH1</italic>, 33%&#8211;52% for <italic toggle="yes">MSH2</italic> and <italic toggle="yes">EPCAM</italic>, 10%&#8211;44% for <italic toggle="yes">MSH6</italic>, and 8.7%&#8211;20% for <italic toggle="yes">PMS2</italic>, indicating variability in the incidence of CRC depending on the causative gene [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR335">335</xref>, <xref ref-type="bibr" rid="CR410">410</xref>, <xref ref-type="bibr" rid="CR429">429</xref>&#8211;<xref ref-type="bibr" rid="CR433">433</xref>]. Although performed retrospectively, an international collaborative study that included 5255 cases also reported a difference in the incidence of CRC depending on the causative gene, as well as differences according to sex and continent [<xref ref-type="bibr" rid="CR434">434</xref>]. Japanese researchers participated in that study; however, comparisons with other continents were not possible because of the limited number of cases from Asia. Based on the findings to date, colonoscopy surveillance for CRC in patients with Lynch syndrome should take into account the causative gene and the sex of the patient.</p><p id="Par483">Five prospective cohort studies, six retrospective studies, one meta-analysis, and four guidelines were reviewed to determine the age at which colonoscopy surveillance should start. The annual incidence of CRC in patients with Lynch syndrome in their 20&#160;s has been reported to be&#8201;&lt;&#8201;1% regardless of the causative gene, and the incidence of CRC before the age of 25&#160;years is extremely low [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR315">315</xref>, <xref ref-type="bibr" rid="CR316">316</xref>, <xref ref-type="bibr" rid="CR353">353</xref>, <xref ref-type="bibr" rid="CR410">410</xref>, <xref ref-type="bibr" rid="CR429">429</xref>, <xref ref-type="bibr" rid="CR433">433</xref>, <xref ref-type="bibr" rid="CR436">436</xref>&#8211;<xref ref-type="bibr" rid="CR444">444</xref>]. The cumulative incidence of CRC by the age of 30&#160;years was found to be 0%&#8211;2.4% for <italic toggle="yes">MLH1</italic>, 0.4%&#8211;3.0% for <italic toggle="yes">MSH2</italic>/<italic toggle="yes">EPCAM</italic>, 0%&#8211;0.05% for <italic toggle="yes">MSH6</italic>, and 0.02%&#8211;0.1% for <italic toggle="yes">PMS2</italic> in females. In contrast, the cumulative incidence of CRC was 0.9%&#8211;4.5% for <italic toggle="yes">MLH1</italic>, 0.7%&#8211;2.6% for <italic toggle="yes">MSH2</italic>/<italic toggle="yes">EPCAM</italic>, 0%&#8211;0.5% for <italic toggle="yes">MSH6</italic>, and 0.2%&#8211;0.4% for <italic toggle="yes">PMS2</italic> in males. Furthermore, the cumulative incidence of CRC by the age of 40&#160;years was 0.09%&#8211;2.5% for <italic toggle="yes">MSH6</italic> and 0.07&#8211;0.7% for <italic toggle="yes">PMS2</italic> in females and 1.2%&#8211;9.9% for <italic toggle="yes">MSH6</italic> and 0.5%&#8211;2.1% for <italic toggle="yes">PMS2</italic> in males [<xref ref-type="bibr" rid="CR434">434</xref>]. Although the incidence rates were higher in males for all causative genes, the sex-related differences were not sufficiently significant to affect planning of surveillance. Therefore, in patients with Lynch syndrome, colonoscopy surveillance should begin at the age of 20&#8211;25&#160;years for those with <italic toggle="yes">MLH1</italic> or <italic toggle="yes">MSH2</italic> as the causative gene and at 30&#8211;35&#160;years for their counterparts with <italic toggle="yes">MSH6</italic> or <italic toggle="yes">PMS2</italic> as the causative gene when the onset of CRC is late. However, while the evidence for starting surveillance earlier is limited and should be determined on a case-by-case basis, surveillance may start 2&#8211;5&#160;years earlier than the age of the youngest affected family member [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par484">One prospective cohort study and two retrospective observational studies investigated the interval for colonoscopy surveillance. One observational study that included patients with Lynch syndrome and <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, or <italic toggle="yes">MSH6</italic> as the causative gene reported that the cumulative incidence of CRC and the stage at diagnosis were similar regardless of whether lower gastrointestinal endoscopy was performed once a year, twice a year, or at 2&#8211;3-year intervals [<xref ref-type="bibr" rid="CR338">338</xref>]. A prospective cohort study found that 69% of CRCs occurred more than 2&#160;years after the last lower gastrointestinal endoscopy [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par485">Studies from Europe and the USA have reported high cost-effectiveness for gene-specific colonoscopy surveillance in patients with Lynch syndrome [<xref ref-type="bibr" rid="CR445">445</xref>, <xref ref-type="bibr" rid="CR446">446</xref>]. Starting colonoscopy surveillance at the age of 25&#160;years rather than at 20&#160;years in patients with Lynch syndrome and <italic toggle="yes">MLH1</italic> or <italic toggle="yes">MSH2</italic> as the causative gene and at the age of 35 or 40&#160;years for those with <italic toggle="yes">MSH6</italic> or <italic toggle="yes">PMS2</italic> as the causative gene is more cost-effective. Furthermore, a 3-year surveillance interval is more cost-effective for patients who have Lynch syndrome with <italic toggle="yes">MSH6</italic> or <italic toggle="yes">PMS2</italic> as the causative gene. However, in Japan, no cost-effectiveness analysis has been reported regarding the cost of colonoscopy surveillance or the cumulative CRC incidence rate for each causative gene.</p><p id="Par486">Based on these findings, the interval for colonoscopy surveillance should be every 1&#8211;2&#160;years in patients who have Lynch syndrome with <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>/<italic toggle="yes">EPCAM</italic>, or <italic toggle="yes">MSH6</italic> as the causative gene and every 1&#8211;3&#160;years for those with <italic toggle="yes">PMS2</italic> as the causative gene. Patients with a history of CRC or adenoma, those who are male, those with <italic toggle="yes">MLH1</italic> or <italic toggle="yes">MSH2</italic> as the causative gene, and those over 40&#160;years of age should undergo annual surveillance [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR447">447</xref>].</p></sec><sec id="Sec142"><title>CQ8: Is chemoprevention as effective as surveillance in patients with Lynch syndrome?</title><p id="Par487">(<bold>Evidence level: B, Recommendation level: 2, Agreement rate: 100%).</bold></p><p id="Par488"><bold>Recommendation:</bold> It is weakly recommended that aspirin should not be administered for cancer chemoprevention in patients with Lynch syndrome.</p><p id="Par489">Comments</p><p id="Par490">Five randomized controlled trials that examined the effectiveness and safety of chemoprevention in patients with Lynch syndrome were reviewed, the most well-known being the CAPP2 trial conducted in Europe and the USA [<xref ref-type="bibr" rid="CR448">448</xref>]. CAPP2 was a double-blind study that evaluated the ability of aspirin 600&#160;mg/day and resistant starch 30&#160;g/day to prevent Lynch syndrome-associated tumors and colorectal adenomas or cancers in patients with Lynch syndrome. After 10&#160;years of follow-up, the group that received aspirin for longer than 2&#160;years showed a significant reduction in the incidence of CRC when compared with the placebo group (HR, 0.65; 95% CI 0.43&#8211;0.97) [<xref ref-type="bibr" rid="CR449">449</xref>]. Furthermore, the risk of CRC increased by 7% for every 1-unit increase in body mass index in the placebo group; however, no increase in risk was found in the aspirin-treated group [<xref ref-type="bibr" rid="CR342">342</xref>]. In CAPP2, the number of evaluable participants decreased by approximately 40% over 20&#160;years, so caution is required when interpreting the data from this trial.</p><p id="Par491">Long-term use of aspirin increases the risk of gastrointestinal complications and is contraindicated after 28&#160;weeks of pregnancy. Furthermore, studies in the general population have suggested that the effect of aspirin on the risk of CRC may depend on body weight, indicating that the benefits of a fixed dose may be outweighed by the risks if the individual is not within the optimal weight range [<xref ref-type="bibr" rid="CR450">450</xref>]. Therefore, it is weakly recommended that aspirin should not be administered for cancer chemoprevention in patients with Lynch syndrome at this time. The randomized non-inferiority CAPP3 study is presently underway to determine the optimal aspirin dose, comparing 600&#160;mg/day with 300&#160;mg/day and 100&#160;mg/day in patients with Lynch syndrome.</p><p id="Par492">The final follow-up results from CAPP2 showed that treatment with resistant starch did not affect the incidence of CRC [<xref ref-type="bibr" rid="CR451">451</xref>]. However, resistant starch reduced the risk of non-colorectal Lynch syndrome-associated cancers (particularly in the stomach, duodenum, bile duct, and pancreas) by 46% (HR, 0.54; 95% CI 0.33&#8211;0.86). The mechanism by which resistant starch reduces the risk of non-colorectal cancers is not yet understood. Therefore, based solely on the findings of CAPP2, it is not recommended to routinely consume resistant starch to reduce the risk of non-colorectal Lynch syndrome-associated cancers. Moreover, insufficient evidence exists for the use of sulindac, celecoxib, or ibuprofen.</p></sec><sec id="Sec143"><title>CQ9: Is risk-reducing surgery (i.e., hysterectomy or bilateral salpingo-oophorectomy) beneficial for patients with Lynch syndrome?</title><p id="Par493">(<bold>Evidence level: C, Recommendation level: None, Agreement rate: 94.4%).</bold></p><p id="Par494"><bold>Recommendation:</bold> Although risk-reducing surgery in women with Lynch syndrome does not reduce mortality, it should be considered as an option to reduce the risk of endometrial and ovarian cancers. However, this option should be considered on a case-by-case basis according to factors such as the desire for childbearing, complications, family history of Lynch syndrome-related tumors, and the type of MMR gene involved.</p><p id="Par495">Comments</p><p id="Par496"><bold>1. Tumor suppression:</bold> Two case&#8211;control studies and one prospective cohort study were reviewed. The case&#8211;control studies indicated that hysterectomy and bilateral salpingo-oophorectomy reduce the risk of developing endometrial and ovarian cancers. According to a report on risk-reducing surgery published by Schmeler et al., none of 61 women who underwent hysterectomy developed endometrial cancer during an average postoperative follow-up of 13.3&#160;years [<xref ref-type="bibr" rid="CR383">383</xref>]. In contrast, 33% of 210 women who did not undergo hysterectomy developed endometrial cancer during an average follow-up of 7.4&#160;years. Similarly, none of the 47 women who underwent bilateral salpingo-oophorectomy developed ovarian cancer after an average follow-up of 11.2&#160;years. In contrast, 5.5% of 223 women who did not undergo bilateral salpingo-oophorectomy developed ovarian cancer during an average follow-up of 10.6&#160;years. Four of 41 women who underwent risk-reducing surgery (hysterectomy plus bilateral salpingo-oophorectomy, n&#8201;=&#8201;32; hysterectomy alone, n&#8201;=&#8201;7; bilateral salpingo-oophorectomy alone, n&#8201;=&#8201;2) had endometrial cancer/hyperplasia in the surgical specimens. In contrast, nine of the 45 women who did not undergo risk-reducing surgery developed endometrial cancer/hyperplasia and two developed ovarian cancer during surveillance [<xref ref-type="bibr" rid="CR452">452</xref>]. The international multicenter Prospective Lynch Syndrome Database (PLSD) study, which was performed primarily in Europe, investigated the age-specific effects of risk-reducing surgery on the risks of endometrial and ovarian cancers in women with Lynch syndrome [<xref ref-type="bibr" rid="CR453">453</xref>]. For women who underwent risk-reducing hysterectomy at the age of 25&#160;years, the risk of developing endometrial cancer by the age of 70&#160;years was reduced by 35% in carriers of the <italic toggle="yes">MLH1</italic> variant, by 47% in <italic toggle="yes">MSH2</italic> carriers, by 41% in <italic toggle="yes">MSH6</italic> carriers, and by 13% in <italic toggle="yes">PMS2</italic> carriers. Similarly, for those who underwent risk-reducing hysterectomy at the age of 40&#160;years, the risk reduction by the age of 70&#160;years was 34% for <italic toggle="yes">MLH1</italic> carriers, 45% for <italic toggle="yes">MSH2</italic> carriers, 40% for <italic toggle="yes">MSH6</italic> carriers, and 13% for <italic toggle="yes">PMS2</italic> carriers. Therefore, the effect of risk-reducing hysterectomy on the risk of endometrial cancer is similar whether performed at the age of 25&#160;years or 40&#160;years, and there is little benefit in performing the surgery before the age of 40&#160;years. Moreover, for women who underwent risk-reducing bilateral salpingo-oophorectomy at the age of 25&#160;years, the risk of developing ovarian cancer by the age of 70&#160;years was reduced by 11% for carriers of the <italic toggle="yes">MLH1</italic> variant, 17% for <italic toggle="yes">MSH2</italic>, 11% for <italic toggle="yes">MSH6</italic>, and 3% for <italic toggle="yes">PMS2</italic>. Similarly, the risk reduction by the age of 70&#160;years was 9% for <italic toggle="yes">MLH1</italic>, 16% for <italic toggle="yes">MSH2</italic>, 9% for <italic toggle="yes">MSH6</italic>, and 3% for <italic toggle="yes">PMS2</italic> among those who underwent the procedure at the age of 40&#160;years. Therefore, the effect on the risk of ovarian cancer is similar whether the surgery is performed at the age of 25&#160;years or 40&#160;years, and the benefits of undergoing the surgery before 40&#160;years of age are limited.</p><p id="Par497"><bold>2. Improvement of prognosis:</bold> No study has directly investigated the effectiveness of risk-reducing surgery on prognosis. Two prospective cohort studies [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR454">454</xref>] reported that women with Lynch syndrome who underwent surveillance without preventive hysterectomy or bilateral salpingo-oophorectomy had a relatively good prognosis, even if they developed endometrial or ovarian cancer. Among 123 women diagnosed with Lynch syndrome (The surveillance compliance rate was 97.1%), 19 of 103 patients (18%) who underwent surveillance using endometrial biopsy and transvaginal ultrasound every 2&#8211;3&#160;years starting at the age of 35&#160;years developed endometrial cancer (median age 49&#160;years). Only 2 of these 19 women were symptomatic at diagnosis, and no deaths were observed during a median follow-up of 8&#160;years. Ovarian cancer occurred in 6 of 112 women, with no deaths during a median follow-up of 2&#160;years [<xref ref-type="bibr" rid="CR454">454</xref>]. In a prospective cohort study of data from the PLSD, which allowed for both surveillance and risk-reducing surgery during the study period, 186 of 1057 women with Lynch syndrome underwent hysterectomy and 153 underwent bilateral salpingo-oophorectomy. Among those who remained under surveillance, 72 developed endometrial cancer, with a 10-year survival rate of 98%. Furthermore, 19 women developed ovarian cancer, with a 10-year survival rate of 88%, indicating a relatively favorable prognosis [<xref ref-type="bibr" rid="CR10">10</xref>]. The PLSD study also showed that risk-reducing bilateral salpingo-oophorectomy before the age of 40&#160;years does not improve life expectancy, particularly in carriers with PGVs in <italic toggle="yes">MSH6</italic> and <italic toggle="yes">PMS2</italic> [<xref ref-type="bibr" rid="CR453">453</xref>].</p><p id="Par498"><bold>3. Improved cost-effectiveness:</bold> Health economics studies from Europe and the USA have reported that risk-reducing surgery in women with Lynch syndrome is cost-effective [<xref ref-type="bibr" rid="CR455">455</xref>&#8211;<xref ref-type="bibr" rid="CR457">457</xref>]. However, careful consideration is required before its implementation in Japan.</p><p id="Par499"><bold>4. Psychological impact and quality of life:</bold> Two questionnaire surveys of women with Lynch syndrome who underwent risk-reducing surgery (hysterectomy&#8201;&#177;&#8201;bilateral salpingo-oophorectomy) found that although psychological anxiety related to cancer was reduced, there were concerns regarding the effects of iatrogenic menopause [<xref ref-type="bibr" rid="CR458">458</xref>, <xref ref-type="bibr" rid="CR459">459</xref>].</p><p id="Par500"><bold>5. Perioperative complications:</bold> In one study, serious complications occurred in one (1.6%) of 61 women who underwent risk-reducing surgery [<xref ref-type="bibr" rid="CR383">383</xref>]. Notably, this case had a history of surgery and radiation therapy for rectal cancer.</p></sec><sec id="Sec144"><title>CQ10: Is screening for HP infection beneficial in patients with Lynch syndrome?</title><p id="Par501">(<bold>Evidence level: C, Recommendation level: 2, Agreement rate: 88.9</bold>%).</p><p id="Par502"><bold>Recommendation:</bold> It is weakly recommended that screening for HP infection should be performed in patients with Lynch syndrome to reduce the risk of gastric cancer.</p><p id="Par503">Comments</p><p id="Par504">We reviewed one prospective observational cohort study, nine retrospective cohort studies, one retrospective observational study, three reviews, and one guideline that examined the significance of upper gastrointestinal endoscopy and HP testing for the surveillance of gastric cancer in Lynch syndrome. The risk of gastric cancer in the general population is higher in East Asia than in Western countries. Similarly, the risk of developing gastric cancer is higher in East Asian patients with Lynch syndrome than in their Western counterparts. The HP infection rate largely influences this geographic difference in the risk of gastric cancer. HP infection leads to chronic inflammation of the stomach, resulting in atrophic gastritis and intestinal metaplasia, which increase the risk of intestinal-type (differentiated) gastric adenocarcinoma [<xref ref-type="bibr" rid="CR460">460</xref>]. Therefore, this guideline considers geographic differences and examines the recommendation for screening for HP infection and subsequent eradication therapy in patients with Lynch syndrome.</p><p id="Par505">The lifetime risk of developing gastric cancer in patients with Lynch syndrome has been reported to be up to 13% in Western countries [<xref ref-type="bibr" rid="CR316">316</xref>, <xref ref-type="bibr" rid="CR335">335</xref>], but is as high as 41% in East Asia [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR404">404</xref>, <xref ref-type="bibr" rid="CR462">462</xref>], indicating a higher lifetime risk of gastric cancer in East Asians. Risk factors for gastric cancer or premalignant lesions in Lynch syndrome include male sex, advanced age, and more severe atrophic gastritis [<xref ref-type="bibr" rid="CR316">316</xref>, <xref ref-type="bibr" rid="CR335">335</xref>, <xref ref-type="bibr" rid="CR463">463</xref>]. Furthermore, the PLSD study, which analyzed data primarily from Europe, found that the risk of developing gastric cancer varied depending on the causative gene. The cumulative relative risk of developing gastric cancer by the age of 75&#160;years in carriers of pathogenic variants in <italic toggle="yes">MLH1</italic> or <italic toggle="yes">MSH2</italic> is 8.9 and 9.7 times higher, respectively, than in the general population [<xref ref-type="bibr" rid="CR410">410</xref>]. However, no correlation has been found between a history of gastric cancer in a first-degree relative and the risk of developing gastric cancer in the proband [<xref ref-type="bibr" rid="CR464">464</xref>].</p><p id="Par506">Studies from Western countries have not demonstrated an association of development of gastric cancer with chronic gastritis or HP infection in patients with Lynch syndrome [<xref ref-type="bibr" rid="CR465">465</xref>, <xref ref-type="bibr" rid="CR466">466</xref>]. However, many of the gastric cancers associated with Lynch syndrome are of the intestinal type [<xref ref-type="bibr" rid="CR280">280</xref>, <xref ref-type="bibr" rid="CR403">403</xref>]. In contrast, a retrospective cohort study from Japan indicated that atrophic gastritis is a risk factor for development of gastric cancer in patients with Lynch syndrome [<xref ref-type="bibr" rid="CR404">404</xref>]. Another retrospective cohort study from Japan also reported that all six gastric cancer specimens in patients with Lynch syndrome who were tested for HP were infected [<xref ref-type="bibr" rid="CR11">11</xref>]. Therefore, although there is no direct evidence of involvement of HP infection in the development of gastric cancer in Lynch syndrome, the presence of atrophic gastritis, the high rate of HP infection in gastric cancers that do develop, and the prevalence of intestinal-type gastric adenocarcinoma suggest that HP infection is a risk factor for gastric cancer in Lynch syndrome [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par507">In view of the evidence to date, the recommendation for screening tests to confirm the presence of HP infection in the surveillance for gastric cancer in patients with Lynch syndrome in addition to upper gastrointestinal endoscopy is weak. Eradication therapy should be considered if HP infection is confirmed.</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank Kazushige Kawai and Megumi Ishiguro for their support in preparing the JSCCR guidelines 2024 for HCRC (Japanese version). We also thank members of the Japanese Society for Hereditary Tumors (JSHT) for their total support to the guidelines.</p></ack><notes notes-type="funding-information"><title>Funding</title><p>Preparation of these guidelines was funded by the JSCCR. No financial support was received from any other organization or corporation.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No new data were generated or analyzed in the development of this guideline. The recommendations are based on previously published studies, which are cited within the guideline document.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par508">All members with the exception of the discussion chair (committee chair) voted in all CQs. None of the committee members reported on economic COIs, determined according to the rules of the JSCCR. Also, none of the commissioners had academic COIs for CQs. Therefore, all of the committee members except the discussion chair voted in all CQs.</p><p id="Par509">As a result of the self-reported declarations of conflicts of interest (COI) by the members of the JSCCR HCRC Guideline Committee and the JSCCR Guideline Evaluation Committee, the following companies were disclosed:</p><p id="Par510">AstraZeneca K.K., Eisai Co., Ltd., Olympus Corporation, Asahi Kasei Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Fuji Pharma Co., Ltd., Taiho pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd. and Amino Up Co., Ltd.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Kumagai</surname><given-names>H</given-names></name><etal/></person-group><article-title>Clinical guidelines for diagnosis and management of Peutz-Jeghers syndrome in children and adults</article-title><source>Digestion</source><year>2023</year><volume>104</volume><fpage>335</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1159/000529799</pub-id><pub-id pub-id-type="pmid">37054692</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Yamamoto H, Sakamoto H, Kumagai H et al (2023) Clinical guidelines for diagnosis and management of Peutz-Jeghers syndrome in children and adults. Digestion 104:335&#8211;347. 10.1159/000529799<pub-id pub-id-type="pmid">37054692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000529799</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Umeno</surname><given-names>J</given-names></name><name name-style="western"><surname>Jimbo</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clinical guidelines for diagnosis and management of juvenile polyposis syndrome in children and adults - Secondary publication</article-title><source>J Anus Rectum Colon</source><year>2023</year><volume>7</volume><fpage>115</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.23922/jarc.2023-002</pub-id><pub-id pub-id-type="pmid">37113581</pub-id><pub-id pub-id-type="pmcid">PMC10129355</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Matsumoto T, Umeno J, Jimbo K et al (2023) Clinical guidelines for diagnosis and management of juvenile polyposis syndrome in children and adults - Secondary publication. J Anus Rectum Colon 7:115&#8211;125. 10.23922/jarc.2023-002<pub-id pub-id-type="pmid">37113581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23922/jarc.2023-002</pub-id><pub-id pub-id-type="pmcid">PMC10129355</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takayama</surname><given-names>T</given-names></name><name name-style="western"><surname>Muguruma</surname><given-names>N</given-names></name><name name-style="western"><surname>Igarashi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical guidelines for diagnosis and management of Cowden syndrome/<italic toggle="yes">PTEN</italic> hamartoma tumor syndrome in children and adults - secondary publication</article-title><source>J Anus Rectum Colon</source><year>2023</year><volume>7</volume><fpage>284</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.23922/jarc.2023-028</pub-id><pub-id pub-id-type="pmid">37900693</pub-id><pub-id pub-id-type="pmcid">PMC10600266</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Takayama T, Muguruma N, Igarashi M et al (2023) Clinical guidelines for diagnosis and management of Cowden syndrome/<italic toggle="yes">PTEN</italic> hamartoma tumor syndrome in children and adults - secondary publication. J Anus Rectum Colon 7:284&#8211;300. 10.23922/jarc.2023-028<pub-id pub-id-type="pmid">37900693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23922/jarc.2023-028</pub-id><pub-id pub-id-type="pmcid">PMC10600266</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gala</surname><given-names>MK</given-names></name><name name-style="western"><surname>Mizukami</surname><given-names>Y</given-names></name><name name-style="western"><surname>Le</surname><given-names>LP</given-names></name><etal/></person-group><article-title>Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas</article-title><source>Gastroenterology</source><year>2014</year><volume>146</volume><fpage>520</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2013.10.045</pub-id><pub-id pub-id-type="pmid">24512911</pub-id><pub-id pub-id-type="pmcid">PMC3978775</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Gala MK, Mizukami Y, Le LP et al (2014) Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. Gastroenterology 146:520&#8211;529<pub-id pub-id-type="pmid">24512911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2013.10.045</pub-id><pub-id pub-id-type="pmcid">PMC3978775</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaeger</surname><given-names>E</given-names></name><name name-style="western"><surname>Leedham</surname><given-names>S</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>A</given-names></name><etal/></person-group><article-title>Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1</article-title><source>Nat Genet</source><year>2012</year><volume>44</volume><fpage>699</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1038/ng.2263</pub-id><pub-id pub-id-type="pmid">22561515</pub-id><pub-id pub-id-type="pmcid">PMC4594751</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Jaeger E, Leedham S, Lewis A et al (2012) Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat Genet 44:699&#8211;703. 10.1038/ng.2263<pub-id pub-id-type="pmid">22561515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2263</pub-id><pub-id pub-id-type="pmcid">PMC4594751</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchanan</surname><given-names>D</given-names></name><name name-style="western"><surname>Young</surname><given-names>J</given-names></name></person-group><article-title>A perspective on biallelic MUTYH mutations in patients with hyperplastic polyposis syndrome</article-title><source>Gastroenterology</source><year>2009</year><volume>136</volume><fpage>2407</fpage><lpage>2408</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.12.076</pub-id><pub-id pub-id-type="pmid">19406141</pub-id><pub-id pub-id-type="pmcid">PMC2738852</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Buchanan D, Young J (2009) A perspective on biallelic MUTYH mutations in patients with hyperplastic polyposis syndrome. Gastroenterology 136:2407&#8211;2408<pub-id pub-id-type="pmid">19406141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2008.12.076</pub-id><pub-id pub-id-type="pmcid">PMC2738852</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yurgelun</surname><given-names>MB</given-names></name><name name-style="western"><surname>Kulke</surname><given-names>MH</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Cancer susceptibility gene mutations in individuals with colorectal cancer</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><fpage>1086</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.71.0012</pub-id><pub-id pub-id-type="pmid">28135145</pub-id><pub-id pub-id-type="pmcid">PMC5455355</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Yurgelun MB, Kulke MH, Fuchs CS et al (2017) Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol 35:1086&#8211;1095. 10.1200/JCO.2016.71.0012<pub-id pub-id-type="pmid">28135145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2016.71.0012</pub-id><pub-id pub-id-type="pmcid">PMC5455355</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uson</surname><given-names>PLS</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Riegert-Johnson</surname><given-names>D</given-names></name><name name-style="western"><surname>Boardman</surname><given-names>L</given-names></name><etal/></person-group><article-title>Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: A multicenter prospective study</article-title><source>Clin Gastroenterol Hepatol</source><year>2022</year><volume>20</volume><fpage>e508</fpage><lpage>e528</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2021.04.013</pub-id><pub-id pub-id-type="pmid">33857637</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Uson PLS Jr, Riegert-Johnson D, Boardman L et al (2022) Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: A multicenter prospective study. Clin Gastroenterol Hepatol 20:e508&#8211;e528<pub-id pub-id-type="pmid">33857637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2021.04.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">National Comprehensive Cancer Network (2023) NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal. Version 2. Available from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nccn.org/guidelines/guidelines-detail?category=2&amp;id=1436">https://www.nccn.org/guidelines/guidelines-detail?category=2&amp;id=1436</ext-link></mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#248;ller</surname><given-names>P</given-names></name><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>T</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>I</given-names></name><etal/></person-group><article-title>Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database</article-title><source>Gut</source><year>2017</year><volume>66</volume><fpage>464</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2015-309675</pub-id><pub-id pub-id-type="pmid">26657901</pub-id><pub-id pub-id-type="pmcid">PMC5534760</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">M&#248;ller P, Sepp&#228;l&#228; T, Bernstein I et al (2017) Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut 66:464&#8211;472<pub-id pub-id-type="pmid">26657901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2015-309675</pub-id><pub-id pub-id-type="pmcid">PMC5534760</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saita</surname><given-names>C</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Horiguchi</surname><given-names>SI</given-names></name><etal/></person-group><article-title>Tumor development in Japanese patients with Lynch syndrome</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><fpage>e0195572</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0195572</pub-id><pub-id pub-id-type="pmid">29672549</pub-id><pub-id pub-id-type="pmcid">PMC5908237</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Saita C, Yamaguchi T, Horiguchi SI et al (2018) Tumor development in Japanese patients with Lynch syndrome. PLoS ONE 13:e0195572. 10.1371/journal.pone.0195572<pub-id pub-id-type="pmid">29672549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0195572</pub-id><pub-id pub-id-type="pmcid">PMC5908237</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knudson</surname><given-names>AG</given-names><suffix>Jr</suffix></name></person-group><article-title>Mutation and cancer: statistical study of retinoblastoma</article-title><source>Proc Natl Acad Sci U S A</source><year>1971</year><volume>68</volume><fpage>820</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1073/pnas.68.4.820</pub-id><pub-id pub-id-type="pmid">5279523</pub-id><pub-id pub-id-type="pmcid">PMC389051</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68:820&#8211;823<pub-id pub-id-type="pmid">5279523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.68.4.820</pub-id><pub-id pub-id-type="pmcid">PMC389051</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Japanese Association of Medical Sciences (2011) Guidelines for genetic tests and diagnoses in medical practice. Avialable from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://jams.med.or.jp/guideline/index.html">https://jams.med.or.jp/guideline/index.html</ext-link></mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiyozumi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Matsubayashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Horiuchi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients</article-title><source>Cancer Med</source><year>2019</year><volume>8</volume><fpage>5534</fpage><lpage>5543</lpage><pub-id pub-id-type="doi">10.1002/cam4.2432</pub-id><pub-id pub-id-type="pmid">31386297</pub-id><pub-id pub-id-type="pmcid">PMC6745857</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Kiyozumi Y, Matsubayashi H, Horiuchi Y et al (2019) Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients. Cancer Med 8:5534&#8211;5543. 10.1002/cam4.2432<pub-id pub-id-type="pmid">31386297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.2432</pub-id><pub-id pub-id-type="pmcid">PMC6745857</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>A</given-names></name><name name-style="western"><surname>Tekkis</surname><given-names>PP</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis</article-title><source>Colorectal Dis</source><year>2011</year><volume>13</volume><fpage>1222</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1318.2010.02345.x</pub-id><pub-id pub-id-type="pmid">20528895</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Sinha A, Tekkis PP, Gibbons DC et al (2011) Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis. Colorectal Dis 13:1222&#8211;1229. 10.1111/j.1463-1318.2010.02345.x<pub-id pub-id-type="pmid">20528895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1463-1318.2010.02345.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chenbhanich</surname><given-names>J</given-names></name><name name-style="western"><surname>Atsawarungruangkit</surname><given-names>A</given-names></name><name name-style="western"><surname>Korpaisarn</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prevalence of thyroid diseases in familial adenomatous polyposis: a systematic review and meta-analysis</article-title><source>Fam Cancer</source><year>2019</year><volume>18</volume><fpage>53</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1007/s10689-018-0085-3</pub-id><pub-id pub-id-type="pmid">29663106</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Chenbhanich J, Atsawarungruangkit A, Korpaisarn S et al (2019) Prevalence of thyroid diseases in familial adenomatous polyposis: a systematic review and meta-analysis. Fam Cancer 18:53&#8211;62<pub-id pub-id-type="pmid">29663106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-018-0085-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Susswein</surname><given-names>LR</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>ML</given-names></name><name name-style="western"><surname>Nusbaum</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing</article-title><source>Genet Med</source><year>2016</year><volume>18</volume><issue>8</issue><fpage>823</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1038/gim.2015.166</pub-id><pub-id pub-id-type="pmid">26681312</pub-id><pub-id pub-id-type="pmcid">PMC4985612</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Susswein LR, Marshall ML, Nusbaum R et al (2016) Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med 18(8):823&#8211;832<pub-id pub-id-type="pmid">26681312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2015.166</pub-id><pub-id pub-id-type="pmcid">PMC4985612</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yurgelun</surname><given-names>MB</given-names></name><name name-style="western"><surname>Allen</surname><given-names>B</given-names></name><name name-style="western"><surname>Kaldate</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome</article-title><source>Gastroenterology</source><year>2015</year><volume>149</volume><fpage>604</fpage><lpage>613.e20</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.05.006</pub-id><pub-id pub-id-type="pmid">25980754</pub-id><pub-id pub-id-type="pmcid">PMC4550537</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Yurgelun MB, Allen B, Kaldate RR et al (2015) Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. Gastroenterology 149:604-613.e20<pub-id pub-id-type="pmid">25980754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2015.05.006</pub-id><pub-id pub-id-type="pmcid">PMC4550537</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoffel</surname><given-names>EM</given-names></name><name name-style="western"><surname>Koeppe</surname><given-names>E</given-names></name><name name-style="western"><surname>Everett</surname><given-names>J</given-names></name><etal/></person-group><article-title>Germline genetic features of young individuals with colorectal cancer</article-title><source>Gastroenterology</source><year>2018</year><volume>154</volume><fpage>897</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2017.11.004</pub-id><pub-id pub-id-type="pmid">29146522</pub-id><pub-id pub-id-type="pmcid">PMC5847426</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Stoffel EM, Koeppe E, Everett J et al (2018) Germline genetic features of young individuals with colorectal cancer. Gastroenterology 154:897&#8211;905<pub-id pub-id-type="pmid">29146522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2017.11.004</pub-id><pub-id pub-id-type="pmcid">PMC5847426</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eijzenga</surname><given-names>W</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>DE</given-names></name><name name-style="western"><surname>Aaronson</surname><given-names>NK</given-names></name><etal/></person-group><article-title>Specific psychosocial issues of individuals undergoing genetic counseling for cancer-a literature review</article-title><source>J Genet Couns</source><year>2014</year><volume>23</volume><fpage>133</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1007/s10897-013-9649-4</pub-id><pub-id pub-id-type="pmid">23996531</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Eijzenga W, Hahn DE, Aaronson NK et al (2014) Specific psychosocial issues of individuals undergoing genetic counseling for cancer-a literature review. J Genet Couns 23:133&#8211;146. 10.1007/s10897-013-9649-4<pub-id pub-id-type="pmid">23996531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10897-013-9649-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Yen T, Stanich PP, Axell L, et al. (1998): APC-associated polyposis conditions. GeneReviews&#174;. Seattle(WA: University of Washington, Seattle; 1993&#8211;2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK1345">https://www.ncbi.nlm.nih.gov/books/NBK1345</ext-link><pub-id pub-id-type="pmid">20301519</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morin</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Sparks</surname><given-names>AB</given-names></name><name name-style="western"><surname>Korinek</surname><given-names>V</given-names></name><etal/></person-group><article-title>Activation of &#946;-catenin-Tcf signaling in colon cancer by mutation in &#946;-catenin or APC</article-title><source>Science</source><year>1997</year><volume>275</volume><fpage>1787</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1126/science.275.5307.1787</pub-id><pub-id pub-id-type="pmid">9065402</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Morin PJ, Sparks AB, Korinek V et al (1997) Activation of &#946;-catenin-Tcf signaling in colon cancer by mutation in &#946;-catenin or APC. Science 275:1787&#8211;1790<pub-id pub-id-type="pmid">9065402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.275.5307.1787</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behrens</surname><given-names>J</given-names></name><name name-style="western"><surname>Jerchow</surname><given-names>BA</given-names></name><name name-style="western"><surname>Wurtele</surname><given-names>M</given-names></name><etal/></person-group><article-title>Functional interaction of an axin homolog, conductin, with &#946;-catenin, APC, and GSK3&#946;</article-title><source>Science</source><year>1998</year><volume>280</volume><fpage>596</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1126/science.280.5363.596</pub-id><pub-id pub-id-type="pmid">9554852</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Behrens J, Jerchow BA, Wurtele M et al (1998) Functional interaction of an axin homolog, conductin, with &#946;-catenin, APC, and GSK3&#946;. Science 280:596&#8211;599<pub-id pub-id-type="pmid">9554852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.280.5363.596</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Iijima</surname><given-names>T</given-names></name><etal/></person-group><article-title>Difference in characteristics of <italic toggle="yes">APC</italic> mutations between colonic and extracolonic tumors of FAP patients: variations with phenotype</article-title><source>Int J Cancer</source><year>2008</year><volume>122</volume><fpage>2491</fpage><lpage>2497</lpage><pub-id pub-id-type="doi">10.1002/ijc.23390</pub-id><pub-id pub-id-type="pmid">18224684</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Miyaki M, Yamaguchi T, Iijima T et al (2008) Difference in characteristics of <italic toggle="yes">APC</italic> mutations between colonic and extracolonic tumors of FAP patients: variations with phenotype. Int J Cancer 122:2491&#8211;2497. 10.1002/ijc.23390<pub-id pub-id-type="pmid">18224684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.23390</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagase</surname><given-names>H</given-names></name><name name-style="western"><surname>Miyoshi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Horii</surname><given-names>A</given-names></name><etal/></person-group><article-title>Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients</article-title><source>Cancer Res</source><year>1992</year><volume>52</volume><fpage>4055</fpage><lpage>4057</lpage><pub-id pub-id-type="pmid">1319838</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Nagase H, Miyoshi Y, Horii A et al (1992) Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients. Cancer Res 52:4055&#8211;4057<pub-id pub-id-type="pmid">1319838</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nugent</surname><given-names>KP</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>RK</given-names></name><name name-style="western"><surname>Hodgson</surname><given-names>SV</given-names></name><etal/></person-group><article-title>Phenotypic expression in familial adenomatous polyposis: partial prediction by mutation analysis</article-title><source>Gut</source><year>1994</year><volume>35</volume><fpage>1622</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.1136/gut.35.11.1622</pub-id><pub-id pub-id-type="pmid">7828985</pub-id><pub-id pub-id-type="pmcid">PMC1375624</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Nugent KP, Phillips RK, Hodgson SV et al (1994) Phenotypic expression in familial adenomatous polyposis: partial prediction by mutation analysis. Gut 35:1622&#8211;1623<pub-id pub-id-type="pmid">7828985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.35.11.1622</pub-id><pub-id pub-id-type="pmcid">PMC1375624</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knudsen</surname><given-names>AL</given-names></name><name name-style="western"><surname>Bisgaard</surname><given-names>ML</given-names></name><name name-style="western"><surname>B&#252;low</surname><given-names>S</given-names></name></person-group><article-title>Attenuated familial adenomatous polyposis (AFAP). A review of the literature</article-title><source>Fam Cancer</source><year>2003</year><volume>2</volume><fpage>43</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1023/A:1023286520725</pub-id><pub-id pub-id-type="pmid">14574166</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Knudsen AL, Bisgaard ML, B&#252;low S (2003) Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2:43&#8211;55<pub-id pub-id-type="pmid">14574166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1023286520725</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>H</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>H</given-names></name><etal/></person-group><article-title>Association between the age and the development of colorectal cancer in patients with familial adenomatous polyposis: a multi-institutional study</article-title><source>Surg Today</source><year>2017</year><volume>47</volume><fpage>470</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1007/s00595-016-1398-1</pub-id><pub-id pub-id-type="pmid">27506752</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Kobayashi H, Ishida H, Ueno H et al (2017) Association between the age and the development of colorectal cancer in patients with familial adenomatous polyposis: a multi-institutional study. Surg Today 47:470&#8211;475<pub-id pub-id-type="pmid">27506752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00595-016-1398-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murata</surname><given-names>M</given-names></name><name name-style="western"><surname>Utsunomiya</surname><given-names>J</given-names></name><name name-style="western"><surname>Iwama</surname><given-names>T</given-names></name><etal/></person-group><article-title>Frequency of adenomatosis coli in Japan</article-title><source>Jinrui Idengaku Zasshi</source><year>1981</year><volume>26</volume><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/BF01871370</pub-id><pub-id pub-id-type="pmid">7265541</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Murata M, Utsunomiya J, Iwama T et al (1981) Frequency of adenomatosis coli in Japan. Jinrui Idengaku Zasshi 26:19&#8211;30<pub-id pub-id-type="pmid">7265541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01871370</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasen</surname><given-names>HF</given-names></name><name name-style="western"><surname>M&#246;slein</surname><given-names>G</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>A</given-names></name><etal/></person-group><article-title>Guidelines for the clinical management of familial adenomatous polyposis (FAP)</article-title><source>Gut</source><year>2008</year><volume>57</volume><fpage>704</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1136/gut.2007.136127</pub-id><pub-id pub-id-type="pmid">18194984</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Vasen HF, M&#246;slein G, Alonso A et al (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57:704&#8211;713<pub-id pub-id-type="pmid">18194984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.2007.136127</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Bussey</surname><given-names>HJR</given-names></name><name name-style="western"><surname>Morson</surname><given-names>BC</given-names></name></person-group><source>Familial polyposis coli. Gastrointestinal Tract Cancer</source><year>1978</year><publisher-loc>Boston</publisher-loc><publisher-name>Springer</publisher-name></element-citation><mixed-citation id="mc-CR31" publication-type="book">Bussey HJR, Morson BC (1978) Familial polyposis coli. Gastrointestinal Tract Cancer. Springer, Boston</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwama</surname><given-names>T</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>K</given-names></name><name name-style="western"><surname>Morita</surname><given-names>T</given-names></name><etal/></person-group><article-title>A clinical overview of familial adenomatous polyposis derived from the database of the Polyposis Registry of Japan</article-title><source>Int J Clin Oncol</source><year>2004</year><volume>9</volume><fpage>308</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1007/s10147-004-0414-4</pub-id><pub-id pub-id-type="pmid">15375708</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Iwama T, Tamura K, Morita T et al (2004) A clinical overview of familial adenomatous polyposis derived from the database of the Polyposis Registry of Japan. Int J Clin Oncol 9:308&#8211;316<pub-id pub-id-type="pmid">15375708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10147-004-0414-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grover</surname><given-names>S</given-names></name><name name-style="western"><surname>Kastrinos</surname><given-names>F</given-names></name><name name-style="western"><surname>Steyerberg</surname><given-names>EW</given-names></name><etal/></person-group><article-title>Prevalence and phenotypes of <italic toggle="yes">APC</italic> and <italic toggle="yes">MUTYH</italic> mutations in patients with multiple colorectal adenomas</article-title><source>JAMA</source><year>2012</year><volume>308</volume><fpage>485</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1001/jama.2012.8780</pub-id><pub-id pub-id-type="pmid">22851115</pub-id><pub-id pub-id-type="pmcid">PMC3770297</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Grover S, Kastrinos F, Steyerberg EW et al (2012) Prevalence and phenotypes of <italic toggle="yes">APC</italic> and <italic toggle="yes">MUTYH</italic> mutations in patients with multiple colorectal adenomas. JAMA 308:485&#8211;492<pub-id pub-id-type="pmid">22851115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2012.8780</pub-id><pub-id pub-id-type="pmcid">PMC3770297</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>SR</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>RE</given-names></name><etal/></person-group><article-title>The molecular basis of Turcot&#700;s syndrome</article-title><source>N Engl J Med</source><year>1995</year><volume>332</volume><fpage>839</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1056/NEJM199503303321302</pub-id><pub-id pub-id-type="pmid">7661930</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Hamilton SR, Liu B, Parsons RE et al (1995) The molecular basis of Turcot&#700;s syndrome. N Engl J Med 332:839&#8211;847<pub-id pub-id-type="pmid">7661930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM199503303321302</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takao</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Eguchi</surname><given-names>H</given-names></name><etal/></person-group><article-title><italic toggle="yes">APC</italic> germline variant analysis in the adenomatous polyposis phenotype in Japanese patients</article-title><source>Int J Clin Oncol</source><year>2021</year><volume>26</volume><fpage>1661</fpage><lpage>1670</lpage><pub-id pub-id-type="doi">10.1007/s10147-021-01946-4</pub-id><pub-id pub-id-type="pmid">34106356</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Takao M, Yamaguchi T, Eguchi H et al (2021) <italic toggle="yes">APC</italic> germline variant analysis in the adenomatous polyposis phenotype in Japanese patients. Int J Clin Oncol 26:1661&#8211;1670<pub-id pub-id-type="pmid">34106356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10147-021-01946-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aretz</surname><given-names>S</given-names></name><name name-style="western"><surname>Stienen</surname><given-names>D</given-names></name><name name-style="western"><surname>Friedrichs</surname><given-names>N</given-names></name><etal/></person-group><article-title>Somatic APC mosaicism: a frequent cause of familial adenomatous polyposis (FAP)</article-title><source>Hum Mutat</source><year>2007</year><volume>28</volume><fpage>985</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1002/humu.20549</pub-id><pub-id pub-id-type="pmid">17486639</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Aretz S, Stienen D, Friedrichs N et al (2007) Somatic APC mosaicism: a frequent cause of familial adenomatous polyposis (FAP). Hum Mutat 28:985&#8211;992. 10.1002/humu.20549<pub-id pub-id-type="pmid">17486639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/humu.20549</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hes</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>M</given-names></name><name name-style="western"><surname>Bik</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Somatic <italic toggle="yes">APC</italic> mosaicism: an underestimated cause of polyposis coli</article-title><source>Gut</source><year>2008</year><volume>57</volume><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1136/gut.2006.117796</pub-id><pub-id pub-id-type="pmid">17604324</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Hes FJ, Nielsen M, Bik EC et al (2008) Somatic <italic toggle="yes">APC</italic> mosaicism: an underestimated cause of polyposis coli. Gut 57:71&#8211;76<pub-id pub-id-type="pmid">17604324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.2006.117796</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>B</given-names></name><name name-style="western"><surname>Won</surname><given-names>D</given-names></name><name name-style="western"><surname>Jang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Next-generation sequencing with comprehensive bioinformatics analysis facilitates somatic mosaic <italic toggle="yes">APC</italic> gene mutation detection in patients with familial adenomatous polyposis</article-title><source>BMC Med Genomics</source><year>2019</year><volume>12</volume><fpage>103</fpage><pub-id pub-id-type="doi">10.1186/s12920-019-0553-0</pub-id><pub-id pub-id-type="pmid">31269945</pub-id><pub-id pub-id-type="pmcid">PMC6610853</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Kim B, Won D, Jang M et al (2019) Next-generation sequencing with comprehensive bioinformatics analysis facilitates somatic mosaic <italic toggle="yes">APC</italic> gene mutation detection in patients with familial adenomatous polyposis. BMC Med Genomics 12:103. 10.1186/s12920-019-0553-0<pub-id pub-id-type="pmid">31269945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12920-019-0553-0</pub-id><pub-id pub-id-type="pmcid">PMC6610853</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>AM</given-names></name><name name-style="western"><surname>Crobach</surname><given-names>S</given-names></name><name name-style="western"><surname>Geurts-Giele</surname><given-names>WR</given-names></name><etal/></person-group><article-title>Distinct patterns of somatic mosaicism in the <italic toggle="yes">APC</italic> gene in neoplasms from patients with unexplained adenomatous polyposis</article-title><source>Gastroenterology</source><year>2017</year><volume>152</volume><fpage>546</fpage><lpage>549.e3</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.10.040</pub-id><pub-id pub-id-type="pmid">27816598</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Jansen AM, Crobach S, Geurts-Giele WR et al (2017) Distinct patterns of somatic mosaicism in the <italic toggle="yes">APC</italic> gene in neoplasms from patients with unexplained adenomatous polyposis. Gastroenterology 152:546-549.e3<pub-id pub-id-type="pmid">27816598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2016.10.040</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Worthley</surname><given-names>DL</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>KD</given-names></name><name name-style="western"><surname>Wayte</surname><given-names>N</given-names></name><etal/></person-group><article-title>Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome</article-title><source>Gut</source><year>2012</year><volume>61</volume><fpage>774</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2011-300348</pub-id><pub-id pub-id-type="pmid">21813476</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Worthley DL, Phillips KD, Wayte N et al (2012) Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 61:774&#8211;779<pub-id pub-id-type="pmid">21813476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2011-300348</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>W</given-names></name><name name-style="western"><surname>Kidambi</surname><given-names>T</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genetic syndromes associated with gastric cancer</article-title><source>Gastrointest Endosc Clin N Am</source><year>2022</year><volume>32</volume><fpage>147</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/j.giec.2021.08.004</pub-id><pub-id pub-id-type="pmid">34798983</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Kim W, Kidambi T, Lin J et al (2022) Genetic syndromes associated with gastric cancer. Gastrointest Endosc Clin N Am 32:147&#8211;162. 10.1016/j.giec.2021.08.004<pub-id pub-id-type="pmid">34798983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.giec.2021.08.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tacheci</surname><given-names>I</given-names></name><name name-style="western"><surname>Repak</surname><given-names>R</given-names></name><name name-style="western"><surname>Podhola</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)-a <italic toggle="yes">helicobacter</italic>-opposite point</article-title><source>Best Pract Res Clin Gastroenterol</source><year>2021</year><volume>50</volume><fpage>101728</fpage><pub-id pub-id-type="doi">10.1016/j.bpg.2021.101728</pub-id><pub-id pub-id-type="pmid">33975682</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Tacheci I, Repak R, Podhola M et al (2021) Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)-a <italic toggle="yes">helicobacter</italic>-opposite point. Best Pract Res Clin Gastroenterol 50:101728. 10.1016/j.bpg.2021.101728<pub-id pub-id-type="pmid">33975682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bpg.2021.101728</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Tassan</surname><given-names>N</given-names></name><name name-style="western"><surname>Chmiel</surname><given-names>NH</given-names></name><name name-style="western"><surname>Maynard</surname><given-names>J</given-names></name><etal/></person-group><article-title>Inherited variants of MYH associated with somatic G: C&#8211;&gt;T: A mutations in colorectal tumors</article-title><source>Nat Genet</source><year>2002</year><volume>30</volume><fpage>227</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1038/ng828</pub-id><pub-id pub-id-type="pmid">11818965</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Al-Tassan N, Chmiel NH, Maynard J et al (2002) Inherited variants of MYH associated with somatic G: C&#8211;&gt;T: A mutations in colorectal tumors. Nat Genet 30:227&#8211;232<pub-id pub-id-type="pmid">11818965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng828</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Nielsen M, Infante E, Brand R (2019) <italic toggle="yes">MUTYH</italic> Polyposis.: University of Washington, GeneReviews&#174;. Seattle: University of Washington, Seattle; 1993&#8211;2024.<pub-id pub-id-type="pmid">23035301</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lubbe</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Di Bernardo</surname><given-names>MC</given-names></name><name name-style="western"><surname>Chandler</surname><given-names>IP</given-names></name><etal/></person-group><article-title>Clinical implications of the colorectal cancer risk associated with <italic toggle="yes">MUTYH</italic> mutation</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>3975</fpage><lpage>3980</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.21.6853</pub-id><pub-id pub-id-type="pmid">19620482</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Lubbe SJ, Di Bernardo MC, Chandler IP et al (2009) Clinical implications of the colorectal cancer risk associated with <italic toggle="yes">MUTYH</italic> mutation. J Clin Oncol 27:3975&#8211;3980. 10.1200/JCO.2008.21.6853<pub-id pub-id-type="pmid">19620482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2008.21.6853</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takao</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Eguchi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Characteristics of <italic toggle="yes">MUTYH</italic> variants in Japanese colorectal polyposis patients</article-title><source>Int J Clin Oncol</source><year>2018</year><volume>23</volume><fpage>497</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1007/s10147-017-1234-7</pub-id><pub-id pub-id-type="pmid">29330641</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Takao M, Yamaguchi T, Eguchi H et al (2018) Characteristics of <italic toggle="yes">MUTYH</italic> variants in Japanese colorectal polyposis patients. Int J Clin Oncol 23:497&#8211;503<pub-id pub-id-type="pmid">29330641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10147-017-1234-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theodoratou</surname><given-names>E</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>H</given-names></name><name name-style="western"><surname>Tenesa</surname><given-names>A</given-names></name><etal/></person-group><article-title>A large-scale meta-analysis to refine colorectal cancer risk estimates associated with <italic toggle="yes">MUTYH</italic> variants</article-title><source>Br J Cancer</source><year>2010</year><volume>103</volume><fpage>1875</fpage><lpage>1884</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605966</pub-id><pub-id pub-id-type="pmid">21063410</pub-id><pub-id pub-id-type="pmcid">PMC3008602</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Theodoratou E, Campbell H, Tenesa A et al (2010) A large-scale meta-analysis to refine colorectal cancer risk estimates associated with <italic toggle="yes">MUTYH</italic> variants. Br J Cancer 103:1875&#8211;1884<pub-id pub-id-type="pmid">21063410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjc.6605966</pub-id><pub-id pub-id-type="pmcid">PMC3008602</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Win</surname><given-names>AK</given-names></name><name name-style="western"><surname>Dowty</surname><given-names>JG</given-names></name><name name-style="western"><surname>Cleary</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Risk of colorectal cancer for carriers of mutations in <italic toggle="yes">MUTYH</italic>, with and without a family history of cancer</article-title><source>Gastroenterology</source><year>2014</year><volume>146</volume><fpage>1208</fpage><lpage>1211.e1-5</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2014.01.022</pub-id><pub-id pub-id-type="pmid">24444654</pub-id><pub-id pub-id-type="pmcid">PMC3992182</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Win AK, Dowty JG, Cleary SP et al (2014) Risk of colorectal cancer for carriers of mutations in <italic toggle="yes">MUTYH</italic>, with and without a family history of cancer. Gastroenterology 146:1208-1211.e1-5<pub-id pub-id-type="pmid">24444654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2014.01.022</pub-id><pub-id pub-id-type="pmcid">PMC3992182</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W</given-names></name></person-group><article-title>Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence</article-title><source>Gut</source><year>2014</year><volume>63</volume><fpage>326</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2012-304121</pub-id><pub-id pub-id-type="pmid">23946381</pub-id><pub-id pub-id-type="pmcid">PMC4020522</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Ma X, Zhang B, Zheng W (2014) Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Gut 63:326&#8211;336<pub-id pub-id-type="pmid">23946381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2012-304121</pub-id><pub-id pub-id-type="pmcid">PMC4020522</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>AB</given-names></name><name name-style="western"><surname>Sutcliffe</surname><given-names>EG</given-names></name><name name-style="western"><surname>Arvai</surname><given-names>K</given-names></name><etal/></person-group><article-title>Monoallelic <italic toggle="yes">MUTYH</italic> pathogenic variants ascertained via multi-gene hereditary cancer panels are not associated with colorectal, endometrial, or breast cancer</article-title><source>Fam Cancer</source><year>2022</year><volume>21</volume><fpage>415</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1007/s10689-021-00285-7</pub-id><pub-id pub-id-type="pmid">34981295</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Thompson AB, Sutcliffe EG, Arvai K et al (2022) Monoallelic <italic toggle="yes">MUTYH</italic> pathogenic variants ascertained via multi-gene hereditary cancer panels are not associated with colorectal, endometrial, or breast cancer. Fam Cancer 21:415&#8211;422<pub-id pub-id-type="pmid">34981295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-021-00285-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>P</given-names></name><name name-style="western"><surname>Burgers</surname><given-names>PM</given-names></name></person-group><article-title>DNA polymerases that propagate the eukaryotic DNA replication fork</article-title><source>Crit Rev Biochem Mol Biol</source><year>2005</year><volume>40</volume><fpage>115</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1080/10409230590935433</pub-id><pub-id pub-id-type="pmid">15814431</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Garg P, Burgers PM (2005) DNA polymerases that propagate the eukaryotic DNA replication fork. Crit Rev Biochem Mol Biol 40:115&#8211;128. 10.1080/10409230590935433<pub-id pub-id-type="pmid">15814431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10409230590935433</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palles</surname><given-names>C</given-names></name><name name-style="western"><surname>Cazier</surname><given-names>JB</given-names></name><name name-style="western"><surname>Howarth</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Germline mutations affecting the proofreading domains of <italic toggle="yes">POLE</italic> and <italic toggle="yes">POLD1</italic> predispose to colorectal adenomas and carcinomas</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><fpage>136</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1038/ng.2503</pub-id><pub-id pub-id-type="pmid">23263490</pub-id><pub-id pub-id-type="pmcid">PMC3785128</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Palles C, Cazier JB, Howarth KM et al (2013) Germline mutations affecting the proofreading domains of <italic toggle="yes">POLE</italic> and <italic toggle="yes">POLD1</italic> predispose to colorectal adenomas and carcinomas. Nat Genet 45:136&#8211;144. 10.1038/ng.2503<pub-id pub-id-type="pmid">23263490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2503</pub-id><pub-id pub-id-type="pmcid">PMC3785128</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mur</surname><given-names>P</given-names></name><name name-style="western"><surname>Garc&#237;a-Mulero</surname><given-names>S</given-names></name><name name-style="western"><surname>Del Valle</surname><given-names>J</given-names></name><etal/></person-group><article-title>Role of <italic toggle="yes">POLE</italic> and <italic toggle="yes">POLD1</italic> in familial cancer</article-title><source>Genet Med</source><year>2020</year><volume>22</volume><fpage>2089</fpage><lpage>2100</lpage><pub-id pub-id-type="doi">10.1038/s41436-020-0922-2</pub-id><pub-id pub-id-type="pmid">32792570</pub-id><pub-id pub-id-type="pmcid">PMC7708298</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Mur P, Garc&#237;a-Mulero S, Del Valle J et al (2020) Role of <italic toggle="yes">POLE</italic> and <italic toggle="yes">POLD1</italic> in familial cancer. Genet Med 22:2089&#8211;2100<pub-id pub-id-type="pmid">32792570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-020-0922-2</pub-id><pub-id pub-id-type="pmcid">PMC7708298</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellido</surname><given-names>F</given-names></name><name name-style="western"><surname>Pineda</surname><given-names>M</given-names></name><name name-style="western"><surname>Aiza</surname><given-names>G</given-names></name><etal/></person-group><article-title><italic toggle="yes">POLE</italic> and <italic toggle="yes">POLD1</italic> mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance</article-title><source>Genet Med</source><year>2016</year><volume>18</volume><fpage>325</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1038/gim.2015.75</pub-id><pub-id pub-id-type="pmid">26133394</pub-id><pub-id pub-id-type="pmcid">PMC4823640</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Bellido F, Pineda M, Aiza G et al (2016) <italic toggle="yes">POLE</italic> and <italic toggle="yes">POLD1</italic> mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med 18:325&#8211;332<pub-id pub-id-type="pmid">26133394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2015.75</pub-id><pub-id pub-id-type="pmcid">PMC4823640</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esteban-Jurado</surname><given-names>C</given-names></name><name name-style="western"><surname>Gim&#233;nez-Zaragoza</surname><given-names>D</given-names></name><name name-style="western"><surname>Mu&#241;oz</surname><given-names>J</given-names></name><etal/></person-group><article-title><italic toggle="yes">POLE</italic> and <italic toggle="yes">POLD1</italic> screening in 155 patients with multiple polyps and early-onset colorectal cancer</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>26732</fpage><lpage>26743</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.15810</pub-id><pub-id pub-id-type="pmid">28423643</pub-id><pub-id pub-id-type="pmcid">PMC5432293</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Esteban-Jurado C, Gim&#233;nez-Zaragoza D, Mu&#241;oz J et al (2017) <italic toggle="yes">POLE</italic> and <italic toggle="yes">POLD1</italic> screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget 8:26732&#8211;26743. 10.18632/oncotarget.15810<pub-id pub-id-type="pmid">28423643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.15810</pub-id><pub-id pub-id-type="pmcid">PMC5432293</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valle</surname><given-names>L</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Ill&#225;n</surname><given-names>E</given-names></name><name name-style="western"><surname>Bellido</surname><given-names>F</given-names></name><etal/></person-group><article-title>New insights into <italic toggle="yes">POLE</italic> and <italic toggle="yes">POLD1</italic> germline mutations in familial colorectal cancer and polyposis</article-title><source>Hum Mol Genet</source><year>2014</year><volume>23</volume><fpage>3506</fpage><lpage>3512</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu058</pub-id><pub-id pub-id-type="pmid">24501277</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Valle L, Hern&#225;ndez-Ill&#225;n E, Bellido F et al (2014) New insights into <italic toggle="yes">POLE</italic> and <italic toggle="yes">POLD1</italic> germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet 23:3506&#8211;3512<pub-id pub-id-type="pmid">24501277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddu058</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsayed</surname><given-names>FA</given-names></name><name name-style="western"><surname>Kets</surname><given-names>CM</given-names></name><name name-style="western"><surname>Ruano</surname><given-names>D</given-names></name><etal/></person-group><article-title>Germline variants in <italic toggle="yes">POLE</italic> are associated with early onset mismatch repair deficient colorectal cancer</article-title><source>Eur J Hum Genet</source><year>2015</year><volume>23</volume><fpage>1080</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2014.242</pub-id><pub-id pub-id-type="pmid">25370038</pub-id><pub-id pub-id-type="pmcid">PMC4351893</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Elsayed FA, Kets CM, Ruano D et al (2015) Germline variants in <italic toggle="yes">POLE</italic> are associated with early onset mismatch repair deficient colorectal cancer. Eur J Hum Genet 23:1080&#8211;1084. 10.1038/ejhg.2014.242<pub-id pub-id-type="pmid">25370038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ejhg.2014.242</pub-id><pub-id pub-id-type="pmcid">PMC4351893</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spier</surname><given-names>I</given-names></name><name name-style="western"><surname>Holzapfel</surname><given-names>S</given-names></name><name name-style="western"><surname>Altm&#252;ller</surname><given-names>J</given-names></name><etal/></person-group><article-title>Frequency and phenotypic spectrum of germline mutations in <italic toggle="yes">POLE</italic> and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas</article-title><source>Int J Cancer</source><year>2015</year><volume>137</volume><fpage>320</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1002/ijc.29396</pub-id><pub-id pub-id-type="pmid">25529843</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Spier I, Holzapfel S, Altm&#252;ller J et al (2015) Frequency and phenotypic spectrum of germline mutations in <italic toggle="yes">POLE</italic> and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer 137:320&#8211;331. 10.1002/ijc.29396<pub-id pub-id-type="pmid">25529843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.29396</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchanan</surname><given-names>DD</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>JR</given-names></name><name name-style="western"><surname>Clendenning</surname><given-names>M</given-names></name><etal/></person-group><article-title>Risk of colorectal cancer for carriers of a germ-line mutation in <italic toggle="yes">POLE</italic> or <italic toggle="yes">POLD1</italic></article-title><source>Genet Med</source><year>2018</year><volume>20</volume><fpage>890</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1038/gim.2017.185</pub-id><pub-id pub-id-type="pmid">29120461</pub-id><pub-id pub-id-type="pmcid">PMC5943186</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Buchanan DD, Stewart JR, Clendenning M et al (2018) Risk of colorectal cancer for carriers of a germ-line mutation in <italic toggle="yes">POLE</italic> or <italic toggle="yes">POLD1</italic>. Genet Med 20:890&#8211;895<pub-id pub-id-type="pmid">29120461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2017.185</pub-id><pub-id pub-id-type="pmcid">PMC5943186</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aoude</surname><given-names>LG</given-names></name><name name-style="western"><surname>Heitzer</surname><given-names>E</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>P</given-names></name><etal/></person-group><article-title><italic toggle="yes">POLE</italic> mutations in families predisposed to cutaneous melanoma</article-title><source>Fam Cancer</source><year>2015</year><volume>14</volume><fpage>621</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1007/s10689-015-9826-8</pub-id><pub-id pub-id-type="pmid">26251183</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Aoude LG, Heitzer E, Johansson P et al (2015) <italic toggle="yes">POLE</italic> mutations in families predisposed to cutaneous melanoma. Fam Cancer 14:621&#8211;628<pub-id pub-id-type="pmid">26251183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-015-9826-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>MF</given-names></name><name name-style="western"><surname>Johansen</surname><given-names>J</given-names></name><name name-style="western"><surname>Bj&#248;rnevoll</surname><given-names>I</given-names></name><etal/></person-group><article-title>A novel <italic toggle="yes">POLE</italic> mutation associated with cancers of colon, pancreas, ovaries and small intestine</article-title><source>Fam Cancer</source><year>2015</year><volume>14</volume><issue>3</issue><fpage>437</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1007/s10689-015-9803-2</pub-id><pub-id pub-id-type="pmid">25860647</pub-id><pub-id pub-id-type="pmcid">PMC4559173</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Hansen MF, Johansen J, Bj&#248;rnevoll I et al (2015) A novel <italic toggle="yes">POLE</italic> mutation associated with cancers of colon, pancreas, ovaries and small intestine. Fam Cancer 14(3):437&#8211;448<pub-id pub-id-type="pmid">25860647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-015-9803-2</pub-id><pub-id pub-id-type="pmcid">PMC4559173</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohlin</surname><given-names>A</given-names></name><name name-style="western"><surname>Zagoras</surname><given-names>T</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>S</given-names></name><etal/></person-group><article-title>A mutation in <italic toggle="yes">POLE</italic> predisposing to a multi-tumour phenotype</article-title><source>Int J Oncol</source><year>2014</year><volume>45</volume><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.3892/ijo.2014.2410</pub-id><pub-id pub-id-type="pmid">24788313</pub-id><pub-id pub-id-type="pmcid">PMC4079162</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Rohlin A, Zagoras T, Nilsson S et al (2014) A mutation in <italic toggle="yes">POLE</italic> predisposing to a multi-tumour phenotype. Int J Oncol 45:77&#8211;81. 10.3892/ijo.2014.2410<pub-id pub-id-type="pmid">24788313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo.2014.2410</pub-id><pub-id pub-id-type="pmcid">PMC4079162</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palles</surname><given-names>C</given-names></name><name name-style="western"><surname>Martin</surname><given-names>L</given-names></name><name name-style="western"><surname>Domingo</surname><given-names>E</given-names></name><etal/></person-group><article-title>The clinical features of polymerase proofreading associated polyposis (PPAP) and recommendations for patient management</article-title><source>Fam Cancer</source><year>2022</year><volume>21</volume><fpage>197</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1007/s10689-021-00256-y</pub-id><pub-id pub-id-type="pmid">33948826</pub-id><pub-id pub-id-type="pmcid">PMC8964588</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Palles C, Martin L, Domingo E et al (2022) The clinical features of polymerase proofreading associated polyposis (PPAP) and recommendations for patient management. Fam Cancer 21:197&#8211;209<pub-id pub-id-type="pmid">33948826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-021-00256-y</pub-id><pub-id pub-id-type="pmcid">PMC8964588</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>T</given-names></name><name name-style="western"><surname>Nomizu</surname><given-names>T</given-names></name><name name-style="western"><surname>Eguchi</surname><given-names>H</given-names></name><etal/></person-group><article-title>The first case report of polymerase proofreading-associated polyposis in <italic toggle="yes">POLD1</italic> variant, c.1433G&gt;A p. S478N, in Japan</article-title><source>Jpn J Clin Oncol</source><year>2020</year><volume>50</volume><fpage>1080</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyaa090</pub-id><pub-id pub-id-type="pmid">32548621</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Ito T, Nomizu T, Eguchi H et al (2020) The first case report of polymerase proofreading-associated polyposis in <italic toggle="yes">POLD1</italic> variant, c.1433G&gt;A p. S478N, in Japan. Jpn J Clin Oncol 50:1080&#8211;1083. 10.1093/jjco/hyaa090<pub-id pub-id-type="pmid">32548621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jjco/hyaa090</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ikeda</surname><given-names>M</given-names></name><name name-style="western"><surname>Orimo</surname><given-names>H</given-names></name><name name-style="western"><surname>Moriyama</surname><given-names>H</given-names></name><etal/></person-group><article-title>Close correlation between mutations of <italic toggle="yes">E2F4</italic> and <italic toggle="yes">hMSH3</italic> genes in colorectal cancers with microsatellite instability</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>594</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">9485005</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Ikeda M, Orimo H, Moriyama H et al (1998) Close correlation between mutations of <italic toggle="yes">E2F4</italic> and <italic toggle="yes">hMSH3</italic> genes in colorectal cancers with microsatellite instability. Cancer Res 58:594&#8211;598<pub-id pub-id-type="pmid">9485005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adam</surname><given-names>R</given-names></name><name name-style="western"><surname>Spier</surname><given-names>I</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B</given-names></name><etal/></person-group><article-title>Exome sequencing identifies biallelic <italic toggle="yes">MSH3</italic> germline mutations as a recessive subtype of colorectal adenomatous polyposis</article-title><source>Am J Hum Genet</source><year>2016</year><volume>99</volume><fpage>337</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2016.06.015</pub-id><pub-id pub-id-type="pmid">27476653</pub-id><pub-id pub-id-type="pmcid">PMC4974087</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Adam R, Spier I, Zhao B et al (2016) Exome sequencing identifies biallelic <italic toggle="yes">MSH3</italic> germline mutations as a recessive subtype of colorectal adenomatous polyposis. Am J Hum Genet 99:337&#8211;351<pub-id pub-id-type="pmid">27476653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2016.06.015</pub-id><pub-id pub-id-type="pmcid">PMC4974087</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salo-Mullen</surname><given-names>EE</given-names></name><name name-style="western"><surname>Maio</surname><given-names>A</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prevalence and characterization of biallelic and monoallelic <italic toggle="yes">NTHL1</italic> and <italic toggle="yes">MSH3</italic> variant carriers from a pan-cancer patient population</article-title><source>JCO Precis Oncol</source><year>2021</year><volume>5</volume><fpage>PO.20.00443</fpage><pub-id pub-id-type="doi">10.1200/PO.20.00443</pub-id><pub-id pub-id-type="pmid">34250384</pub-id><pub-id pub-id-type="pmcid">PMC8232072</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Salo-Mullen EE, Maio A, Mukherjee S et al (2021) Prevalence and characterization of biallelic and monoallelic <italic toggle="yes">NTHL1</italic> and <italic toggle="yes">MSH3</italic> variant carriers from a pan-cancer patient population. JCO Precis Oncol 5:PO.20.00443. 10.1200/PO.20.00443<pub-id pub-id-type="pmid">34250384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.20.00443</pub-id><pub-id pub-id-type="pmcid">PMC8232072</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olkinuora</surname><given-names>A</given-names></name><name name-style="western"><surname>Nieminen</surname><given-names>TT</given-names></name><name name-style="western"><surname>Martensson</surname><given-names>E</given-names></name><etal/></person-group><article-title>Biallelic germline nonsense variant of <italic toggle="yes">MLH3</italic> underlies polyposis predisposition</article-title><source>Genet Med</source><year>2019</year><volume>21</volume><issue>8</issue><fpage>1868</fpage><lpage>1873</lpage><pub-id pub-id-type="doi">10.1038/s41436-018-0405-x</pub-id><pub-id pub-id-type="pmid">30573798</pub-id><pub-id pub-id-type="pmcid">PMC6752675</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Olkinuora A, Nieminen TT, Martensson E et al (2019) Biallelic germline nonsense variant of <italic toggle="yes">MLH3</italic> underlies polyposis predisposition. Genet Med 21(8):1868&#8211;1873<pub-id pub-id-type="pmid">30573798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-018-0405-x</pub-id><pub-id pub-id-type="pmcid">PMC6752675</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nawaz</surname><given-names>S</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>MI</given-names></name><name name-style="western"><surname>Hamid</surname><given-names>BS</given-names></name><etal/></person-group><article-title>A loss-of-function variant in DNA mismatch repair gene <italic toggle="yes">MLH3</italic> underlies severe oligozoospermia</article-title><source>J Hum Genet</source><year>2021</year><volume>66</volume><fpage>725</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1038/s10038-021-00907-z</pub-id><pub-id pub-id-type="pmid">33517345</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Nawaz S, Ullah MI, Hamid BS et al (2021) A loss-of-function variant in DNA mismatch repair gene <italic toggle="yes">MLH3</italic> underlies severe oligozoospermia. J Hum Genet 66:725&#8211;730. 10.1038/s10038-021-00907-z<pub-id pub-id-type="pmid">33517345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s10038-021-00907-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><etal/></person-group><article-title>Whole-exome sequencing of a large Chinese azoospermia and severe oligospermia cohort identifies novel infertility causative variants and genes</article-title><source>Hum Mol Genet</source><year>2020</year><volume>29</volume><fpage>2451</fpage><lpage>2459</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddaa101</pub-id><pub-id pub-id-type="pmid">32469048</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Chen S, Wang G, Zheng X et al (2020) Whole-exome sequencing of a large Chinese azoospermia and severe oligospermia cohort identifies novel infertility causative variants and genes. Hum Mol Genet 29:2451&#8211;2459. 10.1093/hmg/ddaa101<pub-id pub-id-type="pmid">32469048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddaa101</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krokan</surname><given-names>HE</given-names></name><name name-style="western"><surname>Bj&#248;r&#229;s</surname><given-names>M</given-names></name></person-group><article-title>Base excision repair</article-title><source>Cold Spring Harb Perspect Biol</source><year>2013</year><volume>5</volume><fpage>a012583</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a012583</pub-id><pub-id pub-id-type="pmid">23545420</pub-id><pub-id pub-id-type="pmcid">PMC3683898</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Krokan HE, Bj&#248;r&#229;s M (2013) Base excision repair. Cold Spring Harb Perspect Biol 5:a012583<pub-id pub-id-type="pmid">23545420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a012583</pub-id><pub-id pub-id-type="pmcid">PMC3683898</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weren</surname><given-names>RD</given-names></name><name name-style="western"><surname>Ligtenberg</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kets</surname><given-names>CM</given-names></name><etal/></person-group><article-title>A germline homozygous mutation in the base-excision repair gene <italic toggle="yes">NTHL1</italic> causes adenomatous polyposis and colorectal cancer</article-title><source>Nat Genet</source><year>2015</year><volume>47</volume><fpage>668</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1038/ng.3287</pub-id><pub-id pub-id-type="pmid">25938944</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Weren RD, Ligtenberg MJ, Kets CM et al (2015) A germline homozygous mutation in the base-excision repair gene <italic toggle="yes">NTHL1</italic> causes adenomatous polyposis and colorectal cancer. Nat Genet 47:668&#8211;671. 10.1038/ng.3287<pub-id pub-id-type="pmid">25938944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3287</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivera</surname><given-names>B</given-names></name><name name-style="western"><surname>Castellsagu&#233;</surname><given-names>E</given-names></name><name name-style="western"><surname>Bah</surname><given-names>I</given-names></name><etal/></person-group><article-title>Biallelic <italic toggle="yes">NTHL1</italic> mutations in a woman with multiple primary tumors</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>1985</fpage><lpage>1986</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1506878</pub-id><pub-id pub-id-type="pmid">26559593</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Rivera B, Castellsagu&#233; E, Bah I et al (2015) Biallelic <italic toggle="yes">NTHL1</italic> mutations in a woman with multiple primary tumors. N Engl J Med 373:1985&#8211;1986<pub-id pub-id-type="pmid">26559593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc1506878</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broderick</surname><given-names>P</given-names></name><name name-style="western"><surname>Dobbins</surname><given-names>SE</given-names></name><name name-style="western"><surname>Chubb</surname><given-names>D</given-names></name><etal/></person-group><article-title>Validation of recently proposed colorectal cancer susceptibility gene variants in an analysis of families and patients - A systematic review</article-title><source>Gastroenterology</source><year>2017</year><volume>152</volume><issue>75&#8211;77</issue><fpage>e4</fpage><pub-id pub-id-type="pmid">27713038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2016.09.041</pub-id><pub-id pub-id-type="pmcid">PMC5860724</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Broderick P, Dobbins SE, Chubb D et al (2017) Validation of recently proposed colorectal cancer susceptibility gene variants in an analysis of families and patients - A systematic review. Gastroenterology 152(75&#8211;77):e4<pub-id pub-id-type="pmid">27713038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2016.09.041</pub-id><pub-id pub-id-type="pmcid">PMC5860724</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grolleman</surname><given-names>JE</given-names></name><name name-style="western"><surname>de Voer</surname><given-names>RM</given-names></name><name name-style="western"><surname>Elsayed</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Mutational signature analysis reveals <italic toggle="yes">NTHL1</italic> deficiency to cause a multi-tumor phenotype</article-title><source>Cancer Cell</source><year>2019</year><volume>35</volume><fpage>256</fpage><lpage>266.e5</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.12.011</pub-id><pub-id pub-id-type="pmid">30753826</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Grolleman JE, de Voer RM, Elsayed FA et al (2019) Mutational signature analysis reveals <italic toggle="yes">NTHL1</italic> deficiency to cause a multi-tumor phenotype. Cancer Cell 35:256-266.e5<pub-id pub-id-type="pmid">30753826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2018.12.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsayed</surname><given-names>FA</given-names></name><name name-style="western"><surname>Grolleman</surname><given-names>JE</given-names></name><name name-style="western"><surname>Ragunathan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Monoallelic <italic toggle="yes">NTHL1</italic> loss-of-function variants and risk of polyposis and colorectal cancer</article-title><source>Gastroenterology</source><year>2020</year><volume>159</volume><fpage>2241</fpage><lpage>2243.e6</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.08.042</pub-id><pub-id pub-id-type="pmid">32860789</pub-id><pub-id pub-id-type="pmcid">PMC7899696</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Elsayed FA, Grolleman JE, Ragunathan A et al (2020) Monoallelic <italic toggle="yes">NTHL1</italic> loss-of-function variants and risk of polyposis and colorectal cancer. Gastroenterology 159:2241-2243.e6<pub-id pub-id-type="pmid">32860789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2020.08.042</pub-id><pub-id pub-id-type="pmcid">PMC7899696</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palles</surname><given-names>C</given-names></name><name name-style="western"><surname>West</surname><given-names>HD</given-names></name><name name-style="western"><surname>Chew</surname><given-names>E</given-names></name><etal/></person-group><article-title>Germline <italic toggle="yes">MBD4</italic> deficiency causes a multi-tumor predisposition syndrome</article-title><source>Am J Hum Genet</source><year>2022</year><volume>109</volume><fpage>953</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2022.03.018</pub-id><pub-id pub-id-type="pmid">35460607</pub-id><pub-id pub-id-type="pmcid">PMC9118112</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Palles C, West HD, Chew E et al (2022) Germline <italic toggle="yes">MBD4</italic> deficiency causes a multi-tumor predisposition syndrome. Am J Hum Genet 109:953&#8211;960<pub-id pub-id-type="pmid">35460607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2022.03.018</pub-id><pub-id pub-id-type="pmcid">PMC9118112</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanakaya</surname><given-names>K</given-names></name><name name-style="western"><surname>Kumamoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Tada</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A germline <italic toggle="yes">MBD4</italic> mutation was identified in a patient with colorectal oligopolyposis and early-onset cancer: a case report</article-title><source>Oncol Rep</source><year>2019</year><volume>42</volume><fpage>1133</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.3892/or.2019.7239</pub-id><pub-id pub-id-type="pmid">31322271</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Tanakaya K, Kumamoto K, Tada Y et al (2019) A germline <italic toggle="yes">MBD4</italic> mutation was identified in a patient with colorectal oligopolyposis and early-onset cancer: a case report. Oncol Rep 42:1133&#8211;1140. 10.3892/or.2019.7239<pub-id pub-id-type="pmid">31322271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2019.7239</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lammi</surname><given-names>L</given-names></name><name name-style="western"><surname>Arte</surname><given-names>S</given-names></name><name name-style="western"><surname>Somer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mutations in <italic toggle="yes">AXIN2</italic> cause familial tooth agenesis and predispose to colorectal cancer</article-title><source>Am J Hum Genet</source><year>2004</year><volume>74</volume><fpage>1043</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1086/386293</pub-id><pub-id pub-id-type="pmid">15042511</pub-id><pub-id pub-id-type="pmcid">PMC1181967</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Lammi L, Arte S, Somer M et al (2004) Mutations in <italic toggle="yes">AXIN2</italic> cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 74:1043&#8211;1050<pub-id pub-id-type="pmid">15042511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/386293</pub-id><pub-id pub-id-type="pmcid">PMC1181967</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hlouskova</surname><given-names>A</given-names></name><name name-style="western"><surname>Bielik</surname><given-names>P</given-names></name><name name-style="western"><surname>Bonczek</surname><given-names>O</given-names></name><etal/></person-group><article-title>Mutations in <italic toggle="yes">AXIN2</italic> gene as a risk factor for tooth agenesis and cancer: A review</article-title><source>Neuro Endocrinol Lett</source><year>2017</year><volume>38</volume><fpage>131</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">28759178</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Hlouskova A, Bielik P, Bonczek O et al (2017) Mutations in <italic toggle="yes">AXIN2</italic> gene as a risk factor for tooth agenesis and cancer: A review. Neuro Endocrinol Lett 38:131&#8211;137<pub-id pub-id-type="pmid">28759178</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marvin</surname><given-names>ML</given-names></name><name name-style="western"><surname>Mazzoni</surname><given-names>SM</given-names></name><name name-style="western"><surname>Herron</surname><given-names>CM</given-names></name><etal/></person-group><article-title><italic toggle="yes">AXIN2</italic>-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome</article-title><source>Am J Med Genet</source><year>2011</year><pub-id pub-id-type="doi">10.1002/ajmg.a.33927</pub-id><pub-id pub-id-type="pmid">21416598</pub-id><pub-id pub-id-type="pmcid">PMC3094478</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Marvin ML, Mazzoni SM, Herron CM et al (2011) <italic toggle="yes">AXIN2</italic>-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome. Am J Med Genet. 10.1002/ajmg.a.33927<pub-id pub-id-type="pmid">21416598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajmg.a.33927</pub-id><pub-id pub-id-type="pmcid">PMC3094478</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirts</surname><given-names>BH</given-names></name><name name-style="western"><surname>Salipante</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Casadei</surname><given-names>S</given-names></name><etal/></person-group><article-title>Deep sequencing with intronic capture enables identification of an <italic toggle="yes">APC</italic> exon 10 inversion in a patient with polyposis</article-title><source>Genet Med</source><year>2014</year><volume>16</volume><fpage>783</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1038/gim.2014.30</pub-id><pub-id pub-id-type="pmid">24675673</pub-id><pub-id pub-id-type="pmcid">PMC4752361</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Shirts BH, Salipante SJ, Casadei S et al (2014) Deep sequencing with intronic capture enables identification of an <italic toggle="yes">APC</italic> exon 10 inversion in a patient with polyposis. Genet Med 16:783&#8211;786<pub-id pub-id-type="pmid">24675673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2014.30</pub-id><pub-id pub-id-type="pmcid">PMC4752361</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Luijt</surname><given-names>RB</given-names></name><name name-style="western"><surname>Tops</surname><given-names>CM</given-names></name><name name-style="western"><surname>Khan</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Molecular, cytogenetic, and phenotypic studies of a constitutional reciprocal translocation t(5;10)(q22;q25) responsible for familial adenomatous polyposis in a Dutch pedigree</article-title><source>Genes Chromosomes Cancer</source><year>1995</year><volume>13</volume><fpage>192</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1002/gcc.2870130309</pub-id><pub-id pub-id-type="pmid">7669739</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">van der Luijt RB, Tops CM, Khan PM et al (1995) Molecular, cytogenetic, and phenotypic studies of a constitutional reciprocal translocation t(5;10)(q22;q25) responsible for familial adenomatous polyposis in a Dutch pedigree. Genes Chromosomes Cancer 13:192&#8211;202<pub-id pub-id-type="pmid">7669739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gcc.2870130309</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsayed</surname><given-names>FA</given-names></name><name name-style="western"><surname>Tops</surname><given-names>CMJ</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Use of Sanger and next-generation sequencing to screen for mosaic and intronic <italic toggle="yes">APC</italic> variants in unexplained colorectal polyposis patients</article-title><source>Fam Cancer</source><year>2022</year><volume>21</volume><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/s10689-021-00236-2</pub-id><pub-id pub-id-type="pmid">33683519</pub-id><pub-id pub-id-type="pmcid">PMC8799582</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Elsayed FA, Tops CMJ, Nielsen M et al (2022) Use of Sanger and next-generation sequencing to screen for mosaic and intronic <italic toggle="yes">APC</italic> variants in unexplained colorectal polyposis patients. Fam Cancer 21:79&#8211;83<pub-id pub-id-type="pmid">33683519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-021-00236-2</pub-id><pub-id pub-id-type="pmcid">PMC8799582</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bozsik</surname><given-names>A</given-names></name><name name-style="western"><surname>Butz</surname><given-names>H</given-names></name><name name-style="western"><surname>Grolmusz</surname><given-names>VK</given-names></name><etal/></person-group><article-title>Genome sequencing-based discovery of a novel deep intronic <italic toggle="yes">APC</italic> pathogenic variant causing exonization</article-title><source>Eur J Hum Genet</source><year>2023</year><volume>31</volume><fpage>841</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1038/s41431-023-01322-y</pub-id><pub-id pub-id-type="pmid">36828923</pub-id><pub-id pub-id-type="pmcid">PMC10326037</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Bozsik A, Butz H, Grolmusz VK et al (2023) Genome sequencing-based discovery of a novel deep intronic <italic toggle="yes">APC</italic> pathogenic variant causing exonization. Eur J Hum Genet 31:841&#8211;845. 10.1038/s41431-023-01322-y<pub-id pub-id-type="pmid">36828923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41431-023-01322-y</pub-id><pub-id pub-id-type="pmcid">PMC10326037</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavicic</surname><given-names>W</given-names></name><name name-style="western"><surname>Nieminen</surname><given-names>TT</given-names></name><name name-style="western"><surname>Gylling</surname><given-names>A</given-names></name><etal/></person-group><article-title>Promoter-specific alterations of <italic toggle="yes">APC</italic> are a rare cause for mutation-negative familial adenomatous polyposis</article-title><source>Genes Chromosomes Cancer</source><year>2014</year><volume>53</volume><fpage>857</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1002/gcc.22197</pub-id><pub-id pub-id-type="pmid">24946964</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Pavicic W, Nieminen TT, Gylling A et al (2014) Promoter-specific alterations of <italic toggle="yes">APC</italic> are a rare cause for mutation-negative familial adenomatous polyposis. Genes Chromosomes Cancer 53:857&#8211;864. 10.1002/gcc.22197<pub-id pub-id-type="pmid">24946964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gcc.22197</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lynch</surname><given-names>PM</given-names></name><name name-style="western"><surname>Morris</surname><given-names>JS</given-names></name><name name-style="western"><surname>Wen</surname><given-names>S</given-names></name><etal/></person-group><article-title>A proposed staging system and stage-specific interventions for familial adenomatous polyposis</article-title><source>Gastrointest Endosc</source><year>2016</year><volume>84</volume><fpage>115</fpage><lpage>125.e114</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2015.12.029</pub-id><pub-id pub-id-type="pmid">26769407</pub-id><pub-id pub-id-type="pmcid">PMC5570515</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Lynch PM, Morris JS, Wen S et al (2016) A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointest Endosc 84:115-125.e114<pub-id pub-id-type="pmid">26769407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2015.12.029</pub-id><pub-id pub-id-type="pmcid">PMC5570515</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Septer</surname><given-names>S</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>CE</given-names></name><name name-style="western"><surname>Anant</surname><given-names>S</given-names></name><etal/></person-group><article-title>Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate</article-title><source>Fam Cancer</source><year>2016</year><volume>15</volume><fpage>477</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1007/s10689-016-9905-5</pub-id><pub-id pub-id-type="pmid">27056662</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Septer S, Lawson CE, Anant S et al (2016) Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate. Fam Cancer 15:477&#8211;485<pub-id pub-id-type="pmid">27056662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-016-9905-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Distante</surname><given-names>S</given-names></name><name name-style="western"><surname>Nasioulas</surname><given-names>S</given-names></name><name name-style="western"><surname>Somers</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Familial adenomatous polyposis in a 5 year old child: a clinical, pathological, and molecular genetic study</article-title><source>J Med Genet</source><year>1996</year><volume>33</volume><fpage>157</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1136/jmg.33.2.157</pub-id><pub-id pub-id-type="pmid">8929955</pub-id><pub-id pub-id-type="pmcid">PMC1051844</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Distante S, Nasioulas S, Somers GR et al (1996) Familial adenomatous polyposis in a 5 year old child: a clinical, pathological, and molecular genetic study. J Med Genet 33:157&#8211;160<pub-id pub-id-type="pmid">8929955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmg.33.2.157</pub-id><pub-id pub-id-type="pmcid">PMC1051844</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>M</given-names></name><name name-style="western"><surname>Hes</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Nagengast</surname><given-names>FM</given-names></name><etal/></person-group><article-title>Germline mutations in <italic toggle="yes">APC</italic> and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis</article-title><source>Clin Genet</source><year>2007</year><volume>71</volume><fpage>427</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0004.2007.00766.x</pub-id><pub-id pub-id-type="pmid">17489848</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Nielsen M, Hes FJ, Nagengast FM et al (2007) Germline mutations in <italic toggle="yes">APC</italic> and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis. Clin Genet 71:427&#8211;433. 10.1111/j.1399-0004.2007.00766.x<pub-id pub-id-type="pmid">17489848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1399-0004.2007.00766.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burt</surname><given-names>RW</given-names></name><name name-style="western"><surname>Leppert</surname><given-names>MF</given-names></name><name name-style="western"><surname>Slattery</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis</article-title><source>Gastroenterology</source><year>2004</year><volume>127</volume><fpage>444</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2004.05.003</pub-id><pub-id pub-id-type="pmid">15300576</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Burt RW, Leppert MF, Slattery ML et al (2004) Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology 127:444&#8211;451<pub-id pub-id-type="pmid">15300576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2004.05.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishikawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Mutoh</surname><given-names>M</given-names></name><name name-style="western"><surname>Iwama</surname><given-names>T</given-names></name><etal/></person-group><article-title>Endoscopic management of familial adenomatous polyposis in patients refusing colectomy</article-title><source>Endoscopy</source><year>2016</year><volume>48</volume><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">26352809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0034-1392774</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Ishikawa H, Mutoh M, Iwama T et al (2016) Endoscopic management of familial adenomatous polyposis in patients refusing colectomy. Endoscopy 48:51&#8211;55<pub-id pub-id-type="pmid">26352809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0034-1392774</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishikawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>M</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Intensive endoscopic resection for downstaging of polyp burden in patients with familial adenomatous polyposis (J-FAPP study &#8546;): a multicenter prospective interventional study</article-title><source>Endoscopy</source><year>2023</year><volume>55</volume><fpage>344</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1055/a-1945-9120</pub-id><pub-id pub-id-type="pmid">36216266</pub-id><pub-id pub-id-type="pmcid">PMC10060053</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Ishikawa H, Yamada M, Sato Y et al (2023) Intensive endoscopic resection for downstaging of polyp burden in patients with familial adenomatous polyposis (J-FAPP study &#8546;): a multicenter prospective interventional study. Endoscopy 55:344&#8211;352<pub-id pub-id-type="pmid">36216266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-1945-9120</pub-id><pub-id pub-id-type="pmcid">PMC10060053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwama</surname><given-names>T</given-names></name></person-group><article-title>A pathomorphological study of adenomatous polyposis</article-title><source>J Jpn Surg Soc</source><year>1978</year><volume>79</volume><fpage>10</fpage><lpage>24</lpage></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Iwama T (1978) A pathomorphological study of adenomatous polyposis. J Jpn Surg Soc 79:10&#8211;24</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sturt</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>MC</given-names></name><name name-style="western"><surname>Bassett</surname><given-names>P</given-names></name><etal/></person-group><article-title>Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline <italic toggle="yes">APC</italic> mutation</article-title><source>Gut</source><year>2004</year><volume>53</volume><fpage>1832</fpage><lpage>1836</lpage><pub-id pub-id-type="doi">10.1136/gut.2004.042705</pub-id><pub-id pub-id-type="pmid">15542524</pub-id><pub-id pub-id-type="pmcid">PMC1774338</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Sturt NJ, Gallagher MC, Bassett P et al (2004) Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline <italic toggle="yes">APC</italic> mutation. Gut 53:1832&#8211;1836<pub-id pub-id-type="pmid">15542524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.2004.042705</pub-id><pub-id pub-id-type="pmcid">PMC1774338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rozen</surname><given-names>P</given-names></name><name name-style="western"><surname>Macrae</surname><given-names>F</given-names></name></person-group><article-title>Familial adenomatous polyposis: the practical applications of clinical and molecular screening</article-title><source>Fam Cancer</source><year>2006</year><volume>5</volume><fpage>227</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1007/s10689-005-5674-2</pub-id><pub-id pub-id-type="pmid">16998668</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Rozen P, Macrae F (2006) Familial adenomatous polyposis: the practical applications of clinical and molecular screening. Fam Cancer 5:227&#8211;235<pub-id pub-id-type="pmid">16998668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-005-5674-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mori</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>H</given-names></name><name name-style="western"><surname>Chika</surname><given-names>N</given-names></name><etal/></person-group><article-title>Usefulness of genotyping <italic toggle="yes">APC</italic> gene for individualizing management of patients with familial adenomatous polyposis</article-title><source>Int J Clin Oncol</source><year>2023</year><volume>28</volume><fpage>1641</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1007/s10147-023-02419-6</pub-id><pub-id pub-id-type="pmid">37853284</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Mori Y, Ishida H, Chika N et al (2023) Usefulness of genotyping <italic toggle="yes">APC</italic> gene for individualizing management of patients with familial adenomatous polyposis. Int J Clin Oncol 28:1641&#8211;1650<pub-id pub-id-type="pmid">37853284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10147-023-02419-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crabtree</surname><given-names>MD</given-names></name><name name-style="western"><surname>Tomlinson</surname><given-names>IP</given-names></name><name name-style="western"><surname>Talbot</surname><given-names>IC</given-names></name><etal/></person-group><article-title>Variability in the severity of colonic disease in familial adenomatous polyposis results from differences in tumour initiation rather than progression and depends relatively little on patient age</article-title><source>Gut</source><year>2001</year><volume>49</volume><fpage>540</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1136/gut.49.4.540</pub-id><pub-id pub-id-type="pmid">11559652</pub-id><pub-id pub-id-type="pmcid">PMC1728467</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Crabtree MD, Tomlinson IP, Talbot IC et al (2001) Variability in the severity of colonic disease in familial adenomatous polyposis results from differences in tumour initiation rather than progression and depends relatively little on patient age. Gut 49:540&#8211;543<pub-id pub-id-type="pmid">11559652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.49.4.540</pub-id><pub-id pub-id-type="pmcid">PMC1728467</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>K&#216;</given-names></name><name name-style="western"><surname>Juul</surname><given-names>S</given-names></name><name name-style="western"><surname>B&#252;low</surname><given-names>S</given-names></name><etal/></person-group><article-title>Female fecundity before and after operation for familial adenomatous polyposis</article-title><source>Br J Surg</source><year>2003</year><volume>90</volume><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1002/bjs.4082</pub-id><pub-id pub-id-type="pmid">12555301</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Olsen K&#216;, Juul S, B&#252;low S et al (2003) Female fecundity before and after operation for familial adenomatous polyposis. Br J Surg 90:227&#8211;231<pub-id pub-id-type="pmid">12555301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bjs.4082</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kartheuser</surname><given-names>AH</given-names></name><name name-style="western"><surname>Parc</surname><given-names>R</given-names></name><name name-style="western"><surname>Penna</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Ileal pouch-anal anastomosis as the first choice operation in patients with familial adenomatous polyposis: a ten-year experience</article-title><source>Surgery</source><year>1996</year><volume>119</volume><fpage>615</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/S0039-6060(96)80185-1</pub-id><pub-id pub-id-type="pmid">8650601</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Kartheuser AH, Parc R, Penna CP et al (1996) Ileal pouch-anal anastomosis as the first choice operation in patients with familial adenomatous polyposis: a ten-year experience. Surgery 119:615&#8211;623<pub-id pub-id-type="pmid">8650601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0039-6060(96)80185-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rozen</surname><given-names>P</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>Z</given-names></name><name name-style="western"><surname>Rabau</surname><given-names>M</given-names></name><etal/></person-group><article-title>Familial adenomatous polyposis at the Tel Aviv medical center: demographic and clinical features</article-title><source>Fam Cancer</source><year>2001</year><volume>1</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1023/A:1013888226756</pub-id><pub-id pub-id-type="pmid">14574001</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Rozen P, Samuel Z, Rabau M et al (2001) Familial adenomatous polyposis at the Tel Aviv medical center: demographic and clinical features. Fam Cancer 1:75&#8211;82<pub-id pub-id-type="pmid">14574001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1013888226756</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eccles</surname><given-names>DM</given-names></name><name name-style="western"><surname>Lunt</surname><given-names>PW</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>Y</given-names></name><etal/></person-group><article-title>An unusually severe phenotype for familial adenomatous polyposis</article-title><source>Arch Dis Child</source><year>1997</year><volume>77</volume><fpage>431</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1136/adc.77.5.431</pub-id><pub-id pub-id-type="pmid">9487968</pub-id><pub-id pub-id-type="pmcid">PMC1717382</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Eccles DM, Lunt PW, Wallis Y et al (1997) An unusually severe phenotype for familial adenomatous polyposis. Arch Dis Child 77:431&#8211;435<pub-id pub-id-type="pmid">9487968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/adc.77.5.431</pub-id><pub-id pub-id-type="pmcid">PMC1717382</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasen</surname><given-names>HF</given-names></name><name name-style="western"><surname>van Duijvendijk</surname><given-names>P</given-names></name><name name-style="western"><surname>Buskens</surname><given-names>E</given-names></name><etal/></person-group><article-title>Decision analysis in the surgical treatment of patients with familial adenomatous polyposis: a Dutch-Scandinavian collaborative study including 659 patients</article-title><source>Gut</source><year>2001</year><volume>49</volume><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1136/gut.49.2.231</pub-id><pub-id pub-id-type="pmid">11454800</pub-id><pub-id pub-id-type="pmcid">PMC1728380</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Vasen HF, van Duijvendijk P, Buskens E et al (2001) Decision analysis in the surgical treatment of patients with familial adenomatous polyposis: a Dutch-Scandinavian collaborative study including 659 patients. Gut 49:231&#8211;235<pub-id pub-id-type="pmid">11454800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.49.2.231</pub-id><pub-id pub-id-type="pmcid">PMC1728380</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kartheuser</surname><given-names>A</given-names></name><name name-style="western"><surname>Stangherlin</surname><given-names>P</given-names></name><name name-style="western"><surname>Brandt</surname><given-names>D</given-names></name><etal/></person-group><article-title>Restorative proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis revisited</article-title><source>Fam Cancer</source><year>2006</year><volume>5</volume><fpage>241</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1007/s10689-005-5672-4</pub-id><pub-id pub-id-type="pmid">16998670</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Kartheuser A, Stangherlin P, Brandt D et al (2006) Restorative proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis revisited. Fam Cancer 5:241&#8211;260. 10.1007/s10689-005-5672-4<pub-id pub-id-type="pmid">16998670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-005-5672-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueno</surname><given-names>H</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Konishi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prevalence of laparoscopic surgical treatment and its clinical outcomes in patients with familial adenomatous polyposis in Japan</article-title><source>Int J Clin Oncol</source><year>2016</year><volume>21</volume><fpage>713</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1007/s10147-016-0953-5</pub-id><pub-id pub-id-type="pmid">26820718</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Ueno H, Kobayashi H, Konishi T et al (2016) Prevalence of laparoscopic surgical treatment and its clinical outcomes in patients with familial adenomatous polyposis in Japan. Int J Clin Oncol 21:713&#8211;722<pub-id pub-id-type="pmid">26820718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10147-016-0953-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konishi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>H</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>H</given-names></name><etal/></person-group><article-title>Feasibility of laparoscopic total proctocolectomy with ileal pouch-anal anastomosis and total colectomy with ileorectal anastomosis for familial adenomatous polyposis: results of a nationwide multicenter study</article-title><source>Int J Clin Oncol</source><year>2016</year><volume>21</volume><fpage>953</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1007/s10147-016-0977-x</pub-id><pub-id pub-id-type="pmid">27095110</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Konishi T, Ishida H, Ueno H et al (2016) Feasibility of laparoscopic total proctocolectomy with ileal pouch-anal anastomosis and total colectomy with ileorectal anastomosis for familial adenomatous polyposis: results of a nationwide multicenter study. Int J Clin Oncol 21:953&#8211;961<pub-id pub-id-type="pmid">27095110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10147-016-0977-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campos</surname><given-names>FG</given-names></name></person-group><article-title>Surgical treatment of familial adenomatous polyposis: dilemmas and current recommendations</article-title><source>World J Gastroenterol</source><year>2014</year><volume>20</volume><fpage>16620</fpage><lpage>16629</lpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i44.16620</pub-id><pub-id pub-id-type="pmid">25469031</pub-id><pub-id pub-id-type="pmcid">PMC4248206</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Campos FG (2014) Surgical treatment of familial adenomatous polyposis: dilemmas and current recommendations. World J Gastroenterol 20:16620&#8211;16629<pub-id pub-id-type="pmid">25469031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v20.i44.16620</pub-id><pub-id pub-id-type="pmcid">PMC4248206</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kjaer</surname><given-names>MD</given-names></name><name name-style="western"><surname>Laursen</surname><given-names>SB</given-names></name><name name-style="western"><surname>Qvist</surname><given-names>N</given-names></name><etal/></person-group><article-title>Sexual function and body image are similar after laparoscopy-assisted and open ileal pouch-anal anastomosis</article-title><source>World J Surg</source><year>2014</year><volume>38</volume><fpage>2460</fpage><lpage>2465</lpage><pub-id pub-id-type="doi">10.1007/s00268-014-2557-4</pub-id><pub-id pub-id-type="pmid">24711157</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Kjaer MD, Laursen SB, Qvist N et al (2014) Sexual function and body image are similar after laparoscopy-assisted and open ileal pouch-anal anastomosis. World J Surg 38:2460&#8211;2465. 10.1007/s00268-014-2557-4<pub-id pub-id-type="pmid">24711157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00268-014-2557-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fajardo</surname><given-names>AD</given-names></name><name name-style="western"><surname>Dharmarajan</surname><given-names>S</given-names></name><name name-style="western"><surname>George</surname><given-names>V</given-names></name><etal/></person-group><article-title>Laparoscopic versus open 2-stage ileal pouch: laparoscopic approach allows for faster restoration of intestinal continuity</article-title><source>J Am Coll Surg</source><year>2010</year><volume>211</volume><fpage>377</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2010.05.018</pub-id><pub-id pub-id-type="pmid">20800195</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Fajardo AD, Dharmarajan S, George V et al (2010) Laparoscopic versus open 2-stage ileal pouch: laparoscopic approach allows for faster restoration of intestinal continuity. J Am Coll Surg 211:377&#8211;383<pub-id pub-id-type="pmid">20800195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jamcollsurg.2010.05.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Luz Moreira</surname><given-names>A</given-names></name><name name-style="western"><surname>Church</surname><given-names>JM</given-names></name><name name-style="western"><surname>Burke</surname><given-names>CA</given-names></name></person-group><article-title>The evolution of prophylactic colorectal surgery for familial adenomatous polyposis</article-title><source>Dis Colon Rectum</source><year>2009</year><volume>52</volume><fpage>1481</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1007/DCR.0b013e3181ab58fb</pub-id><pub-id pub-id-type="pmid">19617764</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">da Luz Moreira A, Church JM, Burke CA (2009) The evolution of prophylactic colorectal surgery for familial adenomatous polyposis. Dis Colon Rectum 52:1481&#8211;1486<pub-id pub-id-type="pmid">19617764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/DCR.0b013e3181ab58fb</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>A</given-names></name><name name-style="western"><surname>Burns</surname><given-names>EM</given-names></name><name name-style="western"><surname>Latchford</surname><given-names>A</given-names></name><etal/></person-group><article-title>Risk of desmoid formation after laparoscopic versus open colectomy and ileorectal anastomosis for familial adenomatous polyposis</article-title><source>BJS Open</source><year>2018</year><volume>2</volume><fpage>452</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1002/bjs5.90</pub-id><pub-id pub-id-type="pmid">30511045</pub-id><pub-id pub-id-type="pmcid">PMC6253786</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Sinha A, Burns EM, Latchford A et al (2018) Risk of desmoid formation after laparoscopic versus open colectomy and ileorectal anastomosis for familial adenomatous polyposis. BJS Open 2:452&#8211;455. 10.1002/bjs5.90<pub-id pub-id-type="pmid">30511045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bjs5.90</pub-id><pub-id pub-id-type="pmcid">PMC6253786</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chittleborough</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Warrier</surname><given-names>SK</given-names></name><name name-style="western"><surname>Heriot</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Dispelling misconceptions in the management of familial adenomatous polyposis</article-title><source>ANZ J Surg</source><year>2017</year><volume>87</volume><fpage>441</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1111/ans.13919</pub-id><pub-id pub-id-type="pmid">28266097</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Chittleborough TJ, Warrier SK, Heriot AG et al (2017) Dispelling misconceptions in the management of familial adenomatous polyposis. ANZ J Surg 87:441&#8211;445. 10.1111/ans.13919<pub-id pub-id-type="pmid">28266097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ans.13919</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johansen</surname><given-names>C</given-names></name><name name-style="western"><surname>Bitsch</surname><given-names>M</given-names></name><name name-style="western"><surname>B&#252;low</surname><given-names>S</given-names></name></person-group><article-title>Fertility and pregnancy in women with familial adenomatous polyposis</article-title><source>Int J Colorectal Dis</source><year>1990</year><volume>5</volume><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1007/BF00303276</pub-id><pub-id pub-id-type="pmid">1962811</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Johansen C, Bitsch M, B&#252;low S (1990) Fertility and pregnancy in women with familial adenomatous polyposis. Int J Colorectal Dis 5:203&#8211;206<pub-id pub-id-type="pmid">1962811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00303276</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieuwenhuis</surname><given-names>MH</given-names></name><name name-style="western"><surname>Douma</surname><given-names>KF</given-names></name><name name-style="western"><surname>Bleiker</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Female fertility after colorectal surgery for familial adenomatous polyposis: a nationwide cross-sectional study</article-title><source>Ann Surg</source><year>2010</year><volume>252</volume><fpage>341</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e3181e9829f</pub-id><pub-id pub-id-type="pmid">20622653</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Nieuwenhuis MH, Douma KF, Bleiker EM et al (2010) Female fertility after colorectal surgery for familial adenomatous polyposis: a nationwide cross-sectional study. Ann Surg 252:341&#8211;344<pub-id pub-id-type="pmid">20622653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0b013e3181e9829f</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oresland</surname><given-names>T</given-names></name><name name-style="western"><surname>Palmblad</surname><given-names>S</given-names></name><name name-style="western"><surname>Ellstrom</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy</article-title><source>Int J Colorectal Dis</source><year>1994</year><volume>9</volume><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1007/BF00699417</pub-id><pub-id pub-id-type="pmid">8064194</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Oresland T, Palmblad S, Ellstrom M et al (1994) Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int J Colorectal Dis 9:77&#8211;81<pub-id pub-id-type="pmid">8064194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00699417</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartels</surname><given-names>SA</given-names></name><name name-style="western"><surname>D&#8217;Hoore</surname><given-names>A</given-names></name><name name-style="western"><surname>Cuesta</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study</article-title><source>Ann Surg</source><year>2012</year><volume>256</volume><fpage>1045</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e318250caa9</pub-id><pub-id pub-id-type="pmid">22609840</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Bartels SA, D&#8217;Hoore A, Cuesta MA et al (2012) Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. Ann Surg 256:1045&#8211;1048<pub-id pub-id-type="pmid">22609840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0b013e318250caa9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Remzi</surname><given-names>FH</given-names></name><name name-style="western"><surname>Gorgun</surname><given-names>E</given-names></name><name name-style="western"><surname>Bast</surname><given-names>J</given-names></name><etal/></person-group><article-title>Vaginal delivery after ileal pouch-anal anastomosis: a word of caution</article-title><source>Dis Colon Rectum</source><year>2005</year><volume>48</volume><fpage>1691</fpage><lpage>1699</lpage><pub-id pub-id-type="doi">10.1007/s10350-005-0124-7</pub-id><pub-id pub-id-type="pmid">16142432</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Remzi FH, Gorgun E, Bast J et al (2005) Vaginal delivery after ileal pouch-anal anastomosis: a word of caution. Dis Colon Rectum 48:1691&#8211;1699<pub-id pub-id-type="pmid">16142432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10350-005-0124-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juhasz</surname><given-names>ES</given-names></name><name name-style="western"><surname>Fozard</surname><given-names>B</given-names></name><name name-style="western"><surname>Dozois</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Ileal pouch-anal anastomosis function following childbirth. An extended evaluation</article-title><source>Dis Colon Rectum</source><year>1995</year><volume>38</volume><fpage>159</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1007/BF02052444</pub-id><pub-id pub-id-type="pmid">7851170</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Juhasz ES, Fozard B, Dozois RR et al (1995) Ileal pouch-anal anastomosis function following childbirth. An extended evaluation. Dis Colon Rectum 38:159&#8211;165<pub-id pub-id-type="pmid">7851170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02052444</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parc</surname><given-names>Y</given-names></name><name name-style="western"><surname>Piquard</surname><given-names>A</given-names></name><name name-style="western"><surname>Dozois</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Long-term outcome of familial adenomatous polyposis patients after restorative coloproctectomy</article-title><source>Ann Surg</source><year>2004</year><volume>239</volume><fpage>378</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1097/01.sla.0000114216.90947.f6</pub-id><pub-id pub-id-type="pmid">15075655</pub-id><pub-id pub-id-type="pmcid">PMC1356236</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Parc Y, Piquard A, Dozois RR et al (2004) Long-term outcome of familial adenomatous polyposis patients after restorative coloproctectomy. Ann Surg 239:378&#8211;382<pub-id pub-id-type="pmid">15075655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.sla.0000114216.90947.f6</pub-id><pub-id pub-id-type="pmcid">PMC1356236</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson-Fawcett</surname><given-names>MW</given-names></name><name name-style="western"><surname>Marcus</surname><given-names>VA</given-names></name><name name-style="western"><surname>Redston</surname><given-names>M</given-names></name><etal/></person-group><article-title>Adenomatous polyps develop commonly in the ileal pouch of patients with familial adenomatous polyposis</article-title><source>Dis Colon Rectum</source><year>2001</year><volume>44</volume><fpage>347</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1007/BF02234731</pub-id><pub-id pub-id-type="pmid">11289279</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Thompson-Fawcett MW, Marcus VA, Redston M et al (2001) Adenomatous polyps develop commonly in the ileal pouch of patients with familial adenomatous polyposis. Dis Colon Rectum 44:347&#8211;353<pub-id pub-id-type="pmid">11289279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02234731</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Groves</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Beveridge</surname><given-names>LG</given-names></name><name name-style="western"><surname>Swain</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Prevalence and morphology of pouch and ileal adenomas in familial adenomatous polyposis</article-title><source>Dis Colon Rectum</source><year>2005</year><volume>48</volume><fpage>816</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1007/s10350-004-0835-1</pub-id><pub-id pub-id-type="pmid">15747076</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Groves CJ, Beveridge LG, Swain DJ et al (2005) Prevalence and morphology of pouch and ileal adenomas in familial adenomatous polyposis. Dis Colon Rectum 48:816&#8211;823<pub-id pub-id-type="pmid">15747076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10350-004-0835-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tajika</surname><given-names>M</given-names></name><name name-style="western"><surname>Niwa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>V</given-names></name><etal/></person-group><article-title>Risk of ileal pouch neoplasms in patients with familial adenomatous polyposis</article-title><source>World J Gastroenterol</source><year>2013</year><volume>19</volume><fpage>6774</fpage><lpage>6783</lpage><pub-id pub-id-type="doi">10.3748/wjg.v19.i40.6774</pub-id><pub-id pub-id-type="pmid">24187452</pub-id><pub-id pub-id-type="pmcid">PMC3812476</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Tajika M, Niwa Y, Bhatia V et al (2013) Risk of ileal pouch neoplasms in patients with familial adenomatous polyposis. World J Gastroenterol 19:6774&#8211;6783<pub-id pub-id-type="pmid">24187452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v19.i40.6774</pub-id><pub-id pub-id-type="pmcid">PMC3812476</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoehner</surname><given-names>JC</given-names></name><name name-style="western"><surname>Metcalf</surname><given-names>AM</given-names></name></person-group><article-title>Development of invasive adenocarcinoma following colectomy with ileoanal anastomosis for familial polyposis coli. Report of a case</article-title><source>Dis Colon Rectum</source><year>1994</year><volume>37</volume><fpage>824</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1007/BF02050149</pub-id><pub-id pub-id-type="pmid">8055729</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Hoehner JC, Metcalf AM (1994) Development of invasive adenocarcinoma following colectomy with ileoanal anastomosis for familial polyposis coli. Report of a case. Dis Colon Rectum 37:824&#8211;828<pub-id pub-id-type="pmid">8055729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02050149</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ault</surname><given-names>GT</given-names></name><name name-style="western"><surname>Nunoo-Mensah</surname><given-names>JW</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Adenocarcinoma arising in the middle of ileoanal pouches: report of five cases</article-title><source>Dis Colon Rectum</source><year>2009</year><volume>52</volume><fpage>538</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1007/DCR.0b013e318199effe</pub-id><pub-id pub-id-type="pmid">19333060</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Ault GT, Nunoo-Mensah JW, Johnson L et al (2009) Adenocarcinoma arising in the middle of ileoanal pouches: report of five cases. Dis Colon Rectum 52:538&#8211;541<pub-id pub-id-type="pmid">19333060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/DCR.0b013e318199effe</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angriman</surname><given-names>I</given-names></name><name name-style="western"><surname>Scarpa</surname><given-names>M</given-names></name><name name-style="western"><surname>Castagliuolo</surname><given-names>I</given-names></name></person-group><article-title>Relationship between pouch microbiota and pouchitis following restorative proctocolectomy for ulcerative colitis</article-title><source>World J Gastroenterol</source><year>2014</year><volume>20</volume><fpage>9665</fpage><lpage>9674</lpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i29.9665</pub-id><pub-id pub-id-type="pmid">25110406</pub-id><pub-id pub-id-type="pmcid">PMC4123357</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Angriman I, Scarpa M, Castagliuolo I (2014) Relationship between pouch microbiota and pouchitis following restorative proctocolectomy for ulcerative colitis. World J Gastroenterol 20:9665&#8211;9674<pub-id pub-id-type="pmid">25110406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v20.i29.9665</pub-id><pub-id pub-id-type="pmcid">PMC4123357</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koskenvuo</surname><given-names>L</given-names></name><name name-style="western"><surname>Renkonen-Sinisalo</surname><given-names>L</given-names></name><name name-style="western"><surname>J&#228;rvinen</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Risk of cancer and secondary proctectomy after colectomy and ileorectal anastomosis in familial adenomatous polyposis</article-title><source>Int J Colorectal Dis</source><year>2014</year><volume>29</volume><fpage>225</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1007/s00384-013-1796-4</pub-id><pub-id pub-id-type="pmid">24292488</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Koskenvuo L, Renkonen-Sinisalo L, J&#228;rvinen HJ et al (2014) Risk of cancer and secondary proctectomy after colectomy and ileorectal anastomosis in familial adenomatous polyposis. Int J Colorectal Dis 29:225&#8211;230. 10.1007/s00384-013-1796-4<pub-id pub-id-type="pmid">24292488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00384-013-1796-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campos</surname><given-names>FG</given-names></name><name name-style="western"><surname>Perez</surname><given-names>RO</given-names></name><name name-style="western"><surname>Imperiale</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Surgical treatment of familial adenomatous polyposis: ileorectal anastomosis or restorative proctolectomy?</article-title><source>Arq Gastroenterol</source><year>2009</year><volume>46</volume><fpage>294</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1590/S0004-28032009000400009</pub-id><pub-id pub-id-type="pmid">20232009</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Campos FG, Perez RO, Imperiale AR et al (2009) Surgical treatment of familial adenomatous polyposis: ileorectal anastomosis or restorative proctolectomy? Arq Gastroenterol 46:294&#8211;299. 10.1590/S0004-28032009000400009<pub-id pub-id-type="pmid">20232009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/s0004-28032009000400009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieuwenhuis</surname><given-names>MH</given-names></name><name name-style="western"><surname>B&#252;low</surname><given-names>S</given-names></name><name name-style="western"><surname>Bj&#246;rk</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genotype predicting phenotype in familial adenomatous polyposis: a practical application to the choice of surgery</article-title><source>Dis Colon Rectum</source><year>2009</year><volume>52</volume><fpage>1259</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1007/DCR.0b013e3181a0d33b</pub-id><pub-id pub-id-type="pmid">19571702</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Nieuwenhuis MH, B&#252;low S, Bj&#246;rk J et al (2009) Genotype predicting phenotype in familial adenomatous polyposis: a practical application to the choice of surgery. Dis Colon Rectum 52:1259&#8211;1263<pub-id pub-id-type="pmid">19571702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/DCR.0b013e3181a0d33b</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#252;low</surname><given-names>S</given-names></name><name name-style="western"><surname>B&#252;low</surname><given-names>C</given-names></name><name name-style="western"><surname>Vasen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Colectomy and ileorectal anastomosis is still an option for selected patients with familial adenomatous polyposis</article-title><source>Dis Colon Rectum</source><year>2008</year><volume>51</volume><fpage>1318</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.1007/s10350-008-9307-3</pub-id><pub-id pub-id-type="pmid">18523824</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">B&#252;low S, B&#252;low C, Vasen H et al (2008) Colectomy and ileorectal anastomosis is still an option for selected patients with familial adenomatous polyposis. Dis Colon Rectum 51:1318&#8211;1323<pub-id pub-id-type="pmid">18523824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10350-008-9307-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Church</surname><given-names>J</given-names></name><name name-style="western"><surname>Simmang</surname><given-names>C</given-names></name><collab>Standards Task Force; American Society of Colon and Rectal Surgeons; Collaborative Group of the Americas on Inherited Colorectal Cancer and the Standards Committee of The American Society of Colon and Rectal Surgeons</collab></person-group><article-title>Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer)</article-title><source>Dis Colon Rectum</source><year>2003</year><volume>46</volume><fpage>1001</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1007/s10350-004-7273-y</pub-id><pub-id pub-id-type="pmid">12907889</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Church J, Simmang C, Standards Task Force; American Society of Colon and Rectal Surgeons; Collaborative Group of the Americas on Inherited Colorectal Cancer and the Standards Committee of The American Society of Colon and Rectal Surgeons (2003) Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 46:1001&#8211;1012<pub-id pub-id-type="pmid">12907889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10350-004-7273-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianchi</surname><given-names>LK</given-names></name><name name-style="western"><surname>Burke</surname><given-names>CA</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Fundic gland polyp dysplasia is common in familial adenomatous polyposis</article-title><source>Clin Gastroenterol Hepatol</source><year>2008</year><volume>6</volume><fpage>180</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2007.11.018</pub-id><pub-id pub-id-type="pmid">18237868</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Bianchi LK, Burke CA, Bennett AE et al (2008) Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 6:180&#8211;185<pub-id pub-id-type="pmid">18237868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2007.11.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takao</surname><given-names>A</given-names></name><name name-style="western"><surname>Koizumi</surname><given-names>K</given-names></name><name name-style="western"><surname>Takao</surname><given-names>M</given-names></name><etal/></person-group><article-title>Upper gastrointestinal tumors are unrelated to the <italic toggle="yes">APC</italic> genotype in <italic toggle="yes">APC</italic>-associated polyposis</article-title><source>Jpn J Clin Oncol</source><year>2022</year><volume>52</volume><fpage>554</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyac029</pub-id><pub-id pub-id-type="pmid">35296888</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Takao A, Koizumi K, Takao M et al (2022) Upper gastrointestinal tumors are unrelated to the <italic toggle="yes">APC</italic> genotype in <italic toggle="yes">APC</italic>-associated polyposis. Jpn J Clin Oncol 52:554&#8211;561<pub-id pub-id-type="pmid">35296888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jjco/hyac029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimamoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ishiguro</surname><given-names>S</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gastric neoplasms in patients with familial adenomatous polyposis: endoscopic and clinicopathologic features</article-title><source>Gastrointest Endosc</source><year>2021</year><volume>94</volume><fpage>1030</fpage><lpage>1042.e2</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2021.06.010</pub-id><pub-id pub-id-type="pmid">34146551</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Shimamoto Y, Ishiguro S, Takeuchi Y et al (2021) Gastric neoplasms in patients with familial adenomatous polyposis: endoscopic and clinicopathologic features. Gastrointest Endosc 94:1030-1042.e2<pub-id pub-id-type="pmid">34146551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2021.06.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Sassatelli</surname><given-names>R</given-names></name><name name-style="western"><surname>Nigrisoli</surname><given-names>E</given-names></name><etal/></person-group><article-title>Dysplastic changes in gastric fundic gland polyps of patients with familial adenomatous polyposis</article-title><source>Ital J Gastroenterol Hepatol</source><year>1999</year><volume>31</volume><fpage>192</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">10379478</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Bertoni G, Sassatelli R, Nigrisoli E et al (1999) Dysplastic changes in gastric fundic gland polyps of patients with familial adenomatous polyposis. Ital J Gastroenterol Hepatol 31:192&#8211;197<pub-id pub-id-type="pmid">10379478</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobashi</surname><given-names>M</given-names></name><name name-style="western"><surname>Iwamuro</surname><given-names>M</given-names></name><name name-style="western"><surname>Kuraoka</surname><given-names>S</given-names></name><etal/></person-group><article-title>Endoscopic findings of gastric neoplasms in familial adenomatous polyposis are associated with the phenotypic variations and grades of dysplasia</article-title><source>Medicine (Baltimore)</source><year>2022</year><volume>101</volume><fpage>e30997</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000030997</pub-id><pub-id pub-id-type="pmid">36254079</pub-id><pub-id pub-id-type="pmcid">PMC9575760</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Kobashi M, Iwamuro M, Kuraoka S et al (2022) Endoscopic findings of gastric neoplasms in familial adenomatous polyposis are associated with the phenotypic variations and grades of dysplasia. Medicine (Baltimore) 101:e30997<pub-id pub-id-type="pmid">36254079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000030997</pub-id><pub-id pub-id-type="pmcid">PMC9575760</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngamruengphong</surname><given-names>S</given-names></name><name name-style="western"><surname>Boardman</surname><given-names>LA</given-names></name><name name-style="western"><surname>Heigh</surname><given-names>RI</given-names></name><etal/></person-group><article-title>Gastric adenomas in familial adenomatous polyposis are common but subtle, and have a benign course</article-title><source>Hered Cancer Clin Pract</source><year>2014</year><volume>12</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/1897-4287-12-4</pub-id><pub-id pub-id-type="pmid">24565534</pub-id><pub-id pub-id-type="pmcid">PMC3943270</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Ngamruengphong S, Boardman LA, Heigh RI et al (2014) Gastric adenomas in familial adenomatous polyposis are common but subtle, and have a benign course. Hered Cancer Clin Pract 12:4. 10.1186/1897-4287-12-4<pub-id pub-id-type="pmid">24565534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1897-4287-12-4</pub-id><pub-id pub-id-type="pmcid">PMC3943270</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spigelman</surname><given-names>AD</given-names></name><name name-style="western"><surname>Williams</surname><given-names>CB</given-names></name><name name-style="western"><surname>Talbot</surname><given-names>IC</given-names></name><etal/></person-group><article-title>Upper gastrointestinal cancer in patients with familial adenomatous polyposis</article-title><source>Lancet</source><year>1989</year><volume>2</volume><fpage>783</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(89)90840-4</pub-id><pub-id pub-id-type="pmid">2571019</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Spigelman AD, Williams CB, Talbot IC et al (1989) Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 2:783&#8211;785<pub-id pub-id-type="pmid">2571019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(89)90840-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Gurudu</surname><given-names>SR</given-names></name><name name-style="western"><surname>Koptiuch</surname><given-names>C</given-names></name><etal/></person-group><article-title>American society for gastrointestinal endoscopy guideline on the role of endoscopy in familial adenomatous polyposis syndromes</article-title><source>Gastrointest Endosc</source><year>2020</year><volume>91</volume><fpage>963</fpage><lpage>982.e2</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2020.01.028</pub-id><pub-id pub-id-type="pmid">32169282</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Yang J, Gurudu SR, Koptiuch C et al (2020) American society for gastrointestinal endoscopy guideline on the role of endoscopy in familial adenomatous polyposis syndromes. Gastrointest Endosc 91:963-982.e2<pub-id pub-id-type="pmid">32169282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2020.01.028</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iida</surname><given-names>M</given-names></name><name name-style="western"><surname>Yao</surname><given-names>T</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>H</given-names></name><etal/></person-group><article-title>Natural history of duodenal lesions in Japanese patients with familial adenomatosiscoli (Gardner&#700;s syndrome)</article-title><source>Gastroenterology</source><year>1989</year><volume>96</volume><fpage>1301</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(89)80017-4</pub-id><pub-id pub-id-type="pmid">2703115</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Iida M, Yao T, Itoh H et al (1989) Natural history of duodenal lesions in Japanese patients with familial adenomatosiscoli (Gardner&#700;s syndrome). Gastroenterology 96:1301&#8211;1306<pub-id pub-id-type="pmid">2703115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0016-5085(89)80017-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moozar</surname><given-names>KL</given-names></name><name name-style="western"><surname>Madlensky</surname><given-names>L</given-names></name><name name-style="western"><surname>Berk</surname><given-names>T</given-names></name><etal/></person-group><article-title>Slow progression of periampullary neoplasia in familial adenomatous polyposis</article-title><source>J Gastrointest Surg</source><year>2002</year><volume>6</volume><fpage>831</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1016/S1091-255X(02)00062-8</pub-id><pub-id pub-id-type="pmid">12504221</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Moozar KL, Madlensky L, Berk T et al (2002) Slow progression of periampullary neoplasia in familial adenomatous polyposis. J Gastrointest Surg 6:831&#8211;837. 10.1016/S1091-255X(02)00062-8<pub-id pub-id-type="pmid">12504221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1091-255x(02)00062-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brosens</surname><given-names>LA</given-names></name><name name-style="western"><surname>Keller</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Offerhaus</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Prevention and management of duodenal polyps in familial adenomatous polyposis</article-title><source>Gut</source><year>2005</year><volume>54</volume><fpage>1034</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1136/gut.2004.053843</pub-id><pub-id pub-id-type="pmid">15951555</pub-id><pub-id pub-id-type="pmcid">PMC1774628</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Brosens LA, Keller JJ, Offerhaus GJ et al (2005) Prevention and management of duodenal polyps in familial adenomatous polyposis. Gut 54:1034&#8211;1043. 10.1136/gut.2004.053843<pub-id pub-id-type="pmid">15951555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.2004.053843</pub-id><pub-id pub-id-type="pmcid">PMC1774628</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamaguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>H</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>H</given-names></name><etal/></person-group><article-title>Upper gastrointestinal tumours in Japanese familial adenomatous polyposis patients</article-title><source>Jpn J Clin Oncol</source><year>2016</year><volume>46</volume><fpage>310</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyv210</pub-id><pub-id pub-id-type="pmid">26819281</pub-id><pub-id pub-id-type="pmcid">PMC4886134</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Yamaguchi T, Ishida H, Ueno H et al (2016) Upper gastrointestinal tumours in Japanese familial adenomatous polyposis patients. Jpn J Clin Oncol 46:310&#8211;315. 10.1093/jjco/hyv210<pub-id pub-id-type="pmid">26819281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jjco/hyv210</pub-id><pub-id pub-id-type="pmcid">PMC4886134</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moussata</surname><given-names>D</given-names></name><name name-style="western"><surname>Napoleon</surname><given-names>B</given-names></name><name name-style="western"><surname>Lepilliez</surname><given-names>V</given-names></name><etal/></person-group><article-title>Endoscopic treatment of severe duodenal polyposis as an alternative to surgery for patients with familial adenomatous polyposis</article-title><source>Gastrointest Endosc</source><year>2014</year><volume>80</volume><fpage>817</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2014.03.012</pub-id><pub-id pub-id-type="pmid">24814771</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Moussata D, Napoleon B, Lepilliez V et al (2014) Endoscopic treatment of severe duodenal polyposis as an alternative to surgery for patients with familial adenomatous polyposis. Gastrointest Endosc 80:817&#8211;825<pub-id pub-id-type="pmid">24814771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2014.03.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karstensen</surname><given-names>JG</given-names></name><name name-style="western"><surname>B&#252;low</surname><given-names>S</given-names></name><name name-style="western"><surname>Burisch</surname><given-names>J</given-names></name><etal/></person-group><article-title>Validation of the endoscopic part of the Spigelman classification for evaluating duodenal adenomatosis in familial adenomatous polyposis: a prospective study of interrater and intrarater reliability</article-title><source>Am J Gastroenterol</source><year>2022</year><volume>117</volume><fpage>343</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.14309/ajg.0000000000001582</pub-id><pub-id pub-id-type="pmid">34913876</pub-id><pub-id pub-id-type="pmcid">PMC8812431</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Karstensen JG, B&#252;low S, Burisch J et al (2022) Validation of the endoscopic part of the Spigelman classification for evaluating duodenal adenomatosis in familial adenomatous polyposis: a prospective study of interrater and intrarater reliability. Am J Gastroenterol 117:343&#8211;345<pub-id pub-id-type="pmid">34913876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14309/ajg.0000000000001582</pub-id><pub-id pub-id-type="pmcid">PMC8812431</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galle</surname><given-names>TS</given-names></name><name name-style="western"><surname>Juel</surname><given-names>K</given-names></name><name name-style="western"><surname>B&#252;low</surname><given-names>S</given-names></name></person-group><article-title>Causes of death in familial adenomatous polyposis</article-title><source>Scand J Gastroenterol</source><year>1999</year><volume>34</volume><fpage>808</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1080/003655299750025741</pub-id><pub-id pub-id-type="pmid">10499482</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Galle TS, Juel K, B&#252;low S (1999) Causes of death in familial adenomatous polyposis. Scand J Gastroenterol 34:808&#8211;812<pub-id pub-id-type="pmid">10499482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/003655299750025741</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Offerhaus</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Giardiello</surname><given-names>FM</given-names></name><name name-style="western"><surname>Krush</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>The risk of upper gastrointestinal cancer in familial adenomatous polyposis</article-title><source>Gastroenterology</source><year>1992</year><volume>102</volume><fpage>1980</fpage><lpage>1982</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(92)90322-P</pub-id><pub-id pub-id-type="pmid">1316858</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Offerhaus GJ, Giardiello FM, Krush AJ et al (1992) The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 102:1980&#8211;1982<pub-id pub-id-type="pmid">1316858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0016-5085(92)90322-p</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JG</given-names></name><name name-style="western"><surname>Park</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>YO</given-names></name><etal/></person-group><article-title>Risk of gastric cancer among Korean familial adenomatous polyposis patients. Report of three cases</article-title><source>Dis Colon Rectum</source><year>1992</year><volume>35</volume><fpage>996</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1007/BF02253505</pub-id><pub-id pub-id-type="pmid">1327683</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Park JG, Park KJ, Ahn YO et al (1992) Risk of gastric cancer among Korean familial adenomatous polyposis patients. Report of three cases. Dis Colon Rectum 35:996&#8211;998<pub-id pub-id-type="pmid">1327683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02253505</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#252;low</surname><given-names>S</given-names></name><name name-style="western"><surname>Bj&#246;rk</surname><given-names>J</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>IJ</given-names></name><etal/></person-group><article-title>Duodenal adenomatosis in familial adenomatous polyposis</article-title><source>Gut</source><year>2004</year><volume>53</volume><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1136/gut.2003.027771</pub-id><pub-id pub-id-type="pmid">14960520</pub-id><pub-id pub-id-type="pmcid">PMC1773976</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">B&#252;low S, Bj&#246;rk J, Christensen IJ et al (2004) Duodenal adenomatosis in familial adenomatous polyposis. Gut 53:381&#8211;386<pub-id pub-id-type="pmid">14960520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.2003.027771</pub-id><pub-id pub-id-type="pmcid">PMC1773976</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bj&#246;rk</surname><given-names>J</given-names></name><name name-style="western"><surname>Akerbrant</surname><given-names>H</given-names></name><name name-style="western"><surname>Iselius</surname><given-names>L</given-names></name><etal/></person-group><article-title>Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and <italic toggle="yes">APC</italic> gene mutations</article-title><source>Gastroenterology</source><year>2001</year><volume>121</volume><fpage>1127</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1053/gast.2001.28707</pub-id><pub-id pub-id-type="pmid">11677205</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Bj&#246;rk J, Akerbrant H, Iselius L et al (2001) Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and <italic toggle="yes">APC</italic> gene mutations. Gastroenterology 121:1127&#8211;1135<pub-id pub-id-type="pmid">11677205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/gast.2001.28707</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saurin</surname><given-names>JC</given-names></name><name name-style="western"><surname>Gutknecht</surname><given-names>C</given-names></name><name name-style="western"><surname>Napoleon</surname><given-names>B</given-names></name><etal/></person-group><article-title>Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>493</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.06.028</pub-id><pub-id pub-id-type="pmid">14752072</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Saurin JC, Gutknecht C, Napoleon B et al (2004) Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 22:493&#8211;498<pub-id pub-id-type="pmid">14752072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2004.06.028</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Ceron</surname><given-names>M</given-names></name><name name-style="western"><surname>van den Broek</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Mathus-Vliegen</surname><given-names>EM</given-names></name><etal/></person-group><article-title>The role of high-resolution endoscopy and narrow-band imaging in the evaluation of upper GI neoplasia in familial adenomatous polyposis</article-title><source>Gastrointest Endosc</source><year>2013</year><volume>77</volume><fpage>542</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2012.11.033</pub-id><pub-id pub-id-type="pmid">23352497</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Lopez-Ceron M, van den Broek FJ, Mathus-Vliegen EM et al (2013) The role of high-resolution endoscopy and narrow-band imaging in the evaluation of upper GI neoplasia in familial adenomatous polyposis. Gastrointest Endosc 77:542&#8211;550<pub-id pub-id-type="pmid">23352497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2012.11.033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iida</surname><given-names>M</given-names></name><name name-style="western"><surname>Hizawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Long-term course of gastric and duodenal lesions in familial adenomatous polyposis</article-title><source>Stomach Intest</source><year>1997</year><volume>32</volume><fpage>563</fpage><lpage>576</lpage></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Iida M, Hizawa K, Matsumoto T et al (1997) Long-term course of gastric and duodenal lesions in familial adenomatous polyposis. Stomach Intest 32:563&#8211;576</mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>AD</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>A</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>A</given-names></name><etal/></person-group><article-title>Natural history of ampullary adenomas in familial adenomatous polyposis: a long-term follow-up study</article-title><source>Gastrointest Endosc</source><year>2022</year><volume>95</volume><fpage>455</fpage><lpage>467.e3</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2021.09.036</pub-id><pub-id pub-id-type="pmid">34624304</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Singh AD, Bhatt A, Joseph A et al (2022) Natural history of ampullary adenomas in familial adenomatous polyposis: a long-term follow-up study. Gastrointest Endosc 95:455-467.e3<pub-id pub-id-type="pmid">34624304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2021.09.036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>NA</given-names></name><name name-style="western"><surname>Shah</surname><given-names>RS</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J</given-names></name><etal/></person-group><article-title>Risks, benefits, and effects on management for biopsy of the papilla in patients with familial adenomatous polyposis</article-title><source>Clin Gastroenterol Hepatol</source><year>2021</year><volume>19</volume><fpage>760</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2020.05.054</pub-id><pub-id pub-id-type="pmid">32492482</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Mehta NA, Shah RS, Yoon J et al (2021) Risks, benefits, and effects on management for biopsy of the papilla in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 19:760&#8211;767<pub-id pub-id-type="pmid">32492482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2020.05.054</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoki</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>T</given-names></name><name name-style="western"><surname>Nonaka</surname><given-names>S</given-names></name><etal/></person-group><article-title>Feasibility of endoscopic resection using bipolar snare for nonampullary duodenal tumours in familial adenomatous polyposis patients</article-title><source>Fam Cancer</source><year>2018</year><volume>17</volume><fpage>517</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1007/s10689-017-0063-1</pub-id><pub-id pub-id-type="pmid">29189961</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Inoki K, Nakajima T, Nonaka S et al (2018) Feasibility of endoscopic resection using bipolar snare for nonampullary duodenal tumours in familial adenomatous polyposis patients. Fam Cancer 17:517&#8211;524<pub-id pub-id-type="pmid">29189961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-017-0063-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamada</surname><given-names>K</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Feasibility of cold snare polypectomy for multiple duodenal adenomas in patients with familial adenomatous polyposis: a pilot study</article-title><source>Dig Dis Sci</source><year>2016</year><volume>61</volume><fpage>2755</fpage><lpage>2759</lpage><pub-id pub-id-type="doi">10.1007/s10620-016-4165-7</pub-id><pub-id pub-id-type="pmid">27126203</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Hamada K, Takeuchi Y, Ishikawa H et al (2016) Feasibility of cold snare polypectomy for multiple duodenal adenomas in patients with familial adenomatous polyposis: a pilot study. Dig Dis Sci 61:2755&#8211;2759<pub-id pub-id-type="pmid">27126203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10620-016-4165-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamada</surname><given-names>K</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Safety of cold snare polypectomy for duodenal adenomas in familial adenomatous polyposis: a prospective exploratory study</article-title><source>Endoscopy</source><year>2018</year><volume>50</volume><fpage>511</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1055/s-0043-124765</pub-id><pub-id pub-id-type="pmid">29351704</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Hamada K, Takeuchi Y, Ishikawa H et al (2018) Safety of cold snare polypectomy for duodenal adenomas in familial adenomatous polyposis: a prospective exploratory study. Endoscopy 50:511&#8211;517<pub-id pub-id-type="pmid">29351704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0043-124765</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakahira</surname><given-names>H</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kanesaka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Wide-field underwater EMR followed by line-assisted complete closure for a large duodenal adenoma</article-title><source>VideoGIE</source><year>2019</year><volume>4</volume><fpage>469</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1016/j.vgie.2019.07.004</pub-id><pub-id pub-id-type="pmid">31709333</pub-id><pub-id pub-id-type="pmcid">PMC6831944</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Nakahira H, Takeuchi Y, Kanesaka T et al (2019) Wide-field underwater EMR followed by line-assisted complete closure for a large duodenal adenoma. VideoGIE 4:469&#8211;471<pub-id pub-id-type="pmid">31709333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vgie.2019.07.004</pub-id><pub-id pub-id-type="pmcid">PMC6831944</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alarcon</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Burke</surname><given-names>CA</given-names></name><name name-style="western"><surname>Church</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Familial adenomatous polyposis: efficacy of endoscopic and surgical treatment for advanced duodenal adenomas</article-title><source>Dis Colon Rectum</source><year>1999</year><volume>42</volume><fpage>1533</fpage><lpage>1536</lpage><pub-id pub-id-type="doi">10.1007/BF02236201</pub-id><pub-id pub-id-type="pmid">10613470</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Alarcon FJ, Burke CA, Church JM et al (1999) Familial adenomatous polyposis: efficacy of endoscopic and surgical treatment for advanced duodenal adenomas. Dis Colon Rectum 42:1533&#8211;1536<pub-id pub-id-type="pmid">10613470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02236201</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yabuuchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>M</given-names></name><name name-style="western"><surname>Kakushima</surname><given-names>N</given-names></name><etal/></person-group><article-title>Risk factors for non-ampullary duodenal adenocarcinoma: a systematic review</article-title><source>Dig Dis</source><year>2022</year><volume>40</volume><fpage>147</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1159/000516561</pub-id><pub-id pub-id-type="pmid">34000722</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Yabuuchi Y, Yoshida M, Kakushima N et al (2022) Risk factors for non-ampullary duodenal adenocarcinoma: a systematic review. Dig Dis 40:147&#8211;155. 10.1159/000516561<pub-id pub-id-type="pmid">34000722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000516561</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Groves</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>BP</given-names></name><name name-style="western"><surname>Spigelman</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study</article-title><source>Gut</source><year>2002</year><volume>50</volume><fpage>636</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1136/gut.50.5.636</pub-id><pub-id pub-id-type="pmid">11950808</pub-id><pub-id pub-id-type="pmcid">PMC1773219</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Groves CJ, Saunders BP, Spigelman AD et al (2002) Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut 50:636&#8211;641<pub-id pub-id-type="pmid">11950808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.50.5.636</pub-id><pub-id pub-id-type="pmcid">PMC1773219</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noh</surname><given-names>JH</given-names></name><name name-style="western"><surname>Song</surname><given-names>EM</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Prevalence and endoscopic treatment outcomes of upper gastrointestinal neoplasms in familial adenomatous polyposis</article-title><source>Surg Endosc</source><year>2022</year><volume>36</volume><fpage>1310</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1007/s00464-021-08406-0</pub-id><pub-id pub-id-type="pmid">33709227</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Noh JH, Song EM, Ahn JY et al (2022) Prevalence and endoscopic treatment outcomes of upper gastrointestinal neoplasms in familial adenomatous polyposis. Surg Endosc 36:1310&#8211;1319<pub-id pub-id-type="pmid">33709227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00464-021-08406-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roos</surname><given-names>VH</given-names></name><name name-style="western"><surname>Bastiaansen</surname><given-names>BA</given-names></name><name name-style="western"><surname>Kallenberg</surname><given-names>FGJ</given-names></name><etal/></person-group><article-title>Endoscopic management of duodenal adenomas in patients with familial adenomatous polyposis</article-title><source>Gastrointest Endosc</source><year>2021</year><volume>93</volume><fpage>457</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2020.05.065</pub-id><pub-id pub-id-type="pmid">32535190</pub-id></element-citation><mixed-citation id="mc-CR163" publication-type="journal">Roos VH, Bastiaansen BA, Kallenberg FGJ et al (2021) Endoscopic management of duodenal adenomas in patients with familial adenomatous polyposis. Gastrointest Endosc 93:457&#8211;466<pub-id pub-id-type="pmid">32535190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2020.05.065</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Busquets</surname><given-names>J</given-names></name><name name-style="western"><surname>Lopez-Dominguez</surname><given-names>J</given-names></name><name name-style="western"><surname>Gonzalez-Castillo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pancreas sparing duodenectomy in the treatment of primary duodenal neoplasms and other situations with duodenal involvement</article-title><source>Hepatobiliary Pancreat Dis Int</source><year>2021</year><volume>20</volume><fpage>485</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1016/j.hbpd.2021.02.007</pub-id><pub-id pub-id-type="pmid">33753002</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Busquets J, Lopez-Dominguez J, Gonzalez-Castillo A et al (2021) Pancreas sparing duodenectomy in the treatment of primary duodenal neoplasms and other situations with duodenal involvement. Hepatobiliary Pancreat Dis Int 20:485&#8211;492. 10.1016/j.hbpd.2021.02.007<pub-id pub-id-type="pmid">33753002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hbpd.2021.02.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naples</surname><given-names>R</given-names></name><name name-style="western"><surname>Simon</surname><given-names>R</given-names></name><name name-style="western"><surname>Moslim</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term outcomes of pancreas-sparing duodenectomy for duodenal polyposis in familial adenomatous polyposis syndrome</article-title><source>J Gastrointest Surg</source><year>2021</year><volume>25</volume><fpage>1233</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1007/s11605-020-04621-7</pub-id><pub-id pub-id-type="pmid">32410179</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Naples R, Simon R, Moslim M et al (2021) Long-term outcomes of pancreas-sparing duodenectomy for duodenal polyposis in familial adenomatous polyposis syndrome. J Gastrointest Surg 25:1233&#8211;1240. 10.1007/s11605-020-04621-7<pub-id pub-id-type="pmid">32410179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11605-020-04621-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aelvoet</surname><given-names>AS</given-names></name><name name-style="western"><surname>Bastiaansen</surname><given-names>BAJ</given-names></name><name name-style="western"><surname>Fockens</surname><given-names>P</given-names></name><etal/></person-group><article-title>Pancreas-preserving total duodenectomy for advanced duodenal polyposis in patients with familial adenomatous polyposis: short and long-term outcomes</article-title><source>HPB (Oxford)</source><year>2022</year><volume>24</volume><fpage>1642</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1016/j.hpb.2022.04.004</pub-id><pub-id pub-id-type="pmid">35568653</pub-id></element-citation><mixed-citation id="mc-CR166" publication-type="journal">Aelvoet AS, Bastiaansen BAJ, Fockens P et al (2022) Pancreas-preserving total duodenectomy for advanced duodenal polyposis in patients with familial adenomatous polyposis: short and long-term outcomes. HPB (Oxford) 24:1642&#8211;1650<pub-id pub-id-type="pmid">35568653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hpb.2022.04.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angsuwatcharakon</surname><given-names>P</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>O</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Management of ampullary adenomas in familial adenomatous polyposis syndrome: 16 years of experience from a tertiary cancer center</article-title><source>Gastrointest Endosc</source><year>2020</year><volume>92</volume><fpage>323</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2020.02.040</pub-id><pub-id pub-id-type="pmid">32145286</pub-id></element-citation><mixed-citation id="mc-CR167" publication-type="journal">Angsuwatcharakon P, Ahmed O, Lynch PM et al (2020) Management of ampullary adenomas in familial adenomatous polyposis syndrome: 16 years of experience from a tertiary cancer center. Gastrointest Endosc 92:323&#8211;330<pub-id pub-id-type="pmid">32145286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2020.02.040</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwama</surname><given-names>T</given-names></name><name name-style="western"><surname>Mishima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Utsunomiya</surname><given-names>J</given-names></name></person-group><article-title>The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment</article-title><source>Ann Surg</source><year>1993</year><volume>217</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1097/00000658-199302000-00002</pub-id><pub-id pub-id-type="pmid">8382467</pub-id><pub-id pub-id-type="pmcid">PMC1242747</pub-id></element-citation><mixed-citation id="mc-CR168" publication-type="journal">Iwama T, Mishima Y, Utsunomiya J (1993) The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg 217:101&#8211;108<pub-id pub-id-type="pmid">8382467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000658-199302000-00002</pub-id><pub-id pub-id-type="pmcid">PMC1242747</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knudsen</surname><given-names>AL</given-names></name><name name-style="western"><surname>Bulow</surname><given-names>S</given-names></name></person-group><article-title>Desmoid tumour in familial adenomatous polyposis</article-title><source>A review of literature Fam Cancer</source><year>2001</year><volume>1</volume><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">14574007</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1013841813544</pub-id></element-citation><mixed-citation id="mc-CR169" publication-type="journal">Knudsen AL, Bulow S (2001) Desmoid tumour in familial adenomatous polyposis. A review of literature Fam Cancer 1:111&#8211;119<pub-id pub-id-type="pmid">14574007</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1013841813544</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieuwenhuis</surname><given-names>MH</given-names></name><name name-style="western"><surname>De Vos Tot Nederveen Cappel</surname><given-names>W</given-names></name><name name-style="western"><surname>Botma</surname><given-names>A</given-names></name><etal/></person-group><article-title>Desmoid tumors in a Dutch cohort of patients with familial adenomatous polyposis</article-title><source>Clin Gastroenterol Hepatol</source><year>2008</year><volume>6</volume><fpage>215</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2007.11.011</pub-id><pub-id pub-id-type="pmid">18237870</pub-id></element-citation><mixed-citation id="mc-CR170" publication-type="journal">Nieuwenhuis MH, De Vos Tot Nederveen Cappel W, Botma A et al (2008) Desmoid tumors in a Dutch cohort of patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 6:215&#8211;219<pub-id pub-id-type="pmid">18237870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2007.11.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Speake</surname><given-names>D</given-names></name><name name-style="western"><surname>Evans</surname><given-names>DG</given-names></name><name name-style="western"><surname>Lalloo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Desmoid tumours in patients with familial adenomatous polyposis and desmoid region adenomatous polyposis coli mutations</article-title><source>Br J Surg</source><year>2007</year><volume>94</volume><fpage>1009</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1002/bjs.5633</pub-id><pub-id pub-id-type="pmid">17410559</pub-id></element-citation><mixed-citation id="mc-CR171" publication-type="journal">Speake D, Evans DG, Lalloo F et al (2007) Desmoid tumours in patients with familial adenomatous polyposis and desmoid region adenomatous polyposis coli mutations. Br J Surg 94:1009&#8211;1013. 10.1002/bjs.5633<pub-id pub-id-type="pmid">17410559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bjs.5633</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hinoi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>H</given-names></name><etal/></person-group><article-title>Risk factors for the development of desmoid tumor after colectomy in patients with familial adenomatous polyposis: Multicenter retrospective cohort study in Japan</article-title><source>Ann Surg Oncol</source><year>2016</year><volume>23</volume><fpage>559</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1245/s10434-016-5380-3</pub-id><pub-id pub-id-type="pmid">27387679</pub-id></element-citation><mixed-citation id="mc-CR172" publication-type="journal">Saito Y, Hinoi T, Ueno H et al (2016) Risk factors for the development of desmoid tumor after colectomy in patients with familial adenomatous polyposis: Multicenter retrospective cohort study in Japan. Ann Surg Oncol 23:559&#8211;565<pub-id pub-id-type="pmid">27387679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-016-5380-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamano</surname><given-names>T</given-names></name><name name-style="western"><surname>Hamanaka</surname><given-names>M</given-names></name><name name-style="western"><surname>Babaya</surname><given-names>A</given-names></name><etal/></person-group><article-title>Management strategies in Lynch syndrome and familial adenomatous polyposis: a national healthcare survey in Japan</article-title><source>Cancer Sci</source><year>2017</year><volume>108</volume><fpage>243</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1111/cas.13123</pub-id><pub-id pub-id-type="pmid">27870147</pub-id><pub-id pub-id-type="pmcid">PMC5329156</pub-id></element-citation><mixed-citation id="mc-CR173" publication-type="journal">Yamano T, Hamanaka M, Babaya A et al (2017) Management strategies in Lynch syndrome and familial adenomatous polyposis: a national healthcare survey in Japan. Cancer Sci 108:243&#8211;249. 10.1111/cas.13123<pub-id pub-id-type="pmid">27870147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cas.13123</pub-id><pub-id pub-id-type="pmcid">PMC5329156</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Latchford</surname><given-names>AR</given-names></name><name name-style="western"><surname>Sturt</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Neale</surname><given-names>K</given-names></name><etal/></person-group><article-title>A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis</article-title><source>Br J Surg</source><year>2006</year><volume>93</volume><fpage>1258</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1002/bjs.5425</pub-id><pub-id pub-id-type="pmid">16952208</pub-id></element-citation><mixed-citation id="mc-CR174" publication-type="journal">Latchford AR, Sturt NJ, Neale K et al (2006) A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis. Br J Surg 93:1258&#8211;1264. 10.1002/bjs.5425<pub-id pub-id-type="pmid">16952208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bjs.5425</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevenson</surname><given-names>JK</given-names></name><name name-style="western"><surname>Reid</surname><given-names>BJ</given-names></name></person-group><article-title>Unfamiliar aspects of familial polyposis coli</article-title><source>Am J Surg</source><year>1986</year><volume>152</volume><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/0002-9610(86)90147-9</pub-id><pub-id pub-id-type="pmid">3728822</pub-id></element-citation><mixed-citation id="mc-CR175" publication-type="journal">Stevenson JK, Reid BJ (1986) Unfamiliar aspects of familial polyposis coli. Am J Surg 152:81&#8211;86<pub-id pub-id-type="pmid">3728822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0002-9610(86)90147-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benoit</surname><given-names>L</given-names></name><name name-style="western"><surname>Faivre</surname><given-names>L</given-names></name><name name-style="western"><surname>Cheynel</surname><given-names>N</given-names></name><etal/></person-group><article-title>3&#700; mutation of the <italic toggle="yes">APC</italic> gene and family history of FAP in a patient with apparently sporadic desmoid tumors</article-title><source>J Clin Gastroenterol</source><year>2007</year><volume>41</volume><fpage>297</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1097/MCG.0b013e3180325252</pub-id><pub-id pub-id-type="pmid">17426470</pub-id></element-citation><mixed-citation id="mc-CR176" publication-type="journal">Benoit L, Faivre L, Cheynel N et al (2007) 3&#700; mutation of the <italic toggle="yes">APC</italic> gene and family history of FAP in a patient with apparently sporadic desmoid tumors. J Clin Gastroenterol 41:297&#8211;300<pub-id pub-id-type="pmid">17426470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCG.0b013e3180325252</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR177"><label>177.</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walter</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhenzhen Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Guillaud</surname><given-names>O</given-names></name><etal/></person-group><article-title>Management of desmoid tumours: a large national database of familial adenomatous patients shows a link to colectomy modalities and low efficacy of medical treatments</article-title><source>United Eur Gastroenterol J</source><year>2017</year><volume>5</volume><fpage>735</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1177/2050640616678150</pub-id><pub-id pub-id-type="pmcid">PMC5548349</pub-id><pub-id pub-id-type="pmid">28815038</pub-id></element-citation><mixed-citation id="mc-CR177" publication-type="journal">Walter T, Zhenzhen Wang C, Guillaud O et al (2017) Management of desmoid tumours: a large national database of familial adenomatous patients shows a link to colectomy modalities and low efficacy of medical treatments. United Eur Gastroenterol J 5:735&#8211;741. 10.1177/2050640616678150<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2050640616678150</pub-id><pub-id pub-id-type="pmcid">PMC5548349</pub-id><pub-id pub-id-type="pmid">28815038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178.</label><citation-alternatives><element-citation id="ec-CR178" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertario</surname><given-names>L</given-names></name><name name-style="western"><surname>Russo</surname><given-names>A</given-names></name><name name-style="western"><surname>Sala</surname><given-names>P</given-names></name><etal/></person-group><article-title>Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis</article-title><source>Int J Cancer</source><year>2001</year><volume>95</volume><fpage>102</fpage><lpage>107</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0215(20010320)95:2&amp;#x0003c;102::AID-IJC1018&amp;#x0003e;3.0.CO;2-8</pub-id><pub-id pub-id-type="pmid">11241320</pub-id></element-citation><mixed-citation id="mc-CR178" publication-type="journal">Bertario L, Russo A, Sala P et al (2001) Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 95:102&#8211;107. 10.1002/1097-0215(20010320)95:2%3c102::AID-IJC1018%3e3.0.CO;2-8<pub-id pub-id-type="pmid">11241320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0215(20010320)95:2&lt;102::aid-ijc1018&gt;3.0.co;2-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR179"><label>179.</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieuwenhuis</surname><given-names>MH</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>JH</given-names></name><name name-style="western"><surname>B&#252;low</surname><given-names>S</given-names></name><etal/></person-group><article-title>Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study</article-title><source>Dis Colon Rectum</source><year>2011</year><volume>54</volume><fpage>1229</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.1097/DCR.0b013e318227e4e8</pub-id><pub-id pub-id-type="pmid">21904137</pub-id></element-citation><mixed-citation id="mc-CR179" publication-type="journal">Nieuwenhuis MH, Lefevre JH, B&#252;low S et al (2011) Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum 54:1229&#8211;1234<pub-id pub-id-type="pmid">21904137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/DCR.0b013e318227e4e8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Church</surname><given-names>J</given-names></name><name name-style="western"><surname>Xhaja</surname><given-names>X</given-names></name><name name-style="western"><surname>LaGuardia</surname><given-names>L</given-names></name><etal/></person-group><article-title>Desmoids and genotype in familial adenomatous polyposis</article-title><source>Dis Colon Rectum</source><year>2015</year><volume>58</volume><fpage>444</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1097/DCR.0000000000000316</pub-id><pub-id pub-id-type="pmid">25751801</pub-id></element-citation><mixed-citation id="mc-CR180" publication-type="journal">Church J, Xhaja X, LaGuardia L et al (2015) Desmoids and genotype in familial adenomatous polyposis. Dis Colon Rectum 58:444&#8211;448<pub-id pub-id-type="pmid">25751801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/DCR.0000000000000316</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR181"><label>181.</label><citation-alternatives><element-citation id="ec-CR181" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Church</surname><given-names>J</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>C</given-names></name><name name-style="western"><surname>Neary</surname><given-names>P</given-names></name><etal/></person-group><article-title>A desmoid tumor-staging system separates patients with intra-abdominal, familial adenomatous polyposis-associated desmoid disease by behavior and prognosis</article-title><source>Dis Colon Rectum</source><year>2008</year><volume>51</volume><fpage>897</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1007/s10350-008-9232-5</pub-id><pub-id pub-id-type="pmid">18322756</pub-id></element-citation><mixed-citation id="mc-CR181" publication-type="journal">Church J, Lynch C, Neary P et al (2008) A desmoid tumor-staging system separates patients with intra-abdominal, familial adenomatous polyposis-associated desmoid disease by behavior and prognosis. Dis Colon Rectum 51:897&#8211;901<pub-id pub-id-type="pmid">18322756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10350-008-9232-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR182"><label>182.</label><citation-alternatives><element-citation id="ec-CR182" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishida</surname><given-names>H</given-names></name><name name-style="western"><surname>Chikatani</surname><given-names>K</given-names></name><name name-style="western"><surname>Mori</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Diagnosis, treatment, and proposal of the new classification system for the severity of desmoid tumors associated with familial adenomatous polyposis</article-title><source>J Hered Tumors</source><year>2020</year><volume>20</volume><fpage>45</fpage><lpage>58</lpage></element-citation><mixed-citation id="mc-CR182" publication-type="journal">Ishida H, Chikatani K, Mori Y et al (2020) Diagnosis, treatment, and proposal of the new classification system for the severity of desmoid tumors associated with familial adenomatous polyposis. J Heredi Tumors 20:45&#8211;58</mixed-citation></citation-alternatives></ref><ref id="CR183"><label>183.</label><citation-alternatives><element-citation id="ec-CR183" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumamoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>H</given-names></name><name name-style="western"><surname>Tomita</surname><given-names>N</given-names></name></person-group><article-title>Recent advances and current management for desmoid tumor associated with familial adenomatous polyposis</article-title><source>J Anus Rectum Colon</source><year>2023</year><volume>7</volume><fpage>38</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.23922/jarc.2022-074</pub-id><pub-id pub-id-type="pmid">37113586</pub-id><pub-id pub-id-type="pmcid">PMC10129359</pub-id></element-citation><mixed-citation id="mc-CR183" publication-type="journal">Kumamoto K, Ishida H, Tomita N (2023) Recent advances and current management for desmoid tumor associated with familial adenomatous polyposis. J Anus Rectum Colon 7:38&#8211;51. 10.23922/jarc.2022-074<pub-id pub-id-type="pmid">37113586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23922/jarc.2022-074</pub-id><pub-id pub-id-type="pmcid">PMC10129359</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR184"><label>184.</label><citation-alternatives><element-citation id="ec-CR184" publication-type="journal"><person-group person-group-type="author"><collab>Desmoid Tumor Working G</collab></person-group><article-title>The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients</article-title><source>Eur J Cancer</source><year>2020</year><volume>127</volume><fpage>96</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2019.11.013</pub-id><pub-id pub-id-type="pmid">32004793</pub-id></element-citation><mixed-citation id="mc-CR184" publication-type="journal">Desmoid Tumor Working G (2020) The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer 127:96&#8211;107<pub-id pub-id-type="pmid">32004793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2019.11.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR185"><label>185.</label><citation-alternatives><element-citation id="ec-CR185" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bocale</surname><given-names>D</given-names></name><name name-style="western"><surname>Rotelli</surname><given-names>MT</given-names></name><name name-style="western"><surname>Cavallini</surname><given-names>A</given-names></name><etal/></person-group><article-title>Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review</article-title><source>Colorectal Dis</source><year>2011</year><volume>13</volume><fpage>e388</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1318.2011.02758.x</pub-id><pub-id pub-id-type="pmid">21831172</pub-id></element-citation><mixed-citation id="mc-CR185" publication-type="journal">Bocale D, Rotelli MT, Cavallini A et al (2011) Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Dis 13:e388-395. 10.1111/j.1463-1318.2011.02758.x<pub-id pub-id-type="pmid">21831172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1463-1318.2011.02758.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR186"><label>186.</label><citation-alternatives><element-citation id="ec-CR186" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skapek</surname><given-names>SX</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>JR</given-names></name><name name-style="western"><surname>Hill</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Safety and efficacy of high&#8208;dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study</article-title><source>Pediatr Blood Cancer</source><year>2013</year><volume>60</volume><fpage>1108</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1002/pbc.24457</pub-id><pub-id pub-id-type="pmid">23281268</pub-id><pub-id pub-id-type="pmcid">PMC4646066</pub-id></element-citation><mixed-citation id="mc-CR186" publication-type="journal">Skapek SX, Anderson JR, Hill DA et al (2013) Safety and efficacy of high&#8208;dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children&#8217;s Oncology Group (COG) Phase II Study. Pediatr Blood Cancer 60:1108&#8211;1112. 10.1002/pbc.24457<pub-id pub-id-type="pmid">23281268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pbc.24457</pub-id><pub-id pub-id-type="pmcid">PMC4646066</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR187"><label>187.</label><citation-alternatives><element-citation id="ec-CR187" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chugh</surname><given-names>R</given-names></name><name name-style="western"><surname>Wathen</surname><given-names>JK</given-names></name><name name-style="western"><surname>Patel</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Sarcoma Alliance for Research through C: Efficacy of imatinib in aggressive fibromatosis: Results of a phase &#8545; multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial</article-title><source>Clin Cancer Res</source><year>2010</year><volume>16</volume><fpage>4884</fpage><lpage>4891</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1177</pub-id><pub-id pub-id-type="pmid">20724445</pub-id></element-citation><mixed-citation id="mc-CR187" publication-type="journal">Chugh R, Wathen JK, Patel SR et al (2010) Sarcoma Alliance for Research through C: Efficacy of imatinib in aggressive fibromatosis: Results of a phase &#8545; multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 16:4884&#8211;4891. 10.1158/1078-0432.CCR-10-1177<pub-id pub-id-type="pmid">20724445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-10-1177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR188"><label>188.</label><citation-alternatives><element-citation id="ec-CR188" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heinrich</surname><given-names>MC</given-names></name><name name-style="western"><surname>McArthur</surname><given-names>GA</given-names></name><name name-style="western"><surname>Demetri</surname><given-names>GD</given-names></name><etal/></person-group><article-title>Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>1195</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.04.0717</pub-id><pub-id pub-id-type="pmid">16505440</pub-id></element-citation><mixed-citation id="mc-CR188" publication-type="journal">Heinrich MC, McArthur GA, Demetri GD et al (2006) Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 24:1195&#8211;1203. 10.1200/JCO.2005.04.0717<pub-id pub-id-type="pmid">16505440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2005.04.0717</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR189"><label>189.</label><citation-alternatives><element-citation id="ec-CR189" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasper</surname><given-names>B</given-names></name><name name-style="western"><surname>Gruenwald</surname><given-names>V</given-names></name><name name-style="western"><surname>Reichardt</surname><given-names>P</given-names></name><etal/></person-group><article-title>2017) Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase &#8545; study of the German Interdisciplinary Sarcoma Group (GISG</article-title><source>Eur J Cancer</source><year>2017</year><volume>76</volume><fpage>60</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2017.02.001</pub-id><pub-id pub-id-type="pmid">28282612</pub-id></element-citation><mixed-citation id="mc-CR189" publication-type="journal">Kasper B, Gruenwald V, Reichardt P et al (2017) 2017) Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase &#8545; study of the German Interdisciplinary Sarcoma Group (GISG. Eur J Cancer 76:60&#8211;67<pub-id pub-id-type="pmid">28282612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2017.02.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR190"><label>190.</label><citation-alternatives><element-citation id="ec-CR190" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penel</surname><given-names>N</given-names></name><name name-style="western"><surname>Le Cesne</surname><given-names>A</given-names></name><name name-style="western"><surname>Bui</surname><given-names>BN</given-names></name><etal/></person-group><article-title>Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase &#8545; trial with a long-term follow-up</article-title><source>Ann Oncol</source><year>2011</year><volume>22</volume><fpage>452</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdq341</pub-id><pub-id pub-id-type="pmid">20622000</pub-id></element-citation><mixed-citation id="mc-CR190" publication-type="journal">Penel N, Le Cesne A, Bui BN et al (2011) Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase &#8545; trial with a long-term follow-up. Ann Oncol 22:452&#8211;457<pub-id pub-id-type="pmid">20622000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdq341</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR191"><label>191.</label><citation-alternatives><element-citation id="ec-CR191" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gounder</surname><given-names>MM</given-names></name><name name-style="western"><surname>Mahoney</surname><given-names>MR</given-names></name><name name-style="western"><surname>Van Tine</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Sorafenib for advanced and refractory desmoid tumors</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><fpage>2417</fpage><lpage>2428</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1805052</pub-id><pub-id pub-id-type="pmid">30575484</pub-id><pub-id pub-id-type="pmcid">PMC6447029</pub-id></element-citation><mixed-citation id="mc-CR191" publication-type="journal">Gounder MM, Mahoney MR, Van Tine BA et al (2018) Sorafenib for advanced and refractory desmoid tumors. N Engl J Med 379:2417&#8211;2428<pub-id pub-id-type="pmid">30575484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1805052</pub-id><pub-id pub-id-type="pmcid">PMC6447029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR192"><label>192.</label><citation-alternatives><element-citation id="ec-CR192" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toulmonde</surname><given-names>M</given-names></name><name name-style="western"><surname>Pulido</surname><given-names>M</given-names></name><name name-style="western"><surname>Ray-Coquard</surname><given-names>I</given-names></name><etal/></person-group><article-title>Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study</article-title><source>Lancet Oncol</source><year>2019</year><volume>20</volume><fpage>1263</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30276-1</pub-id><pub-id pub-id-type="pmid">31331699</pub-id></element-citation><mixed-citation id="mc-CR192" publication-type="journal">Toulmonde M, Pulido M, Ray-Coquard I et al (2019) Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol 20:1263&#8211;1272<pub-id pub-id-type="pmid">31331699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(19)30276-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR193"><label>193.</label><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsukamoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Takahama</surname><given-names>T</given-names></name><name name-style="western"><surname>Mavrogenis</surname><given-names>AF</given-names></name><etal/></person-group><article-title>Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review</article-title><source>Musculoskelet Surg</source><year>2023</year><volume>107</volume><fpage>7</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1007/s12306-022-00738-x</pub-id><pub-id pub-id-type="pmid">35150408</pub-id></element-citation><mixed-citation id="mc-CR193" publication-type="journal">Tsukamoto S, Takahama T, Mavrogenis AF et al (2023) Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review. Musculoskelet Surg 107:7&#8211;18<pub-id pub-id-type="pmid">35150408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12306-022-00738-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR194"><label>194.</label><citation-alternatives><element-citation id="ec-CR194" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azzarelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Gronchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Bertulli</surname><given-names>R</given-names></name><etal/></person-group><article-title>Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis</article-title><source>Cancer</source><year>2001</year><volume>92</volume><fpage>1259</fpage><lpage>1264</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(20010901)92:5&amp;#x0003c;1259::AID-CNCR1446&amp;#x0003e;3.0.CO;2-Y</pub-id><pub-id pub-id-type="pmid">11571741</pub-id></element-citation><mixed-citation id="mc-CR194" publication-type="journal">Azzarelli A, Gronchi A, Bertulli R et al (2001) Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 92:1259&#8211;1264. 10.1002/1097-0142(20010901)92:5%3c1259::AID-CNCR1446%3e3.0.CO;2-Y<pub-id pub-id-type="pmid">11571741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(20010901)92:5&lt;1259::aid-cncr1446&gt;3.0.co;2-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR195"><label>195.</label><citation-alternatives><element-citation id="ec-CR195" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skapek</surname><given-names>SX</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>WS</given-names></name><name name-style="western"><surname>Granowetter</surname><given-names>L</given-names></name><etal/></person-group><article-title>Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase &#8545; Trial</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>501</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.08.2966</pub-id><pub-id pub-id-type="pmid">17290057</pub-id></element-citation><mixed-citation id="mc-CR195" publication-type="journal">Skapek SX, Ferguson WS, Granowetter L et al (2007) Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase &#8545; Trial. J Clin Oncol 25:501&#8211;506<pub-id pub-id-type="pmid">17290057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2006.08.2966</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR196"><label>196.</label><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gega</surname><given-names>M</given-names></name><name name-style="western"><surname>Yanagi</surname><given-names>H</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>R</given-names></name><etal/></person-group><article-title>Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>102</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.02.1923</pub-id><pub-id pub-id-type="pmid">16382119</pub-id></element-citation><mixed-citation id="mc-CR196" publication-type="journal">Gega M, Yanagi H, Yoshikawa R et al (2006) Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 24:102&#8211;105. 10.1200/JCO.2005.02.1923<pub-id pub-id-type="pmid">16382119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2005.02.1923</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR197"><label>197.</label><citation-alternatives><element-citation id="ec-CR197" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Napolitano</surname><given-names>A</given-names></name><name name-style="western"><surname>Provenzano</surname><given-names>S</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis</article-title><source>ESMO Open</source><year>2020</year><volume>5</volume><fpage>e000604</fpage><pub-id pub-id-type="doi">10.1136/esmoopen-2019-000604</pub-id><pub-id pub-id-type="pmid">31958289</pub-id><pub-id pub-id-type="pmcid">PMC7003390</pub-id></element-citation><mixed-citation id="mc-CR197" publication-type="journal">Napolitano A, Provenzano S, Colombo C et al (2020) Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. ESMO Open 5:e000604<pub-id pub-id-type="pmid">31958289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/esmoopen-2019-000604</pub-id><pub-id pub-id-type="pmcid">PMC7003390</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR198"><label>198.</label><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>SK</given-names></name><name name-style="western"><surname>Neale</surname><given-names>KF</given-names></name><name name-style="western"><surname>Landgrebe</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Desmoid tumours complicating familial adenomatous polyposis</article-title><source>Br J Surg</source><year>1999</year><volume>86</volume><fpage>1185</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2168.1999.01222.x</pub-id><pub-id pub-id-type="pmid">10504375</pub-id></element-citation><mixed-citation id="mc-CR198" publication-type="journal">Clark SK, Neale KF, Landgrebe JC et al (1999) Desmoid tumours complicating familial adenomatous polyposis. Br J Surg 86:1185&#8211;1189<pub-id pub-id-type="pmid">10504375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2168.1999.01222.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR199"><label>199.</label><citation-alternatives><element-citation id="ec-CR199" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Marchis</surname><given-names>ML</given-names></name><name name-style="western"><surname>Tonelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Quaresmini</surname><given-names>D</given-names></name><etal/></person-group><article-title>Desmoid tumors in familial adenomatous polyposis</article-title><source>Anticancer Res</source><year>2017</year><volume>37</volume><fpage>3357</fpage><lpage>3366</lpage><pub-id pub-id-type="doi">10.21873/anticanres.11702</pub-id><pub-id pub-id-type="pmid">28668823</pub-id></element-citation><mixed-citation id="mc-CR199" publication-type="journal">de Marchis ML, Tonelli F, Quaresmini D et al (2017) Desmoid tumors in familial adenomatous polyposis. Anticancer Res 37:3357&#8211;3366<pub-id pub-id-type="pmid">28668823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21873/anticanres.11702</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR200"><label>200.</label><citation-alternatives><element-citation id="ec-CR200" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burtenshaw</surname><given-names>SM</given-names></name><name name-style="western"><surname>Cannell</surname><given-names>AJ</given-names></name><name name-style="western"><surname>McAlister</surname><given-names>ED</given-names></name><etal/></person-group><article-title>Toward observation as first-line management in abdominal desmoid tumors</article-title><source>Ann Surg Oncol</source><year>2016</year><volume>23</volume><fpage>2212</fpage><lpage>2219</lpage><pub-id pub-id-type="doi">10.1245/s10434-016-5159-6</pub-id><pub-id pub-id-type="pmid">27020588</pub-id></element-citation><mixed-citation id="mc-CR200" publication-type="journal">Burtenshaw SM, Cannell AJ, McAlister ED et al (2016) Toward observation as first-line management in abdominal desmoid tumors. Ann Surg Oncol 23:2212&#8211;2219<pub-id pub-id-type="pmid">27020588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-016-5159-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR201"><label>201.</label><citation-alternatives><element-citation id="ec-CR201" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwama</surname><given-names>T</given-names></name><name name-style="western"><surname>Kuwabara</surname><given-names>K</given-names></name><name name-style="western"><surname>Ushiama</surname><given-names>M</given-names></name><etal/></person-group><article-title>Identification of somatic <italic toggle="yes">APC</italic> mutations in recurrent desmoid tumors in a patient with familial adenomatous polyposis to determine actual recurrence of the original tumor or de novo occurrence</article-title><source>Fam Cancer</source><year>2009</year><volume>8</volume><fpage>51</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1007/s10689-008-9207-7</pub-id><pub-id pub-id-type="pmid">18704758</pub-id></element-citation><mixed-citation id="mc-CR201" publication-type="journal">Iwama T, Kuwabara K, Ushiama M et al (2009) Identification of somatic <italic toggle="yes">APC</italic> mutations in recurrent desmoid tumors in a patient with familial adenomatous polyposis to determine actual recurrence of the original tumor or de novo occurrence. Fam Cancer 8:51&#8211;54<pub-id pub-id-type="pmid">18704758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-008-9207-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR202"><label>202.</label><citation-alternatives><element-citation id="ec-CR202" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieuwenhuis</surname><given-names>MH</given-names></name><name name-style="western"><surname>Mathus-Vliegen</surname><given-names>EM</given-names></name><name name-style="western"><surname>Baeten</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients</article-title><source>Br J Cancer</source><year>2011</year><volume>104</volume><fpage>37</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605997</pub-id><pub-id pub-id-type="pmid">21063417</pub-id><pub-id pub-id-type="pmcid">PMC3039799</pub-id></element-citation><mixed-citation id="mc-CR202" publication-type="journal">Nieuwenhuis MH, Mathus-Vliegen EM, Baeten CG et al (2011) Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Br J Cancer 104:37&#8211;42. 10.1038/sj.bjc.6605997<pub-id pub-id-type="pmid">21063417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjc.6605997</pub-id><pub-id pub-id-type="pmcid">PMC3039799</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR203"><label>203.</label><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Merchant</surname><given-names>NB</given-names></name><etal/></person-group><article-title>Surgical management of intra-abdominal desmoid tumours</article-title><source>Br J Surg</source><year>2000</year><volume>87</volume><fpage>608</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2168.2000.01400.x</pub-id><pub-id pub-id-type="pmid">10792318</pub-id></element-citation><mixed-citation id="mc-CR203" publication-type="journal">Smith AJ, Lewis JJ, Merchant NB et al (2000) Surgical management of intra-abdominal desmoid tumours. Br J Surg 87:608&#8211;613. 10.1046/j.1365-2168.2000.01400.x<pub-id pub-id-type="pmid">10792318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2168.2000.01400.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR204"><label>204.</label><citation-alternatives><element-citation id="ec-CR204" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>H</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>H</given-names></name><etal/></person-group><article-title>The treatment of desmoid tumors associated with familial adenomatous polyposis: the results of a Japanese multicenter observational study</article-title><source>Surg Today</source><year>2017</year><volume>47</volume><fpage>1259</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.1007/s00595-017-1500-3</pub-id><pub-id pub-id-type="pmid">28251376</pub-id></element-citation><mixed-citation id="mc-CR204" publication-type="journal">Inoue Y, Ishida H, Ueno H et al (2017) The treatment of desmoid tumors associated with familial adenomatous polyposis: the results of a Japanese multicenter observational study. Surg Today 47:1259&#8211;1267<pub-id pub-id-type="pmid">28251376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00595-017-1500-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR205"><label>205.</label><citation-alternatives><element-citation id="ec-CR205" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Church</surname><given-names>J</given-names></name><name name-style="western"><surname>Berk</surname><given-names>T</given-names></name><name name-style="western"><surname>Boman</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Staging intra-abdominal desmoid tumors in familial adenomatous polyposis: a search for a uniform approach to a troubling disease</article-title><source>Dis Colon Rectum</source><year>2005</year><volume>48</volume><fpage>1528</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1007/s10350-005-0018-8</pub-id><pub-id pub-id-type="pmid">15906134</pub-id></element-citation><mixed-citation id="mc-CR205" publication-type="journal">Church J, Berk T, Boman BM et al (2005) Staging intra-abdominal desmoid tumors in familial adenomatous polyposis: a search for a uniform approach to a troubling disease. Dis Colon Rectum 48:1528&#8211;1534<pub-id pub-id-type="pmid">15906134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10350-005-0018-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR206"><label>206.</label><citation-alternatives><element-citation id="ec-CR206" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>A</given-names></name><name name-style="western"><surname>Watabe</surname><given-names>H</given-names></name><name name-style="western"><surname>Iwama</surname><given-names>T</given-names></name><etal/></person-group><article-title>The prevalence of small intestinal polyps in patients with familial adenomatous polyposis: a prospective capsule endoscopy study</article-title><source>Fam Cancer</source><year>2014</year><volume>13</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1007/s10689-013-9668-1</pub-id><pub-id pub-id-type="pmid">23743563</pub-id></element-citation><mixed-citation id="mc-CR206" publication-type="journal">Yamada A, Watabe H, Iwama T et al (2014) The prevalence of small intestinal polyps in patients with familial adenomatous polyposis: a prospective capsule endoscopy study. Fam Cancer 13:23&#8211;28<pub-id pub-id-type="pmid">23743563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-013-9668-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR207"><label>207.</label><citation-alternatives><element-citation id="ec-CR207" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monahan</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Bradshaw</surname><given-names>N</given-names></name><name name-style="western"><surname>Dolwani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI/United Kingdom Cancer Genetics Group (UKCGG)</article-title><source>Gut</source><year>2020</year><volume>69</volume><fpage>411</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2019-319915</pub-id><pub-id pub-id-type="pmid">31780574</pub-id><pub-id pub-id-type="pmcid">PMC7034349</pub-id></element-citation><mixed-citation id="mc-CR207" publication-type="journal">Monahan KJ, Bradshaw N, Dolwani S et al (2020) Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI/United Kingdom Cancer Genetics Group (UKCGG). Gut 69:411&#8211;444<pub-id pub-id-type="pmid">31780574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2019-319915</pub-id><pub-id pub-id-type="pmcid">PMC7034349</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR208"><label>208.</label><citation-alternatives><element-citation id="ec-CR208" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burke</surname><given-names>CA</given-names></name><name name-style="western"><surname>Santisi</surname><given-names>J</given-names></name><name name-style="western"><surname>Church</surname><given-names>J</given-names></name><etal/></person-group><article-title>The utility of capsule endoscopy small bowel surveillance in patients with polyposis</article-title><source>Am J Gastroenterol</source><year>2005</year><volume>100</volume><fpage>1498</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.41506.x</pub-id><pub-id pub-id-type="pmid">15984971</pub-id></element-citation><mixed-citation id="mc-CR208" publication-type="journal">Burke CA, Santisi J, Church J et al (2005) The utility of capsule endoscopy small bowel surveillance in patients with polyposis. Am J Gastroenterol 100:1498&#8211;1502<pub-id pub-id-type="pmid">15984971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1572-0241.2005.41506.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR209"><label>209.</label><citation-alternatives><element-citation id="ec-CR209" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavallo</surname><given-names>D</given-names></name><name name-style="western"><surname>Ballardini</surname><given-names>G</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>A</given-names></name><etal/></person-group><article-title>Wireless capsule endoscopy in adolescents with familial adenomatous polyposis</article-title><source>Tumori</source><year>2016</year><volume>102</volume><fpage>40</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.5301/tj.5000390</pub-id><pub-id pub-id-type="pmid">26219574</pub-id></element-citation><mixed-citation id="mc-CR209" publication-type="journal">Cavallo D, Ballardini G, Ferrari A et al (2016) Wireless capsule endoscopy in adolescents with familial adenomatous polyposis. Tumori 102:40&#8211;44. 10.5301/tj.5000390<pub-id pub-id-type="pmid">26219574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5301/tj.5000390</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR210"><label>210.</label><citation-alternatives><element-citation id="ec-CR210" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iaquinto</surname><given-names>G</given-names></name><name name-style="western"><surname>Fornasarig</surname><given-names>M</given-names></name><name name-style="western"><surname>Quaia</surname><given-names>M</given-names></name><etal/></person-group><article-title>Capsule endoscopy is useful and safe for small-bowel surveillance in familial adenomatous polyposis</article-title><source>Gastrointest Endosc</source><year>2008</year><volume>67</volume><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2007.07.048</pub-id><pub-id pub-id-type="pmid">18155426</pub-id></element-citation><mixed-citation id="mc-CR210" publication-type="journal">Iaquinto G, Fornasarig M, Quaia M et al (2008) Capsule endoscopy is useful and safe for small-bowel surveillance in familial adenomatous polyposis. Gastrointest Endosc 67:61&#8211;67<pub-id pub-id-type="pmid">18155426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2007.07.048</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR211"><label>211.</label><citation-alternatives><element-citation id="ec-CR211" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Araujo</surname><given-names>IK</given-names></name><name name-style="western"><surname>Pages</surname><given-names>M</given-names></name><name name-style="western"><surname>Romero</surname><given-names>C</given-names></name><etal/></person-group><article-title>Twelve-year asymptomatic retention of a colon capsule endoscope</article-title><source>Gastrointest Endosc</source><year>2017</year><volume>85</volume><fpage>681</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2016.04.045</pub-id><pub-id pub-id-type="pmid">27156654</pub-id></element-citation><mixed-citation id="mc-CR211" publication-type="journal">Araujo IK, Pages M, Romero C et al (2017) Twelve-year asymptomatic retention of a colon capsule endoscope. Gastrointest Endosc 85:681&#8211;682<pub-id pub-id-type="pmid">27156654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2016.04.045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR212"><label>212.</label><citation-alternatives><element-citation id="ec-CR212" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulmann</surname><given-names>K</given-names></name><name name-style="western"><surname>Hollerbach</surname><given-names>S</given-names></name><name name-style="western"><surname>Kraus</surname><given-names>K</given-names></name><etal/></person-group><article-title>Feasibility and diagnostic utility of video capsule endoscopy for the detection of small bowel polyps in patients with hereditary polyposis syndromes</article-title><source>Am J Gastroenterol</source><year>2005</year><volume>100</volume><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.40102.x</pub-id><pub-id pub-id-type="pmid">15654777</pub-id></element-citation><mixed-citation id="mc-CR212" publication-type="journal">Schulmann K, Hollerbach S, Kraus K et al (2005) Feasibility and diagnostic utility of video capsule endoscopy for the detection of small bowel polyps in patients with hereditary polyposis syndromes. Am J Gastroenterol 100:27&#8211;37<pub-id pub-id-type="pmid">15654777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1572-0241.2005.40102.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR213"><label>213.</label><citation-alternatives><element-citation id="ec-CR213" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>K</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Small intestinal involvement and genotype-phenotype correlation in familial adenomatous polyposis</article-title><source>Techn Innovat Gastrointest Endosc</source><year>2022</year><volume>2022</volume><fpage>24</fpage><lpage>34</lpage></element-citation><mixed-citation id="mc-CR213" publication-type="journal">Tanaka K, Sato Y, Ishikawa H et al (2022) Small intestinal involvement and genotype-phenotype correlation in familial adenomatous polyposis. Techn Innovat Gastrointest Endosc 2022:24&#8211;34</mixed-citation></citation-alternatives></ref><ref id="CR214"><label>214.</label><citation-alternatives><element-citation id="ec-CR214" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukushi</surname><given-names>G</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>M</given-names></name><name name-style="western"><surname>Kakugawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Genotype-phenotype correlation of small-intestinal polyps on small-bowel capsule endoscopy in familial adenomatous polyposis</article-title><source>Gastrointest Endosc</source><year>2023</year><volume>97</volume><fpage>59</fpage><lpage>68.e7</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2022.08.042</pub-id><pub-id pub-id-type="pmid">36084716</pub-id></element-citation><mixed-citation id="mc-CR214" publication-type="journal">Fukushi G, Yamada M, Kakugawa Y et al (2023) Genotype-phenotype correlation of small-intestinal polyps on small-bowel capsule endoscopy in familial adenomatous polyposis. Gastrointest Endosc 97:59-68.e7<pub-id pub-id-type="pmid">36084716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2022.08.042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR215"><label>215.</label><citation-alternatives><element-citation id="ec-CR215" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiroky</surname><given-names>JS</given-names></name><name name-style="western"><surname>Lerner-Ellis</surname><given-names>JP</given-names></name><name name-style="western"><surname>Govindarajan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Characteristics of adrenal masses in familial adenomatous polyposis</article-title><source>Dis Colon Rectum</source><year>2018</year><volume>61</volume><fpage>679</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1097/DCR.0000000000001008</pub-id><pub-id pub-id-type="pmid">29377868</pub-id></element-citation><mixed-citation id="mc-CR215" publication-type="journal">Shiroky JS, Lerner-Ellis JP, Govindarajan A et al (2018) Characteristics of adrenal masses in familial adenomatous polyposis. Dis Colon Rectum 61:679&#8211;685<pub-id pub-id-type="pmid">29377868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/DCR.0000000000001008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR216"><label>216.</label><citation-alternatives><element-citation id="ec-CR216" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>TG</given-names></name><name name-style="western"><surname>Clark</surname><given-names>SK</given-names></name><name name-style="western"><surname>Katz</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Adrenal masses are associated with familial adenomatous polyposis</article-title><source>Dis Colon Rectum</source><year>2000</year><volume>43</volume><fpage>1739</fpage><lpage>1742</lpage><pub-id pub-id-type="doi">10.1007/BF02236860</pub-id><pub-id pub-id-type="pmid">11156460</pub-id></element-citation><mixed-citation id="mc-CR216" publication-type="journal">Smith TG, Clark SK, Katz DE et al (2000) Adrenal masses are associated with familial adenomatous polyposis. Dis Colon Rectum 43:1739&#8211;1742<pub-id pub-id-type="pmid">11156460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02236860</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR217"><label>217.</label><citation-alternatives><element-citation id="ec-CR217" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchesa</surname><given-names>P</given-names></name><name name-style="western"><surname>Fazio</surname><given-names>VW</given-names></name><name name-style="western"><surname>Church</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Adrenal masses in patients with familial adenomatous polyposis</article-title><source>Dis Colon Rectum</source><year>1997</year><volume>40</volume><fpage>1023</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1007/BF02050923</pub-id><pub-id pub-id-type="pmid">9293929</pub-id></element-citation><mixed-citation id="mc-CR217" publication-type="journal">Marchesa P, Fazio VW, Church JM et al (1997) Adrenal masses in patients with familial adenomatous polyposis. Dis Colon Rectum 40:1023&#8211;1028<pub-id pub-id-type="pmid">9293929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02050923</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR218"><label>218.</label><citation-alternatives><element-citation id="ec-CR218" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aretz</surname><given-names>S</given-names></name><name name-style="western"><surname>Koch</surname><given-names>A</given-names></name><name name-style="western"><surname>Uhlhaas</surname><given-names>S</given-names></name><etal/></person-group><article-title>Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for <italic toggle="yes">APC</italic> germline mutations?</article-title><source>Pediatr Blood Cancer</source><year>2006</year><volume>47</volume><fpage>811</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1002/pbc.20698</pub-id><pub-id pub-id-type="pmid">16317745</pub-id></element-citation><mixed-citation id="mc-CR218" publication-type="journal">Aretz S, Koch A, Uhlhaas S et al (2006) Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for <italic toggle="yes">APC</italic> germline mutations? Pediatr Blood Cancer 47:811&#8211;818. 10.1002/pbc.20698<pub-id pub-id-type="pmid">16317745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pbc.20698</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR219"><label>219.</label><citation-alternatives><element-citation id="ec-CR219" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trobaugh-Lotrario</surname><given-names>AD</given-names></name><name name-style="western"><surname>L&#243;pez-Terrada</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><etal/></person-group><article-title>Hepatoblastoma in patients with molecularly proven familial adenomatous polyposis: Clinical characteristics and rationale for surveillance screening</article-title><source>Pediatr Blood Cancer</source><year>2018</year><volume>65</volume><fpage>e27103</fpage><pub-id pub-id-type="doi">10.1002/pbc.27103</pub-id><pub-id pub-id-type="pmid">29719120</pub-id></element-citation><mixed-citation id="mc-CR219" publication-type="journal">Trobaugh-Lotrario AD, L&#243;pez-Terrada D, Li P et al (2018) Hepatoblastoma in patients with molecularly proven familial adenomatous polyposis: Clinical characteristics and rationale for surveillance screening. Pediatr Blood Cancer 65:e27103<pub-id pub-id-type="pmid">29719120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pbc.27103</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR220"><label>220.</label><citation-alternatives><element-citation id="ec-CR220" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyer</surname><given-names>W</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S</given-names></name><name name-style="western"><surname>Attard</surname><given-names>T</given-names></name><etal/></person-group><article-title>Management of familial adenomatous polyposis in children and adolescents: Position paper from the ESPGHAN polyposis working group</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2019</year><volume>68</volume><fpage>428</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1097/MPG.0000000000002247</pub-id><pub-id pub-id-type="pmid">30585891</pub-id></element-citation><mixed-citation id="mc-CR220" publication-type="journal">Hyer W, Cohen S, Attard T et al (2019) Management of familial adenomatous polyposis in children and adolescents: Position paper from the ESPGHAN polyposis working group. J Pediatr Gastroenterol Nutr 68:428&#8211;441<pub-id pub-id-type="pmid">30585891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MPG.0000000000002247</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR221"><label>221.</label><citation-alternatives><element-citation id="ec-CR221" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sada</surname><given-names>H</given-names></name><name name-style="western"><surname>Hinoi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>H</given-names></name><etal/></person-group><article-title>Prevalence of and risk factors for thyroid carcinoma in patients with familial adenomatous polyposis: results of a multicenter study in Japan and a systematic review</article-title><source>Surg Today</source><year>2019</year><volume>49</volume><fpage>72</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1007/s00595-018-1710-3</pub-id><pub-id pub-id-type="pmid">30182306</pub-id></element-citation><mixed-citation id="mc-CR221" publication-type="journal">Sada H, Hinoi T, Ueno H et al (2019) Prevalence of and risk factors for thyroid carcinoma in patients with familial adenomatous polyposis: results of a multicenter study in Japan and a systematic review. Surg Today 49:72&#8211;81. 10.1007/s00595-018-1710-3<pub-id pub-id-type="pmid">30182306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00595-018-1710-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR222"><label>222.</label><citation-alternatives><element-citation id="ec-CR222" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>RL</given-names></name><name name-style="western"><surname>Steinhaus</surname><given-names>KA</given-names></name><name name-style="western"><surname>Uhrich</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Recommendations for standardized human pedigree nomenclature. Pedigree Standardization Task Force of the National Society of Genetic Counselors</article-title><source>Am J Hum Genet</source><year>1995</year><volume>56</volume><fpage>745</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">7887430</pub-id><pub-id pub-id-type="pmcid">PMC1801187</pub-id></element-citation><mixed-citation id="mc-CR222" publication-type="journal">Bennett RL, Steinhaus KA, Uhrich SB et al (1995) Recommendations for standardized human pedigree nomenclature. Pedigree Standardization Task Force of the National Society of Genetic Counselors. Am J Hum Genet 56:745&#8211;752<pub-id pub-id-type="pmid">7887430</pub-id><pub-id pub-id-type="pmcid">PMC1801187</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR223"><label>223.</label><citation-alternatives><element-citation id="ec-CR223" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>RL</given-names></name><name name-style="western"><surname>French</surname><given-names>KS</given-names></name><name name-style="western"><surname>Resta</surname><given-names>RG</given-names></name><etal/></person-group><article-title>Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors</article-title><source>J Genet Couns</source><year>2008</year><volume>17</volume><fpage>424</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1007/s10897-008-9169-9</pub-id><pub-id pub-id-type="pmid">18792771</pub-id></element-citation><mixed-citation id="mc-CR223" publication-type="journal">Bennett RL, French KS, Resta RG et al (2008) Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. J Genet Couns 17:424&#8211;433. 10.1007/s10897-008-9169-9<pub-id pub-id-type="pmid">18792771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10897-008-9169-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR224"><label>224.</label><citation-alternatives><element-citation id="ec-CR224" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>RL</given-names></name><name name-style="western"><surname>French</surname><given-names>KS</given-names></name><name name-style="western"><surname>Resta</surname><given-names>RG</given-names></name><etal/></person-group><article-title>Practice resource-focused revision: Standardized pedigree nomenclature update centered on sex and gender inclusivity: A practice resource of the National Society of Genetic Counselors</article-title><source>J Genet Couns</source><year>2022</year><volume>31</volume><fpage>1238</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1002/jgc4.1621</pub-id><pub-id pub-id-type="pmid">36106433</pub-id></element-citation><mixed-citation id="mc-CR224" publication-type="journal">Bennett RL, French KS, Resta RG et al (2022) Practice resource-focused revision: Standardized pedigree nomenclature update centered on sex and gender inclusivity: A practice resource of the National Society of Genetic Counselors. J Genet Couns 31:1238&#8211;1248. 10.1002/jgc4.1621<pub-id pub-id-type="pmid">36106433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jgc4.1621</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR225"><label>225.</label><citation-alternatives><element-citation id="ec-CR225" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anele</surname><given-names>CC</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Martin</surname><given-names>I</given-names></name><etal/></person-group><article-title>Polyp progression in paediatric patients with familial adenomatous polyposis: A single-centre Experience</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2020</year><volume>71</volume><fpage>612</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1097/MPG.0000000000002845</pub-id><pub-id pub-id-type="pmid">33093367</pub-id></element-citation><mixed-citation id="mc-CR225" publication-type="journal">Anele CC, Xiang J, Martin I et al (2020) Polyp progression in paediatric patients with familial adenomatous polyposis: A single-centre Experience. J Pediatr Gastroenterol Nutr 71:612&#8211;616<pub-id pub-id-type="pmid">33093367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MPG.0000000000002845</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR226"><label>226.</label><citation-alternatives><element-citation id="ec-CR226" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarvepalli</surname><given-names>S</given-names></name><name name-style="western"><surname>Burke</surname><given-names>CA</given-names></name><name name-style="western"><surname>Monachese</surname><given-names>M</given-names></name><etal/></person-group><article-title>Natural history of colonic polyposis in young patients with familial adenomatous polyposis</article-title><source>Gastrointest Endosc</source><year>2018</year><volume>88</volume><fpage>726</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2018.05.021</pub-id><pub-id pub-id-type="pmid">29864420</pub-id></element-citation><mixed-citation id="mc-CR226" publication-type="journal">Sarvepalli S, Burke CA, Monachese M et al (2018) Natural history of colonic polyposis in young patients with familial adenomatous polyposis. Gastrointest Endosc 88:726&#8211;733<pub-id pub-id-type="pmid">29864420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2018.05.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR227"><label>227.</label><citation-alternatives><element-citation id="ec-CR227" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kakuta</surname><given-names>F</given-names></name><name name-style="western"><surname>Hoshi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Abukawa</surname><given-names>D</given-names></name></person-group><article-title>The efficacy and safety of polyethylene glycol plus ascorbic acid for bowel cleansing before colonoscopy in children</article-title><source>Gastroenterol Endosc</source><year>2018</year><volume>60</volume><fpage>125</fpage><lpage>131</lpage></element-citation><mixed-citation id="mc-CR227" publication-type="journal">Kakuta F, Hoshi Y, Abukawa D (2018) The efficacy and safety of polyethylene glycol plus ascorbic acid for bowel cleansing before colonoscopy in children. Gastroenterol Endosc 60:125&#8211;131</mixed-citation></citation-alternatives></ref><ref id="CR228"><label>228.</label><citation-alternatives><element-citation id="ec-CR228" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giardiello</surname><given-names>FM</given-names></name><name name-style="western"><surname>Offerhaus</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Krush</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Risk of hepatoblastoma in familial adenomatous polyposis</article-title><source>J Pediatr</source><year>1991</year><volume>119</volume><fpage>766</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(05)80297-5</pub-id><pub-id pub-id-type="pmid">1658283</pub-id></element-citation><mixed-citation id="mc-CR228" publication-type="journal">Giardiello FM, Offerhaus GJ, Krush AJ et al (1991) Risk of hepatoblastoma in familial adenomatous polyposis. J Pediatr 119:766&#8211;768<pub-id pub-id-type="pmid">1658283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-3476(05)80297-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR229"><label>229.</label><citation-alternatives><element-citation id="ec-CR229" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Syngal</surname><given-names>S</given-names></name><name name-style="western"><surname>Brand</surname><given-names>RE</given-names></name><name name-style="western"><surname>Church</surname><given-names>JM</given-names></name><etal/></person-group><article-title>American College of Gastroenterology: ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes</article-title><source>Am J Gastroenterol</source><year>2015</year><volume>110</volume><fpage>223</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1038/ajg.2014.435</pub-id><pub-id pub-id-type="pmid">25645574</pub-id><pub-id pub-id-type="pmcid">PMC4695986</pub-id></element-citation><mixed-citation id="mc-CR229" publication-type="journal">Syngal S, Brand RE, Church JM et al (2015) American College of Gastroenterology: ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110:223&#8211;262<pub-id pub-id-type="pmid">25645574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ajg.2014.435</pub-id><pub-id pub-id-type="pmcid">PMC4695986</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR230"><label>230.</label><citation-alternatives><element-citation id="ec-CR230" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bisgaard</surname><given-names>ML</given-names></name><name name-style="western"><surname>Fenger</surname><given-names>K</given-names></name><name name-style="western"><surname>B&#252;low</surname><given-names>S</given-names></name><etal/></person-group><article-title>Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate</article-title><source>Hum Mutat</source><year>1994</year><volume>3</volume><fpage>121</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1002/humu.1380030206</pub-id><pub-id pub-id-type="pmid">8199592</pub-id></element-citation><mixed-citation id="mc-CR230" publication-type="journal">Bisgaard ML, Fenger K, B&#252;low S et al (1994) Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3:121&#8211;125<pub-id pub-id-type="pmid">8199592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/humu.1380030206</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR231"><label>231.</label><citation-alternatives><element-citation id="ec-CR231" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guill&#233;n-Ponce</surname><given-names>C</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>R</given-names></name><name name-style="western"><surname>S&#225;nchez-Heras</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Clinical guideline seom: hereditary colorectal cancer</article-title><source>Clin Transl Oncol</source><year>2015</year><volume>17</volume><fpage>962</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1007/s12094-015-1439-z</pub-id><pub-id pub-id-type="pmid">26586118</pub-id><pub-id pub-id-type="pmcid">PMC4689750</pub-id></element-citation><mixed-citation id="mc-CR231" publication-type="journal">Guill&#233;n-Ponce C, Serrano R, S&#225;nchez-Heras AB et al (2015) Clinical guideline seom: hereditary colorectal cancer. Clin Transl Oncol 17:962&#8211;971<pub-id pub-id-type="pmid">26586118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12094-015-1439-z</pub-id><pub-id pub-id-type="pmcid">PMC4689750</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR232"><label>232.</label><citation-alternatives><element-citation id="ec-CR232" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoffel</surname><given-names>EM</given-names></name><name name-style="western"><surname>Mangu</surname><given-names>PB</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.58.1322</pub-id><pub-id pub-id-type="pmid">25452455</pub-id><pub-id pub-id-type="pmcid">PMC5321096</pub-id></element-citation><mixed-citation id="mc-CR232" publication-type="journal">Stoffel EM, Mangu PB, Gruber SB et al (2015) Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol 33:209&#8211;217<pub-id pub-id-type="pmid">25452455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2014.58.1322</pub-id><pub-id pub-id-type="pmcid">PMC5321096</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR233"><label>233.</label><citation-alternatives><element-citation id="ec-CR233" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herzig</surname><given-names>D</given-names></name><name name-style="western"><surname>Hardiman</surname><given-names>K</given-names></name><name name-style="western"><surname>Weiser</surname><given-names>M</given-names></name><etal/></person-group><article-title>The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the management of inherited polyposis syndromes</article-title><source>Dis Colon Rectum</source><year>2017</year><volume>60</volume><fpage>881</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1097/DCR.0000000000000912</pub-id><pub-id pub-id-type="pmid">28796726</pub-id><pub-id pub-id-type="pmcid">PMC5701653</pub-id></element-citation><mixed-citation id="mc-CR233" publication-type="journal">Herzig D, Hardiman K, Weiser M et al (2017) The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the management of inherited polyposis syndromes. Dis Colon Rectum 60:881&#8211;894<pub-id pub-id-type="pmid">28796726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/DCR.0000000000000912</pub-id><pub-id pub-id-type="pmcid">PMC5701653</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR234"><label>234.</label><citation-alternatives><element-citation id="ec-CR234" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giardiello</surname><given-names>FM</given-names></name><name name-style="western"><surname>Yang</surname><given-names>VW</given-names></name><name name-style="western"><surname>Hylind</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Primary chemoprevention of familial adenomatous polyposis with sulindac</article-title><source>N Engl J Med</source><year>2022</year><volume>346</volume><fpage>1054</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa012015</pub-id><pub-id pub-id-type="pmcid">PMC2225537</pub-id><pub-id pub-id-type="pmid">11932472</pub-id></element-citation><mixed-citation id="mc-CR234" publication-type="journal">Giardiello FM, Yang VW, Hylind LM et al (2022) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346:1054&#8211;1059<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa012015</pub-id><pub-id pub-id-type="pmcid">PMC2225537</pub-id><pub-id pub-id-type="pmid">11932472</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR235"><label>235.</label><citation-alternatives><element-citation id="ec-CR235" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giardiello</surname><given-names>FM</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>SR</given-names></name><name name-style="western"><surname>Krush</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis</article-title><source>N Engl J Med</source><year>1993</year><volume>328</volume><fpage>1313</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1056/NEJM199305063281805</pub-id><pub-id pub-id-type="pmid">8385741</pub-id></element-citation><mixed-citation id="mc-CR235" publication-type="journal">Giardiello FM, Hamilton SR, Krush AJ et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313&#8211;1316<pub-id pub-id-type="pmid">8385741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM199305063281805</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR236"><label>236.</label><citation-alternatives><element-citation id="ec-CR236" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuhann</surname><given-names>TM</given-names></name><name name-style="western"><surname>Haub</surname><given-names>K</given-names></name><name name-style="western"><surname>Steinke-Lange</surname><given-names>V</given-names></name><etal/></person-group><article-title>Long-term chemoprevention in patients with adenomatous polyposis coli: an observational study</article-title><source>Fam Cancer</source><year>2022</year><volume>21</volume><fpage>463</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1007/s10689-022-00292-2</pub-id><pub-id pub-id-type="pmid">35570229</pub-id></element-citation><mixed-citation id="mc-CR236" publication-type="journal">Neuhann TM, Haub K, Steinke-Lange V et al (2022) Long-term chemoprevention in patients with adenomatous polyposis coli: an observational study. Fam Cancer 21:463&#8211;472<pub-id pub-id-type="pmid">35570229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-022-00292-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR237"><label>237.</label><citation-alternatives><element-citation id="ec-CR237" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burke</surname><given-names>CA</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>E</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>P</given-names></name><etal/></person-group><article-title>Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>1028</fpage><lpage>1039</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1916063</pub-id><pub-id pub-id-type="pmid">32905675</pub-id></element-citation><mixed-citation id="mc-CR237" publication-type="journal">Burke CA, Dekker E, Lynch P et al (2020) Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis. N Engl J Med 383:1028&#8211;1039<pub-id pub-id-type="pmid">32905675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1916063</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR238"><label>238.</label><citation-alternatives><element-citation id="ec-CR238" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balaguer</surname><given-names>F</given-names></name><name name-style="western"><surname>Stoffel</surname><given-names>EM</given-names></name><name name-style="western"><surname>Burke</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Combination of sulindac and eflornithine delays the need for lower gastrointestinal surgery in patients with familial adenomatous polyposis: Post hoc analysis of a randomized clinical trial</article-title><source>Dis Colon Rectum</source><year>2022</year><volume>65</volume><fpage>536</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1097/DCR.0000000000002095</pub-id><pub-id pub-id-type="pmid">34261858</pub-id></element-citation><mixed-citation id="mc-CR238" publication-type="journal">Balaguer F, Stoffel EM, Burke CA et al (2022) Combination of sulindac and eflornithine delays the need for lower gastrointestinal surgery in patients with familial adenomatous polyposis: Post hoc analysis of a randomized clinical trial. Dis Colon Rectum 65:536&#8211;545<pub-id pub-id-type="pmid">34261858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/DCR.0000000000002095</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR239"><label>239.</label><citation-alternatives><element-citation id="ec-CR239" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samadder</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Kuwada</surname><given-names>SK</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Association of sulindac and erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis: Secondary analysis of a randomized clinical trial</article-title><source>JAMA Oncol</source><year>2018</year><volume>4</volume><fpage>671</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2017.5431</pub-id><pub-id pub-id-type="pmid">29423501</pub-id><pub-id pub-id-type="pmcid">PMC5885170</pub-id></element-citation><mixed-citation id="mc-CR239" publication-type="journal">Samadder NJ, Kuwada SK, Boucher KM et al (2018) Association of sulindac and erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis: Secondary analysis of a randomized clinical trial. JAMA Oncol 4:671&#8211;677<pub-id pub-id-type="pmid">29423501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2017.5431</pub-id><pub-id pub-id-type="pmcid">PMC5885170</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR240"><label>240.</label><citation-alternatives><element-citation id="ec-CR240" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinbach</surname><given-names>G</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>PM</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>RK</given-names></name><etal/></person-group><article-title>The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><fpage>1946</fpage><lpage>1952</lpage><pub-id pub-id-type="doi">10.1056/NEJM200006293422603</pub-id><pub-id pub-id-type="pmid">10874062</pub-id></element-citation><mixed-citation id="mc-CR240" publication-type="journal">Steinbach G, Lynch PM, Phillips RK et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946&#8211;1952<pub-id pub-id-type="pmid">10874062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM200006293422603</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR241"><label>241.</label><citation-alternatives><element-citation id="ec-CR241" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burke</surname><given-names>CA</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>R</given-names></name><name name-style="western"><surname>Berger</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Children&#8217;s International Polyposis (CHIP) study: a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis</article-title><source>Clin Exp Gastroenterol</source><year>2017</year><volume>10</volume><fpage>177</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.2147/CEG.S121841</pub-id><pub-id pub-id-type="pmid">28765715</pub-id><pub-id pub-id-type="pmcid">PMC5525455</pub-id></element-citation><mixed-citation id="mc-CR241" publication-type="journal">Burke CA, Phillips R, Berger MF et al (2017) Children&#8217;s International Polyposis (CHIP) study: a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis. Clin Exp Gastroenterol 10:177&#8211;185. 10.2147/CEG.S121841<pub-id pub-id-type="pmid">28765715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CEG.S121841</pub-id><pub-id pub-id-type="pmcid">PMC5525455</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR242"><label>242.</label><citation-alternatives><element-citation id="ec-CR242" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solomon</surname><given-names>SD</given-names></name><name name-style="western"><surname>McMurray</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Pfeffer</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>1071</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa050405</pub-id><pub-id pub-id-type="pmid">15713944</pub-id></element-citation><mixed-citation id="mc-CR242" publication-type="journal">Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071&#8211;1080<pub-id pub-id-type="pmid">15713944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa050405</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR243"><label>243.</label><citation-alternatives><element-citation id="ec-CR243" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higuchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Iwama</surname><given-names>T</given-names></name><name name-style="western"><surname>Yoshinaga</surname><given-names>K</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>4756</fpage><lpage>4760</lpage><pub-id pub-id-type="pmid">14581346</pub-id></element-citation><mixed-citation id="mc-CR243" publication-type="journal">Higuchi T, Iwama T, Yoshinaga K et al (2003) A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 9:4756&#8211;4760<pub-id pub-id-type="pmid">14581346</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR244"><label>244.</label><citation-alternatives><element-citation id="ec-CR244" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwama</surname><given-names>T</given-names></name><name name-style="western"><surname>Akasu</surname><given-names>T</given-names></name><name name-style="western"><surname>Utsunomiya</surname><given-names>J</given-names></name><etal/></person-group><article-title>Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial</article-title><source>Int J Clin Oncol</source><year>2006</year><volume>11</volume><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1007/s10147-005-0548-z</pub-id><pub-id pub-id-type="pmid">16622748</pub-id></element-citation><mixed-citation id="mc-CR244" publication-type="journal">Iwama T, Akasu T, Utsunomiya J et al (2006) Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial. Int J Clin Oncol 11:133&#8211;139<pub-id pub-id-type="pmid">16622748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10147-005-0548-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR245"><label>245.</label><citation-alternatives><element-citation id="ec-CR245" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bresalier</surname><given-names>RS</given-names></name><name name-style="western"><surname>Sandler</surname><given-names>RS</given-names></name><name name-style="western"><surname>Quan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>1092</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa050493</pub-id><pub-id pub-id-type="pmid">15713943</pub-id></element-citation><mixed-citation id="mc-CR245" publication-type="journal">Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092&#8211;1102<pub-id pub-id-type="pmid">15713943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa050493</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR246"><label>246.</label><citation-alternatives><element-citation id="ec-CR246" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Clark</surname><given-names>SK</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis</article-title><source>Gut</source><year>2010</year><volume>59</volume><fpage>918</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1136/gut.2009.200642</pub-id><pub-id pub-id-type="pmid">20348368</pub-id></element-citation><mixed-citation id="mc-CR246" publication-type="journal">West NJ, Clark SK, Phillips RK et al (2010) Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 59:918&#8211;925 (<bold>[PMID: 20348368]</bold>)<pub-id pub-id-type="pmid">20348368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.2009.200642</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR247"><label>247.</label><citation-alternatives><element-citation id="ec-CR247" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hull</surname><given-names>MA</given-names></name><name name-style="western"><surname>Sprange</surname><given-names>K</given-names></name><name name-style="western"><surname>Hepburn</surname><given-names>T</given-names></name><etal/></person-group><article-title>Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2&#215;2 factorial trial</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>2583</fpage><lpage>2594</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31775-6</pub-id><pub-id pub-id-type="pmid">30466866</pub-id><pub-id pub-id-type="pmcid">PMC6294731</pub-id></element-citation><mixed-citation id="mc-CR247" publication-type="journal">Hull MA, Sprange K, Hepburn T et al (2018) Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2&#215;2 factorial trial. Lancet 392:2583&#8211;2594<pub-id pub-id-type="pmid">30466866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)31775-6</pub-id><pub-id pub-id-type="pmcid">PMC6294731</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR248"><label>248.</label><citation-alternatives><element-citation id="ec-CR248" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burn</surname><given-names>J</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>DT</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>PD</given-names></name><etal/></person-group><article-title>A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis</article-title><source>Cancer Prev Res (Phila)</source><year>2011</year><volume>4</volume><fpage>655</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-11-0106</pub-id><pub-id pub-id-type="pmid">21543343</pub-id><pub-id pub-id-type="pmcid">PMC3092423</pub-id></element-citation><mixed-citation id="mc-CR248" publication-type="journal">Burn J, Bishop DT, Chapman PD et al (2011) A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 4:655&#8211;665<pub-id pub-id-type="pmid">21543343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1940-6207.CAPR-11-0106</pub-id><pub-id pub-id-type="pmcid">PMC3092423</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR249"><label>249.</label><citation-alternatives><element-citation id="ec-CR249" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishikawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Wakabayashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>S</given-names></name><etal/></person-group><article-title>Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial</article-title><source>Cancer Med</source><year>2013</year><volume>2</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1002/cam4.46</pub-id><pub-id pub-id-type="pmid">24133627</pub-id><pub-id pub-id-type="pmcid">PMC3797560</pub-id></element-citation><mixed-citation id="mc-CR249" publication-type="journal">Ishikawa H, Wakabayashi K, Suzuki S et al (2013) Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med 2:50&#8211;56. 10.1002/cam4.46<pub-id pub-id-type="pmid">24133627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.46</pub-id><pub-id pub-id-type="pmcid">PMC3797560</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR250"><label>250.</label><citation-alternatives><element-citation id="ec-CR250" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishikawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Mutoh</surname><given-names>M</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study &#8547;): a multicentre, double-blind, randomised, two-by-two factorial design trial</article-title><source>Lancet Gastroenterol Hepatol</source><year>2021</year><volume>6</volume><fpage>474</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(21)00018-2</pub-id><pub-id pub-id-type="pmid">33812492</pub-id></element-citation><mixed-citation id="mc-CR250" publication-type="journal">Ishikawa H, Mutoh M, Sato Y et al (2021) Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study &#8547;): a multicentre, double-blind, randomised, two-by-two factorial design trial. Lancet Gastroenterol Hepatol 6:474&#8211;481<pub-id pub-id-type="pmid">33812492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(21)00018-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR251"><label>251.</label><citation-alternatives><element-citation id="ec-CR251" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>E</given-names></name><name name-style="western"><surname>Mutoh</surname><given-names>M</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Cost-effectiveness of preventive aspirin use and intensive downstaging polypectomy in patients with familial adenomatous polyposis: A microsimulation modeling study</article-title><source>Cancer Med</source><year>2023</year><volume>12</volume><fpage>19137</fpage><lpage>19148</lpage><pub-id pub-id-type="doi">10.1002/cam4.6488</pub-id><pub-id pub-id-type="pmid">37649281</pub-id><pub-id pub-id-type="pmcid">PMC10557886</pub-id></element-citation><mixed-citation id="mc-CR251" publication-type="journal">Saito E, Mutoh M, Ishikawa H et al (2023) Cost-effectiveness of preventive aspirin use and intensive downstaging polypectomy in patients with familial adenomatous polyposis: A microsimulation modeling study. Cancer Med 12:19137&#8211;19148. 10.1002/cam4.6488<pub-id pub-id-type="pmid">37649281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.6488</pub-id><pub-id pub-id-type="pmcid">PMC10557886</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR252"><label>252.</label><citation-alternatives><element-citation id="ec-CR252" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cloud</surname><given-names>GC</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>JD</given-names></name><name name-style="western"><surname>Thao</surname><given-names>LTP</given-names></name><etal/></person-group><article-title>Low-dose aspirin and the risk of stroke and intracerebral bleeding in healthy older people: Secondary analysis of a randomized clinical trial</article-title><source>JAMA Netw Open</source><year>2023</year><volume>6</volume><fpage>e2325803</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.25803</pub-id><pub-id pub-id-type="pmid">37494038</pub-id><pub-id pub-id-type="pmcid">PMC10372701</pub-id></element-citation><mixed-citation id="mc-CR252" publication-type="journal">Cloud GC, Williamson JD, Thao LTP et al (2023) Low-dose aspirin and the risk of stroke and intracerebral bleeding in healthy older people: Secondary analysis of a randomized clinical trial. JAMA Netw Open 6:e2325803<pub-id pub-id-type="pmid">37494038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.25803</pub-id><pub-id pub-id-type="pmcid">PMC10372701</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR253"><label>253.</label><citation-alternatives><element-citation id="ec-CR253" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghorbanoghli</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bastiaansen</surname><given-names>BA</given-names></name><name name-style="western"><surname>Langers</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis</article-title><source>J Med Genet</source><year>2018</year><volume>55</volume><fpage>11</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2017-104545</pub-id><pub-id pub-id-type="pmid">28490611</pub-id></element-citation><mixed-citation id="mc-CR253" publication-type="journal">Ghorbanoghli Z, Bastiaansen BA, Langers AM et al (2018) Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis. J Med Genet 55:11&#8211;14<pub-id pub-id-type="pmid">28490611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmedgenet-2017-104545</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR254"><label>254.</label><citation-alternatives><element-citation id="ec-CR254" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#252;low</surname><given-names>S</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>IJ</given-names></name><name name-style="western"><surname>H&#248;jen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Duodenal surveillance improves the prognosis after duodenal cancer in familial adenomatous polyposis</article-title><source>Colorectal Dis</source><year>2012</year><volume>14</volume><fpage>947</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1318.2011.02844.x</pub-id><pub-id pub-id-type="pmid">21973191</pub-id></element-citation><mixed-citation id="mc-CR254" publication-type="journal">B&#252;low S, Christensen IJ, H&#248;jen H et al (2012) Duodenal surveillance improves the prognosis after duodenal cancer in familial adenomatous polyposis. Colorectal Dis 14:947&#8211;952<pub-id pub-id-type="pmid">21973191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1463-1318.2011.02844.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR255"><label>255.</label><citation-alternatives><element-citation id="ec-CR255" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwama</surname><given-names>T</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>K</given-names></name><name name-style="western"><surname>Morita</surname><given-names>T</given-names></name><etal/></person-group><article-title>Japanese Society for Cancer of the Colon and Rectum: A clinical overview of familial adenomatous polyposis derived from the database of the Polyposis Registry of Japan</article-title><source>Int J Clin Oncol</source><year>2004</year><volume>9</volume><fpage>308</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1007/s10147-004-0414-4</pub-id><pub-id pub-id-type="pmid">15375708</pub-id></element-citation><mixed-citation id="mc-CR255" publication-type="journal">Iwama T, Tamura K, Morita T et al (2004) Japanese Society for Cancer of the Colon and Rectum: A clinical overview of familial adenomatous polyposis derived from the database of the Polyposis Registry of Japan. Int J Clin Oncol 9:308&#8211;316. 10.1007/s10147-004-0414-4<pub-id pub-id-type="pmid">15375708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10147-004-0414-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR256"><label>256.</label><citation-alternatives><element-citation id="ec-CR256" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Iida</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>S</given-names></name><etal/></person-group><article-title>Natural history of ampullary adenoma in familial adenomatous polyposis: reconfirmation of benign nature during extended surveillance</article-title><source>Am J Gastroenterol</source><year>2000</year><volume>95</volume><fpage>1557</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2000.02094.x</pub-id><pub-id pub-id-type="pmid">10894596</pub-id></element-citation><mixed-citation id="mc-CR256" publication-type="journal">Matsumoto T, Iida M, Nakamura S et al (2000) Natural history of ampullary adenoma in familial adenomatous polyposis: reconfirmation of benign nature during extended surveillance. Am J Gastroenterol 95:1557&#8211;1562<pub-id pub-id-type="pmid">10894596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1572-0241.2000.02094.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR257"><label>257.</label><citation-alternatives><element-citation id="ec-CR257" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>MD</given-names></name><name name-style="western"><surname>Mackey</surname><given-names>R</given-names></name><name name-style="western"><surname>Brown</surname><given-names>N</given-names></name><etal/></person-group><article-title>Outcome based on management for duodenal adenomas: sporadic versus familial disease</article-title><source>J Gastrointest Surg</source><year>2010</year><volume>14</volume><fpage>229</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1007/s11605-009-1091-4</pub-id><pub-id pub-id-type="pmid">19937193</pub-id></element-citation><mixed-citation id="mc-CR257" publication-type="journal">Johnson MD, Mackey R, Brown N et al (2010) Outcome based on management for duodenal adenomas: sporadic versus familial disease. J Gastrointest Surg 14:229&#8211;235. 10.1007/s11605-009-1091-4<pub-id pub-id-type="pmid">19937193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11605-009-1091-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR258"><label>258.</label><citation-alternatives><element-citation id="ec-CR258" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaganmohan</surname><given-names>S</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>PM</given-names></name><name name-style="western"><surname>Raju</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Endoscopic management of duodenal adenomas in familial adenomatous polyposis&#8211;a single-center experience</article-title><source>Dig Dis Sci</source><year>2012</year><volume>57</volume><fpage>732</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1007/s10620-011-1917-2</pub-id><pub-id pub-id-type="pmid">21960285</pub-id></element-citation><mixed-citation id="mc-CR258" publication-type="journal">Jaganmohan S, Lynch PM, Raju RP et al (2012) Endoscopic management of duodenal adenomas in familial adenomatous polyposis&#8211;a single-center experience. Dig Dis Sci 57:732&#8211;737<pub-id pub-id-type="pmid">21960285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10620-011-1917-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR259"><label>259.</label><citation-alternatives><element-citation id="ec-CR259" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomita</surname><given-names>N</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>H</given-names></name><name name-style="western"><surname>Tanakaya</surname><given-names>K</given-names></name><etal/></person-group><article-title>Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the clinical practice of hereditary colorectal cancer</article-title><source>Int J Clin Oncol</source><year>2021</year><volume>26</volume><fpage>1353</fpage><lpage>1419</lpage><pub-id pub-id-type="doi">10.1007/s10147-021-01881-4</pub-id><pub-id pub-id-type="pmid">34185173</pub-id><pub-id pub-id-type="pmcid">PMC8286959</pub-id></element-citation><mixed-citation id="mc-CR259" publication-type="journal">Tomita N, Ishida H, Tanakaya K et al (2021) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the clinical practice of hereditary colorectal cancer. Int J Clin Oncol 26:1353&#8211;1419<pub-id pub-id-type="pmid">34185173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10147-021-01881-4</pub-id><pub-id pub-id-type="pmcid">PMC8286959</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR260"><label>260.</label><citation-alternatives><element-citation id="ec-CR260" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yachida</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>T</given-names></name><name name-style="western"><surname>Nonaka</surname><given-names>S</given-names></name><etal/></person-group><article-title>Characteristics and clinical outcomes of duodenal neoplasia in Japanese patients with familial adenomatous polyposis</article-title><source>J Clin Gastroenterol</source><year>2017</year><volume>51</volume><fpage>407</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1097/MCG.0000000000000555</pub-id><pub-id pub-id-type="pmid">27306941</pub-id></element-citation><mixed-citation id="mc-CR260" publication-type="journal">Yachida T, Nakajima T, Nonaka S et al (2017) Characteristics and clinical outcomes of duodenal neoplasia in Japanese patients with familial adenomatous polyposis. J Clin Gastroenterol 51:407&#8211;411<pub-id pub-id-type="pmid">27306941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCG.0000000000000555</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR261"><label>261.</label><citation-alternatives><element-citation id="ec-CR261" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hamada</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakahira</surname><given-names>H</given-names></name><etal/></person-group><article-title>Efficacy and safety of intensive downstaging polypectomy (IDP) for multiple duodenal adenomas in patients with familial adenomatous polyposis: A prospective cohort study</article-title><source>Endoscopy</source><year>2023</year><volume>55</volume><fpage>515</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1055/a-1983-5963</pub-id><pub-id pub-id-type="pmid">36410678</pub-id></element-citation><mixed-citation id="mc-CR261" publication-type="journal">Takeuchi Y, Hamada K, Nakahira H et al (2023) Efficacy and safety of intensive downstaging polypectomy (IDP) for multiple duodenal adenomas in patients with familial adenomatous polyposis: A prospective cohort study. Endoscopy 55:515&#8211;523<pub-id pub-id-type="pmid">36410678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-1983-5963</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR262"><label>262.</label><citation-alternatives><element-citation id="ec-CR262" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekiya</surname><given-names>M</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Yano</surname><given-names>T</given-names></name><etal/></person-group><article-title>Double-balloon endoscopy facilitates efficient endoscopic resection of duodenal and jejunal polyps in patients with familial adenomatous polyposis</article-title><source>Endoscopy</source><year>2021</year><volume>53</volume><fpage>517</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1055/a-1189-9550</pub-id><pub-id pub-id-type="pmid">32464675</pub-id></element-citation><mixed-citation id="mc-CR262" publication-type="journal">Sekiya M, Sakamoto H, Yano T et al (2021) Double-balloon endoscopy facilitates efficient endoscopic resection of duodenal and jejunal polyps in patients with familial adenomatous polyposis. Endoscopy 53:517&#8211;521<pub-id pub-id-type="pmid">32464675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-1189-9550</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR263"><label>263.</label><citation-alternatives><element-citation id="ec-CR263" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laleman</surname><given-names>W</given-names></name><name name-style="western"><surname>Verreth</surname><given-names>A</given-names></name><name name-style="western"><surname>Topal</surname><given-names>B</given-names></name><etal/></person-group><article-title>Endoscopic resection of ampullary lesions: a single-center 8-year retrospective cohort study of 91 patients with long-term follow-up</article-title><source>Surg Endosc</source><year>2013</year><volume>27</volume><fpage>3865</fpage><lpage>3876</lpage><pub-id pub-id-type="doi">10.1007/s00464-013-2996-2</pub-id><pub-id pub-id-type="pmid">23708714</pub-id></element-citation><mixed-citation id="mc-CR263" publication-type="journal">Laleman W, Verreth A, Topal B et al (2013) Endoscopic resection of ampullary lesions: a single-center 8-year retrospective cohort study of 91 patients with long-term follow-up. Surg Endosc 27:3865&#8211;3876<pub-id pub-id-type="pmid">23708714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00464-013-2996-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR264"><label>264.</label><citation-alternatives><element-citation id="ec-CR264" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramai</surname><given-names>D</given-names></name><name name-style="western"><surname>Facciorusso</surname><given-names>A</given-names></name><name name-style="western"><surname>Singh</surname><given-names>J</given-names></name><etal/></person-group><article-title>Endoscopic management of ampullary adenomas in familial adenomatous polyposis syndrome: A systematic review with pooled analysis</article-title><source>Dig Dis Sci</source><year>2022</year><volume>67</volume><fpage>3220</fpage><lpage>3227</lpage><pub-id pub-id-type="doi">10.1007/s10620-021-07132-w</pub-id><pub-id pub-id-type="pmid">34251561</pub-id></element-citation><mixed-citation id="mc-CR264" publication-type="journal">Ramai D, Facciorusso A, Singh J et al (2022) Endoscopic management of ampullary adenomas in familial adenomatous polyposis syndrome: A systematic review with pooled analysis. Dig Dis Sci 67:3220&#8211;3227<pub-id pub-id-type="pmid">34251561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10620-021-07132-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR265"><label>265.</label><citation-alternatives><element-citation id="ec-CR265" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>R</given-names></name><name name-style="western"><surname>Huelsen</surname><given-names>A</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><etal/></person-group><article-title>Endoscopic ampullectomy for non-invasive ampullary lesions: a single-center 10-year retrospective cohort study</article-title><source>Surg Endosc</source><year>2021</year><volume>35</volume><fpage>684</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1007/s00464-020-07433-7</pub-id><pub-id pub-id-type="pmid">32215745</pub-id></element-citation><mixed-citation id="mc-CR265" publication-type="journal">Lee R, Huelsen A, Gupta S et al (2021) Endoscopic ampullectomy for non-invasive ampullary lesions: a single-center 10-year retrospective cohort study. Surg Endosc 35:684&#8211;692. 10.1007/s00464-020-07433-7<pub-id pub-id-type="pmid">32215745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00464-020-07433-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR266"><label>266.</label><citation-alternatives><element-citation id="ec-CR266" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aelvoet</surname><given-names>AS</given-names></name><name name-style="western"><surname>Struik</surname><given-names>D</given-names></name><name name-style="western"><surname>Bastiaansen</surname><given-names>BAJ</given-names></name><etal/></person-group><article-title>Colectomy and desmoid tumours in familial adenomatous polyposis: a systematic review and meta-analysis</article-title><source>Fam Cancer</source><year>2022</year><volume>21</volume><fpage>429</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1007/s10689-022-00288-y</pub-id><pub-id pub-id-type="pmid">35022961</pub-id><pub-id pub-id-type="pmcid">PMC9636104</pub-id></element-citation><mixed-citation id="mc-CR266" publication-type="journal">Aelvoet AS, Struik D, Bastiaansen BAJ et al (2022) Colectomy and desmoid tumours in familial adenomatous polyposis: a systematic review and meta-analysis. Fam Cancer 21:429&#8211;439 (<bold>[PMID: 35022961]</bold>)<pub-id pub-id-type="pmid">35022961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-022-00288-y</pub-id><pub-id pub-id-type="pmcid">PMC9636104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR267"><label>267.</label><citation-alternatives><element-citation id="ec-CR267" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uchino</surname><given-names>S</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Miyauchi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Age- and gender-specific risk of thyroid cancer in patients with familial adenomatous polyposis</article-title><source>J Clin Endocrinol Metab</source><year>2016</year><volume>101</volume><fpage>4611</fpage><lpage>4617</lpage><pub-id pub-id-type="doi">10.1210/jc.2016-2043</pub-id><pub-id pub-id-type="pmid">27623068</pub-id></element-citation><mixed-citation id="mc-CR267" publication-type="journal">Uchino S, Ishikawa H, Miyauchi A et al (2016) Age- and gender-specific risk of thyroid cancer in patients with familial adenomatous polyposis. J Clin Endocrinol Metab 101:4611&#8211;4617. 10.1210/jc.2016-2043<pub-id pub-id-type="pmid">27623068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2016-2043</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR268"><label>268.</label><citation-alternatives><element-citation id="ec-CR268" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monachese</surname><given-names>M</given-names></name><name name-style="western"><surname>Mankaney</surname><given-names>G</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>R</given-names></name><etal/></person-group><article-title>Outcome of thyroid ultrasound screening in FAP patients with a normal baseline exam</article-title><source>Fam Cancer</source><year>2019</year><volume>18</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/s10689-018-0097-z</pub-id><pub-id pub-id-type="pmid">30003385</pub-id></element-citation><mixed-citation id="mc-CR268" publication-type="journal">Monachese M, Mankaney G, Lopez R et al (2019) Outcome of thyroid ultrasound screening in FAP patients with a normal baseline exam. Fam Cancer 18:75&#8211;82. 10.1007/s10689-018-0097-z<pub-id pub-id-type="pmid">30003385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-018-0097-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR269"><label>269.</label><citation-alternatives><element-citation id="ec-CR269" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suter</surname><given-names>CM</given-names></name><name name-style="western"><surname>Martin</surname><given-names>DI</given-names></name><name name-style="western"><surname>Ward</surname><given-names>RL</given-names></name></person-group><article-title>Germline epimutation of <italic toggle="yes">MLH1</italic> in individuals with multiple cancers</article-title><source>Nat Genet</source><year>2004</year><volume>36</volume><fpage>497</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/ng1342</pub-id><pub-id pub-id-type="pmid">15064764</pub-id></element-citation><mixed-citation id="mc-CR269" publication-type="journal">Suter CM, Martin DI, Ward RL (2004) Germline epimutation of <italic toggle="yes">MLH1</italic> in individuals with multiple cancers. Nat Genet 36:497&#8211;501. 10.1038/ng1342<pub-id pub-id-type="pmid">15064764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng1342</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR270"><label>270.</label><citation-alternatives><element-citation id="ec-CR270" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hampel</surname><given-names>H</given-names></name><name name-style="western"><surname>Frankel</surname><given-names>WL</given-names></name><name name-style="western"><surname>Martin</surname><given-names>E</given-names></name><etal/></person-group><article-title>Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>1851</fpage><lpage>1860</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043146</pub-id><pub-id pub-id-type="pmid">15872200</pub-id></element-citation><mixed-citation id="mc-CR270" publication-type="journal">Hampel H, Frankel WL, Martin E et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352:1851&#8211;1860<pub-id pub-id-type="pmid">15872200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa043146</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR271"><label>271.</label><citation-alternatives><element-citation id="ec-CR271" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunlop</surname><given-names>MG</given-names></name><name name-style="western"><surname>Farrington</surname><given-names>SM</given-names></name><name name-style="western"><surname>Carothers</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Cancer risk associated with germline DNA mismatch repair gene mutations</article-title><source>Hum Mol Genet</source><year>1997</year><volume>6</volume><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1093/hmg/6.1.105</pub-id><pub-id pub-id-type="pmid">9002677</pub-id></element-citation><mixed-citation id="mc-CR271" publication-type="journal">Dunlop MG, Farrington SM, Carothers AD et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6:105&#8211;110. 10.1093/hmg/6.1.105<pub-id pub-id-type="pmid">9002677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/6.1.105</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR272"><label>272.</label><citation-alternatives><element-citation id="ec-CR272" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrow</surname><given-names>E</given-names></name><name name-style="western"><surname>Alduaij</surname><given-names>W</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations</article-title><source>Clin Genet</source><year>2008</year><volume>74</volume><fpage>233</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0004.2008.01035.x</pub-id><pub-id pub-id-type="pmid">18554281</pub-id></element-citation><mixed-citation id="mc-CR272" publication-type="journal">Barrow E, Alduaij W, Robinson L et al (2008) Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin Genet 74:233&#8211;242. 10.1111/j.1399-0004.2008.01035.x<pub-id pub-id-type="pmid">18554281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1399-0004.2008.01035.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR273"><label>273.</label><citation-alternatives><element-citation id="ec-CR273" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grover</surname><given-names>S</given-names></name><name name-style="western"><surname>Syngal</surname><given-names>S</given-names></name></person-group><article-title>Genetic testing in gastroenterology: Lynch syndrome</article-title><source>Best Pract Res Clin Gastroenterol</source><year>2009</year><volume>23</volume><fpage>185</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.bpg.2009.02.006</pub-id><pub-id pub-id-type="pmid">19414145</pub-id></element-citation><mixed-citation id="mc-CR273" publication-type="journal">Grover S, Syngal S (2009) Genetic testing in gastroenterology: Lynch syndrome. Best Pract Res Clin Gastroenterol 23:185&#8211;196. 10.1016/j.bpg.2009.02.006<pub-id pub-id-type="pmid">19414145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bpg.2009.02.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR274"><label>274.</label><citation-alternatives><element-citation id="ec-CR274" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yanaba</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Muir-Torre syndrome caused by partial duplication of <italic toggle="yes">MSH2</italic> gene by Alu-mediated nonhomologous recombination</article-title><source>Br J Dermatol</source><year>2008</year><volume>158</volume><fpage>150</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2007.08233.x</pub-id><pub-id pub-id-type="pmid">17941949</pub-id></element-citation><mixed-citation id="mc-CR274" publication-type="journal">Yanaba K, Nakagawa H, Takeda Y et al (2008) Muir-Torre syndrome caused by partial duplication of <italic toggle="yes">MSH2</italic> gene by Alu-mediated nonhomologous recombination. Br J Dermatol 158:150&#8211;156. 10.1111/j.1365-2133.2007.08233.x<pub-id pub-id-type="pmid">17941949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2007.08233.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR275"><label>275.</label><citation-alternatives><element-citation id="ec-CR275" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Win</surname><given-names>AK</given-names></name><name name-style="western"><surname>Young</surname><given-names>JP</given-names></name><name name-style="western"><surname>Lindor</surname><given-names>NM</given-names></name><etal/></person-group><article-title>Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>958</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.39.55</pub-id><pub-id pub-id-type="pmid">22331944</pub-id><pub-id pub-id-type="pmcid">PMC3341109</pub-id></element-citation><mixed-citation id="mc-CR275" publication-type="journal">Win AK, Young JP, Lindor NM et al (2012) Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 30:958&#8211;964. 10.1200/JCO.2011.39.55<pub-id pub-id-type="pmid">22331944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2011.39.5590</pub-id><pub-id pub-id-type="pmcid">PMC3341109</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR276"><label>276.</label><citation-alternatives><element-citation id="ec-CR276" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raymond</surname><given-names>VM</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Elevated risk of prostate cancer among men with Lynch syndrome</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>1713</fpage><lpage>1718</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.44.1238</pub-id><pub-id pub-id-type="pmid">23530095</pub-id><pub-id pub-id-type="pmcid">PMC3641694</pub-id></element-citation><mixed-citation id="mc-CR276" publication-type="journal">Raymond VM, Mukherjee B, Wang F et al (2013) Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol 31:1713&#8211;1718. 10.1200/JCO.2012.44.1238<pub-id pub-id-type="pmid">23530095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2012.44.1238</pub-id><pub-id pub-id-type="pmcid">PMC3641694</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR277"><label>277.</label><citation-alternatives><element-citation id="ec-CR277" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoffel</surname><given-names>E</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>B</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>VM</given-names></name><etal/></person-group><article-title>Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome</article-title><source>Gastroenterology</source><year>2009</year><volume>137</volume><fpage>1621</fpage><lpage>1627</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.07.039</pub-id><pub-id pub-id-type="pmid">19622357</pub-id><pub-id pub-id-type="pmcid">PMC2767441</pub-id></element-citation><mixed-citation id="mc-CR277" publication-type="journal">Stoffel E, Mukherjee B, Raymond VM et al (2009) Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137:1621&#8211;1627<pub-id pub-id-type="pmid">19622357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2009.07.039</pub-id><pub-id pub-id-type="pmcid">PMC2767441</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR278"><label>278.</label><citation-alternatives><element-citation id="ec-CR278" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrow</surname><given-names>E</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>L</given-names></name><name name-style="western"><surname>Alduaij</surname><given-names>W</given-names></name><etal/></person-group><article-title>Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations</article-title><source>Clin Genet</source><year>2009</year><volume>75</volume><fpage>141</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0004.2008.01125.x</pub-id><pub-id pub-id-type="pmid">19215248</pub-id></element-citation><mixed-citation id="mc-CR278" publication-type="journal">Barrow E, Robinson L, Alduaij W et al (2009) Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 75:141&#8211;149. 10.1111/j.1399-0004.2008.01125.x<pub-id pub-id-type="pmid">19215248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1399-0004.2008.01125.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR279"><label>279.</label><citation-alternatives><element-citation id="ec-CR279" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hampel</surname><given-names>H</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>JA</given-names></name><name name-style="western"><surname>Pukkala</surname><given-names>E</given-names></name><etal/></person-group><article-title>Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset</article-title><source>Gastroenterology</source><year>2005</year><volume>129</volume><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/j.gastro.2005.05.011</pub-id><pub-id pub-id-type="pmid">16083698</pub-id></element-citation><mixed-citation id="mc-CR279" publication-type="journal">Hampel H, Stephens JA, Pukkala E et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129:415&#8211;421<pub-id pub-id-type="pmid">16083698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gastro.2005.05.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR280"><label>280.</label><citation-alternatives><element-citation id="ec-CR280" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watson</surname><given-names>P</given-names></name><name name-style="western"><surname>Vasen</surname><given-names>HFA</given-names></name><name name-style="western"><surname>Mecklin</surname><given-names>JP</given-names></name><etal/></person-group><article-title>The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome</article-title><source>Int J Cancer</source><year>2008</year><volume>123</volume><fpage>444</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1002/ijc.23508</pub-id><pub-id pub-id-type="pmid">18398828</pub-id><pub-id pub-id-type="pmcid">PMC2627772</pub-id></element-citation><mixed-citation id="mc-CR280" publication-type="journal">Watson P, Vasen HFA, Mecklin JP et al (2008) The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 123:444&#8211;449. 10.1002/ijc.23508<pub-id pub-id-type="pmid">18398828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.23508</pub-id><pub-id pub-id-type="pmcid">PMC2627772</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR281"><label>281.</label><citation-alternatives><element-citation id="ec-CR281" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aarnio</surname><given-names>M</given-names></name><name name-style="western"><surname>Sankila</surname><given-names>R</given-names></name><name name-style="western"><surname>Pukkala</surname><given-names>E</given-names></name><etal/></person-group><article-title>Cancer risk in mutation carriers of DNA-mismatch-repair genes</article-title><source>Int J Cancer</source><year>1999</year><volume>81</volume><fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1097-0215(19990412)81:2&amp;#x0003c;214::AID-IJC8&amp;#x0003e;3.0.CO;2-L</pub-id><pub-id pub-id-type="pmid">10188721</pub-id></element-citation><mixed-citation id="mc-CR281" publication-type="journal">Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214&#8211;218<pub-id pub-id-type="pmid">10188721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(sici)1097-0215(19990412)81:2&lt;214::aid-ijc8&gt;3.0.co;2-l</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR282"><label>282.</label><citation-alternatives><element-citation id="ec-CR282" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kastrinos</surname><given-names>F</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>B</given-names></name><name name-style="western"><surname>Tayob</surname><given-names>N</given-names></name><etal/></person-group><article-title>Risk of pancreatic cancer in families with Lynch syndrome</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>1790</fpage><lpage>1795</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.1529</pub-id><pub-id pub-id-type="pmid">19861671</pub-id><pub-id pub-id-type="pmcid">PMC4091624</pub-id></element-citation><mixed-citation id="mc-CR282" publication-type="journal">Kastrinos F, Mukherjee B, Tayob N et al (2009) Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302:1790&#8211;1795<pub-id pub-id-type="pmid">19861671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2009.1529</pub-id><pub-id pub-id-type="pmcid">PMC4091624</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR283"><label>283.</label><mixed-citation publication-type="other">Kohlmann W, Gruber SB (2004) Lynch Syndrome. GeneReviews<sup>&#174;</sup>. Seattle: University of Washington, 1993&#8211;2019.</mixed-citation></ref><ref id="CR284"><label>284.</label><citation-alternatives><element-citation id="ec-CR284" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kempers</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kuiper</surname><given-names>RP</given-names></name><name name-style="western"><surname>Ockeloen</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study</article-title><source>Lancet Oncol</source><year>2011</year><volume>12</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(10)70265-5</pub-id><pub-id pub-id-type="pmid">21145788</pub-id><pub-id pub-id-type="pmcid">PMC3670774</pub-id></element-citation><mixed-citation id="mc-CR284" publication-type="journal">Kempers MJ, Kuiper RP, Ockeloen CW et al (2011) Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 12:49&#8211;55<pub-id pub-id-type="pmid">21145788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(10)70265-5</pub-id><pub-id pub-id-type="pmcid">PMC3670774</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR285"><label>285.</label><citation-alternatives><element-citation id="ec-CR285" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tutlewska</surname><given-names>K</given-names></name><name name-style="western"><surname>Lubinski</surname><given-names>J</given-names></name><name name-style="western"><surname>Kurzawski</surname><given-names>G</given-names></name></person-group><article-title>Germline deletions in the <italic toggle="yes">EPCAM</italic> gene as a cause of Lynch syndrome - literature review</article-title><source>Hered Cancer Clin Pract</source><year>2013</year><volume>11</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/1897-4287-11-9</pub-id><pub-id pub-id-type="pmid">23938213</pub-id><pub-id pub-id-type="pmcid">PMC3765447</pub-id></element-citation><mixed-citation id="mc-CR285" publication-type="journal">Tutlewska K, Lubinski J, Kurzawski G (2013) Germline deletions in the <italic toggle="yes">EPCAM</italic> gene as a cause of Lynch syndrome - literature review. Hered Cancer Clin Pract 11:9<pub-id pub-id-type="pmid">23938213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1897-4287-11-9</pub-id><pub-id pub-id-type="pmcid">PMC3765447</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR286"><label>286.</label><citation-alternatives><element-citation id="ec-CR286" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuiper</surname><given-names>RP</given-names></name><name name-style="western"><surname>Vissers</surname><given-names>LE</given-names></name><name name-style="western"><surname>Venkatachalam</surname><given-names>R</given-names></name><etal/></person-group><article-title>Recurrence and variability of germline EPCAM deletions in Lynch syndrome</article-title><source>Hum Mutat</source><year>2011</year><volume>32</volume><fpage>407</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1002/humu.21446</pub-id><pub-id pub-id-type="pmid">21309036</pub-id></element-citation><mixed-citation id="mc-CR286" publication-type="journal">Kuiper RP, Vissers LE, Venkatachalam R et al (2011) Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat 32:407&#8211;414. 10.1002/humu.21446<pub-id pub-id-type="pmid">21309036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/humu.21446</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR287"><label>287.</label><citation-alternatives><element-citation id="ec-CR287" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Win</surname><given-names>AK</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>MA</given-names></name><name name-style="western"><surname>Dowty</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Prevalence and penetrance of major genes and polygenes for colorectal cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2017</year><volume>26</volume><fpage>404</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-16-0693</pub-id><pub-id pub-id-type="pmid">27799157</pub-id><pub-id pub-id-type="pmcid">PMC5336409</pub-id></element-citation><mixed-citation id="mc-CR287" publication-type="journal">Win AK, Jenkins MA, Dowty JG et al (2017) Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomarkers Prev 26:404&#8211;412<pub-id pub-id-type="pmid">27799157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-16-0693</pub-id><pub-id pub-id-type="pmcid">PMC5336409</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR288"><label>288.</label><citation-alternatives><element-citation id="ec-CR288" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenblum</surname><given-names>RE</given-names></name><name name-style="western"><surname>Ang</surname><given-names>C</given-names></name><name name-style="western"><surname>Suckiel</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Lynch syndrome-associated variants and cancer rates in an ancestrally diverse biobank</article-title><source>JCO Precis Oncol</source><year>2020</year><volume>1</volume><fpage>1429</fpage><lpage>1444</lpage><pub-id pub-id-type="doi">10.1200/PO.20.00290</pub-id><pub-id pub-id-type="pmcid">PMC7713527</pub-id><pub-id pub-id-type="pmid">33283134</pub-id></element-citation><mixed-citation id="mc-CR288" publication-type="journal">Rosenblum RE, Ang C, Suckiel SA et al (2020) Lynch syndrome-associated variants and cancer rates in an ancestrally diverse biobank. JCO Precis Oncol 1:1429&#8211;1444<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.20.00290</pub-id><pub-id pub-id-type="pmcid">PMC7713527</pub-id><pub-id pub-id-type="pmid">33283134</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR289"><label>289.</label><citation-alternatives><element-citation id="ec-CR289" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>AP</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Fahed</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Association of rare pathogenic DNA variants for familial hypercholesterolemia, hereditary breast and ovarian cancer syndrome, and Lynch syndrome with disease risk in adults according to family history</article-title><source>JAMA Netw Open</source><year>2020</year><volume>3</volume><fpage>e203959</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.3959</pub-id><pub-id pub-id-type="pmid">32347951</pub-id><pub-id pub-id-type="pmcid">PMC7292735</pub-id></element-citation><mixed-citation id="mc-CR289" publication-type="journal">Patel AP, Wang M, Fahed AC et al (2020) Association of rare pathogenic DNA variants for familial hypercholesterolemia, hereditary breast and ovarian cancer syndrome, and Lynch syndrome with disease risk in adults according to family history. JAMA Netw Open 3:e203959<pub-id pub-id-type="pmid">32347951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.3959</pub-id><pub-id pub-id-type="pmcid">PMC7292735</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR290"><label>290.</label><citation-alternatives><element-citation id="ec-CR290" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canard</surname><given-names>G</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>JH</given-names></name><name name-style="western"><surname>Colas</surname><given-names>C</given-names></name><etal/></person-group><article-title>Screening for Lynch syndrome in colorectal cancer: are we doing enough?</article-title><source>Ann Surg Oncol</source><year>2012</year><volume>19</volume><fpage>809</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1245/s10434-011-2014-7</pub-id><pub-id pub-id-type="pmid">21879275</pub-id></element-citation><mixed-citation id="mc-CR290" publication-type="journal">Canard G, Lefevre JH, Colas C et al (2012) Screening for Lynch syndrome in colorectal cancer: are we doing enough? Ann Surg Oncol 19:809&#8211;816. 10.1245/s10434-011-2014-7<pub-id pub-id-type="pmid">21879275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-011-2014-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR291"><label>291.</label><citation-alternatives><element-citation id="ec-CR291" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juli&#233;</surname><given-names>C</given-names></name><name name-style="western"><surname>Tr&#233;sallet</surname><given-names>C</given-names></name><name name-style="western"><surname>Brouquet</surname><given-names>A</given-names></name><etal/></person-group><article-title>Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening</article-title><source>Am J Gastroenterol</source><year>2008</year><volume>103</volume><fpage>2825</fpage><lpage>2835</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2008.02084.x</pub-id><pub-id pub-id-type="pmid">18759827</pub-id></element-citation><mixed-citation id="mc-CR291" publication-type="journal">Juli&#233; C, Tr&#233;sallet C, Brouquet A et al (2008) Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol 103:2825&#8211;2835<pub-id pub-id-type="pmid">18759827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1572-0241.2008.02084.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR292"><label>292.</label><citation-alternatives><element-citation id="ec-CR292" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujita</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Population-based screening for hereditary colorectal cancer variants in Japan</article-title><source>Clin Gastroenterol Hepatol</source><year>2022</year><volume>20</volume><fpage>2132</fpage><lpage>2141.e9</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2020.12.007</pub-id><pub-id pub-id-type="pmid">33309985</pub-id></element-citation><mixed-citation id="mc-CR292" publication-type="journal">Fujita M, Liu X, Iwasaki Y et al (2022) Population-based screening for hereditary colorectal cancer variants in Japan. Clin Gastroenterol Hepatol 20:2132-2141.e9<pub-id pub-id-type="pmid">33309985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2020.12.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR293"><label>293.</label><citation-alternatives><element-citation id="ec-CR293" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chika</surname><given-names>N</given-names></name><name name-style="western"><surname>Eguchi</surname><given-names>H</given-names></name><name name-style="western"><surname>Kumamoto</surname><given-names>K</given-names></name><etal/></person-group><article-title>Prevalence of Lynch syndrome and Lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population</article-title><source>Jpn J Clin Oncol</source><year>2017</year><volume>47</volume><fpage>108</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyw178</pub-id><pub-id pub-id-type="pmid">27920101</pub-id></element-citation><mixed-citation id="mc-CR293" publication-type="journal">Chika N, Eguchi H, Kumamoto K et al (2017) Prevalence of Lynch syndrome and Lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population. Jpn J Clin Oncol 47:108&#8211;117. 10.1093/jjco/hyw178<pub-id pub-id-type="pmid">27920101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jjco/hyw178</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR294"><label>294.</label><citation-alternatives><element-citation id="ec-CR294" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasen</surname><given-names>HF</given-names></name><name name-style="western"><surname>Watson</surname><given-names>P</given-names></name><name name-style="western"><surname>Mecklin</surname><given-names>JP</given-names></name><etal/></person-group><article-title>New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC</article-title><source>Gastroenterology</source><year>1999</year><volume>116</volume><fpage>1453</fpage><lpage>1456</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(99)70510-X</pub-id><pub-id pub-id-type="pmid">10348829</pub-id></element-citation><mixed-citation id="mc-CR294" publication-type="journal">Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453&#8211;1456<pub-id pub-id-type="pmid">10348829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0016-5085(99)70510-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR295"><label>295.</label><citation-alternatives><element-citation id="ec-CR295" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Umar</surname><given-names>A</given-names></name><name name-style="western"><surname>Boland</surname><given-names>CR</given-names></name><name name-style="western"><surname>Terdiman</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability</article-title><source>J Natl Cancer Inst</source><year>2004</year><volume>96</volume><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1093/jnci/djh034</pub-id><pub-id pub-id-type="pmid">14970275</pub-id><pub-id pub-id-type="pmcid">PMC2933058</pub-id></element-citation><mixed-citation id="mc-CR295" publication-type="journal">Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261&#8211;268<pub-id pub-id-type="pmid">14970275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djh034</pub-id><pub-id pub-id-type="pmcid">PMC2933058</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR296"><label>296.</label><citation-alternatives><element-citation id="ec-CR296" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blaker</surname><given-names>H</given-names></name><name name-style="western"><surname>Haupt</surname><given-names>S</given-names></name><name name-style="western"><surname>Morak</surname><given-names>M</given-names></name><etal/></person-group><article-title>Age-dependent performance of BRAF mutation testing in Lynch syndrome diagnostics</article-title><source>Int J Cancer</source><year>2020</year><volume>147</volume><fpage>2801</fpage><lpage>2810</lpage><pub-id pub-id-type="doi">10.1002/ijc.33273</pub-id><pub-id pub-id-type="pmid">32875553</pub-id></element-citation><mixed-citation id="mc-CR296" publication-type="journal">Blaker H, Haupt S, Morak M et al (2020) Age-dependent performance of BRAF mutation testing in Lynch syndrome diagnostics. Int J Cancer 147:2801&#8211;2810. 10.1002/ijc.33273<pub-id pub-id-type="pmid">32875553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.33273</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR297"><label>297.</label><citation-alternatives><element-citation id="ec-CR297" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ladabaum</surname><given-names>U</given-names></name><name name-style="western"><surname>Ford</surname><given-names>JM</given-names></name><name name-style="western"><surname>Martel</surname><given-names>M</given-names></name><etal/></person-group><article-title>American Gastroenterological Association Technical Review on the diagnosis and management of Lynch syndrome</article-title><source>Gastroenterology</source><year>2015</year><volume>149</volume><issue>783&#8211;813</issue><fpage>e20</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2015.07.037</pub-id><pub-id pub-id-type="pmid">26226576</pub-id></element-citation><mixed-citation id="mc-CR297" publication-type="journal">Ladabaum U, Ford JM, Martel M et al (2015) American Gastroenterological Association Technical Review on the diagnosis and management of Lynch syndrome. Gastroenterology 149(783&#8211;813):e20<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2015.07.037</pub-id><pub-id pub-id-type="pmid">26226576</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR298"><label>298.</label><citation-alternatives><element-citation id="ec-CR298" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreira</surname><given-names>L</given-names></name><name name-style="western"><surname>Balaguer</surname><given-names>F</given-names></name><name name-style="western"><surname>Lindor</surname><given-names>N</given-names></name><etal/></person-group><article-title>Identification of Lynch syndrome among patients with colorectal cancer</article-title><source>JAMA</source><year>2012</year><volume>308</volume><fpage>1555</fpage><lpage>1565</lpage><pub-id pub-id-type="doi">10.1001/jama.2012.13088</pub-id><pub-id pub-id-type="pmid">23073952</pub-id><pub-id pub-id-type="pmcid">PMC3873721</pub-id></element-citation><mixed-citation id="mc-CR298" publication-type="journal">Moreira L, Balaguer F, Lindor N et al (2012) Identification of Lynch syndrome among patients with colorectal cancer. JAMA 308:1555&#8211;1565<pub-id pub-id-type="pmid">23073952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2012.13088</pub-id><pub-id pub-id-type="pmcid">PMC3873721</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR299"><label>299.</label><citation-alternatives><element-citation id="ec-CR299" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Cai</surname><given-names>MY</given-names></name><name name-style="western"><surname>Li</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features</article-title><source>Int J Cancer</source><year>2019</year><volume>144</volume><fpage>2161</fpage><lpage>2168</lpage><pub-id pub-id-type="doi">10.1002/ijc.32044</pub-id><pub-id pub-id-type="pmid">30521064</pub-id></element-citation><mixed-citation id="mc-CR299" publication-type="journal">Jiang W, Cai MY, Li SY et al (2019) Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. Int J Cancer 144:2161&#8211;2168<pub-id pub-id-type="pmid">30521064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.32044</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR300"><label>300.</label><citation-alternatives><element-citation id="ec-CR300" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sjursen</surname><given-names>W</given-names></name><name name-style="western"><surname>Haukanes</surname><given-names>BI</given-names></name><name name-style="western"><surname>Grindedal</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Current clinical criteria for Lynch syndrome are not sensitive enough to identify <italic toggle="yes">MSH6</italic> mutation carriers</article-title><source>J Med Genet</source><year>2010</year><volume>47</volume><fpage>579</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1136/jmg.2010.077677</pub-id><pub-id pub-id-type="pmid">20587412</pub-id><pub-id pub-id-type="pmcid">PMC2976029</pub-id></element-citation><mixed-citation id="mc-CR300" publication-type="journal">Sjursen W, Haukanes BI, Grindedal EM et al (2010) Current clinical criteria for Lynch syndrome are not sensitive enough to identify <italic toggle="yes">MSH6</italic> mutation carriers. J Med Genet 47:579&#8211;585<pub-id pub-id-type="pmid">20587412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmg.2010.077677</pub-id><pub-id pub-id-type="pmcid">PMC2976029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR301"><label>301.</label><citation-alternatives><element-citation id="ec-CR301" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furukawa</surname><given-names>Y</given-names></name></person-group><article-title>Review of hereditary colorectal cancer [HNPCC]&#8212;current state in Japan</article-title><source>Front Colorectal Cancer</source><year>2010</year><volume>3</volume><fpage>120</fpage><lpage>124</lpage></element-citation><mixed-citation id="mc-CR301" publication-type="journal">Furukawa Y (2010) Review of hereditary colorectal cancer [HNPCC]&#8212;current state in Japan. Front Colorectal Cancer 3:120&#8211;124</mixed-citation></citation-alternatives></ref><ref id="CR302"><label>302.</label><citation-alternatives><element-citation id="ec-CR302" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pi&#241;ol</surname><given-names>V</given-names></name><name name-style="western"><surname>Castells</surname><given-names>A</given-names></name><name name-style="western"><surname>Andreu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer</article-title><source>JAMA</source><year>2005</year><volume>293</volume><fpage>1986</fpage><lpage>1894</lpage><pub-id pub-id-type="doi">10.1001/jama.293.16.1986</pub-id><pub-id pub-id-type="pmid">15855432</pub-id></element-citation><mixed-citation id="mc-CR302" publication-type="journal">Pi&#241;ol V, Castells A, Andreu M et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293:1986&#8211;1894<pub-id pub-id-type="pmid">15855432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.293.16.1986</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR304"><label>304.</label><citation-alternatives><element-citation id="ec-CR304" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenkins</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>S</given-names></name><name name-style="western"><surname>O'Shea</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study</article-title><source>Gastroenterology</source><year>2007</year><volume>133</volume><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2007.04.044</pub-id><pub-id pub-id-type="pmid">17631130</pub-id><pub-id pub-id-type="pmcid">PMC2933045</pub-id></element-citation><mixed-citation id="mc-CR304" publication-type="journal">Jenkins MA, Hayashi S, O&#8217;Shea AM et al (2007) Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 133:48&#8211;56<pub-id pub-id-type="pmid">17631130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2007.04.044</pub-id><pub-id pub-id-type="pmcid">PMC2933045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR305"><label>305.</label><citation-alternatives><element-citation id="ec-CR305" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekine</surname><given-names>S</given-names></name><name name-style="western"><surname>Mori</surname><given-names>T</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>R</given-names></name><etal/></person-group><article-title>Mismatch repair deficiency commonly precedes adenoma formation in Lynch Syndrome-Associated colorectal tumorigenesis</article-title><source>Mod Pathol</source><year>2017</year><volume>30</volume><fpage>1144</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2017.39</pub-id><pub-id pub-id-type="pmid">28548127</pub-id></element-citation><mixed-citation id="mc-CR305" publication-type="journal">Sekine S, Mori T, Ogawa R et al (2017) Mismatch repair deficiency commonly precedes adenoma formation in Lynch Syndrome-Associated colorectal tumorigenesis. Mod Pathol 30:1144&#8211;1151<pub-id pub-id-type="pmid">28548127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/modpathol.2017.39</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR306"><label>306.</label><citation-alternatives><element-citation id="ec-CR306" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aaltonen</surname><given-names>LA</given-names></name><name name-style="western"><surname>Peltomaki</surname><given-names>P</given-names></name><name name-style="western"><surname>Mecklin</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>1645</fpage><lpage>1648</lpage><pub-id pub-id-type="pmid">8137274</pub-id></element-citation><mixed-citation id="mc-CR306" publication-type="journal">Aaltonen LA, Peltomaki P, Mecklin JP et al (1994) Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 54:1645&#8211;1648<pub-id pub-id-type="pmid">8137274</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR307"><label>307.</label><citation-alternatives><element-citation id="ec-CR307" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aaltonen</surname><given-names>LA</given-names></name><name name-style="western"><surname>Salovaara</surname><given-names>R</given-names></name><name name-style="western"><surname>Kristo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>1481</fpage><lpage>1487</lpage><pub-id pub-id-type="doi">10.1056/NEJM199805213382101</pub-id><pub-id pub-id-type="pmid">9593786</pub-id></element-citation><mixed-citation id="mc-CR307" publication-type="journal">Aaltonen LA, Salovaara R, Kristo P et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338:1481&#8211;1487<pub-id pub-id-type="pmid">9593786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM199805213382101</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR308"><label>308.</label><citation-alternatives><element-citation id="ec-CR308" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peltom&#228;ki</surname><given-names>P</given-names></name></person-group><article-title>Role of DNA mismatch repair defects in the pathogenesis of human cancer</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>1174</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.04.060</pub-id><pub-id pub-id-type="pmid">12637487</pub-id></element-citation><mixed-citation id="mc-CR308" publication-type="journal">Peltom&#228;ki P (2003) Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 21:1174&#8211;1179. 10.1200/JCO.2003.04.060<pub-id pub-id-type="pmid">12637487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2003.04.060</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR309"><label>309.</label><citation-alternatives><element-citation id="ec-CR309" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishikubo</surname><given-names>T</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>K</given-names></name><etal/></person-group><article-title>The clinical features of rectal cancers with high-frequency micro-satellite instability (MSI-H) in Japanese males</article-title><source>Cancer Lett</source><year>2004</year><volume>216</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2004.07.017</pub-id><pub-id pub-id-type="pmid">15500949</pub-id></element-citation><mixed-citation id="mc-CR309" publication-type="journal">Ishikubo T, Nishimura Y, Yamaguchi K et al (2004) The clinical features of rectal cancers with high-frequency micro-satellite instability (MSI-H) in Japanese males. Cancer Lett 216:55&#8211;62. 10.1016/j.canlet.2004.07.017<pub-id pub-id-type="pmid">15500949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2004.07.017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR310"><label>310.</label><citation-alternatives><element-citation id="ec-CR310" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asaka</surname><given-names>S</given-names></name><name name-style="western"><surname>Arai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes&#700; A to Dukes&#700; B</article-title><source>Carcinogenesis</source><year>2009</year><volume>30</volume><fpage>494</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgp017</pub-id><pub-id pub-id-type="pmid">19147861</pub-id></element-citation><mixed-citation id="mc-CR310" publication-type="journal">Asaka S, Arai Y, Nishimura Y et al (2009) Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes&#700; A to Dukes&#700; B. Carcinogenesis 30:494&#8211;499<pub-id pub-id-type="pmid">19147861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgp017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR311"><label>311.</label><citation-alternatives><element-citation id="ec-CR311" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loughrey</surname><given-names>MB</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>J</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>HG</given-names></name><etal/></person-group><article-title>Identifying mismatch repair-deficient colon cancer: near-perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population-based series</article-title><source>Histopathology</source><year>2021</year><volume>78</volume><fpage>401</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1111/his.14233</pub-id><pub-id pub-id-type="pmid">32791559</pub-id></element-citation><mixed-citation id="mc-CR311" publication-type="journal">Loughrey MB, McGrath J, Coleman HG et al (2021) Identifying mismatch repair-deficient colon cancer: near-perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population-based series. Histopathology 78:401&#8211;413. 10.1111/his.14233<pub-id pub-id-type="pmid">32791559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/his.14233</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR312"><label>312.</label><citation-alternatives><element-citation id="ec-CR312" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shia</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>LH</given-names></name><name name-style="western"><surname>Vakiani</surname><given-names>E</given-names></name><etal/></person-group><article-title>Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel</article-title><source>Am J Surg Pathol</source><year>2009</year><volume>33</volume><fpage>1639</fpage><lpage>1645</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e3181b15aa2</pub-id><pub-id pub-id-type="pmid">19701074</pub-id></element-citation><mixed-citation id="mc-CR312" publication-type="journal">Shia J, Tang LH, Vakiani E et al (2009) Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol 33:1639&#8211;1645<pub-id pub-id-type="pmid">19701074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PAS.0b013e3181b15aa2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR313"><label>313.</label><citation-alternatives><element-citation id="ec-CR313" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shia</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Shike</surname><given-names>M</given-names></name><etal/></person-group><article-title>Secondary mutation in a coding mononucleotide tract in <italic toggle="yes">MSH6</italic> causes loss of immunoexpression of <italic toggle="yes">MSH6</italic> in colorectal carcinomas with <italic toggle="yes">MLH1</italic>/<italic toggle="yes">PMS2</italic> deficiency</article-title><source>Mod Pathol</source><year>2013</year><volume>26</volume><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2012.138</pub-id><pub-id pub-id-type="pmid">22918162</pub-id><pub-id pub-id-type="pmcid">PMC3793326</pub-id></element-citation><mixed-citation id="mc-CR313" publication-type="journal">Shia J, Zhang L, Shike M et al (2013) Secondary mutation in a coding mononucleotide tract in <italic toggle="yes">MSH6</italic> causes loss of immunoexpression of <italic toggle="yes">MSH6</italic> in colorectal carcinomas with <italic toggle="yes">MLH1</italic>/<italic toggle="yes">PMS2</italic> deficiency. Mod Pathol 26:131&#8211;138<pub-id pub-id-type="pmid">22918162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/modpathol.2012.138</pub-id><pub-id pub-id-type="pmcid">PMC3793326</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR314"><label>314.</label><citation-alternatives><element-citation id="ec-CR314" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adar</surname><given-names>T</given-names></name><name name-style="western"><surname>Rodgers</surname><given-names>LH</given-names></name><name name-style="western"><surname>Shannon</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome</article-title><source>Cancer</source><year>2018</year><volume>124</volume><fpage>3145</fpage><lpage>3153</lpage><pub-id pub-id-type="doi">10.1002/cncr.31534</pub-id><pub-id pub-id-type="pmid">29750335</pub-id></element-citation><mixed-citation id="mc-CR314" publication-type="journal">Adar T, Rodgers LH, Shannon KM et al (2018) Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome. Cancer 124:3145&#8211;3153<pub-id pub-id-type="pmid">29750335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.31534</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR315"><label>315.</label><citation-alternatives><element-citation id="ec-CR315" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasen</surname><given-names>HF</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>I</given-names></name><name name-style="western"><surname>Aktan-Collan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts</article-title><source>Gut</source><year>2013</year><volume>62</volume><fpage>812</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2012-304356</pub-id><pub-id pub-id-type="pmid">23408351</pub-id><pub-id pub-id-type="pmcid">PMC3647358</pub-id></element-citation><mixed-citation id="mc-CR315" publication-type="journal">Vasen HF, Blanco I, Aktan-Collan K et al (2013) Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62:812&#8211;823<pub-id pub-id-type="pmid">23408351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2012-304356</pub-id><pub-id pub-id-type="pmcid">PMC3647358</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR316"><label>316.</label><citation-alternatives><element-citation id="ec-CR316" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giardiello</surname><given-names>FM</given-names></name><name name-style="western"><surname>Allen</surname><given-names>JI</given-names></name><name name-style="western"><surname>Axilbund</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer</article-title><source>Gastroenterology</source><year>2014</year><volume>147</volume><fpage>502</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2014.04.001</pub-id><pub-id pub-id-type="pmid">25043945</pub-id></element-citation><mixed-citation id="mc-CR316" publication-type="journal">Giardiello FM, Allen JI, Axilbund JE et al (2014) Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 147:502&#8211;526<pub-id pub-id-type="pmid">25043945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2014.04.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR317"><label>317.</label><citation-alternatives><element-citation id="ec-CR317" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kane</surname><given-names>MF</given-names></name><name name-style="western"><surname>Loda</surname><given-names>M</given-names></name><name name-style="western"><surname>Gaida</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>808</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">9041175</pub-id></element-citation><mixed-citation id="mc-CR317" publication-type="journal">Kane MF, Loda M, Gaida GM et al (1997) Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57:808&#8211;811<pub-id pub-id-type="pmid">9041175</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR318"><label>318.</label><citation-alternatives><element-citation id="ec-CR318" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adar</surname><given-names>T</given-names></name><name name-style="western"><surname>Rodgers</surname><given-names>LH</given-names></name><name name-style="western"><surname>Shannon</surname><given-names>KM</given-names></name><etal/></person-group><article-title>A tailored approach to <italic toggle="yes">BRAF</italic> and <italic toggle="yes">MLH1</italic> methylation testing in a universal screening program for Lynch syndrome</article-title><source>Mod Pathol</source><year>2017</year><volume>30</volume><fpage>440</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2016.211</pub-id><pub-id pub-id-type="pmid">28059100</pub-id></element-citation><mixed-citation id="mc-CR318" publication-type="journal">Adar T, Rodgers LH, Shannon KM et al (2017) A tailored approach to <italic toggle="yes">BRAF</italic> and <italic toggle="yes">MLH1</italic> methylation testing in a universal screening program for Lynch syndrome. Mod Pathol 30:440&#8211;447<pub-id pub-id-type="pmid">28059100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/modpathol.2016.211</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR319"><label>319.</label><citation-alternatives><element-citation id="ec-CR319" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spier</surname><given-names>I</given-names></name><name name-style="western"><surname>Holzapfel</surname><given-names>S</given-names></name><name name-style="western"><surname>Altmuller</surname><given-names>J</given-names></name><etal/></person-group><article-title>Frequency and phenotypic spectrum of germline mutations in <italic toggle="yes">POLE</italic> and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas</article-title><source>Int J Cancer</source><year>2015</year><volume>137</volume><fpage>320</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1002/ijc.29396</pub-id><pub-id pub-id-type="pmid">25529843</pub-id></element-citation><mixed-citation id="mc-CR319" publication-type="journal">Spier I, Holzapfel S, Altmuller J et al (2015) Frequency and phenotypic spectrum of germline mutations in <italic toggle="yes">POLE</italic> and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer 137:320&#8211;331. 10.1002/ijc.29396<pub-id pub-id-type="pmid">25529843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.29396</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR320"><label>320.</label><citation-alternatives><element-citation id="ec-CR320" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#237;guez-Soler</surname><given-names>M</given-names></name><name name-style="western"><surname>P&#233;rez-Carbonell</surname><given-names>L</given-names></name><name name-style="western"><surname>Guarinos</surname><given-names>C</given-names></name><etal/></person-group><article-title>Risk of cancer in cases of suspected lynch syndrome without germline mutation</article-title><source>Gastroenterology</source><year>2013</year><volume>144</volume><issue>926&#8211;932</issue><fpage>E1</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2013.01.044</pub-id><pub-id pub-id-type="pmid">23354017</pub-id></element-citation><mixed-citation id="mc-CR320" publication-type="journal">Rodr&#237;guez-Soler M, P&#233;rez-Carbonell L, Guarinos C et al (2013) Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology 144(926&#8211;932):E1<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2013.01.044</pub-id><pub-id pub-id-type="pmid">23354017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR321"><label>321.</label><citation-alternatives><element-citation id="ec-CR321" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carethers</surname><given-names>JM</given-names></name></person-group><article-title>Differentiating Lynch-like from Lynch syndrome</article-title><source>Gastroenterology</source><year>2014</year><volume>146</volume><fpage>602</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2014.01.041</pub-id><pub-id pub-id-type="pmid">24468183</pub-id><pub-id pub-id-type="pmcid">PMC4134259</pub-id></element-citation><mixed-citation id="mc-CR321" publication-type="journal">Carethers JM (2014) Differentiating Lynch-like from Lynch syndrome. Gastroenterology 146:602&#8211;604<pub-id pub-id-type="pmid">24468183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2014.01.041</pub-id><pub-id pub-id-type="pmcid">PMC4134259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR322"><label>322.</label><citation-alternatives><element-citation id="ec-CR322" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wimmer</surname><given-names>K</given-names></name><name name-style="western"><surname>Kratz</surname><given-names>CP</given-names></name><name name-style="western"><surname>Vasen</surname><given-names>HF</given-names></name><etal/></person-group><article-title>Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium&#699;care for CMMRD (&#700;C4CMMRD)</article-title><source>J Med Genet</source><year>2014</year><volume>51</volume><fpage>355</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2014-102284</pub-id><pub-id pub-id-type="pmid">24737826</pub-id></element-citation><mixed-citation id="mc-CR322" publication-type="journal">Wimmer K, Kratz CP, Vasen HF et al (2014) Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium&#699;care for CMMRD (&#700;C4CMMRD). J Med Genet 51:355&#8211;365<pub-id pub-id-type="pmid">24737826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmedgenet-2014-102284</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR323"><label>323.</label><citation-alternatives><element-citation id="ec-CR323" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hizuka</surname><given-names>K</given-names></name><name name-style="western"><surname>Hagiwara</surname><given-names>SI</given-names></name><name name-style="western"><surname>Maeyama</surname><given-names>T</given-names></name><etal/></person-group><article-title>Constitutional mismatch repair deficiency in childhood colorectal cancer harboring a de novo variant in the <italic toggle="yes">MSH6</italic> gene: a case report</article-title><source>BMC Gastroenterol</source><year>2021</year><volume>21</volume><fpage>60</fpage><pub-id pub-id-type="doi">10.1186/s12876-021-01646-3</pub-id><pub-id pub-id-type="pmid">33568103</pub-id><pub-id pub-id-type="pmcid">PMC7876783</pub-id></element-citation><mixed-citation id="mc-CR323" publication-type="journal">Hizuka K, Hagiwara SI, Maeyama T et al (2021) Constitutional mismatch repair deficiency in childhood colorectal cancer harboring a de novo variant in the <italic toggle="yes">MSH6</italic> gene: a case report. BMC Gastroenterol 21:60. 10.1186/s12876-021-01646-3<pub-id pub-id-type="pmid">33568103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12876-021-01646-3</pub-id><pub-id pub-id-type="pmcid">PMC7876783</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR324"><label>324.</label><mixed-citation publication-type="other">Pediatric Chronic Specific Disease Information Center: PMS2 Deficiency. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.shouman.jp/disease/details/10_02_016/">https://www.shouman.jp/disease/details/10_02_016/</ext-link> (Accessed April 1, 2024).</mixed-citation></ref><ref id="CR325"><label>325.</label><citation-alternatives><element-citation id="ec-CR325" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durno</surname><given-names>C</given-names></name><name name-style="western"><surname>Ercan</surname><given-names>AB</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>V</given-names></name><etal/></person-group><article-title>Survival benefit for individuals with constitutional mismatch repair deficiency undergoing surveillance</article-title><source>J Clin Oncol</source><year>2021</year><volume>39</volume><fpage>2779</fpage><lpage>2790</lpage><pub-id pub-id-type="doi">10.1200/JCO.20.02636</pub-id><pub-id pub-id-type="pmid">33945292</pub-id><pub-id pub-id-type="pmcid">PMC8407605</pub-id></element-citation><mixed-citation id="mc-CR325" publication-type="journal">Durno C, Ercan AB, Bianchi V et al (2021) Survival benefit for individuals with constitutional mismatch repair deficiency undergoing surveillance. J Clin Oncol 39:2779&#8211;2790<pub-id pub-id-type="pmid">33945292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.20.02636</pub-id><pub-id pub-id-type="pmcid">PMC8407605</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR326"><label>326.</label><citation-alternatives><element-citation id="ec-CR326" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durno</surname><given-names>C</given-names></name><name name-style="western"><surname>Boland</surname><given-names>CR</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: A consensus statement by the US Multi-Society Task Force on colorectal cancer</article-title><source>Gastroenterology</source><year>2017</year><volume>152</volume><fpage>1605</fpage><lpage>1614</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2017.02.011</pub-id><pub-id pub-id-type="pmid">28363489</pub-id></element-citation><mixed-citation id="mc-CR326" publication-type="journal">Durno C, Boland CR, Cohen S et al (2017) Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: A consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 152:1605&#8211;1614<pub-id pub-id-type="pmid">28363489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2017.02.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR327"><label>327.</label><citation-alternatives><element-citation id="ec-CR327" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasen</surname><given-names>HF</given-names></name><name name-style="western"><surname>Mecklin</surname><given-names>JP</given-names></name><name name-style="western"><surname>Khan</surname><given-names>PM</given-names></name><etal/></person-group><article-title>The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC)</article-title><source>Dis Colon Rectum</source><year>1991</year><volume>34</volume><fpage>424</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1007/BF02053699</pub-id><pub-id pub-id-type="pmid">2022152</pub-id></element-citation><mixed-citation id="mc-CR327" publication-type="journal">Vasen HF, Mecklin JP, Khan PM et al (1991) The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34:424&#8211;425<pub-id pub-id-type="pmid">2022152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02053699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR328"><label>328.</label><citation-alternatives><element-citation id="ec-CR328" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindor</surname><given-names>NM</given-names></name><name name-style="western"><surname>Rabe</surname><given-names>K</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X</article-title><source>JAMA</source><year>2005</year><volume>293</volume><fpage>1979</fpage><lpage>1985</lpage><pub-id pub-id-type="doi">10.1001/jama.293.16.1979</pub-id><pub-id pub-id-type="pmid">15855431</pub-id><pub-id pub-id-type="pmcid">PMC2933042</pub-id></element-citation><mixed-citation id="mc-CR328" publication-type="journal">Lindor NM, Rabe K, Petersen GM et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293:1979&#8211;1985<pub-id pub-id-type="pmid">15855431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.293.16.1979</pub-id><pub-id pub-id-type="pmcid">PMC2933042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR329"><label>329.</label><citation-alternatives><element-citation id="ec-CR329" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamaguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Furukawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Comparison of clinical features between suspected familial colorectal cancer type X and Lynch syndrome in Japanese patients with colorectal cancer: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum</article-title><source>Jpn J Clin Oncol</source><year>2015</year><volume>45</volume><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyu190</pub-id><pub-id pub-id-type="pmid">25404568</pub-id></element-citation><mixed-citation id="mc-CR329" publication-type="journal">Yamaguchi T, Furukawa Y, Nakamura Y et al (2015) Comparison of clinical features between suspected familial colorectal cancer type X and Lynch syndrome in Japanese patients with colorectal cancer: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. Jpn J Clin Oncol 45:153&#8211;159<pub-id pub-id-type="pmid">25404568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jjco/hyu190</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR330"><label>330.</label><citation-alternatives><element-citation id="ec-CR330" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatamori</surname><given-names>H</given-names></name><name name-style="western"><surname>Chino</surname><given-names>A</given-names></name><name name-style="western"><surname>Arai</surname><given-names>M</given-names></name><etal/></person-group><article-title>Malignant potential of colorectal neoplasms in Lynch syndrome: an analysis of 325 lesions endoscopically treated at a single institute</article-title><source>Jpn J Clin Oncol</source><year>2021</year><volume>51</volume><fpage>737</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyab010</pub-id><pub-id pub-id-type="pmid">33558893</pub-id></element-citation><mixed-citation id="mc-CR330" publication-type="journal">Hatamori H, Chino A, Arai M et al (2021) Malignant potential of colorectal neoplasms in Lynch syndrome: an analysis of 325 lesions endoscopically treated at a single institute. Jpn J Clin Oncol 51:737&#8211;743<pub-id pub-id-type="pmid">33558893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jjco/hyab010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR331"><label>331.</label><citation-alternatives><element-citation id="ec-CR331" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jass</surname><given-names>JR</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>SM</given-names></name></person-group><article-title>Evolution of hereditary non-polyposis colorectal cancer</article-title><source>Gut</source><year>1992</year><volume>33</volume><fpage>783</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1136/gut.33.6.783</pub-id><pub-id pub-id-type="pmid">1624160</pub-id><pub-id pub-id-type="pmcid">PMC1379336</pub-id></element-citation><mixed-citation id="mc-CR331" publication-type="journal">Jass JR, Stewart SM (1992) Evolution of hereditary non-polyposis colorectal cancer. Gut 33:783&#8211;786<pub-id pub-id-type="pmid">1624160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.33.6.783</pub-id><pub-id pub-id-type="pmcid">PMC1379336</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR332"><label>332.</label><citation-alternatives><element-citation id="ec-CR332" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jass</surname><given-names>JR</given-names></name><name name-style="western"><surname>Cottier</surname><given-names>DS</given-names></name><name name-style="western"><surname>Pokos</surname><given-names>V</given-names></name><etal/></person-group><article-title>Mixed epithelial polyps in association with hereditary non-polyposis colorectal cancer providing an alternative pathway of cancer histogenesis</article-title><source>Pathology</source><year>1997</year><volume>29</volume><fpage>28</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1080/00313029700169494</pub-id><pub-id pub-id-type="pmid">9094174</pub-id></element-citation><mixed-citation id="mc-CR332" publication-type="journal">Jass JR, Cottier DS, Pokos V et al (1997) Mixed epithelial polyps in association with hereditary non-polyposis colorectal cancer providing an alternative pathway of cancer histogenesis. Pathology 29:28&#8211;33<pub-id pub-id-type="pmid">9094174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00313029700169494</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR333"><label>333.</label><citation-alternatives><element-citation id="ec-CR333" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahadova</surname><given-names>A</given-names></name><name name-style="western"><surname>Gallon</surname><given-names>R</given-names></name><name name-style="western"><surname>Gebert</surname><given-names>J</given-names></name><etal/></person-group><article-title>Three molecular pathways model colorectal carcinogenesis in Lynch syndrome</article-title><source>Int J Cancer</source><year>2018</year><volume>143</volume><fpage>139</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1002/ijc.31300</pub-id><pub-id pub-id-type="pmid">29424427</pub-id></element-citation><mixed-citation id="mc-CR333" publication-type="journal">Ahadova A, Gallon R, Gebert J et al (2018) Three molecular pathways model colorectal carcinogenesis in Lynch syndrome. Int J Cancer 143:139&#8211;150. 10.1002/ijc.31300<pub-id pub-id-type="pmid">29424427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.31300</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR334"><label>334.</label><citation-alternatives><element-citation id="ec-CR334" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>NAJ</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J</given-names></name><name name-style="western"><surname>Green</surname><given-names>K</given-names></name><etal/></person-group><article-title>Association of mismatch repair mutation with age at cancer onset in Lynch syndrome: Implications for stratified surveillance strategies</article-title><source>JAMA Oncol</source><year>2017</year><volume>3</volume><fpage>1702</fpage><lpage>1706</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2017.0619</pub-id><pub-id pub-id-type="pmid">28772289</pub-id><pub-id pub-id-type="pmcid">PMC5824283</pub-id></element-citation><mixed-citation id="mc-CR334" publication-type="journal">Ryan NAJ, Morris J, Green K et al (2017) Association of mismatch repair mutation with age at cancer onset in Lynch syndrome: Implications for stratified surveillance strategies. JAMA Oncol 3:1702&#8211;1706<pub-id pub-id-type="pmid">28772289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2017.0619</pub-id><pub-id pub-id-type="pmcid">PMC5824283</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR335"><label>335.</label><mixed-citation publication-type="other">Sepp&#228;l&#228; TT, Latchford A, Negoi I, et al. (2021) European guidelines from the EHTG and ESCP for Lynch syndrome an updated third edition of the Mallorca guidelines based on gene and gender. Br J Surg 108:484&#8211;498.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bjs.11902</pub-id><pub-id pub-id-type="pmcid">PMC10364896</pub-id><pub-id pub-id-type="pmid">34043773</pub-id></mixed-citation></ref><ref id="CR336"><label>336.</label><citation-alternatives><element-citation id="ec-CR336" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>J&#228;rvinen</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Aarnio</surname><given-names>M</given-names></name><name name-style="western"><surname>Mustonen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer</article-title><source>Gastroenterology</source><year>2000</year><volume>118</volume><fpage>829</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(00)70168-5</pub-id><pub-id pub-id-type="pmid">10784581</pub-id></element-citation><mixed-citation id="mc-CR336" publication-type="journal">J&#228;rvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829&#8211;834<pub-id pub-id-type="pmid">10784581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0016-5085(00)70168-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR337"><label>337.</label><citation-alternatives><element-citation id="ec-CR337" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engel</surname><given-names>C</given-names></name><name name-style="western"><surname>Rahner</surname><given-names>N</given-names></name><name name-style="western"><surname>Schulmann</surname><given-names>K</given-names></name><etal/></person-group><article-title>Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer</article-title><source>Clin Gastroenterol Hepatol</source><year>2010</year><volume>8</volume><fpage>174</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2009.10.003</pub-id><pub-id pub-id-type="pmid">19835992</pub-id></element-citation><mixed-citation id="mc-CR337" publication-type="journal">Engel C, Rahner N, Schulmann K et al (2010) Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 8:174&#8211;182<pub-id pub-id-type="pmid">19835992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2009.10.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR338"><label>338.</label><citation-alternatives><element-citation id="ec-CR338" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engel</surname><given-names>C</given-names></name><name name-style="western"><surname>Vasen</surname><given-names>HF</given-names></name><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>T</given-names></name><etal/></person-group><article-title>No difference in colorectal cancer incidence or stage at detection by colonoscopy among 3 countries with different Lynch syndrome surveillance policies</article-title><source>Gastroenterology</source><year>2018</year><volume>155</volume><fpage>1400</fpage><lpage>1409.e2</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.07.030</pub-id><pub-id pub-id-type="pmid">30063918</pub-id></element-citation><mixed-citation id="mc-CR338" publication-type="journal">Engel C, Vasen HF, Sepp&#228;l&#228; T et al (2018) No difference in colorectal cancer incidence or stage at detection by colonoscopy among 3 countries with different Lynch syndrome surveillance policies. Gastroenterology 155:1400-1409.e2<pub-id pub-id-type="pmid">30063918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2018.07.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR339"><label>339.</label><citation-alternatives><element-citation id="ec-CR339" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>TT</given-names></name><name name-style="western"><surname>Ahadova</surname><given-names>A</given-names></name><name name-style="western"><surname>Dominguez-Valentin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report</article-title><source>Hered Cancer Clin Pract</source><year>2019</year><volume>17</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/s13053-019-0106-8</pub-id><pub-id pub-id-type="pmid">30858900</pub-id><pub-id pub-id-type="pmcid">PMC6394091</pub-id></element-citation><mixed-citation id="mc-CR339" publication-type="journal">Sepp&#228;l&#228; TT, Ahadova A, Dominguez-Valentin M et al (2019) Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. Hered Cancer Clin Pract 17:8<pub-id pub-id-type="pmid">30858900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13053-019-0106-8</pub-id><pub-id pub-id-type="pmcid">PMC6394091</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR340"><label>340.</label><citation-alternatives><element-citation id="ec-CR340" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivero-Sanchez</surname><given-names>L</given-names></name><name name-style="western"><surname>Arnau-Collell</surname><given-names>C</given-names></name><name name-style="western"><surname>Herrero</surname><given-names>J</given-names></name><etal/></person-group><article-title>White-light endoscopy is adequate for Lynch syndrome surveillance in a randomized and noninferiority study</article-title><source>Gastroenterology</source><year>2020</year><volume>158</volume><fpage>895</fpage><lpage>904.e1</lpage><pub-id pub-id-type="doi">10.1186/s13053-019-0106-8</pub-id><pub-id pub-id-type="pmid">31520613</pub-id></element-citation><mixed-citation id="mc-CR340" publication-type="journal">Rivero-Sanchez L, Arnau-Collell C, Herrero J et al (2020) White-light endoscopy is adequate for Lynch syndrome surveillance in a randomized and noninferiority study. Gastroenterology 158:895-904.e1. 10.1186/s13053-019-0106-8<pub-id pub-id-type="pmid">31520613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2019.09.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR341"><label>341.</label><citation-alternatives><element-citation id="ec-CR341" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Botma</surname><given-names>A</given-names></name><name name-style="western"><surname>Nagengast</surname><given-names>FM</given-names></name><name name-style="western"><surname>Braem</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch cohort study</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>4346</fpage><lpage>4353</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.28.0453</pub-id><pub-id pub-id-type="pmid">20733131</pub-id></element-citation><mixed-citation id="mc-CR341" publication-type="journal">Botma A, Nagengast FM, Braem MG et al (2010) Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch cohort study. J Clin Oncol 28:4346&#8211;4353<pub-id pub-id-type="pmid">20733131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2010.28.0453</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR342"><label>342.</label><citation-alternatives><element-citation id="ec-CR342" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Movahedi</surname><given-names>M</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>DT</given-names></name><name name-style="western"><surname>Macrae</surname><given-names>F</given-names></name><etal/></person-group><article-title>Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: A prospective investigation in the CAPP2 Study</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>3591</fpage><lpage>3597</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.58.9952</pub-id><pub-id pub-id-type="pmid">26282643</pub-id></element-citation><mixed-citation id="mc-CR342" publication-type="journal">Movahedi M, Bishop DT, Macrae F et al (2015) Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: A prospective investigation in the CAPP2 Study. J Clin Oncol 33:3591&#8211;3597<pub-id pub-id-type="pmid">26282643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2014.58.9952</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR343"><label>343.</label><citation-alternatives><element-citation id="ec-CR343" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burn</surname><given-names>J</given-names></name><name name-style="western"><surname>Gerdes</surname><given-names>AM</given-names></name><name name-style="western"><surname>Macrae</surname><given-names>F</given-names></name><etal/></person-group><article-title>Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial</article-title><source>Lancet</source><year>2011</year><volume>378</volume><fpage>2081</fpage><lpage>2087</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)61049-0</pub-id><pub-id pub-id-type="pmid">22036019</pub-id><pub-id pub-id-type="pmcid">PMC3243929</pub-id></element-citation><mixed-citation id="mc-CR343" publication-type="journal">Burn J, Gerdes AM, Macrae F et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081&#8211;2087<pub-id pub-id-type="pmid">22036019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(11)61049-0</pub-id><pub-id pub-id-type="pmcid">PMC3243929</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR344"><label>344.</label><citation-alternatives><element-citation id="ec-CR344" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Duijnhoven</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Botma</surname><given-names>A</given-names></name><name name-style="western"><surname>Winkels</surname><given-names>R</given-names></name><etal/></person-group><article-title>Do lifestyle factors influence colorectal cancer risk in Lynch syndrome?</article-title><source>Fam Cancer</source><year>2013</year><volume>12</volume><fpage>285</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1007/s10689-013-9645-8</pub-id><pub-id pub-id-type="pmid">23657759</pub-id></element-citation><mixed-citation id="mc-CR344" publication-type="journal">van Duijnhoven FJ, Botma A, Winkels R et al (2013) Do lifestyle factors influence colorectal cancer risk in Lynch syndrome? Fam Cancer 12:285&#8211;293<pub-id pub-id-type="pmid">23657759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-013-9645-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR345"><label>345.</label><citation-alternatives><element-citation id="ec-CR345" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winkels</surname><given-names>RM</given-names></name><name name-style="western"><surname>Botma</surname><given-names>A</given-names></name><name name-style="western"><surname>Van Duijnhoven</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Smoking increases the risk for colorectal adenomas in patients with Lynch syndrome</article-title><source>Gastroenterology</source><year>2012</year><volume>142</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2011.10.033</pub-id><pub-id pub-id-type="pmid">22062356</pub-id></element-citation><mixed-citation id="mc-CR345" publication-type="journal">Winkels RM, Botma A, Van Duijnhoven FJ et al (2012) Smoking increases the risk for colorectal adenomas in patients with Lynch syndrome. Gastroenterology 142:241&#8211;247<pub-id pub-id-type="pmid">22062356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2011.10.033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR346"><label>346.</label><citation-alternatives><element-citation id="ec-CR346" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chau</surname><given-names>R</given-names></name><name name-style="western"><surname>Dashti</surname><given-names>SG</given-names></name><name name-style="western"><surname>Ait Ouakrim</surname><given-names>D</given-names></name><etal/></person-group><article-title>Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome</article-title><source>Int J Epidemiol</source><year>2016</year><volume>45</volume><fpage>940</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1093/ije/dyw036</pub-id><pub-id pub-id-type="pmid">27063605</pub-id><pub-id pub-id-type="pmcid">PMC5697347</pub-id></element-citation><mixed-citation id="mc-CR346" publication-type="journal">Chau R, Dashti SG, Ait Ouakrim D et al (2016) Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome. Int J Epidemiol 45:940&#8211;953<pub-id pub-id-type="pmid">27063605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyw036</pub-id><pub-id pub-id-type="pmcid">PMC5697347</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR347"><label>347.</label><citation-alternatives><element-citation id="ec-CR347" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diergaarde</surname><given-names>B</given-names></name><name name-style="western"><surname>Braam</surname><given-names>H</given-names></name><name name-style="western"><surname>Vasen</surname><given-names>HF</given-names></name><etal/></person-group><article-title>Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer</article-title><source>Clin Gastroenterol Hepatol</source><year>2007</year><volume>5</volume><fpage>736</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2007.02.019</pub-id><pub-id pub-id-type="pmid">17544999</pub-id></element-citation><mixed-citation id="mc-CR347" publication-type="journal">Diergaarde B, Braam H, Vasen HF et al (2007) Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 5:736&#8211;742<pub-id pub-id-type="pmid">17544999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2007.02.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR348"><label>348.</label><citation-alternatives><element-citation id="ec-CR348" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamiza</surname><given-names>AB</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>LL</given-names></name><name name-style="western"><surname>Tang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Risk factors associated with colorectal cancer in a subset of patients with mutations in <italic toggle="yes">MLH1</italic> and <italic toggle="yes">MSH2</italic> in Taiwan fulfilling the Amsterdam &#8545; criteria for Lynch syndrome</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0130018</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0130018</pub-id><pub-id pub-id-type="pmid">26053027</pub-id><pub-id pub-id-type="pmcid">PMC4460082</pub-id></element-citation><mixed-citation id="mc-CR348" publication-type="journal">Kamiza AB, Hsieh LL, Tang R et al (2015) Risk factors associated with colorectal cancer in a subset of patients with mutations in <italic toggle="yes">MLH1</italic> and <italic toggle="yes">MSH2</italic> in Taiwan fulfilling the Amsterdam &#8545; criteria for Lynch syndrome. PLoS ONE 10:e0130018. 10.1371/journal.pone.0130018<pub-id pub-id-type="pmid">26053027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0130018</pub-id><pub-id pub-id-type="pmcid">PMC4460082</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR349"><label>349.</label><citation-alternatives><element-citation id="ec-CR349" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dashti</surname><given-names>SG</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>DD</given-names></name><name name-style="western"><surname>Jayasekara</surname><given-names>H</given-names></name><etal/></person-group><article-title>Alcohol consumption and the risk of colorectal cancer for mismatch repair gene mutation carriers</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2017</year><volume>26</volume><fpage>366</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-16-0496</pub-id><pub-id pub-id-type="pmid">27811119</pub-id><pub-id pub-id-type="pmcid">PMC5336397</pub-id></element-citation><mixed-citation id="mc-CR349" publication-type="journal">Dashti SG, Buchanan DD, Jayasekara H et al (2017) Alcohol consumption and the risk of colorectal cancer for mismatch repair gene mutation carriers. Cancer Epidemiol Biomarkers Prev 26:366&#8211;375<pub-id pub-id-type="pmid">27811119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-16-0496</pub-id><pub-id pub-id-type="pmcid">PMC5336397</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR350"><label>350.</label><citation-alternatives><element-citation id="ec-CR350" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miguchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Hinoi</surname><given-names>T</given-names></name><name name-style="western"><surname>Tanakaya</surname><given-names>K</given-names></name><etal/></person-group><article-title>Alcohol consumption and early-onset risk of colorectal cancer in Japanese patients with Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum</article-title><source>Surg Today</source><year>2018</year><volume>48</volume><fpage>810</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1007/s00595-018-1654-7</pub-id><pub-id pub-id-type="pmid">29574523</pub-id></element-citation><mixed-citation id="mc-CR350" publication-type="journal">Miguchi M, Hinoi T, Tanakaya K et al (2018) Alcohol consumption and early-onset risk of colorectal cancer in Japanese patients with Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. Surg Today 48:810&#8211;814<pub-id pub-id-type="pmid">29574523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00595-018-1654-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR351"><label>351.</label><citation-alternatives><element-citation id="ec-CR351" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dashti</surname><given-names>SG</given-names></name><name name-style="western"><surname>Win</surname><given-names>AK</given-names></name><name name-style="western"><surname>Hardikar</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Physical activity and the risk of colorectal cancer in Lynch syndrome</article-title><source>Int J Cancer</source><year>2018</year><volume>143</volume><fpage>2250</fpage><lpage>2260</lpage><pub-id pub-id-type="doi">10.1002/ijc.31611</pub-id><pub-id pub-id-type="pmid">29904935</pub-id><pub-id pub-id-type="pmcid">PMC6195467</pub-id></element-citation><mixed-citation id="mc-CR351" publication-type="journal">Dashti SG, Win AK, Hardikar SS et al (2018) Physical activity and the risk of colorectal cancer in Lynch syndrome. Int J Cancer 143:2250&#8211;2260. 10.1002/ijc.31611<pub-id pub-id-type="pmid">29904935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.31611</pub-id><pub-id pub-id-type="pmcid">PMC6195467</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR352"><label>352.</label><citation-alternatives><element-citation id="ec-CR352" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haanstra</surname><given-names>JF</given-names></name><name name-style="western"><surname>Vasen</surname><given-names>HF</given-names></name><name name-style="western"><surname>Sanduleanu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Quality colonoscopy and risk of interval cancer in Lynch syndrome</article-title><source>Int J Colorectal Dis</source><year>2013</year><volume>28</volume><fpage>1643</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1007/s00384-013-1745-2</pub-id><pub-id pub-id-type="pmid">23857598</pub-id></element-citation><mixed-citation id="mc-CR352" publication-type="journal">Haanstra JF, Vasen HF, Sanduleanu S et al (2013) Quality colonoscopy and risk of interval cancer in Lynch syndrome. Int J Colorectal Dis 28:1643&#8211;1649<pub-id pub-id-type="pmid">23857598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00384-013-1745-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR353"><label>353.</label><citation-alternatives><element-citation id="ec-CR353" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#248;ller</surname><given-names>P</given-names></name><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>T</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>I</given-names></name><etal/></person-group><article-title>Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database</article-title><source>Gut</source><year>2017</year><volume>66</volume><fpage>1657</fpage><lpage>1664</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2016-311403</pub-id><pub-id pub-id-type="pmid">27261338</pub-id><pub-id pub-id-type="pmcid">PMC5561364</pub-id></element-citation><mixed-citation id="mc-CR353" publication-type="journal">M&#248;ller P, Sepp&#228;l&#228; T, Bernstein I et al (2017) Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut 66:1657&#8211;1664<pub-id pub-id-type="pmid">27261338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2016-311403</pub-id><pub-id pub-id-type="pmcid">PMC5561364</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR354"><label>354.</label><citation-alternatives><element-citation id="ec-CR354" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anele</surname><given-names>CC</given-names></name><name name-style="western"><surname>Adegbola</surname><given-names>SO</given-names></name><name name-style="western"><surname>Askari</surname><given-names>A</given-names></name><etal/></person-group><article-title>Risk of metachronous colorectal cancer following colectomy in Lynch syndrome: a systematic review and meta-analysis</article-title><source>Colorectal Dis</source><year>2017</year><volume>19</volume><fpage>528</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1111/codi.13679</pub-id><pub-id pub-id-type="pmid">28407411</pub-id></element-citation><mixed-citation id="mc-CR354" publication-type="journal">Anele CC, Adegbola SO, Askari A et al (2017) Risk of metachronous colorectal cancer following colectomy in Lynch syndrome: a systematic review and meta-analysis. Colorectal Dis 19:528&#8211;536<pub-id pub-id-type="pmid">28407411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/codi.13679</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR355"><label>355.</label><citation-alternatives><element-citation id="ec-CR355" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>SS</given-names></name><name name-style="western"><surname>Lythgoe</surname><given-names>MP</given-names></name><name name-style="western"><surname>McPhail</surname><given-names>M</given-names></name><etal/></person-group><article-title>Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis</article-title><source>Fam Cancer</source><year>2018</year><volume>17</volume><fpage>557</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1007/s10689-017-0062-2</pub-id><pub-id pub-id-type="pmid">29189962</pub-id><pub-id pub-id-type="pmcid">PMC6182577</pub-id></element-citation><mixed-citation id="mc-CR355" publication-type="journal">Malik SS, Lythgoe MP, McPhail M et al (2018) Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis. Fam Cancer 17:557&#8211;564<pub-id pub-id-type="pmid">29189962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-017-0062-2</pub-id><pub-id pub-id-type="pmcid">PMC6182577</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR356"><label>356.</label><citation-alternatives><element-citation id="ec-CR356" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Win</surname><given-names>AK</given-names></name><name name-style="western"><surname>Parry</surname><given-names>S</given-names></name><name name-style="western"><surname>Parry</surname><given-names>B</given-names></name><etal/></person-group><article-title>Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers</article-title><source>Ann Surg Oncol</source><year>2013</year><volume>20</volume><fpage>1829</fpage><lpage>1836</lpage><pub-id pub-id-type="doi">10.1245/s10434-012-2858-5</pub-id><pub-id pub-id-type="pmid">23358792</pub-id><pub-id pub-id-type="pmcid">PMC4041733</pub-id></element-citation><mixed-citation id="mc-CR356" publication-type="journal">Win AK, Parry S, Parry B et al (2013) Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol 20:1829&#8211;1836<pub-id pub-id-type="pmid">23358792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-012-2858-5</pub-id><pub-id pub-id-type="pmcid">PMC4041733</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR357"><label>357.</label><citation-alternatives><element-citation id="ec-CR357" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagasaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Arai</surname><given-names>M</given-names></name><name name-style="western"><surname>Chino</surname><given-names>A</given-names></name><etal/></person-group><article-title>Feasibility of segmental colectomy followed by endoscopic surveillance as a treatment strategy for colorectal cancer patients with Lynch syndrome</article-title><source>Dig Surg</source><year>2018</year><volume>35</volume><fpage>448</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1159/000481413</pub-id><pub-id pub-id-type="pmid">29017165</pub-id></element-citation><mixed-citation id="mc-CR357" publication-type="journal">Nagasaki T, Arai M, Chino A et al (2018) Feasibility of segmental colectomy followed by endoscopic surveillance as a treatment strategy for colorectal cancer patients with Lynch syndrome. Dig Surg 35:448&#8211;456<pub-id pub-id-type="pmid">29017165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000481413</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR358"><label>358.</label><citation-alternatives><element-citation id="ec-CR358" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinicrope</surname><given-names>FA</given-names></name><name name-style="western"><surname>Foster</surname><given-names>NR</given-names></name><name name-style="western"><surname>Thibodeau</surname><given-names>SN</given-names></name><etal/></person-group><article-title>DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy</article-title><source>J Natl Cancer Inst</source><year>2011</year><volume>103</volume><fpage>863</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1093/jnci/djr153</pub-id><pub-id pub-id-type="pmid">21597022</pub-id><pub-id pub-id-type="pmcid">PMC3110173</pub-id></element-citation><mixed-citation id="mc-CR358" publication-type="journal">Sinicrope FA, Foster NR, Thibodeau SN et al (2011) DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103:863&#8211;875<pub-id pub-id-type="pmid">21597022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djr153</pub-id><pub-id pub-id-type="pmcid">PMC3110173</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR359"><label>359.</label><citation-alternatives><element-citation id="ec-CR359" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Des Guetz</surname><given-names>G</given-names></name><name name-style="western"><surname>Schischmanoff</surname><given-names>O</given-names></name><name name-style="western"><surname>Nicolas</surname><given-names>P</given-names></name><etal/></person-group><article-title>Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis</article-title><source>Eur J Cancer</source><year>2009</year><volume>45</volume><fpage>1890</fpage><lpage>1896</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2009.04.018</pub-id><pub-id pub-id-type="pmid">19427194</pub-id></element-citation><mixed-citation id="mc-CR359" publication-type="journal">Des Guetz G, Schischmanoff O, Nicolas P et al (2009) Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 45:1890&#8211;1896<pub-id pub-id-type="pmid">19427194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2009.04.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR360"><label>360.</label><citation-alternatives><element-citation id="ec-CR360" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Webber</surname><given-names>EM</given-names></name><name name-style="western"><surname>Kauffman</surname><given-names>TL</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>E</given-names></name><etal/></person-group><article-title>Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy</article-title><source>BMC Cancer</source><year>2015</year><volume>15</volume><fpage>156</fpage><pub-id pub-id-type="doi">10.1186/s12885-015-1093-4</pub-id><pub-id pub-id-type="pmid">25884995</pub-id><pub-id pub-id-type="pmcid">PMC4376504</pub-id></element-citation><mixed-citation id="mc-CR360" publication-type="journal">Webber EM, Kauffman TL, O&#8217;Connor E et al (2015) Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. BMC Cancer 15:156<pub-id pub-id-type="pmid">25884995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-015-1093-4</pub-id><pub-id pub-id-type="pmcid">PMC4376504</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR361"><label>361.</label><citation-alternatives><element-citation id="ec-CR361" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andre</surname><given-names>T</given-names></name><name name-style="western"><surname>de Gramont</surname><given-names>A</given-names></name><name name-style="western"><surname>Vernerey</surname><given-names>D</given-names></name><etal/></person-group><article-title>Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage &#8545; to &#8546; colon cancer: Updated 10-year survival and outcomes according to <italic toggle="yes">BRAF</italic> mutation and mismatch repair status of the MOSAIC study</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>4176</fpage><lpage>4187</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.63.4238</pub-id><pub-id pub-id-type="pmid">26527776</pub-id></element-citation><mixed-citation id="mc-CR361" publication-type="journal">Andre T, de Gramont A, Vernerey D et al (2015) Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage &#8545; to &#8546; colon cancer: Updated 10-year survival and outcomes according to <italic toggle="yes">BRAF</italic> mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 33:4176&#8211;4187<pub-id pub-id-type="pmid">26527776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2015.63.4238</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR362"><label>362.</label><citation-alternatives><element-citation id="ec-CR362" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>R</given-names></name><name name-style="western"><surname>Taieb</surname><given-names>J</given-names></name><name name-style="western"><surname>Fiskum</surname><given-names>J</given-names></name><etal/></person-group><article-title>Microsatellite instability in patients with stage &#8546; colon cancer receiving fluoropyrimidine with or without oxaliplatin: An ACCENT pooled analysis of 12 adjuvant trials</article-title><source>J Clin Oncol</source><year>2021</year><volume>39</volume><fpage>642</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1200/JCO.20.01600</pub-id><pub-id pub-id-type="pmid">33356421</pub-id><pub-id pub-id-type="pmcid">PMC8189604</pub-id></element-citation><mixed-citation id="mc-CR362" publication-type="journal">Cohen R, Taieb J, Fiskum J et al (2021) Microsatellite instability in patients with stage &#8546; colon cancer receiving fluoropyrimidine with or without oxaliplatin: An ACCENT pooled analysis of 12 adjuvant trials. J Clin Oncol 39:642&#8211;651<pub-id pub-id-type="pmid">33356421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.20.01600</pub-id><pub-id pub-id-type="pmcid">PMC8189604</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR363"><label>363.</label><citation-alternatives><element-citation id="ec-CR363" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>B</given-names></name><name name-style="western"><surname>Kopetz</surname><given-names>S</given-names></name><name name-style="western"><surname>Tie</surname><given-names>J</given-names></name><etal/></person-group><article-title>Impact of <italic toggle="yes">BRAF</italic> mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer</article-title><source>Cancer</source><year>2011</year><volume>117</volume><fpage>4623</fpage><lpage>4632</lpage><pub-id pub-id-type="doi">10.1002/cncr.26086</pub-id><pub-id pub-id-type="pmid">21456008</pub-id><pub-id pub-id-type="pmcid">PMC4257471</pub-id></element-citation><mixed-citation id="mc-CR363" publication-type="journal">Tran B, Kopetz S, Tie J et al (2011) Impact of <italic toggle="yes">BRAF</italic> mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117:4623&#8211;4632<pub-id pub-id-type="pmid">21456008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.26086</pub-id><pub-id pub-id-type="pmcid">PMC4257471</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR364"><label>364.</label><citation-alternatives><element-citation id="ec-CR364" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venderbosch</surname><given-names>S</given-names></name><name name-style="western"><surname>Nagtegaal</surname><given-names>ID</given-names></name><name name-style="western"><surname>Maughan</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies</article-title><source>Clin Cancer Res</source><year>2014</year><volume>20</volume><fpage>5322</fpage><lpage>5330</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0332</pub-id><pub-id pub-id-type="pmid">25139339</pub-id><pub-id pub-id-type="pmcid">PMC4201568</pub-id></element-citation><mixed-citation id="mc-CR364" publication-type="journal">Venderbosch S, Nagtegaal ID, Maughan TS et al (2014) Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 20:5322&#8211;5330<pub-id pub-id-type="pmid">25139339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-14-0332</pub-id><pub-id pub-id-type="pmcid">PMC4201568</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR365"><label>365.</label><citation-alternatives><element-citation id="ec-CR365" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>DT</given-names></name><name name-style="western"><surname>Uram</surname><given-names>JN</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>PD-1 blockade in tumors with mismatch-repair deficiency</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><fpage>2509</fpage><lpage>2520</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1500596</pub-id><pub-id pub-id-type="pmid">26028255</pub-id><pub-id pub-id-type="pmcid">PMC4481136</pub-id></element-citation><mixed-citation id="mc-CR365" publication-type="journal">Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509&#8211;2520<pub-id pub-id-type="pmid">26028255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1500596</pub-id><pub-id pub-id-type="pmcid">PMC4481136</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR366"><label>366.</label><citation-alternatives><element-citation id="ec-CR366" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romiti</surname><given-names>A</given-names></name><name name-style="western"><surname>Rulli</surname><given-names>E</given-names></name><name name-style="western"><surname>Pilozzi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Exploring the prognostic role of microsatellite instability in patients with stage &#8545; colorectal cancer: A systematic review and meta-analysis</article-title><source>Clin Colorectal Cancer</source><year>2017</year><volume>16</volume><fpage>e55</fpage><lpage>e59</lpage><pub-id pub-id-type="pmid">27670891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clcc.2016.08.007</pub-id></element-citation><mixed-citation id="mc-CR366" publication-type="journal">Romiti A, Rulli E, Pilozzi E et al (2017) Exploring the prognostic role of microsatellite instability in patients with stage &#8545; colorectal cancer: A systematic review and meta-analysis. Clin Colorectal Cancer 16:e55&#8211;e59<pub-id pub-id-type="pmid">27670891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clcc.2016.08.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR367"><label>367.</label><citation-alternatives><element-citation id="ec-CR367" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>DT</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>LA</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Kim</surname><given-names>TW</given-names></name><etal/></person-group><article-title>Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164</article-title><source>Eur J Cancer</source><year>2023</year><volume>186</volume><fpage>185</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2023.02.016</pub-id><pub-id pub-id-type="pmid">37141828</pub-id></element-citation><mixed-citation id="mc-CR367" publication-type="journal">Le DT, Diaz LA Jr, Kim TW et al (2023) Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur J Cancer 186:185&#8211;195<pub-id pub-id-type="pmid">37141828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2023.02.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR368"><label>368.</label><citation-alternatives><element-citation id="ec-CR368" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maio</surname><given-names>M</given-names></name><name name-style="western"><surname>Ascierto</surname><given-names>PA</given-names></name><name name-style="western"><surname>Manzyuk</surname><given-names>L</given-names></name><etal/></person-group><article-title>Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase &#8545; KEYNOTE-158 study</article-title><source>Ann Oncol</source><year>2022</year><volume>33</volume><fpage>929</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.05.519</pub-id><pub-id pub-id-type="pmid">35680043</pub-id></element-citation><mixed-citation id="mc-CR368" publication-type="journal">Maio M, Ascierto PA, Manzyuk L et al (2022) Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase &#8545; KEYNOTE-158 study. Ann Oncol 33:929&#8211;938<pub-id pub-id-type="pmid">35680043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2022.05.519</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR369"><label>369.</label><citation-alternatives><element-citation id="ec-CR369" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Overman</surname><given-names>MJ</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>R</given-names></name><name name-style="western"><surname>Leach</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study</article-title><source>Lancet Oncol</source><year>2017</year><volume>18</volume><fpage>1182</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30422-9</pub-id><pub-id pub-id-type="pmid">28734759</pub-id><pub-id pub-id-type="pmcid">PMC6207072</pub-id></element-citation><mixed-citation id="mc-CR369" publication-type="journal">Overman MJ, McDermott R, Leach JL et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18:1182&#8211;1191<pub-id pub-id-type="pmid">28734759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(17)30422-9</pub-id><pub-id pub-id-type="pmcid">PMC6207072</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR370"><label>370.</label><citation-alternatives><element-citation id="ec-CR370" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Overman</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Lonardi</surname><given-names>S</given-names></name><name name-style="western"><surname>Wong</surname><given-names>KYM</given-names></name><etal/></person-group><article-title>Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2018</year><volume>36</volume><fpage>773</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.76.9901</pub-id><pub-id pub-id-type="pmid">29355075</pub-id></element-citation><mixed-citation id="mc-CR370" publication-type="journal">Overman MJ, Lonardi S, Wong KYM et al (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36:773&#8211;779<pub-id pub-id-type="pmid">29355075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2017.76.9901</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR371"><label>371.</label><citation-alternatives><element-citation id="ec-CR371" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andr&#233;</surname><given-names>T</given-names></name><name name-style="western"><surname>Shiu</surname><given-names>KK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>TW</given-names></name><etal/></person-group><article-title>Pembrolizumab in microsatellite-instability-high advanced colorectal cancer</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>2207</fpage><lpage>2218</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2017699</pub-id><pub-id pub-id-type="pmid">33264544</pub-id></element-citation><mixed-citation id="mc-CR371" publication-type="journal">Andr&#233; T, Shiu KK, Kim TW et al (2020) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383:2207&#8211;2218<pub-id pub-id-type="pmid">33264544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2017699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR372"><label>372.</label><citation-alternatives><element-citation id="ec-CR372" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carnevali</surname><given-names>I</given-names></name><name name-style="western"><surname>Sahnane</surname><given-names>N</given-names></name><name name-style="western"><surname>Chiaravalli</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Strategies for Lynch syndrome identification in selected and unselected gynecological cancers</article-title><source>Eur J Cancer Prev</source><year>2022</year><volume>31</volume><fpage>369</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1097/CEJ.0000000000000711</pub-id><pub-id pub-id-type="pmid">34519692</pub-id></element-citation><mixed-citation id="mc-CR372" publication-type="journal">Carnevali I, Sahnane N, Chiaravalli AM et al (2022) Strategies for Lynch syndrome identification in selected and unselected gynecological cancers. Eur J Cancer Prev 31:369&#8211;376<pub-id pub-id-type="pmid">34519692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CEJ.0000000000000711</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR373"><label>373.</label><citation-alternatives><element-citation id="ec-CR373" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Zang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Endometrial cancer in Lynch syndrome</article-title><source>Int J Cancer</source><year>2022</year><volume>150</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1002/ijc.33763</pub-id><pub-id pub-id-type="pmid">34398969</pub-id></element-citation><mixed-citation id="mc-CR373" publication-type="journal">Zhao S, Chen L, Zang Y et al (2022) Endometrial cancer in Lynch syndrome. Int J Cancer 150:7&#8211;17<pub-id pub-id-type="pmid">34398969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.33763</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR374"><label>374.</label><citation-alternatives><element-citation id="ec-CR374" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>NAJ</given-names></name><name name-style="western"><surname>Glaire</surname><given-names>MA</given-names></name><name name-style="western"><surname>Blake</surname><given-names>D</given-names></name><etal/></person-group><article-title>The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis</article-title><source>Genet Med</source><year>2019</year><volume>21</volume><fpage>2167</fpage><lpage>2180</lpage><pub-id pub-id-type="doi">10.1038/s41436-019-0536-8</pub-id><pub-id pub-id-type="pmid">31086306</pub-id><pub-id pub-id-type="pmcid">PMC8076013</pub-id></element-citation><mixed-citation id="mc-CR374" publication-type="journal">Ryan NAJ, Glaire MA, Blake D et al (2019) The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet Med 21:2167&#8211;2180<pub-id pub-id-type="pmid">31086306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-019-0536-8</pub-id><pub-id pub-id-type="pmcid">PMC8076013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR375"><label>375.</label><citation-alternatives><element-citation id="ec-CR375" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>N</given-names></name><name name-style="western"><surname>Hickey</surname><given-names>M</given-names></name><name name-style="western"><surname>Young</surname><given-names>GP</given-names></name><etal/></person-group><article-title>Screening and risk-reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review</article-title><source>Int J Gynecol Cancer</source><year>2022</year><volume>32</volume><fpage>646</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1136/ijgc-2021-003132</pub-id><pub-id pub-id-type="pmid">35437274</pub-id><pub-id pub-id-type="pmcid">PMC9067008</pub-id></element-citation><mixed-citation id="mc-CR375" publication-type="journal">Lim N, Hickey M, Young GP et al (2022) Screening and risk-reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review. Int J Gynecol Cancer 32:646&#8211;655<pub-id pub-id-type="pmid">35437274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ijgc-2021-003132</pub-id><pub-id pub-id-type="pmcid">PMC9067008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR376"><label>376.</label><citation-alternatives><element-citation id="ec-CR376" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shikama</surname><given-names>A</given-names></name><name name-style="western"><surname>Minaguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas</article-title><source>Gynecol Oncol</source><year>2016</year><volume>140</volume><fpage>226</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2015.11.032</pub-id><pub-id pub-id-type="pmid">26644264</pub-id></element-citation><mixed-citation id="mc-CR376" publication-type="journal">Shikama A, Minaguchi T, Matsumoto K et al (2016) Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas. Gynecol Oncol 140:226&#8211;233<pub-id pub-id-type="pmid">26644264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2015.11.032</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR377"><label>377.</label><citation-alternatives><element-citation id="ec-CR377" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masuda</surname><given-names>K</given-names></name><name name-style="western"><surname>Banno</surname><given-names>K</given-names></name><name name-style="western"><surname>Hirasawa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Relationship of lower uterine segment cancer with Lynch syndrome: a novel case with an <italic toggle="yes">hMLH1</italic> germline mutation</article-title><source>Oncol Rep</source><year>2012</year><volume>28</volume><fpage>1537</fpage><lpage>1543</lpage><pub-id pub-id-type="doi">10.3892/or.2012.2008</pub-id><pub-id pub-id-type="pmid">22940821</pub-id><pub-id pub-id-type="pmcid">PMC3583565</pub-id></element-citation><mixed-citation id="mc-CR377" publication-type="journal">Masuda K, Banno K, Hirasawa A et al (2012) Relationship of lower uterine segment cancer with Lynch syndrome: a novel case with an <italic toggle="yes">hMLH1</italic> germline mutation. Oncol Rep 28:1537&#8211;1543<pub-id pub-id-type="pmid">22940821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2012.2008</pub-id><pub-id pub-id-type="pmcid">PMC3583565</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR378"><label>378.</label><citation-alternatives><element-citation id="ec-CR378" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westin</surname><given-names>SN</given-names></name><name name-style="western"><surname>Lacour</surname><given-names>RA</given-names></name><name name-style="western"><surname>Urbauer</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>5965</fpage><lpage>5971</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.18.6296</pub-id><pub-id pub-id-type="pmid">19001318</pub-id><pub-id pub-id-type="pmcid">PMC2645115</pub-id></element-citation><mixed-citation id="mc-CR378" publication-type="journal">Westin SN, Lacour RA, Urbauer DL et al (2008) Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol 26:5965&#8211;5971<pub-id pub-id-type="pmid">19001318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2008.18.6296</pub-id><pub-id pub-id-type="pmcid">PMC2645115</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR379"><label>379.</label><citation-alternatives><element-citation id="ec-CR379" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>D</given-names></name><name name-style="western"><surname>Lei</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><etal/></person-group><article-title><italic toggle="yes">POLE</italic> and mismatch repair status, checkpoint proteins and tumor-infiltrating lymphocytes in combination, and tumor differentiation: identify endometrial cancers for immunotherapy</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>640018</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.640018</pub-id><pub-id pub-id-type="pmid">33816285</pub-id><pub-id pub-id-type="pmcid">PMC8017289</pub-id></element-citation><mixed-citation id="mc-CR379" publication-type="journal">Dong D, Lei H, Liu D et al (2021) <italic toggle="yes">POLE</italic> and mismatch repair status, checkpoint proteins and tumor-infiltrating lymphocytes in combination, and tumor differentiation: identify endometrial cancers for immunotherapy. Front Oncol 11:640018<pub-id pub-id-type="pmid">33816285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.640018</pub-id><pub-id pub-id-type="pmcid">PMC8017289</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR380"><label>380.</label><citation-alternatives><element-citation id="ec-CR380" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ran</surname><given-names>X</given-names></name><name name-style="western"><surname>Jing</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>The clinical features and management of Lynch syndrome-associated ovarian cancer</article-title><source>J Obstet Gynaecol Res</source><year>2022</year><volume>48</volume><fpage>1538</fpage><lpage>1545</lpage><pub-id pub-id-type="doi">10.1111/jog.15273</pub-id><pub-id pub-id-type="pmid">35478369</pub-id></element-citation><mixed-citation id="mc-CR380" publication-type="journal">Ran X, Jing H, Li Z (2022) The clinical features and management of Lynch syndrome-associated ovarian cancer. J Obstet Gynaecol Res 48:1538&#8211;1545<pub-id pub-id-type="pmid">35478369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jog.15273</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR381"><label>381.</label><citation-alternatives><element-citation id="ec-CR381" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Takehara</surname><given-names>K</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>N</given-names></name><etal/></person-group><article-title>Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma</article-title><source>J Gynecol Oncol</source><year>2022</year><volume>33</volume><fpage>e67</fpage><pub-id pub-id-type="doi">10.3802/jgo.2022.33.e67</pub-id><pub-id pub-id-type="pmid">36032025</pub-id><pub-id pub-id-type="pmcid">PMC9428302</pub-id></element-citation><mixed-citation id="mc-CR381" publication-type="journal">Tanaka T, Takehara K, Yamashita N et al (2022) Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma. J Gynecol Oncol 33:e67<pub-id pub-id-type="pmid">36032025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3802/jgo.2022.33.e67</pub-id><pub-id pub-id-type="pmcid">PMC9428302</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR382"><label>382.</label><citation-alternatives><element-citation id="ec-CR382" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Llach</surname><given-names>J</given-names></name><name name-style="western"><surname>Pellise</surname><given-names>M</given-names></name><name name-style="western"><surname>Monahan</surname><given-names>K</given-names></name></person-group><article-title>Lynch syndrome; towards more personalized management?</article-title><source>Best Pract Res Clin Gastroenterol</source><year>2022</year><volume>58&#8211;59</volume><fpage>101790</fpage><pub-id pub-id-type="doi">10.1016/j.bpg.2022.101790</pub-id><pub-id pub-id-type="pmid">35988964</pub-id></element-citation><mixed-citation id="mc-CR382" publication-type="journal">Llach J, Pellise M, Monahan K (2022) Lynch syndrome; towards more personalized management? Best Pract Res Clin Gastroenterol 58&#8211;59:101790<pub-id pub-id-type="pmid">35988964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bpg.2022.101790</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR383"><label>383.</label><citation-alternatives><element-citation id="ec-CR383" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmeler</surname><given-names>KM</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>HT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><fpage>261</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa052627</pub-id><pub-id pub-id-type="pmid">16421367</pub-id></element-citation><mixed-citation id="mc-CR383" publication-type="journal">Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261&#8211;269<pub-id pub-id-type="pmid">16421367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa052627</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR384"><label>384.</label><citation-alternatives><element-citation id="ec-CR384" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez-Valentin</surname><given-names>M</given-names></name><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>TT</given-names></name><name name-style="western"><surname>Engel</surname><given-names>C</given-names></name><etal/></person-group><article-title>Risk-reducing gynecological surgery in Lynch syndrome: results of an international survey from the Prospective Lynch Syndrome Database</article-title><source>J Clin Med</source><year>2020</year><volume>9</volume><fpage>2290</fpage><pub-id pub-id-type="doi">10.3390/jcm9072290</pub-id><pub-id pub-id-type="pmid">32708519</pub-id><pub-id pub-id-type="pmcid">PMC7408942</pub-id></element-citation><mixed-citation id="mc-CR384" publication-type="journal">Dominguez-Valentin M, Sepp&#228;l&#228; TT, Engel C et al (2020) Risk-reducing gynecological surgery in Lynch syndrome: results of an international survey from the Prospective Lynch Syndrome Database. J Clin Med 9:2290. 10.3390/jcm9072290<pub-id pub-id-type="pmid">32708519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm9072290</pub-id><pub-id pub-id-type="pmcid">PMC7408942</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR385"><label>385.</label><citation-alternatives><element-citation id="ec-CR385" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swanson</surname><given-names>CL</given-names></name><name name-style="western"><surname>Bakkum-Gamez</surname><given-names>JN</given-names></name></person-group><article-title>Preventing ovarian cancer in high-risk women: One surgery at a time</article-title><source>Clin Obstet Gynecol</source><year>2020</year><volume>63</volume><fpage>64</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1097/GRF.0000000000000499</pub-id><pub-id pub-id-type="pmid">31764001</pub-id></element-citation><mixed-citation id="mc-CR385" publication-type="journal">Swanson CL, Bakkum-Gamez JN (2020) Preventing ovarian cancer in high-risk women: One surgery at a time. Clin Obstet Gynecol 63:64&#8211;73<pub-id pub-id-type="pmid">31764001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/GRF.0000000000000499</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR386"><label>386.</label><mixed-citation publication-type="other">Manchanda R, Gaba F, Talaulikar V, et al. (2021) Risk-reducing salpingo-oophorectomy and the use of hormone replacement therapy below the age of natural menopause: Scientific Impact Paper No. 66 October 2021: BJOG 129:e16-e34.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1471-0528.16896</pub-id><pub-id pub-id-type="pmcid">PMC7614764</pub-id><pub-id pub-id-type="pmid">34672090</pub-id></mixed-citation></ref><ref id="CR387"><label>387.</label><citation-alternatives><element-citation id="ec-CR387" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lachiewicz</surname><given-names>MP</given-names></name><name name-style="western"><surname>Kravochuck</surname><given-names>SE</given-names></name><name name-style="western"><surname>O&#8217;Malley</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Prevalence of occult gynecologic malignancy at the time of risk reducing and nonprophylactic surgery in patients with Lynch syndrome</article-title><source>Gynecol Oncol</source><year>2014</year><volume>132</volume><fpage>434</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2013.10.033</pub-id><pub-id pub-id-type="pmid">24211399</pub-id></element-citation><mixed-citation id="mc-CR387" publication-type="journal">Lachiewicz MP, Kravochuck SE, O&#8217;Malley MM et al (2014) Prevalence of occult gynecologic malignancy at the time of risk reducing and nonprophylactic surgery in patients with Lynch syndrome. Gynecol Oncol 132:434&#8211;437<pub-id pub-id-type="pmid">24211399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2013.10.033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR388"><label>388.</label><citation-alternatives><element-citation id="ec-CR388" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fedda</surname><given-names>FA</given-names></name><name name-style="western"><surname>Euscher</surname><given-names>ED</given-names></name><name name-style="western"><surname>Ramalingam</surname><given-names>P</given-names></name><etal/></person-group><article-title>Prophylactic risk-reducing hysterectomies and bilateral salpingo-oophorectomies in patients with Lynch syndrome: A clinicopathologic study of 29 cases and review of the literature</article-title><source>Int J Gynecol Pathol</source><year>2020</year><volume>39</volume><fpage>313</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1097/PGP.0000000000000643</pub-id><pub-id pub-id-type="pmid">31851061</pub-id></element-citation><mixed-citation id="mc-CR388" publication-type="journal">Fedda FA, Euscher ED, Ramalingam P et al (2020) Prophylactic risk-reducing hysterectomies and bilateral salpingo-oophorectomies in patients with Lynch syndrome: A clinicopathologic study of 29 cases and review of the literature. Int J Gynecol Pathol 39:313&#8211;320<pub-id pub-id-type="pmid">31851061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PGP.0000000000000643</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR389"><label>389.</label><citation-alternatives><element-citation id="ec-CR389" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>CC</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>LA</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Women&#700;s preferences for cancer risk management strategies in Lynch syndrome</article-title><source>Gynecol Oncol</source><year>2019</year><volume>152</volume><fpage>514</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2018.11.027</pub-id><pub-id pub-id-type="pmid">30876497</pub-id><pub-id pub-id-type="pmcid">PMC6422049</pub-id></element-citation><mixed-citation id="mc-CR389" publication-type="journal">Sun CC, Meyer LA, Daniels MS et al (2019) Women&#700;s preferences for cancer risk management strategies in Lynch syndrome. Gynecol Oncol 152:514&#8211;521<pub-id pub-id-type="pmid">30876497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2018.11.027</pub-id><pub-id pub-id-type="pmcid">PMC6422049</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR390"><label>390.</label><citation-alternatives><element-citation id="ec-CR390" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmeler</surname><given-names>KM</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>MS</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>PT</given-names></name><etal/></person-group><article-title>Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome</article-title><source>Obstet Gynecol</source><year>2010</year><volume>115</volume><fpage>432</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1097/AOG.0b013e3181b6f4f9</pub-id><pub-id pub-id-type="pmid">20093870</pub-id><pub-id pub-id-type="pmcid">PMC4250042</pub-id></element-citation><mixed-citation id="mc-CR390" publication-type="journal">Schmeler KM, Daniels MS, Soliman PT et al (2010) Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. Obstet Gynecol 115:432&#8211;434<pub-id pub-id-type="pmid">20093870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AOG.0b013e3181b6f4f9</pub-id><pub-id pub-id-type="pmcid">PMC4250042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR391"><label>391.</label><citation-alternatives><element-citation id="ec-CR391" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roupr&#234;t</surname><given-names>M</given-names></name><name name-style="western"><surname>Yates</surname><given-names>DR</given-names></name><name name-style="western"><surname>Comperat</surname><given-names>E</given-names></name><etal/></person-group><article-title>Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum</article-title><source>Eur Urol</source><year>2008</year><volume>54</volume><fpage>1226</fpage><lpage>1236</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2008.08.008</pub-id><pub-id pub-id-type="pmid">18715695</pub-id></element-citation><mixed-citation id="mc-CR391" publication-type="journal">Roupr&#234;t M, Yates DR, Comperat E et al (2008) Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. Eur Urol 54:1226&#8211;1236<pub-id pub-id-type="pmid">18715695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2008.08.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR392"><label>392.</label><citation-alternatives><element-citation id="ec-CR392" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrow</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Ingham</surname><given-names>S</given-names></name><name name-style="western"><surname>O&#8217;Hara</surname><given-names>C</given-names></name><etal/></person-group><article-title>The spectrum of urological malignancy in Lynch syndrome</article-title><source>Fam Cancer</source><year>2013</year><volume>12</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1007/s10689-012-9573-z</pub-id><pub-id pub-id-type="pmid">23054215</pub-id></element-citation><mixed-citation id="mc-CR392" publication-type="journal">Barrow PJ, Ingham S, O&#8217;Hara C et al (2013) The spectrum of urological malignancy in Lynch syndrome. Fam Cancer 12:57&#8211;63<pub-id pub-id-type="pmid">23054215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-012-9573-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR393"><label>393.</label><citation-alternatives><element-citation id="ec-CR393" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urakami</surname><given-names>S</given-names></name><name name-style="western"><surname>Inoshita</surname><given-names>N</given-names></name><name name-style="western"><surname>Oka</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening</article-title><source>Int J Urol</source><year>2018</year><volume>25</volume><fpage>151</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1111/iju.13481</pub-id><pub-id pub-id-type="pmid">29164703</pub-id></element-citation><mixed-citation id="mc-CR393" publication-type="journal">Urakami S, Inoshita N, Oka S et al (2018) Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening. Int J Urol 25:151&#8211;156<pub-id pub-id-type="pmid">29164703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/iju.13481</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR394"><label>394.</label><citation-alternatives><element-citation id="ec-CR394" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joost</surname><given-names>P</given-names></name><name name-style="western"><surname>Therkildsen</surname><given-names>C</given-names></name><name name-style="western"><surname>Dominguez-Valentin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Urinary tract cancer in Lynch syndrome; increased risk in carriers of <italic toggle="yes">MSH2</italic> mutations</article-title><source>Urology</source><year>2015</year><volume>86</volume><fpage>1212</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2015.08.018</pub-id><pub-id pub-id-type="pmid">26385421</pub-id></element-citation><mixed-citation id="mc-CR394" publication-type="journal">Joost P, Therkildsen C, Dominguez-Valentin M et al (2015) Urinary tract cancer in Lynch syndrome; increased risk in carriers of <italic toggle="yes">MSH2</italic> mutations. Urology 86:1212&#8211;1217<pub-id pub-id-type="pmid">26385421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.urology.2015.08.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR395"><label>395.</label><citation-alternatives><element-citation id="ec-CR395" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Win</surname><given-names>AK</given-names></name><name name-style="western"><surname>Lindor</surname><given-names>NM</given-names></name><name name-style="western"><surname>Young</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome</article-title><source>J Natl Cancer Inst</source><year>2012</year><volume>104</volume><fpage>1363</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1093/jnci/djs351</pub-id><pub-id pub-id-type="pmid">22933731</pub-id><pub-id pub-id-type="pmcid">PMC3529597</pub-id></element-citation><mixed-citation id="mc-CR395" publication-type="journal">Win AK, Lindor NM, Young JP et al (2012) Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J Natl Cancer Inst 104:1363&#8211;1372<pub-id pub-id-type="pmid">22933731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djs351</pub-id><pub-id pub-id-type="pmcid">PMC3529597</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR396"><label>396.</label><citation-alternatives><element-citation id="ec-CR396" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skeldon</surname><given-names>SC</given-names></name><name name-style="western"><surname>Semotiuk</surname><given-names>K</given-names></name><name name-style="western"><surname>Aronson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer</article-title><source>Eur Urol</source><year>2013</year><volume>63</volume><fpage>379</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2012.07.047</pub-id><pub-id pub-id-type="pmid">22883484</pub-id></element-citation><mixed-citation id="mc-CR396" publication-type="journal">Skeldon SC, Semotiuk K, Aronson M et al (2013) Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol 63:379&#8211;385<pub-id pub-id-type="pmid">22883484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2012.07.047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR397"><label>397.</label><citation-alternatives><element-citation id="ec-CR397" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>D</given-names></name><name name-style="western"><surname>Matin</surname><given-names>SF</given-names></name><name name-style="western"><surname>Lawrentschuk</surname><given-names>N</given-names></name><etal/></person-group><article-title>Systematic review: An update on the spectrum of urological malignancies in Lynch syndrome</article-title><source>Bladder Cancer</source><year>2018</year><volume>4</volume><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.3233/BLC-180180</pub-id><pub-id pub-id-type="pmid">30112437</pub-id><pub-id pub-id-type="pmcid">PMC6087433</pub-id></element-citation><mixed-citation id="mc-CR397" publication-type="journal">Huang D, Matin SF, Lawrentschuk N et al (2018) Systematic review: An update on the spectrum of urological malignancies in Lynch syndrome. Bladder Cancer 4:261&#8211;268<pub-id pub-id-type="pmid">30112437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/BLC-180180</pub-id><pub-id pub-id-type="pmcid">PMC6087433</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR398"><label>398.</label><citation-alternatives><element-citation id="ec-CR398" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowty</surname><given-names>JG</given-names></name><name name-style="western"><surname>Win</surname><given-names>AK</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>DD</given-names></name><etal/></person-group><article-title>Cancer risks for <italic toggle="yes">MLH1</italic> and <italic toggle="yes">MSH2</italic> mutation carriers</article-title><source>Hum Mutat</source><year>2013</year><volume>34</volume><fpage>490</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1002/humu.22262</pub-id><pub-id pub-id-type="pmid">23255516</pub-id><pub-id pub-id-type="pmcid">PMC3887142</pub-id></element-citation><mixed-citation id="mc-CR398" publication-type="journal">Dowty JG, Win AK, Buchanan DD et al (2013) Cancer risks for <italic toggle="yes">MLH1</italic> and <italic toggle="yes">MSH2</italic> mutation carriers. Hum Mutat 34:490&#8211;497. 10.1002/humu.22262<pub-id pub-id-type="pmid">23255516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/humu.22262</pub-id><pub-id pub-id-type="pmcid">PMC3887142</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR399"><label>399.</label><citation-alternatives><element-citation id="ec-CR399" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raymond</surname><given-names>VM</given-names></name><name name-style="western"><surname>Everett</surname><given-names>JN</given-names></name><name name-style="western"><surname>Furtado</surname><given-names>LV</given-names></name><etal/></person-group><article-title>Adrenocortical carcinoma is a Lynch syndrome-associated cancer</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>3012</fpage><lpage>3018</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.48.0988</pub-id><pub-id pub-id-type="pmid">23752102</pub-id><pub-id pub-id-type="pmcid">PMC3739861</pub-id></element-citation><mixed-citation id="mc-CR399" publication-type="journal">Raymond VM, Everett JN, Furtado LV et al (2013) Adrenocortical carcinoma is a Lynch syndrome-associated cancer. J Clin Oncol 31:3012&#8211;3018<pub-id pub-id-type="pmid">23752102</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2012.48.0988</pub-id><pub-id pub-id-type="pmcid">PMC3739861</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR400"><label>400.</label><citation-alternatives><element-citation id="ec-CR400" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harper</surname><given-names>HL</given-names></name><name name-style="western"><surname>McKenney</surname><given-names>JK</given-names></name><name name-style="western"><surname>Heald</surname><given-names>B</given-names></name><etal/></person-group><article-title>Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and Lynch syndrome</article-title><source>Mod Pathol</source><year>2017</year><volume>30</volume><fpage>146</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2016.171</pub-id><pub-id pub-id-type="pmid">27713421</pub-id></element-citation><mixed-citation id="mc-CR400" publication-type="journal">Harper HL, McKenney JK, Heald B et al (2017) Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and Lynch syndrome. Mod Pathol 30:146&#8211;156<pub-id pub-id-type="pmid">27713421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/modpathol.2016.171</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR401"><label>401.</label><citation-alternatives><element-citation id="ec-CR401" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metcalfe</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Petros</surname><given-names>FG</given-names></name><name name-style="western"><surname>Rao</surname><given-names>P</given-names></name><etal/></person-group><article-title>Universal point of care testing for Lynch syndrome in patients with upper tract urothelial carcinoma</article-title><source>J Urol</source><year>2018</year><volume>199</volume><fpage>60</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2017.08.002</pub-id><pub-id pub-id-type="pmid">28797715</pub-id></element-citation><mixed-citation id="mc-CR401" publication-type="journal">Metcalfe MJ, Petros FG, Rao P et al (2018) Universal point of care testing for Lynch syndrome in patients with upper tract urothelial carcinoma. J Urol 199:60&#8211;65<pub-id pub-id-type="pmid">28797715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.juro.2017.08.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR402"><label>402.</label><citation-alternatives><element-citation id="ec-CR402" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JY</given-names></name><name name-style="western"><surname>Byeon</surname><given-names>JS</given-names></name></person-group><article-title>Genetic counseling and surveillance focused on Lynch syndrome</article-title><source>J Anus Rectum Colon</source><year>2019</year><volume>3</volume><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.23922/jarc.2019-002</pub-id><pub-id pub-id-type="pmid">31559369</pub-id><pub-id pub-id-type="pmcid">PMC6752118</pub-id></element-citation><mixed-citation id="mc-CR402" publication-type="journal">Kim JY, Byeon JS (2019) Genetic counseling and surveillance focused on Lynch syndrome. J Anus Rectum Colon 3:60&#8211;68<pub-id pub-id-type="pmid">31559369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23922/jarc.2019-002</pub-id><pub-id pub-id-type="pmcid">PMC6752118</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR485"><label>403.</label><mixed-citation publication-type="other">Hubosky SG, Boman BM, Charles S et al (2013) Ureteroscopic management of upper tract urothelial carcinoma (UTUC) in patients with Lynch
Syndrome (hereditary nonpolyposis colorectal cancer syndrome). BJU Int 112:813&#8211;819 [PMID: 23452166]<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bju.12008</pub-id><pub-id pub-id-type="pmid">23452166</pub-id></mixed-citation></ref><ref id="CR403"><label>403.</label><citation-alternatives><element-citation id="ec-CR403" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capelle</surname><given-names>L</given-names></name><name name-style="western"><surname>van Grieken</surname><given-names>N</given-names></name><name name-style="western"><surname>Lingsma</surname><given-names>H</given-names></name><etal/></person-group><article-title>Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands</article-title><source>Gastroenterology</source><year>2010</year><volume>138</volume><fpage>487</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.10.051</pub-id><pub-id pub-id-type="pmid">19900449</pub-id></element-citation><mixed-citation id="mc-CR403" publication-type="journal">Capelle L, van Grieken N, Lingsma H et al (2010) Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 138:487&#8211;492<pub-id pub-id-type="pmid">19900449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2009.10.051</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR404"><label>485.</label><citation-alternatives><element-citation id="ec-CR404" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>H</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>M</given-names></name><name name-style="western"><surname>Sekine</surname><given-names>S</given-names></name><etal/></person-group><article-title>Gastric cancer is highly prevalent in Lynch syndrome patients with atrophic gastritis</article-title><source>Gastric Cancer</source><year>2021</year><volume>24</volume><fpage>283</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1007/s10120-020-01113-0</pub-id><pub-id pub-id-type="pmid">32794040</pub-id></element-citation><mixed-citation id="mc-CR404" publication-type="journal">Cho H, Yamada M, Sekine S et al (2021) Gastric cancer is highly prevalent in Lynch syndrome patients with atrophic gastritis. Gastric Cancer 24:283&#8211;291<pub-id pub-id-type="pmid">32794040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10120-020-01113-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR405"><label>405.</label><citation-alternatives><element-citation id="ec-CR405" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ikenoue</surname><given-names>T</given-names></name><name name-style="western"><surname>Arai</surname><given-names>M</given-names></name><name name-style="western"><surname>Ishioka</surname><given-names>C</given-names></name><etal/></person-group><article-title>Importance of gastric cancer for the diagnosis and surveillance of Japanese Lynch syndrome patients</article-title><source>J Hum Genet</source><year>2019</year><volume>64</volume><fpage>1187</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1038/s10038-019-0674-5</pub-id><pub-id pub-id-type="pmid">31588121</pub-id></element-citation><mixed-citation id="mc-CR405" publication-type="journal">Ikenoue T, Arai M, Ishioka C et al (2019) Importance of gastric cancer for the diagnosis and surveillance of Japanese Lynch syndrome patients. J Hum Genet 64:1187&#8211;1194. 10.1038/s10038-019-0674-5<pub-id pub-id-type="pmid">31588121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s10038-019-0674-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR406"><label>406.</label><citation-alternatives><element-citation id="ec-CR406" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrow</surname><given-names>E</given-names></name><name name-style="western"><surname>Hill</surname><given-names>J</given-names></name><name name-style="western"><surname>Evans</surname><given-names>DG</given-names></name></person-group><article-title>Cancer risk in Lynch Syndrome</article-title><source>Fam Cancer</source><year>2013</year><volume>12</volume><fpage>229</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1007/s10689-013-9615-1</pub-id><pub-id pub-id-type="pmid">23604856</pub-id></element-citation><mixed-citation id="mc-CR406" publication-type="journal">Barrow E, Hill J, Evans DG (2013) Cancer risk in Lynch Syndrome. Fam Cancer 12:229&#8211;240. 10.1007/s10689-013-9615-1<pub-id pub-id-type="pmid">23604856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-013-9615-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR407"><label>407.</label><citation-alternatives><element-citation id="ec-CR407" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arai</surname><given-names>M</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Chino</surname><given-names>A</given-names></name><etal/></person-group><article-title>Incidence and pathological features of tumors on surveillance by colonoscopy and upper gastroduodenal endoscopy in patients with Lynch syndrome</article-title><source>J Fam Tumor</source><year>2010</year><volume>10</volume><fpage>32</fpage><lpage>38</lpage></element-citation><mixed-citation id="mc-CR407" publication-type="journal">Arai M, Ogawa T, Chino A et al (2010) Incidence and pathological features of tumors on surveillance by colonoscopy and upper gastroduodenal endoscopy in patients with Lynch syndrome. J Fam Tumor 10:32&#8211;38</mixed-citation></citation-alternatives></ref><ref id="CR408"><label>408.</label><citation-alternatives><element-citation id="ec-CR408" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olivier</surname><given-names>R</given-names></name><name name-style="western"><surname>Randrian</surname><given-names>V</given-names></name><name name-style="western"><surname>Tougeron</surname><given-names>D</given-names></name><etal/></person-group><article-title>Endoscopy to diagnose and prevent digestive cancers in Lynch syndrome</article-title><source>Cancers (Basel)</source><year>2021</year><volume>13</volume><fpage>3505</fpage><pub-id pub-id-type="doi">10.3390/cancers13143505</pub-id><pub-id pub-id-type="pmid">34298719</pub-id><pub-id pub-id-type="pmcid">PMC8305049</pub-id></element-citation><mixed-citation id="mc-CR408" publication-type="journal">Olivier R, Randrian V, Tougeron D et al (2021) Endoscopy to diagnose and prevent digestive cancers in Lynch syndrome. Cancers (Basel) 13:3505<pub-id pub-id-type="pmid">34298719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13143505</pub-id><pub-id pub-id-type="pmcid">PMC8305049</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR409"><label>409.</label><citation-alternatives><element-citation id="ec-CR409" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shitara</surname><given-names>K</given-names></name><name name-style="western"><surname>Ajani</surname><given-names>JA</given-names></name><name name-style="western"><surname>Moehler</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer</article-title><source>Nature</source><year>2022</year><volume>603</volume><fpage>942</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04508-4</pub-id><pub-id pub-id-type="pmid">35322232</pub-id><pub-id pub-id-type="pmcid">PMC8967713</pub-id></element-citation><mixed-citation id="mc-CR409" publication-type="journal">Shitara K, Ajani JA, Moehler M et al (2022) Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603:942&#8211;948. 10.1038/s41586-022-04508-4<pub-id pub-id-type="pmid">35322232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-04508-4</pub-id><pub-id pub-id-type="pmcid">PMC8967713</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR410"><label>410.</label><citation-alternatives><element-citation id="ec-CR410" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#248;ller</surname><given-names>P</given-names></name><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>TT</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>I</given-names></name><etal/></person-group><article-title>Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database</article-title><source>Gut</source><year>2018</year><volume>67</volume><fpage>1306</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2017-314057</pub-id><pub-id pub-id-type="pmid">28754778</pub-id><pub-id pub-id-type="pmcid">PMC6031262</pub-id></element-citation><mixed-citation id="mc-CR410" publication-type="journal">M&#248;ller P, Sepp&#228;l&#228; TT, Bernstein I et al (2018) Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut 67:1306&#8211;1316<pub-id pub-id-type="pmid">28754778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2017-314057</pub-id><pub-id pub-id-type="pmcid">PMC6031262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR411"><label>411.</label><citation-alternatives><element-citation id="ec-CR411" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abe</surname><given-names>T</given-names></name><name name-style="western"><surname>Blackford</surname><given-names>AL</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>K</given-names></name><etal/></person-group><article-title>Deleterious germline mutations are a risk factor for neoplastic progression among high-risk individuals undergoing pancreatic surveillance</article-title><source>J Clin Oncol</source><year>2019</year><volume>37</volume><fpage>1070</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1200/JCO.18.01512</pub-id><pub-id pub-id-type="pmid">30883245</pub-id><pub-id pub-id-type="pmcid">PMC6494358</pub-id></element-citation><mixed-citation id="mc-CR411" publication-type="journal">Abe T, Blackford AL, Tamura K et al (2019) Deleterious germline mutations are a risk factor for neoplastic progression among high-risk individuals undergoing pancreatic surveillance. J Clin Oncol 37:1070&#8211;1080<pub-id pub-id-type="pmid">30883245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.18.01512</pub-id><pub-id pub-id-type="pmcid">PMC6494358</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR412"><label>412.</label><citation-alternatives><element-citation id="ec-CR412" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goggins</surname><given-names>M</given-names></name><name name-style="western"><surname>Overbeek</surname><given-names>KA</given-names></name><name name-style="western"><surname>Brand</surname><given-names>R</given-names></name><etal/></person-group><article-title>Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium</article-title><source>Gut</source><year>2020</year><volume>69</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2019-319352</pub-id><pub-id pub-id-type="pmid">31672839</pub-id><pub-id pub-id-type="pmcid">PMC7295005</pub-id></element-citation><mixed-citation id="mc-CR412" publication-type="journal">Goggins M, Overbeek KA, Brand R et al (2020) Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 69:7&#8211;17<pub-id pub-id-type="pmid">31672839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2019-319352</pub-id><pub-id pub-id-type="pmcid">PMC7295005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR413"><label>413.</label><citation-alternatives><element-citation id="ec-CR413" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calderwood</surname><given-names>AH</given-names></name><name name-style="western"><surname>Sawhney</surname><given-names>MS</given-names></name><name name-style="western"><surname>Thosani</surname><given-names>NC</given-names></name><etal/></person-group><article-title>American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence</article-title><source>Gastrointest Endosc</source><year>2022</year><volume>95</volume><fpage>827</fpage><lpage>854.e3</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2021.12.002</pub-id><pub-id pub-id-type="pmid">35183359</pub-id></element-citation><mixed-citation id="mc-CR413" publication-type="journal">Calderwood AH, Sawhney MS, Thosani NC et al (2022) American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence. Gastrointest Endosc 95:827-854.e3<pub-id pub-id-type="pmid">35183359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2021.12.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR414"><label>414.</label><citation-alternatives><element-citation id="ec-CR414" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canto</surname><given-names>MI</given-names></name><name name-style="western"><surname>Almario</surname><given-names>JA</given-names></name><name name-style="western"><surname>Schulick</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance</article-title><source>Gastroenterology</source><year>2018</year><volume>155</volume><fpage>740</fpage><lpage>751.e2</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.05.035</pub-id><pub-id pub-id-type="pmid">29803839</pub-id><pub-id pub-id-type="pmcid">PMC6120797</pub-id></element-citation><mixed-citation id="mc-CR414" publication-type="journal">Canto MI, Almario JA, Schulick RD et al (2018) Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology 155:740-751.e2<pub-id pub-id-type="pmid">29803839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2018.05.035</pub-id><pub-id pub-id-type="pmcid">PMC6120797</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR415"><label>415.</label><citation-alternatives><element-citation id="ec-CR415" publication-type="journal"><person-group person-group-type="author"><collab>Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group</collab></person-group><article-title>Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives</article-title><source>Genet Med</source><year>2009</year><volume>11</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1097/GIM.0b013e31818fa2ff</pub-id><pub-id pub-id-type="pmid">19125126</pub-id><pub-id pub-id-type="pmcid">PMC2743612</pub-id></element-citation><mixed-citation id="mc-CR415" publication-type="journal">Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2009) Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11:35&#8211;41<pub-id pub-id-type="pmid">19125126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/GIM.0b013e31818fa2ff</pub-id><pub-id pub-id-type="pmcid">PMC2743612</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR416"><label>416.</label><citation-alternatives><element-citation id="ec-CR416" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Sadeghi</surname><given-names>S</given-names></name><name name-style="western"><surname>Kattan</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Comparative effectiveness of screening strategies for Lynch syndrome</article-title><source>J Natl Cancer Inst</source><year>2015</year><volume>107</volume><fpage>djv005</fpage><pub-id pub-id-type="doi">10.1093/jnci/djv005</pub-id><pub-id pub-id-type="pmid">25794514</pub-id><pub-id pub-id-type="pmcid">PMC4402362</pub-id></element-citation><mixed-citation id="mc-CR416" publication-type="journal">Barzi A, Sadeghi S, Kattan MW et al (2015) Comparative effectiveness of screening strategies for Lynch syndrome. J Natl Cancer Inst 107:djv005. 10.1093/jnci/djv005<pub-id pub-id-type="pmid">25794514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djv005</pub-id><pub-id pub-id-type="pmcid">PMC4402362</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR417"><label>417.</label><citation-alternatives><element-citation id="ec-CR417" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Kuppermann</surname><given-names>M</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B</given-names></name><etal/></person-group><article-title>Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome</article-title><source>Am J Manag Care</source><year>2012</year><volume>18</volume><fpage>e179</fpage><lpage>e185</lpage><pub-id pub-id-type="doi">10.1200/JOP.2011.000535</pub-id><pub-id pub-id-type="pmid">22694112</pub-id></element-citation><mixed-citation id="mc-CR417" publication-type="journal">Wang G, Kuppermann M, Kim B et al (2012) Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome. Am J Manag Care 18:e179&#8211;e185. 10.1200/JOP.2011.000535<pub-id pub-id-type="pmid">22694112</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR418"><label>418.</label><citation-alternatives><element-citation id="ec-CR418" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mvundura</surname><given-names>M</given-names></name><name name-style="western"><surname>Grosse</surname><given-names>SD</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H</given-names></name><etal/></person-group><article-title>The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer</article-title><source>Genet Med</source><year>2010</year><volume>12</volume><fpage>93</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1097/GIM.0b013e3181cd666c</pub-id><pub-id pub-id-type="pmid">20084010</pub-id></element-citation><mixed-citation id="mc-CR418" publication-type="journal">Mvundura M, Grosse SD, Hampel H et al (2010) The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 12:93&#8211;104<pub-id pub-id-type="pmid">20084010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/GIM.0b013e3181cd666c</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR419"><label>419.</label><citation-alternatives><element-citation id="ec-CR419" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ladabaum</surname><given-names>U</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Terdiman</surname><given-names>J</given-names></name><etal/></person-group><article-title>Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis</article-title><source>Ann Intern Med</source><year>2011</year><volume>155</volume><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-155-2-201107190-00002</pub-id><pub-id pub-id-type="pmid">21768580</pub-id><pub-id pub-id-type="pmcid">PMC3793257</pub-id></element-citation><mixed-citation id="mc-CR419" publication-type="journal">Ladabaum U, Wang G, Terdiman J et al (2011) Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 155:69&#8211;79<pub-id pub-id-type="pmid">21768580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-155-2-201107190-00002</pub-id><pub-id pub-id-type="pmcid">PMC3793257</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR420"><label>420.</label><citation-alternatives><element-citation id="ec-CR420" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakayama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Iijima</surname><given-names>T</given-names></name><name name-style="western"><surname>Inokuchi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Clinicopathological features of sporadic MSI colorectal cancer and Lynch syndrome: a single-center retrospective cohort study</article-title><source>Int J Clin Oncol</source><year>2021</year><volume>26</volume><fpage>1881</fpage><lpage>1889</lpage><pub-id pub-id-type="doi">10.1007/s10147-021-01968-y</pub-id><pub-id pub-id-type="pmid">34148153</pub-id></element-citation><mixed-citation id="mc-CR420" publication-type="journal">Nakayama Y, Iijima T, Inokuchi T et al (2021) Clinicopathological features of sporadic MSI colorectal cancer and Lynch syndrome: a single-center retrospective cohort study. Int J Clin Oncol 26:1881&#8211;1889<pub-id pub-id-type="pmid">34148153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10147-021-01968-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR421"><label>421.</label><citation-alternatives><element-citation id="ec-CR421" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiyozumi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Matsubayashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Horiuchi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients</article-title><source>Cancer Med</source><year>2019</year><volume>8</volume><fpage>5534</fpage><lpage>5543</lpage><pub-id pub-id-type="doi">10.1002/cam4.2432</pub-id><pub-id pub-id-type="pmid">31386297</pub-id><pub-id pub-id-type="pmcid">PMC6745857</pub-id></element-citation><mixed-citation id="mc-CR421" publication-type="journal">Kiyozumi Y, Matsubayashi H, Horiuchi Y et al (2019) Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients. Cancer Med 8:5534&#8211;5543<pub-id pub-id-type="pmid">31386297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.2432</pub-id><pub-id pub-id-type="pmcid">PMC6745857</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR422"><label>422.</label><citation-alternatives><element-citation id="ec-CR422" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abu-Ghazaleh</surname><given-names>N</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>V</given-names></name><name name-style="western"><surname>Gorelik</surname><given-names>A</given-names></name><etal/></person-group><article-title>Worldwide prevalence of Lynch syndrome in patients with colorectal cancer: Systematic review and meta-analysis</article-title><source>Genet Med</source><year>2022</year><volume>24</volume><fpage>971</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1016/j.gim.2022.01.014</pub-id><pub-id pub-id-type="pmid">35177335</pub-id></element-citation><mixed-citation id="mc-CR422" publication-type="journal">Abu-Ghazaleh N, Kaushik V, Gorelik A et al (2022) Worldwide prevalence of Lynch syndrome in patients with colorectal cancer: Systematic review and meta-analysis. Genet Med 24:971&#8211;985<pub-id pub-id-type="pmid">35177335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gim.2022.01.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR423"><label>423.</label><citation-alternatives><element-citation id="ec-CR423" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Hoodfar</surname><given-names>E</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Comparison of universal versus age-restricted screening of colorectal tumors for Lynch syndrome using mismatch repair immunohistochemistry: A Cohort Study</article-title><source>Ann Intern Med</source><year>2019</year><volume>171</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.7326/M18-3316</pub-id><pub-id pub-id-type="pmid">31181578</pub-id></element-citation><mixed-citation id="mc-CR423" publication-type="journal">Li D, Hoodfar E, Jiang SF et al (2019) Comparison of universal versus age-restricted screening of colorectal tumors for Lynch syndrome using mismatch repair immunohistochemistry: A Cohort Study. Ann Intern Med 171:19&#8211;26<pub-id pub-id-type="pmid">31181578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M18-3316</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR424"><label>424.</label><citation-alternatives><element-citation id="ec-CR424" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heald</surname><given-names>B</given-names></name><name name-style="western"><surname>Plesec</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing Lynch syndrome in a large academic medical center</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>1336</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.45.1674</pub-id><pub-id pub-id-type="pmid">23401454</pub-id><pub-id pub-id-type="pmcid">PMC4878100</pub-id></element-citation><mixed-citation id="mc-CR424" publication-type="journal">Heald B, Plesec T, Liu X et al (2013) Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing Lynch syndrome in a large academic medical center. J Clin Oncol 31:1336&#8211;1340. 10.1200/JCO.2012.45.1674<pub-id pub-id-type="pmid">23401454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2012.45.1674</pub-id><pub-id pub-id-type="pmcid">PMC4878100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR425"><label>425.</label><citation-alternatives><element-citation id="ec-CR425" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rouba</surname><given-names>AF</given-names></name><name name-style="western"><surname>Matthew</surname><given-names>O</given-names></name><name name-style="western"><surname>Harris</surname><given-names>K</given-names></name><etal/></person-group><article-title>Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in &gt; 28,000 colorectal tumors</article-title><source>J Clin Oncol</source><year>2023</year><volume>41</volume><fpage>30</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1200/JCO.2023.41.4_suppl.30</pub-id></element-citation><mixed-citation id="mc-CR425" publication-type="journal">Rouba AF, Matthew O, Harris K et al (2023) Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in &gt; 28,000 colorectal tumors. J Clin Oncol 41:30&#8211;30</mixed-citation></citation-alternatives></ref><ref id="CR426"><label>426.</label><citation-alternatives><element-citation id="ec-CR426" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liljegren</surname><given-names>A</given-names></name><name name-style="western"><surname>Barker</surname><given-names>G</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>F</given-names></name><etal/></person-group><article-title>Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>3434</fpage><lpage>3439</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.13.2795</pub-id><pub-id pub-id-type="pmid">18612159</pub-id><pub-id pub-id-type="pmcid">PMC2645083</pub-id></element-citation><mixed-citation id="mc-CR426" publication-type="journal">Liljegren A, Barker G, Elliott F et al (2008) Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2. J Clin Oncol 26:3434&#8211;3439. 10.1200/JCO.2007.13.2795<pub-id pub-id-type="pmid">18612159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2007.13.2795</pub-id><pub-id pub-id-type="pmcid">PMC2645083</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR427"><label>427.</label><citation-alternatives><element-citation id="ec-CR427" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahmi</surname><given-names>G</given-names></name><name name-style="western"><surname>Lecomte</surname><given-names>T</given-names></name><name name-style="western"><surname>Malka</surname><given-names>D</given-names></name><etal/></person-group><article-title>Impact of chromoscopy on adenoma detection in patients with Lynch syndrome: a prospective, multicenter, blinded, tandem colonoscopy study</article-title><source>Am J Gastroenterol</source><year>2015</year><volume>110</volume><fpage>288</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1038/ajg.2014.423</pub-id><pub-id pub-id-type="pmid">25601014</pub-id></element-citation><mixed-citation id="mc-CR427" publication-type="journal">Rahmi G, Lecomte T, Malka D et al (2015) Impact of chromoscopy on adenoma detection in patients with Lynch syndrome: a prospective, multicenter, blinded, tandem colonoscopy study. Am J Gastroenterol 110:288&#8211;298<pub-id pub-id-type="pmid">25601014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ajg.2014.423</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR428"><label>428.</label><citation-alternatives><element-citation id="ec-CR428" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dove-Edwin</surname><given-names>I</given-names></name><name name-style="western"><surname>Sasieni</surname><given-names>P</given-names></name><name name-style="western"><surname>Adams</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study</article-title><source>BMJ</source><year>2005</year><volume>331</volume><fpage>1047</fpage><pub-id pub-id-type="doi">10.1136/bmj.38606.794560.EB</pub-id><pub-id pub-id-type="pmid">16243849</pub-id><pub-id pub-id-type="pmcid">PMC1283179</pub-id></element-citation><mixed-citation id="mc-CR428" publication-type="journal">Dove-Edwin I, Sasieni P, Adams J et al (2005) Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ 331:1047<pub-id pub-id-type="pmid">16243849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.38606.794560.EB</pub-id><pub-id pub-id-type="pmcid">PMC1283179</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR429"><label>429.</label><citation-alternatives><element-citation id="ec-CR429" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonadona</surname><given-names>V</given-names></name><name name-style="western"><surname>Bonaiti</surname><given-names>B</given-names></name><name name-style="western"><surname>Olschwang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cancer risks associated with germline mutations in <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, and <italic toggle="yes">MSH6</italic> genes in Lynch syndrome</article-title><source>JAMA</source><year>2011</year><volume>305</volume><fpage>2304</fpage><lpage>2310</lpage><pub-id pub-id-type="doi">10.1001/jama.2011.743</pub-id><pub-id pub-id-type="pmid">21642682</pub-id></element-citation><mixed-citation id="mc-CR429" publication-type="journal">Bonadona V, Bonaiti B, Olschwang S et al (2011) Cancer risks associated with germline mutations in <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, and <italic toggle="yes">MSH6</italic> genes in Lynch syndrome. JAMA 305:2304&#8211;2310<pub-id pub-id-type="pmid">21642682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2011.743</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR430"><label>430.</label><citation-alternatives><element-citation id="ec-CR430" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baglietto</surname><given-names>L</given-names></name><name name-style="western"><surname>Lindor</surname><given-names>NM</given-names></name><name name-style="western"><surname>Dowty</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Risks of Lynch syndrome cancers for MSH6 mutation carriers</article-title><source>J Natl Cancer Inst</source><year>2010</year><volume>102</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1093/jnci/djp473</pub-id><pub-id pub-id-type="pmid">20028993</pub-id><pub-id pub-id-type="pmcid">PMC2815724</pub-id></element-citation><mixed-citation id="mc-CR430" publication-type="journal">Baglietto L, Lindor NM, Dowty JG et al (2010) Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 102:193&#8211;201. 10.1093/jnci/djp473<pub-id pub-id-type="pmid">20028993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djp473</pub-id><pub-id pub-id-type="pmcid">PMC2815724</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR431"><label>431.</label><citation-alternatives><element-citation id="ec-CR431" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suerink</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Girondo</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Klift</surname><given-names>HM</given-names></name><etal/></person-group><article-title>(2019) An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome</article-title><source>Genet Med</source><year>2019</year><volume>21</volume><fpage>2706</fpage><lpage>2712</lpage><pub-id pub-id-type="doi">10.1038/s41436-019-0577-z</pub-id><pub-id pub-id-type="pmid">31204389</pub-id></element-citation><mixed-citation id="mc-CR431" publication-type="journal">Suerink M, Rodr&#237;guez-Girondo M, van der Klift HM et al (2019) (2019) An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. Genet Med 21:2706&#8211;2712<pub-id pub-id-type="pmid">31204389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-019-0577-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR432"><label>432.</label><citation-alternatives><element-citation id="ec-CR432" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senter</surname><given-names>L</given-names></name><name name-style="western"><surname>Clendenning</surname><given-names>M</given-names></name><name name-style="western"><surname>Sotamaa</surname><given-names>K</given-names></name><etal/></person-group><article-title>The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations</article-title><source>Gastroenterology</source><year>2008</year><volume>135</volume><fpage>419</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.04.026</pub-id><pub-id pub-id-type="pmid">18602922</pub-id><pub-id pub-id-type="pmcid">PMC2759321</pub-id></element-citation><mixed-citation id="mc-CR432" publication-type="journal">Senter L, Clendenning M, Sotamaa K et al (2008) The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135:419&#8211;428<pub-id pub-id-type="pmid">18602922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2008.04.026</pub-id><pub-id pub-id-type="pmcid">PMC2759321</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR433"><label>433.</label><citation-alternatives><element-citation id="ec-CR433" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>ten Broeke</surname><given-names>SW</given-names></name><name name-style="western"><surname>van der Klift</surname><given-names>HM</given-names></name><name name-style="western"><surname>Tops</surname><given-names>CMJ</given-names></name><etal/></person-group><article-title>Cancer risks for PMS2-associated Lynch syndrome</article-title><source>J Clin Oncol</source><year>2018</year><volume>36</volume><fpage>2961</fpage><lpage>2968</lpage><pub-id pub-id-type="doi">10.1200/JCO.2018.78.4777</pub-id><pub-id pub-id-type="pmid">30161022</pub-id><pub-id pub-id-type="pmcid">PMC6349460</pub-id></element-citation><mixed-citation id="mc-CR433" publication-type="journal">ten Broeke SW, van der Klift HM, Tops CMJ et al (2018) Cancer risks for PMS2-associated Lynch syndrome. J Clin Oncol 36:2961&#8211;2968<pub-id pub-id-type="pmid">30161022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2018.78.4777</pub-id><pub-id pub-id-type="pmcid">PMC6349460</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR434"><label>434.</label><citation-alternatives><element-citation id="ec-CR434" publication-type="journal"><person-group person-group-type="author"><collab>International Mismatch Repair Consortium</collab></person-group><article-title>Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study</article-title><source>Lancet Oncol</source><year>2021</year><volume>22</volume><fpage>1014</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00189-3</pub-id><pub-id pub-id-type="pmid">34111421</pub-id><pub-id pub-id-type="pmcid">PMC8934577</pub-id></element-citation><mixed-citation id="mc-CR434" publication-type="journal">International Mismatch Repair Consortium (2021) Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncol 22:1014&#8211;1022<pub-id pub-id-type="pmid">34111421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(21)00189-3</pub-id><pub-id pub-id-type="pmcid">PMC8934577</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR436"><label>436.</label><citation-alternatives><element-citation id="ec-CR436" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeJong</surname><given-names>AE</given-names></name><name name-style="western"><surname>Nagengast</surname><given-names>FM</given-names></name><name name-style="western"><surname>Kleibeuker</surname><given-names>JH</given-names></name><etal/></person-group><article-title>What is the appropriate screening protocol in Lynch syndrome?</article-title><source>Fam Cancer</source><year>2006</year><volume>5</volume><fpage>373</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1007/s10689-006-0008-6</pub-id><pub-id pub-id-type="pmid">16826316</pub-id></element-citation><mixed-citation id="mc-CR436" publication-type="journal">DeJong AE, Nagengast FM, Kleibeuker JH et al (2006) What is the appropriate screening protocol in Lynch syndrome? Fam Cancer 5:373&#8211;378<pub-id pub-id-type="pmid">16826316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-006-0008-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR437"><label>437.</label><citation-alternatives><element-citation id="ec-CR437" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendriks</surname><given-names>YMC</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>A</given-names></name><name name-style="western"><surname>Morreau</surname><given-names>H</given-names></name><etal/></person-group><article-title>Cancer risk in hereditary nonpolyposis colorectal cancer due to <italic toggle="yes">MSH6</italic> mutations: impact on counseling and surveillance</article-title><source>Gastroenterology</source><year>2004</year><volume>127</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2004.03.068</pub-id><pub-id pub-id-type="pmid">15236168</pub-id></element-citation><mixed-citation id="mc-CR437" publication-type="journal">Hendriks YMC, Wagner A, Morreau H et al (2004) Cancer risk in hereditary nonpolyposis colorectal cancer due to <italic toggle="yes">MSH6</italic> mutations: impact on counseling and surveillance. Gastroenterology 127:17&#8211;25<pub-id pub-id-type="pmid">15236168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2004.03.068</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR438"><label>438.</label><citation-alternatives><element-citation id="ec-CR438" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quehenberger</surname><given-names>F</given-names></name><name name-style="western"><surname>Vasen</surname><given-names>HFA</given-names></name><name name-style="western"><surname>Van Houwelingen</surname><given-names>HC</given-names></name></person-group><article-title>Risk of colorectal and endometrial cancer for carriers of mutations of the <italic toggle="yes">hMLH1</italic> and <italic toggle="yes">hMSH2</italic> gene: correction for ascertainment</article-title><source>J Med Genet</source><year>2005</year><volume>42</volume><fpage>491</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1136/jmg.2004.024299</pub-id><pub-id pub-id-type="pmid">15937084</pub-id><pub-id pub-id-type="pmcid">PMC1736072</pub-id></element-citation><mixed-citation id="mc-CR438" publication-type="journal">Quehenberger F, Vasen HFA, Van Houwelingen HC (2005) Risk of colorectal and endometrial cancer for carriers of mutations of the <italic toggle="yes">hMLH1</italic> and <italic toggle="yes">hMSH2</italic> gene: correction for ascertainment. J Med Genet 42:491&#8211;496<pub-id pub-id-type="pmid">15937084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmg.2004.024299</pub-id><pub-id pub-id-type="pmcid">PMC1736072</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR439"><label>439.</label><citation-alternatives><element-citation id="ec-CR439" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hampel</surname><given-names>H</given-names></name><name name-style="western"><surname>Frankel</surname><given-names>W</given-names></name><name name-style="western"><surname>Panescu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>7810</fpage><lpage>7817</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1114</pub-id><pub-id pub-id-type="pmid">16885385</pub-id></element-citation><mixed-citation id="mc-CR439" publication-type="journal">Hampel H, Frankel W, Panescu J et al (2006) Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66:7810&#8211;7817<pub-id pub-id-type="pmid">16885385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-06-1114</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR440"><label>440.</label><citation-alternatives><element-citation id="ec-CR440" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenkins</surname><given-names>MA</given-names></name><name name-style="western"><surname>Baglietto</surname><given-names>L</given-names></name><name name-style="western"><surname>Dowty</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study</article-title><source>Clin Gastroenterol Hepatol</source><year>2006</year><volume>4</volume><fpage>489</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2006.01.002</pub-id><pub-id pub-id-type="pmid">16616355</pub-id></element-citation><mixed-citation id="mc-CR440" publication-type="journal">Jenkins MA, Baglietto L, Dowty JG et al (2006) Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol 4:489&#8211;498<pub-id pub-id-type="pmid">16616355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2006.01.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR441"><label>441.</label><citation-alternatives><element-citation id="ec-CR441" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cairns</surname><given-names>SR</given-names></name><name name-style="western"><surname>Scholefield</surname><given-names>JH</given-names></name><name name-style="western"><surname>Steele</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002)</article-title><source>Gut</source><year>2010</year><volume>59</volume><fpage>666</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1136/gut.2009.179804</pub-id><pub-id pub-id-type="pmid">20427401</pub-id></element-citation><mixed-citation id="mc-CR441" publication-type="journal">Cairns SR, Scholefield JH, Steele RJ et al (2010) Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59:666&#8211;689<pub-id pub-id-type="pmid">20427401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.2009.179804</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR442"><label>442.</label><citation-alternatives><element-citation id="ec-CR442" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubenstein</surname><given-names>JH</given-names></name><name name-style="western"><surname>Enns</surname><given-names>R</given-names></name><name name-style="western"><surname>Heidelbaugh</surname><given-names>J</given-names></name><etal/></person-group><article-title>American Gastroenterological Association Institute Guideline on the diagnosis and management of Lynch syndrome</article-title><source>Gastroenterology</source><year>2015</year><volume>149</volume><fpage>777</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.07.036</pub-id><pub-id pub-id-type="pmid">26226577</pub-id></element-citation><mixed-citation id="mc-CR442" publication-type="journal">Rubenstein JH, Enns R, Heidelbaugh J et al (2015) American Gastroenterological Association Institute Guideline on the diagnosis and management of Lynch syndrome. Gastroenterology 149:777&#8211;782<pub-id pub-id-type="pmid">26226577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2015.07.036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR443"><label>443.</label><citation-alternatives><element-citation id="ec-CR443" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenkins</surname><given-names>MA</given-names></name><name name-style="western"><surname>Dowty</surname><given-names>JG</given-names></name><name name-style="western"><surname>Ait Ouakrim</surname><given-names>D</given-names></name><etal/></person-group><article-title>Short-term risk of colorectal cancer in individuals with Lynch syndrome: a meta-analysis</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>326</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.55.8536</pub-id><pub-id pub-id-type="pmid">25534380</pub-id></element-citation><mixed-citation id="mc-CR443" publication-type="journal">Jenkins MA, Dowty JG, Ait Ouakrim D et al (2015) Short-term risk of colorectal cancer in individuals with Lynch syndrome: a meta-analysis. J Clin Oncol 33:326&#8211;331. 10.1200/JCO.2014.55.8536<pub-id pub-id-type="pmid">25534380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2014.55.8536</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR444"><label>444.</label><citation-alternatives><element-citation id="ec-CR444" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>ten Broeke</surname><given-names>SW</given-names></name><name name-style="western"><surname>Brohet</surname><given-names>RM</given-names></name><name name-style="western"><surname>Tops</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.57.8088</pub-id><pub-id pub-id-type="pmid">25512458</pub-id></element-citation><mixed-citation id="mc-CR444" publication-type="journal">ten Broeke SW, Brohet RM, Tops CM et al (2015) Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. J Clin Oncol 33:319&#8211;325. 10.1200/JCO.2014.57.8088<pub-id pub-id-type="pmid">25512458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2014.57.8088</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR445"><label>445.</label><citation-alternatives><element-citation id="ec-CR445" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kastrinos</surname><given-names>F</given-names></name><name name-style="western"><surname>Ingram</surname><given-names>MA</given-names></name><name name-style="western"><surname>Silver</surname><given-names>ER</given-names></name><etal/></person-group><article-title>Gene-specific variation in colorectal cancer surveillance strategies for Lynch syndrome</article-title><source>Gastroenterology</source><year>2021</year><volume>161</volume><fpage>453</fpage><lpage>462.e15</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2021.04.010</pub-id><pub-id pub-id-type="pmid">33839100</pub-id><pub-id pub-id-type="pmcid">PMC9330543</pub-id></element-citation><mixed-citation id="mc-CR445" publication-type="journal">Kastrinos F, Ingram MA, Silver ER et al (2021) Gene-specific variation in colorectal cancer surveillance strategies for Lynch syndrome. Gastroenterology 161:453-462.e15<pub-id pub-id-type="pmid">33839100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2021.04.010</pub-id><pub-id pub-id-type="pmcid">PMC9330543</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR446"><label>446.</label><citation-alternatives><element-citation id="ec-CR446" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Caruana</surname><given-names>M</given-names></name><name name-style="western"><surname>McLoughlin</surname><given-names>K</given-names></name><etal/></person-group><article-title>The predicted effect and cost-effectiveness of tailoring colonoscopic surveillance according to mismatch repair gene in patients with Lynch syndrome</article-title><source>Genet Med</source><year>2022</year><volume>24</volume><fpage>1831</fpage><lpage>1846</lpage><pub-id pub-id-type="doi">10.1016/j.gim.2022.05.016</pub-id><pub-id pub-id-type="pmid">35809086</pub-id></element-citation><mixed-citation id="mc-CR446" publication-type="journal">Kang YJ, Caruana M, McLoughlin K et al (2022) The predicted effect and cost-effectiveness of tailoring colonoscopic surveillance according to mismatch repair gene in patients with Lynch syndrome. Genet Med 24:1831&#8211;1846<pub-id pub-id-type="pmid">35809086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gim.2022.05.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR447"><label>447.</label><citation-alternatives><element-citation id="ec-CR447" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasen</surname><given-names>HF</given-names></name><name name-style="western"><surname>Abdirahman</surname><given-names>M</given-names></name><name name-style="western"><surname>Brohet</surname><given-names>R</given-names></name><etal/></person-group><article-title>One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome</article-title><source>Gastroenterology</source><year>2010</year><volume>138</volume><fpage>2300</fpage><lpage>2306</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2010.02.053</pub-id><pub-id pub-id-type="pmid">20206180</pub-id></element-citation><mixed-citation id="mc-CR447" publication-type="journal">Vasen HF, Abdirahman M, Brohet R et al (2010) One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 138:2300&#8211;2306<pub-id pub-id-type="pmid">20206180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2010.02.053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR448"><label>448.</label><citation-alternatives><element-citation id="ec-CR448" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burn</surname><given-names>J</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>DT</given-names></name><name name-style="western"><surname>Mecklin</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>2567</fpage><lpage>2578</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0801297</pub-id><pub-id pub-id-type="pmid">19073976</pub-id></element-citation><mixed-citation id="mc-CR448" publication-type="journal">Burn J, Bishop DT, Mecklin JP et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359:2567&#8211;2578<pub-id pub-id-type="pmid">19073976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0801297</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR449"><label>449.</label><citation-alternatives><element-citation id="ec-CR449" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burn</surname><given-names>J</given-names></name><name name-style="western"><surname>Sheth</surname><given-names>H</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>F</given-names></name><etal/></person-group><article-title>Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome, 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1855</fpage><lpage>1863</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30366-4</pub-id><pub-id pub-id-type="pmid">32534647</pub-id><pub-id pub-id-type="pmcid">PMC7294238</pub-id></element-citation><mixed-citation id="mc-CR449" publication-type="journal">Burn J, Sheth H, Elliott F et al (2020) Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome, 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet 395:1855&#8211;1863<pub-id pub-id-type="pmid">32534647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30366-4</pub-id><pub-id pub-id-type="pmcid">PMC7294238</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR450"><label>450.</label><citation-alternatives><element-citation id="ec-CR450" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothwell</surname><given-names>PM</given-names></name><name name-style="western"><surname>Cook</surname><given-names>NR</given-names></name><name name-style="western"><surname>Gaziano</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>387</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31133-4</pub-id><pub-id pub-id-type="pmid">30017552</pub-id><pub-id pub-id-type="pmcid">PMC6083400</pub-id></element-citation><mixed-citation id="mc-CR450" publication-type="journal">Rothwell PM, Cook NR, Gaziano JM et al (2018) Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 392:387&#8211;399<pub-id pub-id-type="pmid">30017552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)31133-4</pub-id><pub-id pub-id-type="pmcid">PMC6083400</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR451"><label>451.</label><citation-alternatives><element-citation id="ec-CR451" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathers</surname><given-names>JC</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>F</given-names></name><name name-style="western"><surname>Macrae</surname><given-names>F</given-names></name><etal/></person-group><article-title>Cancer prevention with resistant starch in Lynch syndrome patients in the CAPP2-randomized placebo controlled trial: Planned 10-year follow-up</article-title><source>Cancer Prev Res (Phila)</source><year>2022</year><volume>15</volume><fpage>623</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-22-0044</pub-id><pub-id pub-id-type="pmid">35878732</pub-id><pub-id pub-id-type="pmcid">PMC9433960</pub-id></element-citation><mixed-citation id="mc-CR451" publication-type="journal">Mathers JC, Elliott F, Macrae F et al (2022) Cancer prevention with resistant starch in Lynch syndrome patients in the CAPP2-randomized placebo controlled trial: Planned 10-year follow-up. Cancer Prev Res (Phila) 15:623&#8211;634<pub-id pub-id-type="pmid">35878732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1940-6207.CAPR-22-0044</pub-id><pub-id pub-id-type="pmcid">PMC9433960</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR452"><label>452.</label><citation-alternatives><element-citation id="ec-CR452" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tzortzatos</surname><given-names>G</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>E</given-names></name><name name-style="western"><surname>Soller</surname><given-names>M</given-names></name><etal/></person-group><article-title>The gynecological surveillance of women with Lynch syndrome in Sweden</article-title><source>Gynecol Oncol</source><year>2015</year><volume>138</volume><fpage>717</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2015.07.016</pub-id><pub-id pub-id-type="pmid">26177554</pub-id></element-citation><mixed-citation id="mc-CR452" publication-type="journal">Tzortzatos G, Andersson E, Soller M et al (2015) The gynecological surveillance of women with Lynch syndrome in Sweden. Gynecol Oncol 138:717&#8211;722<pub-id pub-id-type="pmid">26177554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2015.07.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR453"><label>453.</label><citation-alternatives><element-citation id="ec-CR453" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez-Valentin</surname><given-names>M</given-names></name><name name-style="western"><surname>Crosbie</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Engel</surname><given-names>C</given-names></name><etal/></person-group><article-title>Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report</article-title><source>Genet Med</source><year>2021</year><volume>23</volume><fpage>705</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1038/s41436-020-01029-1</pub-id><pub-id pub-id-type="pmid">33257847</pub-id><pub-id pub-id-type="pmcid">PMC8026395</pub-id></element-citation><mixed-citation id="mc-CR453" publication-type="journal">Dominguez-Valentin M, Crosbie EJ, Engel C et al (2021) Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Genet Med 23:705&#8211;712<pub-id pub-id-type="pmid">33257847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-020-01029-1</pub-id><pub-id pub-id-type="pmcid">PMC8026395</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR454"><label>454.</label><citation-alternatives><element-citation id="ec-CR454" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>J&#228;rvinen</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Renkonen-Sinisalo</surname><given-names>L</given-names></name><name name-style="western"><surname>Akt&#225;n-Coll&#225;n</surname><given-names>K</given-names></name><etal/></person-group><article-title>Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>4793</fpage><lpage>4797</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.23.7784</pub-id><pub-id pub-id-type="pmid">19720893</pub-id></element-citation><mixed-citation id="mc-CR454" publication-type="journal">J&#228;rvinen HJ, Renkonen-Sinisalo L, Akt&#225;n-Coll&#225;n K et al (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793&#8211;4797<pub-id pub-id-type="pmid">19720893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2009.23.7784</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR455"><label>455.</label><citation-alternatives><element-citation id="ec-CR455" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>JS</given-names></name><name name-style="western"><surname>Sun</surname><given-names>CC</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome</article-title><source>Cancer</source><year>2008</year><volume>113</volume><fpage>326</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1002/cncr.23554</pub-id><pub-id pub-id-type="pmid">18506736</pub-id></element-citation><mixed-citation id="mc-CR455" publication-type="journal">Kwon JS, Sun CC, Peterson SK et al (2008) Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer 113:326&#8211;335<pub-id pub-id-type="pmid">18506736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.23554</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR456"><label>456.</label><citation-alternatives><element-citation id="ec-CR456" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>KY</given-names></name><name name-style="western"><surname>Caughey</surname><given-names>AB</given-names></name><name name-style="western"><surname>Little</surname><given-names>SE</given-names></name><etal/></person-group><article-title>A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) families</article-title><source>Fam Cancer</source><year>2011</year><volume>10</volume><fpage>535</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1007/s10689-011-9444-z</pub-id><pub-id pub-id-type="pmid">21538078</pub-id></element-citation><mixed-citation id="mc-CR456" publication-type="journal">Yang KY, Caughey AB, Little SE et al (2011) A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) families. Fam Cancer 10:535&#8211;543<pub-id pub-id-type="pmid">21538078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-011-9444-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR457"><label>457.</label><citation-alternatives><element-citation id="ec-CR457" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alblas</surname><given-names>M</given-names></name><name name-style="western"><surname>Peterse</surname><given-names>EFP</given-names></name><name name-style="western"><surname>Du</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cost-effectiveness of prophylactic hysterectomy in first-degree female relatives with Lynch syndrome of patients diagnosed with colorectal cancer in the United States: a microsimulation study</article-title><source>Cancer Med</source><year>2021</year><volume>10</volume><fpage>6835</fpage><lpage>6844</lpage><pub-id pub-id-type="doi">10.1002/cam4.4080</pub-id><pub-id pub-id-type="pmid">34510779</pub-id><pub-id pub-id-type="pmcid">PMC8495276</pub-id></element-citation><mixed-citation id="mc-CR457" publication-type="journal">Alblas M, Peterse EFP, Du M et al (2021) Cost-effectiveness of prophylactic hysterectomy in first-degree female relatives with Lynch syndrome of patients diagnosed with colorectal cancer in the United States: a microsimulation study. Cancer Med 10:6835&#8211;6844<pub-id pub-id-type="pmid">34510779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.4080</pub-id><pub-id pub-id-type="pmcid">PMC8495276</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR458"><label>458.</label><citation-alternatives><element-citation id="ec-CR458" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moldovan</surname><given-names>R</given-names></name><name name-style="western"><surname>Keating</surname><given-names>S</given-names></name></person-group><article-title>Clancy T (1015) The impact of risk-reducing gynaecological surgery in premenopausal women at high risk of endometrial and ovarian cancer due to Lynch syndrome</article-title><source>Fam Cancer</source><year>2015</year><volume>14</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1007/s10689-014-9761-0</pub-id><pub-id pub-id-type="pmid">25342222</pub-id></element-citation><mixed-citation id="mc-CR458" publication-type="journal">Moldovan R, Keating S (2015) Clancy T (1015) The impact of risk-reducing gynaecological surgery in premenopausal women at high risk of endometrial and ovarian cancer due to Lynch syndrome. Fam Cancer 14:51&#8211;60<pub-id pub-id-type="pmid">25342222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-014-9761-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR459"><label>459.</label><citation-alternatives><element-citation id="ec-CR459" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Etchegary</surname><given-names>H</given-names></name><name name-style="western"><surname>Dicks</surname><given-names>E</given-names></name><name name-style="western"><surname>Tamutis</surname><given-names>L</given-names></name><etal/></person-group><article-title>Quality of life following prophylactic gynecological surgery: experiences of female Lynch mutation carriers</article-title><source>Fam Cancer</source><year>2018</year><volume>17</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1007/s10689-017-9997-6</pub-id><pub-id pub-id-type="pmid">28551770</pub-id></element-citation><mixed-citation id="mc-CR459" publication-type="journal">Etchegary H, Dicks E, Tamutis L et al (2018) Quality of life following prophylactic gynecological surgery: experiences of female Lynch mutation carriers. Fam Cancer 17:53&#8211;61<pub-id pub-id-type="pmid">28551770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-017-9997-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR460"><label>460.</label><citation-alternatives><element-citation id="ec-CR460" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukase</surname><given-names>K</given-names></name><name name-style="western"><surname>Kato</surname><given-names>M</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of eradication of <italic toggle="yes">Helicobacter pylori</italic> on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>392</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61159-9</pub-id><pub-id pub-id-type="pmid">18675689</pub-id></element-citation><mixed-citation id="mc-CR460" publication-type="journal">Fukase K, Kato M, Kikuchi S et al (2008) Effect of eradication of <italic toggle="yes">Helicobacter pylori</italic> on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372:392&#8211;397<pub-id pub-id-type="pmid">18675689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(08)61159-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR462"><label>462.</label><citation-alternatives><element-citation id="ec-CR462" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Shin</surname><given-names>KH</given-names></name><name name-style="western"><surname>Park</surname><given-names>JG</given-names></name></person-group><article-title>Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>2994</fpage><lpage>2998</lpage><pub-id pub-id-type="pmid">10955776</pub-id></element-citation><mixed-citation id="mc-CR462" publication-type="journal">Park YJ, Shin KH, Park JG (2000) Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. Clin Cancer Res 6:2994&#8211;2998<pub-id pub-id-type="pmid">10955776</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR463"><label>463.</label><citation-alternatives><element-citation id="ec-CR463" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ortig&#227;o</surname><given-names>R</given-names></name><name name-style="western"><surname>Brito</surname><given-names>M</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>C</given-names></name><etal/></person-group><article-title>Risk factors for gastric cancer in patients with Lynch syndrome</article-title><source>Eur J Gastroenterol Hepatol</source><year>2022</year><volume>34</volume><fpage>912</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1097/MEG.0000000000002405</pub-id><pub-id pub-id-type="pmid">35830349</pub-id></element-citation><mixed-citation id="mc-CR463" publication-type="journal">Ortig&#227;o R, Brito M, Pinto C et al (2022) Risk factors for gastric cancer in patients with Lynch syndrome. Eur J Gastroenterol Hepatol 34:912&#8211;918<pub-id pub-id-type="pmid">35830349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MEG.0000000000002405</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR464"><label>464.</label><citation-alternatives><element-citation id="ec-CR464" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soer</surname><given-names>EC</given-names></name><name name-style="western"><surname>Leicher</surname><given-names>LW</given-names></name><name name-style="western"><surname>Langers</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Equivalent <italic toggle="yes">Helicobacter pylori</italic> infection rates in Lynch syndrome mutation carriers with and without a first-degree relative with gastric cancer</article-title><source>Int J Colorectal Dis</source><year>2016</year><volume>31</volume><fpage>693</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1007/s00384-016-2524-7</pub-id><pub-id pub-id-type="pmid">26847620</pub-id></element-citation><mixed-citation id="mc-CR464" publication-type="journal">Soer EC, Leicher LW, Langers AM et al (2016) Equivalent <italic toggle="yes">Helicobacter pylori</italic> infection rates in Lynch syndrome mutation carriers with and without a first-degree relative with gastric cancer. Int J Colorectal Dis 31:693&#8211;697. 10.1007/s00384-016-2524-7<pub-id pub-id-type="pmid">26847620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00384-016-2524-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR465"><label>465.</label><citation-alternatives><element-citation id="ec-CR465" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Dudzik</surname><given-names>CM</given-names></name><name name-style="western"><surname>Reed</surname><given-names>M</given-names></name><etal/></person-group><article-title>Upper endoscopic surveillance in Lynch syndrome detects gastric and duodenal adenocarcinomas</article-title><source>Cancer Prev Res (Phila)</source><year>2020</year><volume>13</volume><fpage>1047</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-20-0269</pub-id><pub-id pub-id-type="pmid">32859614</pub-id><pub-id pub-id-type="pmcid">PMC7718364</pub-id></element-citation><mixed-citation id="mc-CR465" publication-type="journal">Kumar S, Dudzik CM, Reed M et al (2020) Upper endoscopic surveillance in Lynch syndrome detects gastric and duodenal adenocarcinomas. Cancer Prev Res (Phila) 13:1047&#8211;1054<pub-id pub-id-type="pmid">32859614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1940-6207.CAPR-20-0269</pub-id><pub-id pub-id-type="pmcid">PMC7718364</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR466"><label>466.</label><citation-alternatives><element-citation id="ec-CR466" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saulino</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Characterization of chronic gastritis in Lynch syndrome patients with gastric adenocarcinoma</article-title><source>Gastroenterology Res</source><year>2021</year><volume>14</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.14740/gr1359</pub-id><pub-id pub-id-type="pmid">33737995</pub-id><pub-id pub-id-type="pmcid">PMC7935615</pub-id></element-citation><mixed-citation id="mc-CR466" publication-type="journal">Saulino D, Chen R, Wang K et al (2021) Characterization of chronic gastritis in Lynch syndrome patients with gastric adenocarcinoma. Gastroenterology Res 14:13&#8211;20<pub-id pub-id-type="pmid">33737995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14740/gr1359</pub-id><pub-id pub-id-type="pmcid">PMC7935615</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR467"><label>467.</label><citation-alternatives><element-citation id="ec-CR467" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baglietto</surname><given-names>L</given-names></name><name name-style="western"><surname>Lindor</surname><given-names>NM</given-names></name><name name-style="western"><surname>Dowty</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Risks of Lynch syndrome cancers for MSH6 mutation carriers</article-title><source>J Natl Cancer Inst</source><year>2010</year><volume>102</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1093/jnci/djp473</pub-id><pub-id pub-id-type="pmid">20028993</pub-id><pub-id pub-id-type="pmcid">PMC2815724</pub-id></element-citation><mixed-citation id="mc-CR467" publication-type="journal">Baglietto L, Lindor NM, Dowty JG et al (2010) Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 102:193&#8211;201<pub-id pub-id-type="pmid">20028993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djp473</pub-id><pub-id pub-id-type="pmcid">PMC2815724</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR468"><label>468.</label><citation-alternatives><element-citation id="ec-CR468" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suerink</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Girondo</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Klift</surname><given-names>HM</given-names></name><etal/></person-group><article-title>An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome</article-title><source>Genet Med</source><year>2019</year><volume>21</volume><fpage>2706</fpage><lpage>2712</lpage><pub-id pub-id-type="doi">10.1038/s41436-019-0577-z</pub-id><pub-id pub-id-type="pmid">31204389</pub-id></element-citation><mixed-citation id="mc-CR468" publication-type="journal">Suerink M, Rodr&#237;guez-Girondo M, van der Klift HM et al (2019) An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. Genet Med 21:2706&#8211;2712<pub-id pub-id-type="pmid">31204389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-019-0577-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR469"><label>469.</label><citation-alternatives><element-citation id="ec-CR469" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senter</surname><given-names>L</given-names></name><name name-style="western"><surname>Clendenning</surname><given-names>M</given-names></name><name name-style="western"><surname>Sotamaa</surname><given-names>K</given-names></name><etal/></person-group><article-title>The clinical phenotype of Lynch syndrome due to germline <italic toggle="yes">PMS2</italic> mutations</article-title><source>Gastroenterology</source><year>2008</year><volume>135</volume><fpage>419</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.04.026</pub-id><pub-id pub-id-type="pmid">18602922</pub-id><pub-id pub-id-type="pmcid">PMC2759321</pub-id></element-citation><mixed-citation id="mc-CR469" publication-type="journal">Senter L, Clendenning M, Sotamaa K et al (2008) The clinical phenotype of Lynch syndrome due to germline <italic toggle="yes">PMS2</italic> mutations. Gastroenterology 135:419&#8211;428<pub-id pub-id-type="pmid">18602922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2008.04.026</pub-id><pub-id pub-id-type="pmcid">PMC2759321</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR470"><label>470.</label><citation-alternatives><element-citation id="ec-CR470" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haraldsdottir</surname><given-names>S</given-names></name><name name-style="western"><surname>Rafnar</surname><given-names>T</given-names></name><name name-style="western"><surname>Frankel</surname><given-names>WL</given-names></name><etal/></person-group><article-title>Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in <italic toggle="yes">MSH6</italic> and <italic toggle="yes">PMS2</italic></article-title><source>Nature Comm</source><year>2017</year><volume>8</volume><fpage>14755</fpage><pub-id pub-id-type="doi">10.1038/ncomms14755</pub-id><pub-id pub-id-type="pmcid">PMC5418568</pub-id><pub-id pub-id-type="pmid">28466842</pub-id></element-citation><mixed-citation id="mc-CR470" publication-type="journal">Haraldsdottir S, Rafnar T, Frankel WL et al (2017) Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in <italic toggle="yes">MSH6</italic> and <italic toggle="yes">PMS2</italic>. Nature Comm 8:14755<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms14755</pub-id><pub-id pub-id-type="pmcid">PMC5418568</pub-id><pub-id pub-id-type="pmid">28466842</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR471"><label>471.</label><citation-alternatives><element-citation id="ec-CR471" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#248;ller</surname><given-names>P</given-names></name><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>T</given-names></name><name name-style="western"><surname>Dowty</surname><given-names>JG</given-names></name><etal/></person-group><article-title>European Hereditary Tumour Group (EHTG) and the International Mismatch Repair Consortium (IMRC): Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective Lynch syndrome database and the international mismatch repair consortium</article-title><source>Hered Cancer Clin Pract</source><year>2022</year><volume>20</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/s13053-022-00241-1</pub-id><pub-id pub-id-type="pmid">36182917</pub-id><pub-id pub-id-type="pmcid">PMC9526951</pub-id></element-citation><mixed-citation id="mc-CR471" publication-type="journal">M&#248;ller P, Sepp&#228;l&#228; T, Dowty JG et al (2022) European Hereditary Tumour Group (EHTG) and the International Mismatch Repair Consortium (IMRC): Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective Lynch syndrome database and the international mismatch repair consortium. Hered Cancer Clin Pract 20:36. 10.1186/s13053-022-00241-1<pub-id pub-id-type="pmid">36182917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13053-022-00241-1</pub-id><pub-id pub-id-type="pmcid">PMC9526951</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR472"><label>472.</label><citation-alternatives><element-citation id="ec-CR472" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ten Broeke</surname><given-names>SW</given-names></name><name name-style="western"><surname>van der Klift</surname><given-names>HM</given-names></name><name name-style="western"><surname>Tops</surname><given-names>CMJ</given-names></name><etal/></person-group><article-title>Cancer risks for <italic toggle="yes">PMS2</italic>-associated Lynch syndrome</article-title><source>J Clin Oncol</source><year>2018</year><volume>36</volume><fpage>2961</fpage><lpage>2968</lpage><pub-id pub-id-type="doi">10.1200/JCO.2018.78.4777</pub-id><pub-id pub-id-type="pmid">30161022</pub-id><pub-id pub-id-type="pmcid">PMC6349460</pub-id></element-citation><mixed-citation id="mc-CR472" publication-type="journal">Ten Broeke SW, van der Klift HM, Tops CMJ et al (2018) Cancer risks for <italic toggle="yes">PMS2</italic>-associated Lynch syndrome. J Clin Oncol 36:2961&#8211;2968. 10.1200/JCO.2018.78.4777<pub-id pub-id-type="pmid">30161022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2018.78.4777</pub-id><pub-id pub-id-type="pmcid">PMC6349460</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR473"><label>473.</label><citation-alternatives><element-citation id="ec-CR473" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez-Valentin</surname><given-names>M</given-names></name><name name-style="western"><surname>Sampson</surname><given-names>J</given-names></name><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database</article-title><source>Genet Med</source><year>2020</year><volume>22</volume><fpage>15</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1038/s41436-019-0596-9</pub-id><pub-id pub-id-type="pmid">31337882</pub-id><pub-id pub-id-type="pmcid">PMC7371626</pub-id></element-citation><mixed-citation id="mc-CR473" publication-type="journal">Dominguez-Valentin M, Sampson J, Sepp&#228;l&#228; T et al (2020) Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med 22:15&#8211;25<pub-id pub-id-type="pmid">31337882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-019-0596-9</pub-id><pub-id pub-id-type="pmcid">PMC7371626</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR474"><label>474.</label><citation-alternatives><element-citation id="ec-CR474" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez-Valentin</surname><given-names>M</given-names></name><name name-style="western"><surname>Haupt</surname><given-names>S</given-names></name><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>TT</given-names></name><etal/></person-group><article-title>Mortality by age, gene, and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database</article-title><source>EClinicalMedicine</source><year>2023</year><volume>58</volume><fpage>101909</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2023.101909</pub-id><pub-id pub-id-type="pmid">37181409</pub-id><pub-id pub-id-type="pmcid">PMC10166779</pub-id></element-citation><mixed-citation id="mc-CR474" publication-type="journal">Dominguez-Valentin M, Haupt S, Sepp&#228;l&#228; TT et al (2023) Mortality by age, gene, and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database. EClinicalMedicine 58:101909<pub-id pub-id-type="pmid">37181409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.101909</pub-id><pub-id pub-id-type="pmcid">PMC10166779</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR476"><label>476.</label><citation-alternatives><element-citation id="ec-CR476" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanaya</surname><given-names>N</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>H</given-names></name><name name-style="western"><surname>Morito</surname><given-names>T</given-names></name><etal/></person-group><article-title>Clinical features of biliary tract cancer in Japanese individuals with Lynch syndrome</article-title><source>J Gastrointest Oncol</source><year>2022</year><volume>13</volume><fpage>2532</fpage><lpage>3253</lpage><pub-id pub-id-type="doi">10.21037/jgo-22-165</pub-id><pub-id pub-id-type="pmid">36388648</pub-id><pub-id pub-id-type="pmcid">PMC9660066</pub-id></element-citation><mixed-citation id="mc-CR476" publication-type="journal">Kanaya N, Aoki H, Morito T et al (2022) Clinical features of biliary tract cancer in Japanese individuals with Lynch syndrome. J Gastrointest Oncol 13:2532&#8211;3253<pub-id pub-id-type="pmid">36388648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/jgo-22-165</pub-id><pub-id pub-id-type="pmcid">PMC9660066</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>